Patent application title: FGFR GATEKEEPER MUTANT GENE AND DRUG TARGETING SAME
Inventors:
IPC8 Class: AA61K314184FI
USPC Class:
1 1
Class name:
Publication date: 2019-11-28
Patent application number: 20190358205
Abstract:
The present inventors successfully identified novel gatekeeper mutations
for FGFR. Further, they discovered that mutant FGFR having the mutations
demonstrate resistance to known FGFR inhibitors such as AZD4547, and at
the same time demonstrate sensitivity to specific compounds. Mutant
polypeptides having the mutations may be used as biomarkers in cancer
treatment by FGFR inhibitors to prevent the development of side effects
in therapy by conventional FGFR inhibitors, and to control the
therapeutic mode for receiving the best therapeutic effect, thus making
individualized treatment possible.Claims:
1. A pharmaceutical composition for cancer treatment comprising as an
active ingredient the compound represented by Formula (I) below or a
pharmaceutically acceptable salt thereof, wherein the pharmaceutical
composition for cancer treatment is characterized in being used by
administering it to a patient expressing an FGFR mutant polypeptide
comprising a substitution of valine to phenylalanine at the 7.sup.th
amino acid from the N terminus and/or a substitution of valine to leucine
at the 5.sup.th amino acid from the N terminus in the partial amino acid
sequence described in SEQ ID NO: 53 or 54 in an FGFR polypeptide, or
having a polynucleotide encoding said mutant polypeptide: ##STR00011##
wherein R.sub.1, R.sub.2, R.sub.3, and R.sub.4 each independently
represents the group listed below: R.sub.1 represents hydrogen, hydroxy,
halogen, cyano, nitro, C.sub.1-4 haloalkyl, C.sub.1-6 alkyl, C2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-10 aryl
C.sub.1-4 alkyl, --OR.sub.5, --NR.sub.6R.sub.7,
--(CR.sub.8R.sub.9).sub.nZ.sub.1, --C(O)NR.sub.12R.sub.13, --SR.sub.14,
--SOR.sub.15, --SO.sub.2R.sub.16, --NR.sub.17SO.sub.2R.sub.18, COOH,
C.sub.6-10 aryl which is optionally substituted by one or more groups
independently selected from group P, 5- to 10-membered heteroaryl or 3-
to 10-membered heterocyclyl which is optionally substituted by one or
more groups independently selected from group Q, --COR.sub.19,
--COOR.sub.20, --OC(O)R.sub.21, --NR.sub.22C(O)R.sub.23,
--NR.sub.24C(S)R.sub.25, --C(S)NR.sub.26R.sub.27,
--SO.sub.2NR.sub.28R.sub.29, --OSO.sub.2R.sub.30, --SO.sub.3R.sub.31, or
--Si(R.sub.32).sub.3; R.sub.2 represents hydrogen, hydroxy, halogen,
cyano, nitro, C.sub.1-4 haloalkyl, C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-10 aryl C.sub.1-4 alkyl,
--OR.sub.5, --NR.sub.6R.sub.7, --(CR.sub.8R.sub.9).sub.nZ.sub.1,
--C(O)NR.sub.12R.sub.13, --SR.sub.14, --SOR.sub.15, --SO.sub.2R.sub.16,
--NR.sub.17SO.sub.2R.sub.18, COOH, C.sub.6-10 aryl which is optionally
substituted by one or more groups independently selected from group P, 5-
to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is
optionally substituted by one or more groups independently selected from
group Q, --COR.sub.19, --COOR.sub.20, --OC(O)R.sub.21,
--NR.sub.22C(O)R.sub.23, --NR.sub.24C(S)R.sub.25,
--C(S)NR.sub.26R.sub.27, --SO.sub.2NR.sub.28R.sub.29,
--OSO.sub.2R.sub.30, --SO.sub.3R.sub.31, or --Si(R.sub.32).sub.3; or
R.sub.1 and R.sub.2, together with an atom linked thereto, form 3- to
10-membered heterocyclyl or 5- to 10-membered heteroaryl, wherein the
heterocyclyl or heteroaryl is optionally substituted by halogen; R.sub.3
represents methyl; R.sub.4 represents hydrogen; A is indole; R.sub.5
represents C.sub.1-5 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkyl
C.sub.1-3 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4
haloalkyl, C.sub.1-3 alkoxy C.sub.1-4 alkyl, C.sub.1-3 alkoxy C.sub.1-4
alkoxy C.sub.1-4 alkyl, C.sub.1-4 aminoalkyl, C.sub.1-4 alkylamino
C.sub.1-4 alkyl, di(C.sub.1-4 alkyl)amino C.sub.1-4 alkyl, C.sub.6-10
aryl, C.sub.6-10 aryl C.sub.1-3 alkyl, or 3- to 10-membered heterocyclyl
C.sub.1-3 alkyl, 3- to 10-membered heterocyclyl, 5- to 10-membered
heteroaryl, 5- to 10-membered heteroaryl C.sub.1-3 alkyl, C.sub.1-6
monohydroxy alkyl, C.sub.1-6 dihydroxy alkyl, or C.sub.1-6 trihydroxy
alkyl which is optionally substituted by one or more groups independently
selected from group Q; R.sub.6 and R.sub.7, which can be the same or
different, each represents hydrogen, C.sub.1-4 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.1-3 alkoxy C.sub.1-4 alkyl,
C.sub.6-10 aryl C.sub.1-3 alkyl, 3- to 10-membered heterocyclyl C.sub.1-3
alkyl, 5- to 10-membered heteroaryl C.sub.1-3 alkyl, C.sub.1-6
monohydroxy alkyl, C.sub.1-6 dihydroxy alkyl, C.sub.1-6 trihydroxy alkyl,
3- to 10-membered heterocyclyl, C.sub.1-4 aminoalkyl, C.sub.1-4
alkylamino C.sub.1-4 alkyl, di(C.sub.1-4 alkyl)amino C.sub.1-4 alkyl, or
cyano(C.sub.1-3 alkyl); or alternatively R.sub.6 and R.sub.7, together
with a nitrogen atom linked thereto, form 3- to 10-membered heterocyclyl
or 5- to 10-membered heteroaryl; n represents 1 to 3; R.sub.8 and
R.sub.9, which can be the same or different, each represents hydrogen,
C.sub.1-4 alkyl, or halogen; or alternatively R.sub.8 and R.sub.9,
together with a carbon atom linked thereto, form a cycloaliphatic ring;
Z.sub.1 represents hydrogen, NR.sub.10R.sub.11, --OH, or 3- to
10-membered heterocyclyl or 5- to 10-membered heteroaryl which is
optionally substituted by one or more groups independently selected from
group Q; R.sub.10 and R.sub.11, which can be the same or different, each
represents C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.1-4 haloalkyl, C.sub.1-3 alkoxy C.sub.1-4 alkyl, cyano(C.sub.1-3
alkyl), or C.sub.1-3 alkylsulfonyl C.sub.1-4 alkyl; or alternatively
R.sub.10 and R.sub.11, together with a nitrogen atom linked thereto, form
3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl; R.sub.12
and R.sub.13, which can be the same or different, each represents
hydrogen, C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.1-4 haloalkyl, C.sub.1-3 alkoxy C.sub.1-4 alkyl, C.sub.6-10 aryl,
5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, C.sub.6-10
aryl C.sub.1-4 alkyl, 3- to 10-membered heterocyclyl C.sub.1-3 alkyl, 5-
to 10-membered heteroaryl C.sub.1-3 alkyl, cyano(C.sub.1-3 alkyl),
C.sub.1-3 alkylsulfonyl C.sub.1-4 alkyl, 3- to 10-membered cycloaliphatic
ring, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; or
alternatively R.sub.12 and R.sub.13, together with a nitrogen atom linked
thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered
heteroaryl which is optionally substituted by one or more groups
independently selected from group Q; R.sub.14 represents C.sub.1-4 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.6-10
aryl which is optionally substituted by one or more groups independently
selected from group P, or 5- to 10-membered heteroaryl or 3- to
10-membered heterocyclyl which is optionally substituted by one or more
groups independently selected from group Q; R.sub.15 represents C.sub.1-4
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl,
C.sub.6-10 aryl which is optionally substituted by one or more groups
independently selected from group P, or 5- to 10-membered heteroaryl or
3- to 10-membered heterocyclyl which is optionally substituted by one or
more groups independently selected from group Q; R.sub.16 represents
C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4
haloalkyl, C.sub.6-10 aryl which is optionally substituted by one or more
groups independently selected from group P, or 5- to 10-membered
heteroaryl or 3- to 10-membered heterocyclyl which is optionally
substituted by one or more groups independently selected from group Q;
R.sub.17 represents hydrogen or C.sub.1-4 alkyl; R.sub.18 represents
C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4
haloalkyl, C.sub.6-10 aryl which is optionally substituted by one or more
groups independently selected from group P, or 5- to 10-membered
heteroaryl or 3- to 10-membered heterocyclyl which is optionally
substituted by one or more groups independently selected from group Q;
R.sub.19 represents hydrogen, C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl,
haloalkyl, C.sub.6-10 aryl, or 5- to 10-membered heteroaryl or 3- to
10-membered heterocyclyl which is optionally substituted by one or more
groups independently selected from group Q; R.sub.29 represents C.sub.1-4
alkyl, C.sub.3-7 cycloalkyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl, 5- to
10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R.sub.21
represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.1-4 haloalkyl,
C.sub.6-10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered
heterocyclyl; R.sub.22 represents hydrogen, C.sub.1-4 alkyl, or C.sub.1-4
haloalkyl; R.sub.23 represents hydrogen, C.sub.1-4 alkyl, C.sub.3-7
cycloalkyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl, 5- to 10-membered
heteroaryl, or 3- to 10-membered heterocyclyl; R.sub.24 represents
hydrogen, C.sub.1-4 alkyl, or C.sub.1-4 haloalkyl; R.sub.25 represents
C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.1-4 haloalkyl, C.sub.6-10
aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl;
R.sub.26 and R.sub.27, which can be the same or different, each
represents hydrogen, C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.1-4 haloalkyl, C.sub.1-3 alkoxyl C.sub.1-4 alkyl,
C.sub.6-10 aryl, 5- to 10-membered heteroaryl, 3- to 10-membered
heterocyclyl, C.sub.6-10 aryl C.sub.1-4 alkyl, 3- to 10-membered
heterocyclyl C.sub.1-3 alkyl, 5- to 10-membered heteroaryl C.sub.1-3
alkyl, cyano(C.sub.1-3 alkyl), C.sub.1-3 alkylsulfonyl C.sub.1-4 alkyl,
or 3- to 10-membered cycloaliphatic ring; or alternatively R.sub.26 and
R.sub.27, together with a nitrogen atom linked thereto, form 3- to
10-membered heterocyclyl or 5- to 10-membered heteroaryl; R.sub.28 and
R.sub.29, which can be the same or different, each represents hydrogen,
C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4
haloalkyl, C.sub.1-3 alkoxyl C.sub.1-4 alkyl, C.sub.6-10 aryl, 5- to
10-membered heteroaryl, 3- to 10-membered heterocyclyl, C.sub.6-10 aryl
C.sub.1-4 alkyl, 3- to 10-membered heterocyclyl C.sub.1-3 alkyl, 5- to
10-membered heteroaryl C.sub.1-3 alkyl, cyano(C.sub.1-3 alkyl), C.sub.1-3
alkylsulfonyl C.sub.1-4 alkyl, or 3- to 10-membered cycloaliphatic ring;
or alternatively R.sub.28 and R.sub.29, together with a nitrogen atom
linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered
heteroaryl; R.sub.30 represents C1-4 alkyl, C.sub.3-7 cycloalkyl,
C.sub.1-4 haloalkyl, C.sub.6-10 aryl, 5- to 10-membered heteroaryl, or 3-
to 10-membered heterocyclyl; R.sub.31represents C.sub.1-4 alkyl,
C.sub.3-7 cycloalkyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl, 5- to
10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R.sub.32
represents C.sub.1-4 alkyl or C.sub.6-10 aryl; <group P> halogen,
C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, --OH, C.sub.1-3 alkoxy, C.sub.1-3
haloalkoxy, 3- to 10-membered heterocyclylamino, --SO.sub.2R.sub.16,
--CN, --NO.sub.2, and 3- to 10-membered heterocyclyl; <group Q>
halogen, C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, --OH, C.sub.1-3 alkoxy,
C.sub.1-6 monohydroxy alkyl, C1_6 dihydroxy alkyl, C.sub.1-6 trihydroxy
alkyl, 3- to 10-membered heterocyclyl amine, --SO.sub.2R.sub.16, --CN,
--NO.sub.2, C.sub.3-7 cycloalkyl, --COR.sub.19, and 3- to 10-membered
heterocyclyl which is optionally substituted by C.sub.1-4 alkyl.
2. The pharmaceutical composition of claim 1, comprising as an active ingredient the compound represented by the formula below or a pharmaceutically acceptable salt thereof: ##STR00012##
3. An FGFR mutant polypeptide comprising a substitution of valine to phenylalanine at the 7.sup.th amino acid from the N terminus and/or a substitution of valine to leucine at the 5.sup.th amino acid from the N terminus in the partial amino acid sequence described in SEQ ID NO: 53 or 54 in an FGFR polypeptide.
4. A polynucleotide encoding the mutant polypeptide of claim 3.
5. A vector comprising the polynucleotide of claim 4.
6. A recombinant cell comprising the vector of claim 5.
7. An antibody, or antigen-binding fragment thereof, that specifically binds to the mutant polypeptide of claim 3.
8. A pair of oligonucleotide primers or an oligonucleotide probe(s) comprising an oligonucleotide(s) specifically hybridizing to a polynucleotide encoding the mutant polypeptide of claim 3 for detecting or amplifying the polynucleotide.
9. An oligonucleotide that binds to an mRNA polynucleotide encoding the mutant polypeptide of claim 3 and has an activity to inhibit translation of the mRNA polynucleotide into protein.
10. The oligonucleotide of claim 9, which is an siRNA that cleaves the mRNA polynucleotide.
11. A method for detecting an FGFR mutant polypeptide, which comprises the step of detecting the mutant polypeptide in a sample isolated from a subject by using an antibody, or antigen-binding fragment thereof, that specifically binds to the mutant polypeptide of claim 3.
12. A method for detecting a polynucleotide encoding an FGFR mutant polypeptide, which comprises the step of detecting a polynucleotide encoding the mutant polypeptide in a sample isolated from a subject by using a pair of oligonucleotide primers or an oligonucleotide probe(s) comprising an oligonucleotide(s) specifically hybridizing to a polynucleotide encoding the mutant polypeptide of claim 3 for detecting or amplifying the polynucleotide.
13. A kit for detecting a polynucleotide encoding an FGFR mutant polypeptide, which comprises a pair of oligonucleotide primers or an oligonucleotide probe(s) comprising an oligonucleotide(s) specifically hybridizing to a polynucleotide encoding the mutant polypeptide of claim 3 for detecting or amplifying the polynucleotide.
14. A kit for detecting an FGFR mutant polypeptide, which comprises an antibody or antigen-binding fragment thereof that specifically binds to the mutant polypeptide of claim 3.
15. A method for treating cancer, which comprises determining the presence or absence of the mutant polypeptide of claim 3 or a polynucleotide encoding the mutant polypeptide in a sample isolated from a subject and administering the pharmaceutical composition of claim 1 or 2 to the subject when the mutant polypeptide or the polynucleotide is detected.
16. The method of claim 15, wherein the cancer is bladder cancer, brain tumor, head and neck squamous cell carcinoma, lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, skin melanoma, endometrial cancer, breast cancer, prostate cancer, colon cancer, esophageal cancer, gastric cancer, bile duct cancer, biliary tract cancer, or liver cancer.
17. A method for selecting a patient to which the pharmaceutical composition of claim 1 or 2 is applicable, which comprises the steps of: (a) determining the presence or absence of the mutant polypeptide of claim 3 in a sample isolated from a subject; and (b) selecting a subject confirmed to have the mutant polypeptide as a patient to which the pharmaceutical composition is applicable.
18. A method for selecting a patient to which the pharmaceutical composition of claim 1 or 2 is applicable, which comprises the steps of: (a) determining the presence or absence of a polynucleotide encoding the mutant polypeptide of claim 3 in a sample isolated from a subject; and (b) selecting a subject confirmed to have a polynucleotide encoding the mutant polypeptide as a patient to which the pharmaceutical composition is applicable.
19. The method of claim 18, wherein the cancer is bladder cancer, brain tumor, head and neck squamous cell carcinoma, lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, skin melanoma, endometrial cancer, breast cancer, prostate cancer, colon cancer, esophageal cancer, gastric cancer, bile duct cancer, biliary tract cancer, or liver cancer.
20. The compound defined in claim 1 or 2 or a pharmaceutically acceptable salt thereof for use in cancer treatment in a patient who expresses the mutant polypeptide of claim 3 or has a polynucleotide encoding the mutant polypeptide.
21. The compound of claim 20 or a pharmaceutically acceptable salt thereof, wherein the cancer is bladder cancer, brain tumor, head and neck squamous cell cancer, lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, skin melanoma, endometrial cancer, breast cancer, prostate cancer, colon cancer, esophageal cancer, gastric cancer, bile duct cancer, biliary tract cancer, or liver cancer.
22. A pharmaceutical composition for cancer treatment comprising as an active ingredient the compound represented by the formula below or a pharmaceutically acceptable salt thereof, wherein the cancer expresses an FGFR mutant polypeptide comprising a substitution of valine to phenylalanine at the 7.sup.th amino acid from the N terminus and/or a substitution of valine to leucine at the 5.sup.th amino acid from the N terminus in the partial amino acid sequence described in SEQ ID NO: 53 or 54 in an FGFR polypeptide: ##STR00013##
23. A pharmaceutical composition for cancer treatment comprising as an active ingredient a substance that inhibits the function or expression of an FGFR mutant polypeptide comprising a substitution of valine to phenylalanine at the 7.sup.th amino acid from the N terminus and/or a substitution of valine to leucine at the 5.sup.th amino acid from the N terminus in the partial amino acid sequence described in SEQ ID NO: 53 or 54 in an FGFR polypeptide.
Description:
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a divisional of U.S. application Ser. No. 15/108,014, filed on Jun. 24, 2016, which is the National Stage of International Application No. PCT/JP2014/084521, filed on Dec. 26, 2014, which claims the benefit of Japanese Application No. 2013-273053, filed on Dec. 27, 2013.
TECHNICAL FIELD
[0002] The present invention relates to mutant polypeptides comprising novel gatekeeper mutations; polynucleotides encoding the polypeptides; vectors comprising the polynucleotides; cells comprising the vectors; antibodies and fragments thereof that specifically bind to the polypeptides; oligonucleotide primers or oligonucleotide probes that hybridize to the polynucleotides; oligonucleotides that inhibit the expression of the polypeptides; pharmaceutical compositions comprising the antibodies or oligonucleotides; methods and kits for detecting the polynucleotides or mutant polypeptides; methods for testing whether a subject is resistant to an FGFR inhibitor based on the presence or absence of the polynucleotides or mutant polypeptides; methods for selecting cancer patients for whom an FGFR inhibitor is applicable; pharmaceutical compositions for treating cancer wherein compounds having FGFR inhibitory activity or pharmaceutically acceptable salts thereof are used for administration to patients expressing the mutant polypeptides or carrying the polynucleotides; methods for treating or preventing cancer that comprise the step of administering an effective amount of compounds having FGFR inhibitory activity or pharmaceutically acceptable salts thereof to patients expressing the mutant polypeptides or carrying the polynucleotides; use of compounds having FGFR inhibitory activity or pharmaceutically-acceptable salts thereof in the production of pharmaceutical compositions for cancer treatment for administration to patients expressing the mutant polypeptides or carrying the polynucleotides; compounds having FGFR inhibitory activity or pharmaceutically acceptable salts thereof for use in treating or preventing patients expressing the mutant polypeptides or carrying the polynucleotides; as well as methods for identifying FGFR inhibitors, and such.
Background Art
[0003] Cancer can develop in any organ or tissue, and is highly refractory and lethal. It goes without saying that cancer is a highly cumbersome disease. Recent statistical data show that one out of every two people is diagnosed with cancer during his/her lifetime, and one out of four men and one out of six women die of cancer. Thus, cancer remains an extremely serious disease.
[0004] Fibroblast growth factor receptors (FGFRs) are kinases belonging to the receptor tyrosine kinase family. FGFR1, FGFR2, FGFR3, and FGFR4 constitute the FGFR family. The ligand is fibroblast growth factor (FGF), and 22 types of structurally similar proteins form the family.
[0005] Signals transmitted via FGFR are conveyed to the MAPK pathway or PI3K/AKT pathway. It has been reported that in cancer, signal transduction is involved in cell growth, angiogenesis, cell migration, invasion, metastasis, etc.; and FGFR is activated as a result of overexpression, gene hyper-amplification, mutation, or translocation (Non-patent Document 1). For example, it is known that for FGFR3, genetic translocation is observed in multiple myeloma (Non-patent Document 2); gene mutation is observed in bladder cancer (Non-patent Document 3); and overexpression is observed in ovarian cancer, non-small cell lung carcinoma, and hepatocellular carcinoma.
[0006] The findings described above suggest a connection between FGFR and cancer. Thus, attempts have been made to develop compounds with FGFR-inhibitory activity as anticancer agents (Non-patent Documents 4 and 5).
[0007] Currently, various molecule-targeting drugs specific to various types of kinases are commercially available. However, certain amino acid mutations in EGFR tyrosine kinase which is a target molecule of gefitinib, erlotinib, and such, have become the main cause for acquisition of resistance to gefitinib, erlotinib, and such. Such mutations are called gatekeeper (GK) mutations, and there have been reports on GK mutations in FGFR2 as well (Non-Patent Document 6).
Prior Art Documents
Non-Patent Documents
[0008] [Non-patent Document 1] Cytokine & Growth Factor Reviews, 2005, 16: 139-149
[0009] [Non-patent Document 2] Blood, 2003, 101: 4569-4575
[0010] [Non-patent Document 3] Nature Genetics, 1999 Sep., 23(1): 18-20
[0011] [Non-patent Document 4] Cancer Research, 2012, 72: 2045-2056
[0012] [Non-patent Document 5] J. Med. Chem., 2011, 54: 7066-7083
[0013] [Non-patent Document 6] Neoplasia (2013), 15(8), 975-988
SUMMARY OF THE INVENTION
Problems to be Solved by the Invention
[0014] The present inventors identified novel gatekeeper mutations in the FGFR gene, and also discovered that specific FGFR inhibitors have an inhibitory activity on FGFR carrying those mutations, which activity is equivalent that on FGFR not carrying the mutations.
[0015] In other words, an objective of the present invention is to provide novel antitumor agents that have high anticancer effects even for cancers with an FGFR that has acquired resistance to other FGFR inhibitors as a result of acquiring the above-mentioned mutations.
Means for Solving the Problems
[0016] To solve the above-mentioned problems, the present inventors conducted dedicated research on mutant genes that may cause gatekeeper mutations of various FGFRs, by performing crystal structure analyses on FGFRs. As a result, the inventors identified novel GK mutations (for example, the V564F mutation in SEQ ID NO: 1) and mutations corresponding to the above-mentioned GK mutations (for example, the V562L mutation in SEQ ID NO: 1) and found that FGFRs carrying these mutations demonstrated resistance to known FGFR inhibitors such as AZD4547, and at the same time, they demonstrated sensitivity to Compound A, and thus completed the present invention.
[0017] That is, the present invention specifically relates to: an FGFR mutant polypeptide comprising a novel gate keeper mutation; a polynucleotide encoding the mutant polypeptide; a vector comprising the polynucleotide; a cell comprising the vector; an antibody and a fragment thereof that specifically bind to the mutant polypeptide; oligonucleotide primers or oligonucleotide probe(s) that hybridize to the polynucleotide; an oligonucleotide that inhibits the expression of the mutant polypeptide; a method and a kit for detecting the mutant polypeptide or the polynucleotide; a pharmaceutical composition for cancer treatment characterized in being used by administering it to a patient expressing the mutant polypeptide; a method for treating or preventing cancer by administering the pharmaceutical composition to a patient expressing the mutant polypeptide; a method for selecting a patient to which the pharmaceutical composition is applicable; and a pharmaceutical composition and such for use in cancer treatment in a patient expressing the mutant polypeptide.
[0018] Basic characteristics and various embodiments of the present invention are listed below:
[1] A pharmaceutical composition for cancer treatment comprising as an active ingredient the compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition for cancer treatment is characterized in being used by administering it to a patient expressing an FGFR mutant polypeptide comprising a substitution of valine to phenylalanine at the 7.sup.th amino acid from the N terminus and/or a substitution of valine to leucine at the 5.sup.th amino acid from the N terminus in the partial amino acid sequence described in SEQ ID NO: 53 or 54 in an FGFR polypeptide, or having a polynucleotide encoding said mutant polypeptide:
##STR00001##
wherein R.sub.1, R.sub.2, R.sub.3, and R.sub.4 each independently represents the group listed below: R.sub.1 represents hydrogen, hydroxy, halogen, cyano, nitro, C.sub.1-4 haloalkyl, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-10 aryl C.sub.1-4 alkyl, --OR.sub.5, --NR.sub.6R.sub.7, --(CR.sub.8R.sub.9).sub.nZ.sub.1, --C(O)NR.sub.12R.sub.13, --SR.sub.14, --SOR.sub.15, --SO.sub.2R.sub.16, --NR.sub.17SO.sub.2R.sub.18, COOH, C.sub.6-10 aryl which is optionally substituted by one or more groups independently selected from group P, 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q, --COR.sub.19, --COOR.sub.20, --OC(O)R.sub.21, --NR.sub.22C(O)R.sub.23, --NR.sub.24C(S)R.sub.25, C(S)NR.sub.26R.sub.27, --SO.sub.2NR.sub.28R.sub.29, --OSO.sub.2R.sub.30, --SO.sub.3R.sub.31, or --Si(R.sub.32).sub.3; R.sub.2 represents hydrogen, hydroxy, halogen, cyano, nitro, C.sub.1-4 haloalkyl, C.sub.1-6 alkyl, C2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-10 aryl C.sub.1-4 alkyl, --OR.sub.5, --NR.sub.6R.sub.7, --(CR.sub.8R.sub.9).sub.nZ.sub.1, --C(O)NR.sub.12R.sub.13, --SR.sub.14, --SOR.sub.15, --SO.sub.2R.sub.16, --NR.sub.17SO.sub.2R.sub.18, COOH, C.sub.6-10 aryl which is optionally substituted by one or more groups independently selected from group P, 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q, --COR.sub.19, --COOR.sub.20, --OC(O)R.sub.21, --NR.sub.22C(O)R.sub.23, --NR.sub.24C(S)R.sub.25, --C(S)NR.sub.26R.sub.27, --SO.sub.2NR.sub.28R.sub.29, --OSO.sub.2R.sub.30, --SO.sub.3R.sub.31, or --Si(R.sub.32).sub.3; or R.sub.1 and R.sub.2, together with an atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl, wherein the heterocyclyl or heteroaryl is optionally substituted by halogen; R.sub.3 represents methyl; R.sub.4 represents hydrogen; A is indole; R.sub.5 represents C.sub.1-5 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkyl C.sub.1-3 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.1-3 alkoxy C.sub.1-4 alkyl, C.sub.1-3 alkoxy C.sub.1-4 alkoxy C.sub.1-4 alkyl, C.sub.1-4 aminoalkyl, C.sub.1-4 alkylamino C.sub.1-4 alkyl, di(C.sub.1-4 alkyl)amino C.sub.1-4 alkyl, C.sub.6-10 aryl, C.sub.6-10 aryl C.sub.1-3 alkyl, or 3- to 10-membered heterocyclyl C.sub.1-3 alkyl, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryl C.sub.1-3 alkyl, C.sub.1-6 monohydroxy alkyl, C.sub.1-6 dihydroxy alkyl, or C.sub.1-6 trihydroxy alkyl which is optionally substituted by one or more groups independently selected from group Q; R.sub.6 and R.sub.7, which can be the same or different, each represents hydrogen, C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.1-3 alkoxy C.sub.1-4 alkyl, C.sub.6-10 aryl C.sub.1-3 alkyl, 3- to 10-membered heterocyclyl C.sub.1-3 alkyl, 5- to 10-membered heteroaryl C.sub.1-3 alkyl, C.sub.1-6 monohydroxy alkyl, C.sub.1-6 dihydroxy alkyl, C.sub.1-6 trihydroxy alkyl, 3- to 10-membered heterocyclyl, C.sub.1-4 aminoalkyl, C.sub.1-4 alkylamino C.sub.1-4 alkyl, di(C.sub.1-4 alkyl)amino C.sub.1-4 alkyl, or cyano(C.sub.1-3 alkyl); or alternatively R.sub.6 and R.sub.7, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl; n represents 1 to 3; R.sub.8 and R.sub.9, which can be the same or different, each represents hydrogen, C.sub.1-4 alkyl, or halogen; or alternatively R.sub.8 and R.sub.9, together with a carbon atom linked thereto, form a cycloaliphatic ring; Z.sub.1 represents hydrogen, NR.sub.10R.sub.11, --OH, or 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl which is optionally substituted by one or more groups independently selected from group Q; R.sub.10 and R.sub.11, which can be the same or different, each represents C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.1-3 alkoxy C.sub.1-4 alkyl, cyano(C.sub.1-3 alkyl), or C.sub.1-3 alkylsulfonyl C.sub.1-4 alkyl; or alternatively R.sub.10 and R.sub.11, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl; R.sub.12 and R.sub.13, which can be the same or different, each represents hydrogen, C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.1-3 alkoxy C.sub.1-4 alkyl, C.sub.6-10 aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, C.sub.6-10 aryl C.sub.1-4 alkyl, 3- to 10-membered heterocyclyl C.sub.1-3 alkyl, 5- to 10-membered heteroaryl C.sub.1-3 alkyl, cyano(C.sub.1-3 alkyl), C.sub.1-3 alkylsulfonyl C.sub.1-4 alkyl, 3- to 10-membered cycloaliphatic ring, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; or alternatively R.sub.12 and R.sub.13, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl which is optionally substituted by one or more groups independently selected from group Q; R.sub.14 represents C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl which is optionally substituted by one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q; R.sub.15 represents C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl which is optionally substituted by one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q; R.sub.16 represents C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl which is optionally substituted by one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q; R.sub.17 represents hydrogen or C.sub.1-4 alkyl; R.sub.18 represents C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl which is optionally substituted by one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q; R.sub.19 represents hydrogen, C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q; R20 represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R.sub.21 represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R.sub.22 represents hydrogen, C.sub.1-4 alkyl, or C.sub.1-4 haloalkyl; R.sub.23 represents hydrogen, C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R.sub.24 represents hydrogen, C.sub.1-4 alkyl, or C.sub.1-4 haloalkyl; R.sub.25 represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R.sub.26 and R.sub.27, which can be the same or different, each represents hydrogen, C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.1-3 alkoxyl C.sub.1-4 alkyl, C.sub.6-10 aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, C.sub.6-10 aryl C.sub.1-4 alkyl, 3- to 10-membered heterocyclyl C.sub.1-3 alkyl, 5- to 10-membered heteroaryl C.sub.1-3 alkyl, cyano(C.sub.1-3 alkyl), C.sub.1-3 alkylsulfonyl C.sub.1-4 alkyl, or 3- to 10-membered cycloaliphatic ring; or alternatively R.sub.26 and R.sub.27, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl; R.sub.28 and R.sub.29, which can be the same or different, each represents hydrogen, C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.1-3 alkoxyl C.sub.1-4 alkyl, C.sub.6-10 aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, C.sub.6-10 aryl C.sub.1-4 alkyl, 3- to 10-membered heterocyclyl C.sub.1-3 alkyl, 5- to 10-membered heteroaryl C.sub.1-3 alkyl, cyano(C.sub.1-3 alkyl), C.sub.1-3 alkylsulfonyl C.sub.1-4 alkyl, or 3- to 10-membered cycloaliphatic ring; or alternatively R.sub.28 and R.sub.29, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl; R.sub.30 represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R.sub.31 represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R.sub.32 represents C.sub.1-4 alkyl or C.sub.6-10 aryl; <group P> halogen, C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, --OH, C.sub.1-3 alkoxy, C.sub.1-3 haloalkoxy, 3- to 10-membered heterocyclylamino, --SO.sub.2R16, --CN, --NO2, and 3- to 10-membered heterocyclyl; <group Q> halogen, C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, --OH, C.sub.1-3 alkoxy, C.sub.1-6 monohydroxy alkyl, C.sub.1-6 dihydroxy alkyl, C.sub.1-6 trihydroxy alkyl, 3- to 10-membered heterocyclyl amine, --SO.sub.2R.sub.16, --CN, --NO2, C.sub.3-7 cycloalkyl, --COR.sub.19, and 3- to 10-membered heterocyclyl which is optionally substituted by C.sub.1-4 alkyl; [2] the pharmaceutical composition of [1], comprising as an active ingredient the compound represented by the formula below or a pharmaceutically acceptable salt thereof:
##STR00002##
[3] an FGFR mutant polypeptide comprising a substitution of valine to phenylalanine at the 7.sup.th amino acid from the N terminus and/or a substitution of valine to leucine at the 5.sup.th amino acid from the N terminus in the partial amino acid sequence described in SEQ ID NO: 53 or 54 in an FGFR polypeptide; [4] a polynucleotide encoding the mutant polypeptide of [3]; [5] a vector comprising the polynucleotide of [4]; [6] a recombinant cell comprising the vector of [5]; [7] an antibody, or antigen-binding fragment thereof, that specifically binds to the mutant polypeptide of [3]; [8] a pair of oligonucleotide primers or an oligonucleotide probe(s) comprising an oligonucleotide(s) specifically hybridizing to a polynucleotide encoding the mutant polypeptide of [3] for detecting or amplifying the polynucleotide; [9] an oligonucleotide that binds to an mRNA polynucleotide encoding the mutant polypeptide of [3] and has an activity to inhibit translation of the mRNA polynucleotide into protein; [10] the oligonucleotide of [9], which is an siRNA that cleaves the mRNA polynucleotide; [11] a method for detecting an FGFR mutant polypeptide, which comprises the step of detecting the mutant polypeptide in a sample isolated from a subject by using an antibody, or antigen-binding fragment thereof, that specifically binds to the mutant polypeptide of [3]; [12] a method for detecting a polynucleotide encoding an FGFR mutant polypeptide, which comprises the step of detecting a polynucleotide encoding the mutant polypeptide in a sample isolated from a subject by using a pair of oligonucleotide primers or an oligonucleotide probe(s) comprising an oligonucleotide(s) specifically hybridizing to a polynucleotide encoding the mutant polypeptide of [3] for detecting or amplifying the polynucleotide; [13] a kit for detecting a polynucleotide encoding an FGFR mutant polypeptide, which comprises a pair of oligonucleotide primers or an oligonucleotide probe(s) comprising an oligonucleotide(s) specifically hybridizing to a polynucleotide encoding the mutant polypeptide of [3] for detecting or amplifying the polynucleotide; [14] a kit for detecting an FGFR mutant polypeptide, which comprises an antibody or antigen-binding fragment thereof that specifically binds to the mutant polypeptide of [3]; [15] a method for treating cancer, which comprises determining the presence or absence of the mutant polypeptide of [3] or a polynucleotide encoding the mutant polypeptide in a sample isolated from a subject and administering the pharmaceutical composition of [1] or [2] to the subject when the mutant polypeptide or the polynucleotide is detected; [16] the method of [15], wherein the cancer is bladder cancer, brain tumor, head and neck squamous cell carcinoma, lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, skin melanoma, endometrial cancer, breast cancer, prostate cancer, colon cancer, esophageal cancer, gastric cancer, bile duct cancer, biliary tract cancer, or liver cancer; [17] a method for selecting a patient to which the pharmaceutical composition of [1] or [2] is applicable, which comprises the steps of:
[0019] (a) determining the presence or absence of the mutant polypeptide of [3] in a sample isolated from a subject; and
[0020] (b) selecting a subject confirmed to have the mutant polypeptide as a patient to which the pharmaceutical composition is applicable;
[18] a method for selecting a patient to which the pharmaceutical composition of [1] or [2] is applicable, which comprises the steps of:
[0021] (a) determining the presence or absence of a polynucleotide encoding the mutant polypeptide of [3] in a sample isolated from a subject; and
[0022] (b) selecting a subject confirmed to have a polynucleotide encoding the mutant polypeptide as a patient to which the pharmaceutical composition is applicable;
[19] the method of [18], wherein the cancer is bladder cancer, brain tumor, head and neck squamous cell carcinoma, lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, skin melanoma, endometrial cancer, breast cancer, prostate cancer, colon cancer, esophageal cancer, gastric cancer, bile duct cancer, biliary tract cancer, or liver cancer; [20] the compound defined in[1] or [2] or a pharmaceutically acceptable salt thereof for use in cancer treatment in a patient who expresses the mutant polypeptide of [3] or has a polynucleotide encoding the mutant polypeptide; [21] the compound of [20] or a pharmaceutically acceptable salt thereof, wherein the cancer is bladder cancer, brain tumor, head and neck squamous cell cancer, lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, skin melanoma, endometrial cancer, breast cancer, prostate cancer, colon cancer, esophageal cancer, gastric cancer, bile duct cancer, biliary tract cancer, or liver cancer; [22] a pharmaceutical composition for cancer treatment comprising as an active ingredient the compound represented by the formula below or a pharmaceutically acceptable salt thereof, wherein the cancer expresses an FGFR mutant polypeptide comprising a substitution of valine to phenylalanine at the 7.sup.th amino acid from the N terminus and/or a substitution of valine to leucine at the 5.sup.th amino acid from the N terminus in the partial amino acid sequence described in SEQ ID NO: 53 or 54 in an FGFR polypeptide:
##STR00003##
[23] a pharmaceutical composition for cancer treatment comprising as an active ingredient a substance that inhibits the function or expression of an FGFR mutant polypeptide comprising a substitution of valine to phenylalanine at the 7.sup.th amino acid from the N terminus and/or a substitution of valine to leucine at the 5.sup.th amino acid from the N terminus in the partial amino acid sequence described in SEQ ID NO: 53 or 54 in an FGFR polypeptide; [24] use of the compound defined in the aforementioned [1] or [2] or a pharmaceutically acceptable salt thereof in the manufacture of a pharmaceutical composition for treating or preventing cancer which is to be administered to a patient expressing the mutant polypeptide of [3] or has a polynucleotide encoding the mutant polypeptide; [25] a method for detecting resistance to an FGFR inhibitor selected from the group consisting of PD173074, AZD4547, BGJ398, and AZD2171, which comprises the steps of: (a) determining the presence or absence of the mutant polypeptide of [3] or a polynucleotide encoding the mutant polypeptide in a sample isolated from a subject; and (b) determining that the subject confirmed to have the mutant polypeptide or the polynucleotide has resistance to the FGFR inhibitor; [26] the antibody or antigen-binding fragment thereof of [7], or the oligonucleotide primers or oligonucleotide probe(s) of [8] for use in detecting resistance to an FGFR inhibitor selected from the group consisting of PD173074, AZD4547, BGJ398, and AZD2171; [27] use of the antibody or antigen-binding fragment thereof of [7], or the oligonucleotide primers or oligonucleotide probe(s) of [8] for detecting resistance to an FGFR inhibitor selected from the group consisting of PD173074, AZD4547, BGJ398, and AZD2171; [28] a method for predicting the response of a cancer patient to treatment by an FGFR inhibitor selected from the group consisting of PD173074, AZD4547, BGJ398, and AZD2171, which comprises the steps of: (a) determining the presence or absence of the mutant polypeptide of [3] or a polynucleotide encoding the mutant polypeptide in a sample isolated from the patient; and (b) determining that the patient confirmed to have the mutant polypeptide or the polynucleotide has low sensitivity to the FGFR inhibitor; [29] the antibody or antigen-binding fragment thereof of [7], or the oligonucleotide primers or oligonucleotide probe(s) of [8] for use in predicting the response of a cancer patient to treatment by an FGFR inhibitor selected from the group consisting of PD173074, AZD4547, BGJ398, and AZD2171; [30] use of the antibody or antigen-binding fragment thereof of [7], or the oligonucleotide primers or oligonucleotide probe(s) of [8] for predicting the response of a cancer patient to treatment by an FGFR inhibitor selected from the group consisting of PD173074, AZD4547, BGJ398, and AZD2171; [31] a kit for predicting an effect of an FGFR inhibitor in cancer treatment, which comprises the antibody or antigen-binding fragment thereof of [7], or the oligonucleotide primers or oligonucleotide probe(s) of [8]; and [32] The kit of [31], wherein the FGFR inhibitor is selected from the group consisting of PD173074, AZD4547, BGJ398, and AZD2171.
Effects of the Invention
[0023] The present invention can provide novel antitumor agents that have high anticancer effects on cancers with an FGFR which has acquired resistance to other FGFR inhibitors.
BRIEF DESCRIPTION OF THE DRAWINGS
[0024] FIG. 1 shows the effects of Compounds A and C on tyrosine phosphorylation of FGFR in cells made to express the wild-type FGFR2, the FGFR2 V564F mutant, or the FGFR2 V562L mutant.
[0025] FIG. 2 shows graphs indicating the inhibitory effects of Compounds A, B, and C on proliferation of cells made to express the wild-type FGFR2, the FGFR2 V564F mutant, or the FGFR2 V562L mutant.
[0026] FIG. 3 shows graphs indicating the inhibitory effects of Compounds A, B, C, D, and E on proliferation of cells made to express the TEL-fused wild-type FGFR2 or the TEL-fused FGFR2 V564F mutant.
[0027] FIG. 4 shows graphs indicating the inhibitory effects of Compounds A and C on tumor proliferation in mice carrying tumor cells expressing the TEL-fused wild-type FGFR2 or the TEL-fused FGFR2 V564F mutant.
[0028] FIG. 5 shows graphs indicating the inhibitory effects of Compound A or C on phosphorylation in tumors in mice carrying tumor cells expressing the TEL-fused wild-type FGFR2 or the TEL-fused FGFR2 V564F mutant.
MODE FOR CARRYING OUT THE INVENTION
[0029] The present invention is an invention illustratively described in the above-mentioned [1] to [31] and provides: an FGFR mutant polypeptide comprising a novel gate keeper mutation; a polynucleotide encoding the mutant polypeptide; a vector comprising the polynucleotide; a cell comprising the vector; an antibody and a fragment thereof that specifically bind to the mutant polypeptide; oligonucleotide primers or oligonucleotide probe(s) that hybridize to the polynucleotide; an oligonucleotide that inhibits the expression of the mutant polypeptide; a method and a kit for detecting the mutant polypeptide or the polynucleotide; a pharmaceutical composition for cancer treatment characterized in being used by administering it to a patient expressing the mutant polypeptide; a method for treating or preventing cancer by administering the pharmaceutical composition to a patient expressing the mutant polypeptide; a method for selecting a patient to which the pharmaceutical composition is applicable; a compound having
[0030] FGFR inhibitory activity or a pharmaceutically-acceptable salt thereof for use in treating or preventing cancer in a patient expressing the mutant polypeptide; use of a compound having FGFR inhibitory activity or a pharmaceutically acceptable salt thereof in the manufacture of a pharmaceutical composition for treating or preventing cancer for administration to a patient expressing the mutant polypeptide; a method for detecting resistance to an FGFR inhibitor; a method for predicting response of a cancer patient to treatment using an FGFR inhibitor; and such.
[0031] In the present invention, "FGFR" refers to any FGFR belonging to the FGFR family comprising FGFR1, FGFR2, FGFR3, and FGFR4, which are fibroblast growth factor receptors (FGFRs) belonging to the receptor tyrosine kinase family (Cytokine & Growth Factor Reviews, 2005, 16: 139-149). FGFRs of the present invention may be of any origin, and are preferably FGFRs derived from mammals (humans, mice, rats, guinea pigs, rabbits, sheep, monkeys, goats, donkeys, bovines, horses, pigs, etc.), more preferably human FGFRs, and still more preferably human FGFR2, human FGFR1, FGFR3, each of them are known to have many isoforms.
[0032] In the present invention, "human FGFR2" is a wild-type human FGFR2 polypeptide consisting of the amino acid sequence of SEQ ID NO: 1, 2, 37, 38, 39, 40, 41, 42, 43, or 44 (GenBank Accession No: NP_000132.3, NP_075259.4, NP_001138385.1, NP_001138386.1, NP_001138387.1, NP_001138388.1, NP_001138389.1, NP_001138390.1, NP_001138391.1, or NP_075418.1, respectively), or a mutant polypeptide with one or more (preferably one to ten, and particularly preferably one to five) amino acids being substituted, deleted, or inserted in the wild-type polypeptide.
[0033] In the present invention, "human FGFR1" is a wild-type human FGFR1 polypeptide consisting of the amino acid sequence of SEQ ID NO: 21, 45, 46, 47, 48, 49, or 50 (GenBank Accession No: NP_001167538.1, NP_001167534.1, NP_001167535.1, NP_001167536.1, NP_001167537.1, NP_075594.1, or NP_075598.2, respectively), or a mutant polypeptide with one or more (preferably one to ten, and particularly preferably one to five) amino acids being substituted, deleted, or inserted in the wild-type polypeptide.
[0034] In the present invention, "human FGFR3" is a wild-type human FGFR3 polypeptide consisting of the amino acid sequence of SEQ ID NO: 22, 51, or 52 (GenBank Accession No: NP_000133.1, NP_001156685.1, or NP_075254.1, respectively), or a mutant polypeptide with one or more (preferably one to ten, and particularly preferably one to five) amino acids being substituted, deleted, or inserted in the wild-type polypeptide. The mutant polypeptides also include polypeptides having 70% or greater homology, preferably polypeptides having 80% or greater homology, more preferably polypeptides having 90% or greater homology, and even more preferably polypeptides having 95% or greater homology to the amino acid sequence of the wild-type polypeptide.
[0035] Amino acid sequence (or nucleotide sequence) identity can be determined using the BLAST algorithm by Karlin and Altschul (Proc. Natl. Acad. Sci. USA (1993) 90, 5873-7). Programs such as BLASTN and BLASTX were developed based on this algorithm (Altschul et al., J. Mol. Biol. (1990) 215, 403-10). To analyze nucleotide sequences according to BLASTN based on BLAST, the parameters are set to, for example, score=100 and wordlength=12. On the other hand, parameters used for the analysis of amino acid sequences by BLASTX based on BLAST include, for example, score=50 and wordlength=3. Default parameters for each program are used when using the BLAST and Gapped BLAST programs. Specific techniques for such analyses are known in the art (one can refer to the information on the website of the National Center for Biotechnology Information (NCBI), Basic Local Alignment Search Tool (BLAST)).
[0036] In the present invention, "mutant polypeptide" refers to an FGFR mutant polypeptide containing a substitution of valine to phenylalanine at the 7.sup.th amino acid from the N terminus and/or a substitution of valine to leucine at the 5.sup.th amino acid from the N terminus in the partial amino acid sequence described in SEQ ID NO: 53 or 54 in the FGFR polypeptide, and it may be also called as a polypeptide containing a mutation of the present invention.
[0037] The mutant polypeptide of the present invention is not limited to a FGFR mutant polypeptide consisting of an amino acid sequence in which an above-mentioned mutations are introduced into the amino acid sequence of the wild-type FGFR polypeptide consisting of the above-mentioned full-length amino acid sequence, as long as it is an FGFR mutant polypeptide carrying at least one of the two mutations described above. In addition, the mutant polypeptide includes peptide fragments thereof that contain the mutations, and fused polypeptides formed by fusing such FGFR mutant polypeptides or peptide fragments with other peptides, and the mutant polypeptide may also have one or more (preferably one to ten, and particularly preferably one to five) amino acid substitutions, deletions, additions, or insertions at positions other than the positions of the above-mentioned mutations.
[0038] "Other peptide" which constitute the fusion polypeptides with the FGFR mutant polypeptides or peptide fragments thereof include the TEL (also called ETV6; see Cancer Research, 2001, 61: 8371-8374 and Blood, 2005, 105(5): 2115-2123) polypeptide (a wild-type polypeptide consisting of the amino acid sequence of SEQ ID NO: 33 or mutant polypeptides with one or more amino acids being substituted, deleted, added, or inserted in the wild-type polypeptide, or peptide fragments thereof), the BAIA2P2L1 polypeptide (a wild-type polypeptide consisting of the amino acid sequence of SEQ ID NO: 31 or mutant polypeptides with one or more amino acids being substituted, deleted, added, or inserted in the wild-type polypeptide, or peptide fragments thereof), and the TACC3 polypeptide (a wild-type polypeptide consisting of the amino acid sequence of SEQ ID NO: 32 or mutant polypeptides with one or more amino acids being substituted, deleted, added, or inserted in the wild-type polypeptide, or peptide fragments thereof). A number of other FGFR fusion polypeptides are also known (see, Cancer Discovery 2013; 3: 636-647), and FGFR fusion polypeptides produced by introducing the mutations of the present invention to these fusion polypeptides are also included in the mutant polypeptides of the present invention.
[0039] Preferably, mutant polypeptides of the present invention refers to the FGFR mutant polypeptides selected from (1) to (20) shown below, peptide fragments of (1) to (20) containing those mutations, or fusion polypeptides formed by fusing the FGFR mutant polypeptides of (1) to (20) or peptide fragments thereof with other peptides:
(1) an FGFR2 mutant polypeptide containing at least the V564F and/or V562L mutations in the amino acid sequence of the above-mentioned wild-type FGFR2 polypeptide (SEQ ID NO: 1); (2) an FGFR2 mutant polypeptide containing at least the V565F and/or V563L mutations in the amino acid sequence of the above-mentioned wild-type FGFR2 polypeptide (SEQ ID NO: 2); (3) an FGFR2 mutant polypeptide containing at least the V565F and/or V563L mutations in the amino acid sequence of the above-mentioned wild-type FGFR2 polypeptide (SEQ ID NO: 37); (4) an FGFR2 mutant polypeptide containing at least the V452F and/or V450L mutations in the amino acid sequence of the above-mentioned wild-type FGFR2 polypeptide (SEQ ID NO: 38); (5) an FGFR2 mutant polypeptide containing at least the V475F and/or V473L mutations in the amino acid sequence of the above-mentioned wild-type FGFR2 polypeptide (SEQ ID NO: 39); (6) an FGFR2 mutant polypeptide containing at least the V449F and/or V447L mutations in the amino acid sequence of the above-mentioned wild-type FGFR2 polypeptide (SEQ ID NO: 40); (7) an FGFR2 mutant polypeptide containing at least the V448F and/or V446L mutations in the amino acid sequence of the above-mentioned wild-type FGFR2 polypeptide (SEQ ID NO: 41); (8) an FGFR2 mutant polypeptide containing at least the V447F and/or V445L mutations in the amino acid sequence of the above-mentioned wild-type FGFR2 polypeptide (SEQ ID NO: 42); (9) an FGFR2 mutant polypeptide containing at least the V476F and/or V474L mutations in the amino acid sequence of the above-mentioned wild-type FGFR2 polypeptide (SEQ ID NO: 43); (10) an FGFR2 mutant polypeptide containing at least the V475F and/or V473L mutations in the amino acid sequence of the above-mentioned wild-type FGFR2 polypeptide (SEQ ID NO: 44); (11) an FGFR1 mutant polypeptide containing at least the V559F and/or V557L mutations in the amino acid sequence of the above-mentioned wild-type FGFR1 polypeptide (SEQ ID NO: 21); (12) an FGFR1 mutant polypeptide containing at least the V559F and/or V557L mutations in the amino acid sequence of the above-mentioned wild-type FGFR1 polypeptide (SEQ ID NO: 45); (13) an FGFR1 mutant polypeptide containing at least the V551F and/or V549L mutations in the amino acid sequence of the above-mentioned wild-type FGFR1 polypeptide (SEQ ID NO: 46); (14) an FGFR1 mutant polypeptide containing at least the V559F and/or V557L mutations in the amino acid sequence of the above-mentioned wild-type FGFR1 polypeptide (SEQ ID NO: 47); (15) an FGFR1 mutant polypeptide containing at least the V472F and/or V470L mutations in the amino acid sequence of the above-mentioned wild-type FGFR1 polypeptide (SEQ ID NO: 48); (16) an FGFR1 mutant polypeptide containing at least the V470F and/or V468L mutations in the amino acid sequence of the above-mentioned wild-type FGFR1 polypeptide (SEQ ID NO: 49); (17) an FGFR1 mutant polypeptide containing at least the V561F and/or V559L mutations in the amino acid sequence of the above-mentioned wild-type FGFR1 polypeptide (SEQ ID NO: 50); (18) an FGFR3 mutant polypeptide containing at least the V555F and/or V553L mutations in the amino acid sequence of the above-mentioned wild-type FGFR3 polypeptide (SEQ ID NO: 22); (19) an FGFR3 mutant polypeptide containing at least the V557F and/or V555L mutations in the amino acid sequence of the above-mentioned wild-type FGFR3 polypeptide (SEQ ID NO: 51); or (20) an FGFR3 mutant polypeptide containing at least the V443F and/or V441L mutations in the amino acid sequence of the above-mentioned wild-type FGFR3 polypeptide (SEQ ID NO: 52).
[0040] Particularly preferably, the FGFR mutant polypeptides of the present invention are, for example, an FGFR2 mutant polypeptide comprising the amino acid sequence of SEQ ID NO: 9, 10, 29, or 30; an FGFR1 mutant polypeptide comprising the amino acid sequence of SEQ ID NO: 25 or 26; and an FGFR3 mutant polypeptide comprising the amino acid sequence of SEQ ID NO: 27 or 28; as well as a TEL-fused FGFR2 mutant polypeptide comprising the amino acid sequence of SEQ ID NO: 35 or 36.
[0041] Preferably, the FGFR mutant polypeptides of the present invention retain biological activities (for example, tyrosine phosphorylation activity on the intracellular domain of FGFR, cell proliferation activity, angiogenic activity, cell migration activity, cell infiltration activity, and cell transfer activity, preferably cell proliferation activity) that are the same in degree or stronger than those of the wild-type FGFR polypeptide. Whether the FGFR mutant polypeptide of the present invention has such biological activities can be determined by assay methods known to those skilled in the art (for example, by methods described in the following Examples).
[0042] Polynucleotides of the present invention include polynucleotides encoding an FGFR mutant polypeptide of the present invention described above, which include any polynucleotide that can encode an FGFR mutant polypeptide of the present invention. The polynucleotides include genomic DNAs and cDNAs. Genomic DNAs include exons and introns. Furthermore, the cDNAs may include nucleic acid sequences derived from a portion of an intron sequence that encodes amino acid sequence.
[0043] The polynucleotides also include degenerate polynucleotides constituted with any codon as long as the codon encodes the same amino acids.
[0044] The polynucleotides of the present invention also include polynucleotides encoding mutant polypeptides derived from mammals. In a preferred embodiment, the polynucleotides of the present invention include polynucleotides encoding mutant polypeptides derived from humans.
[0045] The polynucleotides of the present invention may be obtained by any methods. The polynucleotides of the present invention include, for example, all complementary DNAs (cDNAs) prepared from mRNAs, DNAs prepared from genomic DNA, DNAs obtained by chemical synthesis, DNAs obtained by PCR amplification using RNA or DNA as template, and DNAs constructed by appropriately combining these methods.
[0046] Polynucleotides encoding mutant polypeptides of the present invention can be obtained using routine methods by cloning cDNA from mRNA encoding a mutant polypeptide of the present invention or isolating genomic DNA and subjecting it to splicing treatment, or by chemical synthesis.
[0047] For example, in a method that clones cDNA from mRNA encoding a mutant polypeptide of the present invention, first, mRNA encoding a mutant polypeptide of the present invention is prepared from arbitrary tissues or cells expressing and producing the mutant polypeptide of the present invention according to routine methods. This may be achieved, for example, by preparing total RNA using a method such as the guanidine-thiocyanate method, hot phenol method, or AGPC method, and treating the total RNA with affinity chromatography using oligo(dT) cellulose, poly U-Sepharose, or the like.
[0048] Then, cDNA strand synthesis is carried out using the prepared mRNA as template by a known method that uses, for example, reverse transcriptase (Mol. Cell. Biol., Vol. 2, p. 161, 1982; Mol. Cell. Biol., Vol. 3, p. 280, 1983; Gene, Vol. 25, p. 263, 1983). The cDNA is converted to double-stranded cDNA, and inserted into a plasmid vector, phage vector, cosmid vector, or such. To prepare a cDNA library, the resulting vector is transformed into E. coli, or transfected into E. coli after in vitro packaging.
[0049] The present invention also relates to vectors (recombinant vectors) carrying the above-described polynucleotide encoding a mutant polypeptide of the present invention.
[0050] The vectors of the present invention are not particularly limited as long as they can replicate and maintain or self-propagate in various prokaryotic and/or eukaryotic cells as a host. The vectors of the present invention include plasmid vectors and phage vectors.
[0051] Cloning vectors include, for example, pUC19, .lamda.gt10, and .lamda.gt11. When isolating host cells capable of expressing a mutant polypeptide of the present invention, preferably the vector is one that has a promoter which enables expression of the polynucleotide of the present invention.
[0052] Recombinant vectors of the present invention can be prepared using routine methods simply by ligating a polynucleotide encoding a mutant polypeptide of the present invention to a recombinant vector available in the art (plasmid DNA and bacteriophage DNA).
[0053] Recombinant vectors for use in the present invention include, for example, E. coli-derived plasmids (pBR322, pBR325, pUC12, pUC13, pUC19, etc.), yeast-derived plasmids (pSH19, pSH15, etc.), and Bacillus subtilis-derived plasmids (pUB110, pTPS, pC194, etc.).
[0054] Examples of phages are bacteriophages such as .lamda. phage, and animal or insect viruses (pVL1393, Invitrogen) such as retrovirus, vaccinia virus, nuclear polyhedrosis virus, and lentivirus.
[0055] Expression vectors are useful for the purpose of producing a mutant polypeptide of the present invention by expressing a polynucleotide encoding the mutant polypeptide of the present invention. Expression vectors are not particular limited as long as they have the function of producing mutant polypeptides of the present invention by expressing polynucleotides encoding the polypeptides in various prokaryotic and/or eukaryotic cells as a host.
[0056] Such expression vectors include, for example, pMAL C2, pEF-BOS (Nucleic Acid Research, Vol. 18, 1990, p. 5322) and pME18S (Jikken Igaku Bessatsu (Experimental Medicine: SUPPLEMENT), "Idenshi Kougaku Handbook (Handbook of Genetic Engineering)" (1992)).
[0057] Alternatively, mutant polypeptides of the present invention may be produced as fusion proteins with other proteins. For example, when preparing as a fusion protein with glutathione S-transferase (GST), cDNA encoding a mutant polypeptide of the present invention can be subcloned into, for example, plasmid pGEX4T1 (Pharmacia). E. coli DH5.alpha. is transformed with the resulting plasmid, and the transformants are cultured to prepare the fusion protein.
[0058] Alternatively, fusion polypeptides of the present invention may be produced as fusions with influenza hemagglutinin (HA), immunoglobulin constant region, .beta.-galactosidase, maltose-binding protein (MBP), or such. Furthermore, fusion polypeptides of the present invention may be produced as fusions with known peptides, for example, FLAG (Hopp, T. P. et al., BioTechnology (1988) 6, 1204-1210), 6.times.His consisting of 6 histidine (His) residues, 10.times.His, influenza hemagglutinin (HA), fragments of human c-myc, fragments of VSV-GP, fragments of p18HIV, T7-tag, HSV-tag, E-tag, fragments of SV4OT antigen, lck tag, fragments of a-tubulin, B-tag, fragments of Protein C, Stag, StrepTag, and HaloTag.
[0059] When using bacteria, in particular E coli., as a host cell, vectors of the present invention preferably contain at least a promoter-operator region, a start codon, a polynucleotide encoding a mutant polypeptide of the present invention, a stop codon, a terminator region, and a replicon.
[0060] When yeast, animal cells, or insect cells are used as a host, expression vectors preferably contain a promoter, a start codon, a polynucleotide encoding a mutant polypeptide of the present invention, and a stop codon.
[0061] The vectors may also contain DNA encoding a signal peptide, an enhancer sequence, 5' and 3' untranslated regions of the gene encoding a protein of the present invention, splice junctions, polyadenylation sites, a selection marker region, a replicon, and such.
[0062] Furthermore, if necessary, the vectors may contain marker genes (genes for gene amplification, drug resistance genes, etc.) that enable selection of transformed hosts or hosts with gene amplification.
[0063] Marker genes include, for example, the dihydrofolate reductase (DHFR) gene, thymidine kinase gene, neomycin resistance gene, glutamate synthase gene, adenosine deaminase gene, ornithine decarboxylase gene, hygromycin-B-phosphotransferase gene, and aspartate transcarbamylase gene.
[0064] A promoter-operator region for expressing the mutant polypeptide of the present invention in bacteria comprises a promoter, an operator, and a Shine-Dalgarno (SD) sequence (for example, AAGG).
[0065] For example, when the host is the genus Escherichia, it comprises, for example, the Trp promoter, lac promoter, recA promoter, .lamda.PL promoter, lpp promoter, tac promoter, or such.
[0066] Examples of a promoter for expressing the mutant polypeptide of the present invention in yeast are the PH05 promoter, PGK promoter, GAP promoter, ADH promoter, and such.
[0067] When the host is Bacillus, examples are the SL01 promoter, SP02 promoter, penP promoter, and such.
[0068] When the host is a eukaryotic cell such as a mammalian cell, examples are an SV40-derived promoter, retrovirus promoter, heat shock promoter, and such; and SV40 and retrovirus are preferred. Nevertheless, the promoter is not limited to the above examples. In addition, use of an enhancer is effective for expression.
[0069] A preferable initiation codon is, for example, a methionine codon (ATG). A commonly used termination codon (for example, TAG, TAA, TGA) is exemplified as a termination codon. Commonly used natural or synthetic terminators are used as a terminator region.
[0070] A replicon refers to a DNA capable of replicating the whole DNA sequence in host cells, and includes a natural plasmid, an artificially modified plasmid (DNA fragment prepared from a natural plasmid), a synthetic plasmid, and such. Examples of preferable plasmids for E. coli are pBR322 or its artificial derivatives (DNA fragment obtained by treating pBR322 with appropriate restriction enzymes), for yeast are yeast 2.mu. plasmid or yeast chromosomal DNA, and pRSVneo ATCC 37198, and for mammalian cells are plasmid pSV2dhfr ATCC 37145, plasmid pdBPV-MMTneo ATCC 37224, plasmid pSV2neo ATCC 37149, and such.
[0071] An enhancer sequence, polyadenylation site, and splicing junction that are usually used in the art, such as those derived from SV40 can also be used.
[0072] The expression vector of the present invention can be prepared by continuously and circularly linking at least the above-mentioned promoter, initiation codon, polynucleotide encoding the mutant polypeptide of the present invention, termination codon, and terminator region, to an appropriate replicon. If desired, appropriate DNA fragments (for example, linkers, restriction sites, and such), can be used by a common method such as restriction enzyme digestion or ligation using T4 DNA ligase.
[0073] The present invention also relates to recombinant cells transformed with the above-mentioned vectors of the present invention, and recombinant cells of the present invention can be prepared by introducing the expression vector mentioned above into host cells.
[0074] Host cells used in the present invention are not particularly limited as long as they are compatible with an expression vector mentioned above and can be transformed. Examples thereof include various cells such as wild-type cells or artificially established recombinant cells commonly used in the technical field of the present invention (for example, bacteria (the genera Escherichia and Bacillus), yeast (the genus Saccharomyces, the genus Pichia, and such), animal cells, or insect cells).
[0075] E. coli or animal cells are preferred. Specific examples are E. coli (DH5.alpha., TB1, HB101, and such), mouse-derived cells (COP, L, C127, Sp2/0, NS-1, NIH3T3, and such), rat-derived cells (PC12, PC12h), hamster-derived cells (BHK, CHO, and such), monkey-derived cells (COS1, COS3, COS7, CV1, Velo, and such), and human-derived cells (Hela, diploid fibroblast-derived cells, myeloma cells, and HepG2, and such).
[0076] An expression vector can be introduced (transformed (transfected)) into host cells according to routine methods.
[when the host is E. coli, Bacillus subtilis, or such]: Proc. Natl. Acad. Sci. USA, Vol. 69, p. 2110 (1972); Mol. Gen. Genet., Vol. 168, p. 111 (1979); J. Mol. Biol., Vol. 56, p. 209 (1971); [when the host is Saccharomyces cerevisiae]: Proc. Natl. Acad. Sci. USA, Vol. 75, p. 1927 (1978); J. Bacteriol., Vol. 153, p. 163 (1983); [when the host is an animal cell]: Virology, Vol. 52, p. 456 (1973); [when the host is an insect cell]: Mol. Cell. Biol., Vol. 3, pp. 2156-2165 (1983).
[0077] Mutant polypeptides of the present invention can be produced by culturing transformed recombinant cells (hereinafter, the term also refers to inclusion bodies) comprising an expression vector prepared as described above in nutritive media according to routine methods.
[0078] Mutant polypeptides of the present invention can be produced by culturing the above-described recombinant cells, in particular animal cells, and allowing them to secrete into culture supernatants.
[0079] The resulting culture is filtered or centrifuged to obtain a culture filtrate (supernatant). Mutant polypeptides of the present invention are purified and isolated from the culture filtrate by routine methods commonly used to purify and isolate natural or synthetic proteins. Examples of an isolation and purification method are methods that utilize solubility such as the salting out and solvent precipitation methods; methods that utilize difference in molecular weight such as dialysis, ultrafiltration, gel filtration, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis; methods that utilize charge such as ion exchange chromatography and hydroxylapatite chromatography; method that utilize specific affinity such as affinity column chromatography; methods that utilize difference in hydrophobicity such as reverse phase high performance liquid chromatography; and methods that utilize difference in the isoelectric point such as isoelectric focusing.
[0080] Meanwhile, when a mutant polypeptide of the present invention is in the periplasm or cytoplasm of cultured recombinant cells (such as E. coli), the cells are collected by routine methods such as filtration and centrifugation of the culture, and then suspended in an appropriate buffer. After the cell wall and/or cell membrane of the cells are disrupted using methods such as sonication, lysozyme, and cryolysis, a membrane fraction containing the protein of the present invention is obtained using methods such as centrifugation and filtration. The membrane fraction is solubilized with a detergent such as Triton-X100 to obtain the crude solution. Then, the protein of the present invention can be isolated and purified from the crude solution using routine methods such as those exemplified above.
[0081] The present invention also relates to arbitrary oligonucleotides that hybridize to polynucleotides (cDNAs and genomic DNAs) encoding the above-described mutant polypeptides of the present invention.
[0082] Oligonucleotides of the present invention have nucleotide sequences that are complementary to arbitrary partial nucleotide sequences of the cDNAs and genomic DNAs, and which are useful as a pair of oligonucleotide primers consisting of sense and antisense primers in polymerase chain reaction (PCR). The whole nucleotide sequence of a polynucleotide encoding a mutant polypeptide of the present invention or an arbitrary portion of the nucleotide sequence can be amplified by PCR using the pair of oligonucleotide primers.
[0083] Oligonucleotide primers of the present invention include oligonucleotides of any length that are complementary to the nucleotide sequence of a polynucleotide of the present invention. The oligonucleotide primers of the present invention preferably include those having a sequence of at least 12 consecutive nucleotides, more preferably 12 to 50 nucleotides, and still more preferably 12 to 20 nucleotides.
[0084] Oligonucleotides of the present invention are also useful as a probe when handling DNA or RNA hybridization. When used as a probe, the DNAs include a partial nucleotide sequence of 15 or more consecutive nucleotides, preferably a partial nucleotide sequence of 50 or more consecutive nucleotides, more preferably a partial nucleotide sequence of 100 or more consecutive nucleotides, even more preferably a partial nucleotide sequence of 200 or more consecutive nucleotides, and still more preferably a partial nucleotide sequence of 300 or more consecutive nucleotides, which hybridize to a polynucleotide of the present invention.
[0085] The present invention also relates to oligonucleotides that bind to mRNA polynucleotides encoding mutant polypeptides of the present invention and have an activity of inhibiting translation of the mRNAs into proteins. It is particularly preferable that the oligonucleotides include siRNAs that cleave the mRNAs by binding to the mRNA polynucleotides encoding mutant polypeptides of the present invention.
[0086] The oligonucleotides refer to those which bind to mRNAs encoding mutant polypeptides of the present invention and thereby inhibit their expression and include, for example, antisense oligonucleotides, ribozymes, and short interfering RNAs (siRNA). They bind to the mRNAs and then inhibit their translation into proteins.
[0087] An antisense oligonucleotide refers to an oligonucleotide that specifically hybridizes to genomic DNA and/or mRNA, and inhibits their protein expression by inhibiting the transcription and/or translation.
[0088] The binding to a target polynucleotide (mRNA, etc.) may be a result of common base pair complementarity. Alternatively, when an antisense oligonucleotide binds to, for example, a DNA duplex, the binding may be a result of specific interaction at the major grooves in double helix. Target sites for an antisense oligonucleotide include the 5' end of an mRNA, for example, 5' untranslated sequences up to or including the AUG start codon, and 3' untranslated sequences of an mRNA, as well as coding region sequences.
[0089] When using as an antisense oligonucleotide of the present invention, antisense oligonucleotides include partial nucleotide sequences of 5 to 100 consecutive nucleotides, preferably partial nucleotide sequences of 5 to 70 consecutive nucleotides, more preferably partial nucleotide sequences of 5 to 50 consecutive nucleotides, and still more preferably partial nucleotide sequences of 5 to 30 consecutive nucleotides.
[0090] Furthermore, antisense oligonucleotides of the present invention can be partially modified by chemical modification to prolong their half-life in blood (to stabilize them) or increase their intracellular membrane permeability when administered to patients, or to enhance their resistance to degradation or absorption in the digestive organs in oral administration. Such chemical modification includes, for example, chemical modification of a phosphate bond, ribose, nucleobase, sugar moiety in oligonucleotides, and 3' and/or 5' ends of oligonucleotides.
[0091] The modification of phosphate bonds includes, for example, conversion of one or more of the bonds to phosphodiester bonds (D-oligo), phosphorothioate bonds, phosphorodithioate bonds (S-oligo), methyl phosphonate (MP-oligo), phosphoroamidate bonds, non-phosphate bonds and methyl phosphonothioate bonds, and combinations thereof. The modification of ribose includes, for example, conversion to 2'-fluororibose or 2'-O-methylribose. The modification of nucleotide base includes, for example, conversion to 5-propynyluracil or 2-aminoadenine.
[0092] Ribozyme refers to oligonucleotides having a catalytic activity of cleaving mRNA. In general, ribozymes have endonuclease, ligase, or polymerase activity. Ribozymes include various types of trans-acting ribozymes, for example, hammerhead ribozymes and hairpin ribozymes.
[0093] siRNA refers to double-stranded oligonucleotides capable of carrying out RNA interference (for example, Bass, 2001, Nature, 411, 428-429; Elbashir et al., 2001, Nature, 411, 494-498).
[0094] siRNA cleaves mRNA in a sequence-specific manner, and as a result inhibits translation of the mRNA into protein. siRNA includes double-stranded RNAs that are 20 to 25 base pairs long and comprise a sequence complementary to the target polynucleotide sequence. siRNAs of the present invention also include oligonucleotides comprising chemically modified nucleotides and non-nucleotides.
[0095] The present invention also relates to antibodies which bind to the above-described mutant polypeptide of the present invention, and antigen-binding fragments thereof
[0096] Antibodies of the present invention are not limited by their origin, form, function, etc. Antibodies of the present invention may be any antibodies, monoclonal or polyclonal antibodies. However, preferred antibodies of the present invention are monoclonal antibodies. Antibodies of the present invention may be those derived from any animal, such as human antibodies, mouse antibodies, and rat antibodies. Antibodies of the present invention may also be recombinant antibodies such as chimeric antibodies and humanized antibodies. Preferred antibodies of the present invention include chimeric antibodies, human antibodies, and humanized antibodies.
[0097] The humanized antibodies of the present invention can be prepared by methods known to those skilled in the art. The variable region of an antibody is typically composed of three complementarity-determining regions (CDRs) sandwiched by four frames (FRs). The CDRs practically determine the binding specificity of an antibody. The amino acid sequences of CDRs are highly diverse. On the other hand, amino acid sequences that constitute FRs often exhibit high homology among antibodies having different binding specificities. Therefore, it is said that in general the binding specificity of an antibody can be transplanted to a different antibody by grafting the CDRs.
[0098] Humanized antibodies are also referred to as reshaped human antibodies, and they are prepared by transferring the CDRs of an antibody derived from a non-human mammal such as a mouse, to the complementarity determining regions of a human antibody. General genetic recombination techniques for their preparation are also known (see European Patent Application Publication No. 125023 and WO 96/02576).
[0099] Specifically, for example, when the CDRs are derived from a mouse antibody, a DNA sequence is designed such that the CDRs of the mouse antibody are linked with the framework regions (FRs) of a human antibody, and it is synthesized by PCR using, as primers, several oligonucleotides that have portions overlapping the ends of both CDRs and FRs (see the method described in WO 98/13388). The resulting DNA is then ligated to a DNA encoding a human antibody constant region, inserted into an expression vector, and introduced into a host to produce the antibody (see European Patent Application Publication No. EP 239400 and International Patent Application Publication No. WO 96/02576).
[0100] Human antibody framework regions to be linked with CDRs are selected so that the complementarity determining regions form a favorable antigen-binding site. If needed, amino acids of the framework region in an antibody variable region may be substituted, deleted, added, and/or inserted so that the complementarity determining regions of the reshaped human antibody form a proper antigen-binding site. For example, mutations can be introduced into the amino acid sequence of the FR by applying the PCR method used to graft mouse CDRs to human FRs. Specifically, mutations can be introduced into a portion of the nucleotide sequences of primers that anneal to the FRs. The mutations are introduced into FRs synthesized using such primers. Mutant FR sequences having desired properties can be selected by assessing and determining the antigen-binding activity of amino acid-substituted mutant antibodies by the method described above and (Sato, K. et al., Cancer Res. (1993) 53, 851-856).
[0101] In general, constant regions from human antibodies are used for those of humanized antibodies.
[0102] There are no particular limitations to the human antibody constant regions to be used in the present invention; and for example, when using a heavy-chain constant region, it may be a human IgG1 constant region, human IgG2 constant region, human IgG3 constant region, human IgG4 constant region, or human IgM, IgA, IgE, or IgD constant region. Alternatively, when using a light-chain constant region, it may be a human lc chain constant region or human .lamda. chain constant region. Furthermore, constant regions derived from a human antibody may have a naturally-occurring sequence or may be a constant region having a sequence with modification (substitution, deletion, addition, and/or insertion) of one or more amino acids in the naturally-occurring sequence.
[0103] Moreover, after a humanized antibody is prepared, amino acids in the variable region (for example, CDR and FR) and constant region of the humanized antibody may be deleted, added, inserted, and/or substituted with other amino acids. The humanized antibodies of the present invention also include such humanized antibodies with amino acid substitutions and such.
[0104] The origin of the CDRs of a humanized antibody is not particularly limited, and may be any animal. For example, it is possible to use sequences of mouse antibodies, rat antibodies, rabbit antibodies, camel antibodies, and such. CDR sequences of mouse antibodies are preferred.
[0105] When administered to humans for therapeutic purposes, humanized antibodies are useful because their immunogenicity in the human body is reduced. Chimeric antibodies comprise, for example, heavy and light chain constant regions of a human antibody, and heavy and light chain variable regions of an antibody of a non-human mammal, such as mouse. Chimeric antibodies can be prepared using known methods. For example, antibodies can be produced by cloning an antibody gene from hybridomas, inserting it into an appropriate vector, and introducing the construct into hosts (see, for example, Carl, A. K. Borrebaeck, James, W. Larrick, THERAPEUTIC MONOCLONAL ANTIBODIES, Published in the United Kingdom by MACMILLAN PUBLISHERS LTD, 1990). Specifically, cDNAs of the antibody variable regions (V regions) are synthesized from the hybridoma mRNAs using reverse transcriptase. Once DNAs encoding the V regions of an antibody of interest are obtained, they are linked with DNAs encoding the constant regions (C regions) of a desired human antibody. The resulting constructs are inserted into expression vectors. Alternatively, DNAs encoding the antibody V regions may be inserted into an expression vector comprising DNAs encoding the C regions of a human antibody. The DNAs are inserted into an expression vector so that they are expressed under the regulation of expression regulatory regions, for example, enhancers and promoters. In the next step, host cells can be transformed with the expression vector to allow expression of chimeric antibodies.
[0106] Human antibodies can be obtained using methods known to those skilled in the art. For example, desired human antibodies with antigen-binding activity can be obtained by sensitizing human lymphocytes with an antigen of interest or cells expressing an antigen of interest in vitro; and fusing the sensitized lymphocytes with human myeloma cells such as U266 (see Japanese Patent Application Kokoku Publication No. (JP-B) H01-59878 (examined, approved Japanese patent application published for opposition)). Alternatively, the desired human antibody can also be obtained by immunizing a transgenic animal having an entire repertoire of human antibody genes with a desired antigen (see International Patent Application Publication Nos. WO 93/12227, WO 92/03918, WO 94/02602, WO 94/25585, WO 96/34096, and WO 96/33735).
[0107] Alternatively, B cells expressing antibodies that have antigen-binding activity are isolated from a pool of human lymphocytes by flow cytometry, cell array, or such. The antibody genes from selected B cells can be analyzed, and DNA sequences of the human antibodies that bind to the antigen can be determined (Jin, A. et al., Nature Medicine (2009) 15, 1088-92; Scheid, J. F. et al., Nature (2009) 458, 636-640; Wrammert, J. et al., Nature (2008) 453, 667-672; Tiller, T. et al., Journal of Immunological Methods (2008) 329, 112-124). When DNA sequences of the antigen-binding antibodies are revealed, human antibodies can be prepared by constructing appropriate expression vectors carrying the sequences. Such methods are known, and WO 92/01047, WO 92/20791, WO 93/06213, WO 93/11236, WO 93/19172, WO 95/01438, and WO 95/15388 can be used as references.
[0108] Furthermore, techniques for obtaining human antibodies by panning with a human antibody phage library are known. For example, the variable region of a human antibody is expressed as a single chain antibody (scFv) on the phage surface using a phage display method, and phages that bind to the antigen can be selected. By analyzing the genes of selected phages, DNA sequences encoding the variable regions of human antibodies that bind to the antigen can be determined. If the DNA sequences of scFvs that bind to the antigen are identified, appropriate expression vectors comprising these sequences can be constructed to obtain human antibodies. Such methods are well known. Reference can be made to WO 92/01047, WO 92/20791, WO 93/06213, WO 93/11236, WO 93/19172, WO 95/01438, WO 95/15388, and such.
[0109] The antibodies of the present invention include not only divalent antibodies as represented by IgG, but also monovalent antibodies, multivalent antibodies as represented by IgM. In addition, the antibodies of the present invention also include bispecific antibodies capable of binding to different antigens.
[0110] Antibodies of the present invention include not only whole antibody molecules but also any antigen-binding fragments such as low-molecular-weight antibodies.
[0111] Antibodies of the present invention also include modified antibodies that are linked to cytotoxic substances. Antibodies of the present invention also include those with altered sugar chains.
[0112] Low-molecular-weight antibodies (minibodies) included in antigen-binding fragments of the present invention are antibodies comprising an antibody fragment that lacks part of a whole antibody (for example, whole IgG, etc.). The minibodies are not particularly limited, as long as they have the activity to bind to a mutant polypeptide of the present invention.
[0113] Minibodies of the present invention are not particularly limited, as long as they comprise a portion of a whole antibody. It is however preferable that the minibodies comprise an antigen-binding domain. In general, the antigen-binding domain is antibody CDR, and is preferably six CDRs of an antibody. Thus, the preferred antigen-binding domains include, for example, six CDRs of an antibody and antibody variable regions (heavy chain and/or light chain variable regions).
[0114] The minibodies of the present invention preferably have a smaller molecular weight than whole antibodies. However, the minibodies may form multimers, for example, dimers, trimers, or tetramers, and thus their molecular weights can be greater than those of whole antibodies.
[0115] Other specific examples of the antigen-binding molecule fragments include, for example, Fab, Fab', F(ab')2, and Fv. Meanwhile, specific examples of low-molecular-weight antibodies include, for example, Fab, Fab', F(ab')2, Fv, scFv (single chain Fv), diabodies, and sc(Fv)2 (single chain (Fv)2). Multimers (for example, dimers, trimers, tetramers, and polymers) of these antibodies are also included in the low-molecular-weight antibodies of the present invention.
[0116] Antigen-binding fragments can be obtained, for example, by treating antibodies with enzymes to produce antibody fragments. Enzymes known to generate antibody fragments include, for example, papain, pepsin, and plasmin. Alternatively, a gene encoding such an antibody fragment can be constructed, introduced into an expression vector, and expressed in appropriate host cells (see, for example, Co, M. S. et al., J. Immunol. (1994) 152, 2968-2976; Better, M. & Horwitz, A. H. Methods in Enzymology (1989) 178, 476-496; Plueckthun, A. & Skerra, A. Methods in Enzymology (1989) 178, 476-496; Lamoyi, E., Methods in Enzymology (1989) 121, 652-663; Rousseaux, J. et al., Methods in Enzymology (1989) 121, 663-669; Bird, R. E. et al., TIBTECH (1991) 9, 132-137).
[0117] Digestive enzymes cleave at a specific site in an antibody fragment, yielding antibody fragments of specific structures shown below. Genetic engineering techniques can be applied to such enzymatically-obtained antibody fragments to delete an arbitrary portion of the antibody.
[0118] Antibody fragments obtained by using the above-described digestive enzymes are as follows:
Papain digestion: F(ab)2 or Fab Pepsin digestion: F(ab')2 or Fab' Plasmin digestion: Facb
[0119] The minibodies of the present invention include antibody fragments lacking an arbitrary region, as long as they have the activity to bind to a mutant polypeptide of the present invention.
[0120] "Diabody" refers to a bivalent antibody fragment constructed by gene fusion (Holliger P et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993); EP 404,097; WO 93/11161, etc.). Diabodies are dimers composed of two polypeptide chains. In each of the polypeptide chains forming a dimer, a VL and a VH are usually linked by a linker in the same chain. In general, the linker in a diabody is short enough such that the VL and VH cannot bind to each other. Specifically, the number of amino acid residues constituting the linker is, for example, about five residues. Thus, the VL and VH encoded on the same polypeptide cannot form a single-chain variable region fragment, and will form a dimer with another single-chain variable region fragment. As a result, the diabody has two antigen binding sites.
[0121] scFv antibodies are single-chain polypeptides produced by linking a heavy chain variable region ([VH]) to a light chain variable region ([VL]) via a linker or such (Huston, J. S. et al., Proc. Natl. Acad. Sci. U.S.A. (1988) 85, 5879-5883; Plickthun "The Pharmacology of Monoclonal Antibodies" Vol. 113, eds., Resenburg and Moore, Springer Verlag, New York, pp. 269-315, (1994)). The H-chain V region and L-chain V region of scFv may be derived from any antibody described herein. The peptide linker for linking the V regions is not particularly limited. For example, an arbitrary single-chain peptide containing about three to 25 residues can be used as a linker. Specifically, it is possible to use the peptide linkers or such described below.
[0122] The V regions of both chains can be linked, for example, by PCR as described above. To link the V regions by PCR, first, a DNA from the DNAs below that encodes a complete or desired partial amino acid sequence is used as a template:
DNA sequence encoding an H chain or H-chain V region of an antibody, and DNA sequence encoding an L chain or L-chain V region of an antibody.
[0123] DNAs encoding the H-chain and L-chain V regions are amplified by PCR using a pair of primers having sequences corresponding to sequences at both ends of the DNA to be amplified. Then, a DNA encoding the peptide linker portion is prepared. The peptide linker-encoding DNA can also be synthesized by PCR. Here, nucleotide sequences that can be ligated to the amplification products of V regions synthesized separately are added to the 5' end of the primers to be used. Then, PCR is carried out using each DNA of the [H chain V region DNA]-[peptide linker DNA]-[L chain V region DNA], and assembly PCR primers.
[0124] The assembly PCR primers are composed of a combination of a primer that anneals to the 5' end of the [H chain V region DNA] and a primer that anneals to the 3' end of the [L chain V region DNA]. In other words, the assembly PCR primers are a set of primers that can be used to amplify DNA encoding the full-length sequence of an scFv to be synthesized. Meanwhile, nucleotide sequences that can be ligated to the V-region DNAs have been added to the [peptide linker DNA]. Thus, these DNAs are linked together, and then the whole scFv is ultimately generated as an amplification product by the assembly PCR primers. Once the scFv-encoding DNAs are generated, expression vectors carrying these DNAs and recombinant cells transformed with these expression vectors can be obtained by conventional methods. Furthermore, the scFv can be obtained by culturing the resulting recombinant cells to express the scFv-encoding DNAs.
[0125] The order of the heavy chain and light chain variable regions to be linked together is not particularly limited, and they may be arranged in any order. Examples of the arrangement are listed below.
[VH] linker [VL] [VL] linker [VH]
[0126] sc(Fv)2 is a single-chain low-molecular-weight antibody produced by linking two VHs and two VLs using linkers and such (Hudson et al., J Immunol. Methods 1999; 231: 177-189). For example, sc(Fv)2 can be produced by linking scFvs via a linker.
[0127] Antibodies in which two VHs and two VLs are arranged in the order of VH, VL, VH, and VL ([VH] linker [VL] linker [VH] linker [VL]) from the N terminus of the single-chain polypeptide are preferred. However, the order of the two VHs and two VLs is not limited to the above arrangement, and they may be arranged in any order. Examples of the arrangement are listed below:
[VL] linker [VH] linker [VH] linker [VL] [VH] linker [VL] linker [VL] linker [VH] [VH] linker [VH] linker [VL] linker [VL] [VL] linker [VL] linker [VH] linker [VH] [VL] linker [VH] linker [VL] linker [VH]
[0128] The amino acid sequence of the heavy chain variable region or light chain variable region in a low-molecular-weight antibody may contain a substitution, deletion, addition, and/or insertion. Furthermore, the heavy chain variable region and light chain variable region may also lack some portions or be added with other polypeptides, as long as they have antigen binding ability when linked together. Alternatively, the variable regions may be chimerized or humanized.
[0129] In the present invention, linkers which bind the variable regions of the antibody include arbitrary peptide linkers that can be introduced using genetic engineering, or synthetic linkers such as those disclosed in Protein Engineering, 9(3), 299-305, 1996.
[0130] The preferred linkers in the present invention are peptide linkers. The length of the peptide linkers is not particularly limited, and those skilled in the art can appropriately select the length depending on the purpose. A typical length is one to 100 amino acids, preferably 3 to 50 amino acids, more preferably 5 to 30 amino acids, and particularly preferably 12 to 18 amino acids (for example, 15 amino acids).
[0131] Amino acid sequences of such peptide linkers include, for example:
TABLE-US-00001 Ser; Gly.cndot.Ser; Gly.cndot.Gly.cndot.Ser; Ser.cndot.Gly.cndot.Gly; (SEQ ID NO: 13) Gly.cndot.Gly.cndot.Gly.cndot.Ser; (SEQ ID NO: 14) Ser.cndot.Gly.cndot.Gly.cndot.Gly; (SEQ ID NO: 15) Gly.cndot.Gly.cndot.Gly.cndot.Gly.cndot.Ser; (SEQ ID NO: 16) Ser.cndot.Gly.cndot.Gly.cndot.Gly.cndot.Gly; (SEQ ID NO: 17) Gly.cndot.Gly.cndot.Gly.cndot.Gly.cndot.Gly.cndot.Ser; (SEQ ID NO: 18) Ser.cndot.Gly.cndot.Gly.cndot.Gly.cndot.Gly.cndot.Gly; (SEQ ID NO: 19) Gly.cndot.Gly.cndot.Gly.cndot.Gly.cndot.Gly.cndot.Gly.cndot.Ser; (SEQ ID NO: 20) Ser.cndot.Gly.cndot.Gly.cndot.Gly.cndot.Gly.cndot.Gly.cndot.Gly; (Gly.cndot.Gly.cndot.Gly.cndot.Gly.cndot.Ser (SEQ ID NO: 15))n; and (Ser.cndot.Gly.cndot.Gly.cndot.Gly.cndot.Gly (SEQ ID NO: 16))n,
where n is an integer of 1 or larger.
[0132] The amino acid sequence of a peptide linker can be appropriately selected by those skilled in the art according to the purpose. For example, the above-mentioned "n", which determines the length of the peptide linker, is usually 1 to 5, preferably 1 to 3, and more preferably 1 or 2.
[0133] Synthetic linkers (chemical crosslinking agents) include crosslinking agents that are routinely used to crosslink peptides, for example, N-hydroxy succinimide (NHS), disuccinimidyl suberate (DSS), bis(sulfosuccinimidyl) suberate (BS3), dithiobis(succinimidyl propionate) (DSP), dithiobis(sulfosuccinimidyl propionate) (DTSSP), ethylene glycol bis(succinimidyl succinate) (EGS), ethylene glycol bis(sulfosuccinimidyl succinate) (sulfo-EGS), disuccinimidyl tartrate (DST), disulfosuccinimidyl tartrate (sulfo-DST), bis[2-(succinimidoxycarbonyloxy)ethyl] sulfone (BSOCOES), and bis[2-(sulfosuccinimidoxycarbonyloxy)ethyl] sulfone (sulfo-BSOCOES). These crosslinking agents are commercially available.
[0134] When four antibody variable regions are linked, three linkers are usually required. Such multiple linkers may be the same or different.
[0135] The antibodies of the present invention include antibodies in which one or more amino acid residues have been added to the amino acid sequence of an antibody of the present invention. Further, fusion proteins which result from a fusion between one of the above antibodies and a second peptide or protein is included in the present invention. The fusion proteins can be prepared by ligating a polynucleotide encoding an antibody of the present invention with a polynucleotide encoding a second peptide or polypeptide in frame, inserting this into an expression vector, and expressing the fusion construct in a host. Some techniques known to those skilled in the art are available for this purpose. The partner peptide or polypeptide to be fused with an antibody of the present invention may be a known peptide, for example, FLAG (Hopp, T. P. et al., BioTechnology 6, 1204-1210 (1988)), 6.times.His consisting of six His (histidine) residues, 10.times.His, influenza hemagglutinin (HA), human c-myc fragment, VSV-GP fragment, p18HIV fragment, T7-tag, HSV-tag, E-tag, SV40 T antigen fragment, lck tag, .alpha.-tubulin fragment, B-tag, Protein C fragment, Stag, StrepTag, HaloTag. Other partner polypeptides to be fused with the antibodies of the present invention include, for example, GST (glutathione-S-transferase), HA (influenza hemagglutinin), immunoglobulin constant region, .beta.-galactosidase, and MBP (maltose-binding protein). A polynucleotide encoding one of these commercially available peptides or polypeptides can be fused with a polynucleotide encoding an antibody of the present invention. The fusion polypeptide can be prepared by expressing the fusion construct.
[0136] Furthermore, the antibodies of the present invention may be conjugated antibodies which are linked to any of various molecules including polymeric substances such as polyethylene glycol (PEG) and hyaluronic acid, radioactive substances, fluorescent substances, luminescent substances, enzymes, and toxins. Such conjugated antibodies can be obtained by chemically modifying the obtained antibodies. Methods for modifying antibodies have been established in this field (for example, U.S. Pat. Nos. 5,057,313 and 5,156,840). The "antibodies" of the present invention also include such conjugated antibodies.
[0137] Furthermore, the antibodies used in the present invention may be bispecific antibodies. The bispecific antibody refers to an antibody that has variable regions recognizing different epitopes in the same antibody molecule. In the present invention, the bispecific antibodies may recognize different epitopes on the mutant polypeptide molecule of the present invention, or recognize the mutant polypeptide of the present invention with one antigen-binding site and a different substance with the other antigen-binding site.
[0138] Methods for producing bispecific antibodies are known. Bispecific antibodies can be prepared, for example, by linking two antibodies that recognize different antigens. Antibodies to be linked together may be half molecules each of which contains an H chain and an L chain, or quarter molecules that consist of only one H chain. Alternatively, hybridomas producing different monoclonal antibodies can be fused to produce a bispecific antibody-producing fused cell. Furthermore, bispecific antibodies can be produced by genetic engineering techniques.
[0139] The antibodies of the present invention may differ in amino acid sequence, molecular weight, isoelectric point, presence/absence of sugar chains, and conformation depending on the cell or host producing the antibody or the purification method as described below. However, a resulting antibody is included in the present invention, as long as it is functionally equivalent to an antibody of the present invention. For example, when an antibody of the present invention is expressed in prokaryotic cells, for example E. coli, a methionine residue is added to the N terminus of the original antibody amino acid sequence. Such antibodies are included in the present invention.
[0140] Antibodies of the present invention may be antibodies with altered sugar chains. Methods for modifying antibody sugar chains are known to those skilled in the art, and include, for example, methods for improving ADCC by modifying antibody glycosylation, methods for adjusting ADCC by the presence or absence of fucose in antibody sugar chains, methods for preparing antibodies having sugar chains that do not contain .alpha.-1,6 core fucose by producing antibodies in YB2/0 cells, and methods for adding sugar chains having bisecting GlcNAc (WO 99/54342; WO 00/61739; WO 02/31140; WO 02/79255, etc.).
[0141] Antibodies of the present invention can be produced by known methods using as an immunogen a mutant polypeptide of the present invention (derived from mammals such as humans and mice) or a fragment thereof. Specifically, non-human mammals are immunized by a known immunization method, using as a sensitizing antigen a desired antigen or cells expressing a desired antigen. Immune cells prepared from the immunized animals are fused with known parental cells by a general cell fusion method. The resulting monoclonal antibody-producing cells (hybridomas) are sorted by general screening methods, and monoclonal antibodies are prepared by culturing the cells.
[0142] Non-human mammals to be immunized include, for example, animals such as mice, rats, rabbits, sheep, monkeys, goats, donkeys, cows, horses, and pigs. The antigen can be prepared using a polynucleotide encoding the mutant polypeptide of the present invention according to known methods, for example, by methods using baculovirus (for example, WO 98/46777) or such.
[0143] Hybridomas can be prepared, for example, according to the method of Milstein et al. (Kohler, G. and Milstein, C., Methods Enzymol. (1981) 73: 3-46) or such. When the immunogenicity of an antigen is low, immunization may be performed after linking the antigen with a macromolecule having immunogenicity, such as albumin.
[0144] In an embodiment, antibodies that bind to the mutant polypeptides of the present invention include monoclonal antibodies that bind to the mutant polypeptides of the present invention. Immunogens for preparing monoclonal antibodies having binding activity to a mutant polypeptide of the present invention are not particularly limited, as long as antibodies having binding activity to the mutant polypeptide of the present invention can be prepared.
[0145] Meanwhile, the activity of an antibody to bind to a mutant polypeptide of the present invention can be assayed by methods known to those skilled in the art.
[0146] Meanwhile, monoclonal antibodies can also be obtained by DNA immunization. DNA immunization is a method in which a vector DNA constructed such that an antigen protein-encoding gene can be expressed in an animal to be immunized is administered to the animal, and the immunogen is expressed within the body of the animal to provide immunostimulation. As compared to common immunization methods based on the administration of protein antigens, DNA immunization is expected to be advantageous in that:
it enables immunostimulation while retaining the structure of a membrane protein; and the immunogen does not need to be purified.
[0147] In order to obtain monoclonal antibodies by DNA immunization, first, a polynucleotide encoding a mutant polypeptide of the present invention is administered to an animal to be immunized. The polynucleotide encoding a mutant polypeptide of the present invention can be synthesized according to an above-described method by known techniques such as PCR. The resulting DNA (polynucleotide) is inserted into an appropriate expression vector and then administered to an animal to be immunized. The expression vector includes any vectors described above (for example, commercially available expression vectors such as pcDNA3.1). Vectors can be administered to a living body by commonly used methods. For example, DNA immunization can be performed, for example, by using a gene gun to inject gold particles immobilized with an expression vector into cells. A preferred method for obtaining monoclonal antibodies is to perform booster immunization with cells expressing the mutant polypeptide of the present invention after DNA immunization.
[0148] Once the mammal is immunized as described above and the serum level of a desired antibody is confirmed to be increased, immune cells are collected from the mammal and subjected to cell fusion. Preferred immune cells are spleen cells in particular.
[0149] Mammalian myeloma cells are used for fusion with the above immune cells. It is preferred that myeloma cells have appropriate selection markers for screening. The selection marker refers to a phenotype that allows (or does not allow) survival under particular culture conditions. Known selection markers include hypoxanthine-guanine-phosphoribosyltransferase deficiency (hereinafter abbreviated as "HGPRT deficiency") and thymidine kinase deficiency (hereinafter abbreviated as "TK deficiency"). HGPRT- or TK-deficient cells exhibit hypoxanthine-aminopterin-thymidine sensitivity (hereinafter abbreviated as "HAT sensitivity"). In HAT selection medium, HAT-sensitive cells cannot synthesize DNA and thus will die. However, when fused with normal cells, they can continue to synthesize DNA via the salvage pathway of the normal cells and thus can grow even in HAT selection medium.
[0150] HGPRT- or TK-deficient cells can be selected using a medium containing 6-thioguanine, 8-azaguanine (hereinafter abbreviated as "8AG"), or 5'-bromodeoxyuridine. While normal cells are killed due to incorporation of these pyrimidine analogs into DNA, cells lacking these enzymes can survive in the selection medium because they cannot incorporate these pyrimidine analogs. Another selection marker called G418 resistance confers resistance to 2-deoxystreptamine antibiotics (gentamicin analogs) due to the neomycin resistance gene. Various myeloma cells suitable for cell fusion are known.
[0151] Cell fusion between immune cells and myeloma cells can be essentially carried out according to known methods, for example, the method by Kohler and Milstein et al. (Kohler. G. and Milstein, C., Methods Enzymol. (1981) 73, 3-46).
[0152] More specifically, cell fusion can be carried out, for example, in a common culture medium in the presence of a cell fusion-promoting agent. The fusion-promoting agent includes, for example, polyethylene glycol (PEG) and Sendai virus (HVJ). If required, an auxiliary agent such as dimethyl sulfoxide may also be added to improve fusion efficiency.
[0153] The immune cells and myeloma cells may be used at an arbitrarily determined ratio. For example, the ratio of immune cells to myeloma cells is preferably from 1 to 10. Culture media to be used for cell fusion include, for example, media that are suitable for the cell growth of myeloma cell line, such as RPMI1640 and MEM, and other common culture media used for this type of cell culture. In addition, the culture media may also be supplemented with serum supplement such as fetal calf serum (FCS).
[0154] Predetermined amounts of immune cells and myeloma cells are mixed well in the culture medium, and then mixed with a PEG solution pre-heated to about 37.degree. C. to produce fused cells (hybridomas). In the cell fusion method, for example, PEG with mean molecular weight of about 1,000-6,000 can be added to the cells typically at a concentration of 30% to 60% (w/v). Then, successive addition of the appropriate culture medium listed above and removal of supernatant by centrifugation are repeated to eliminate the cell fusion agent and such, which are unfavorable to the growth of hybridomas.
[0155] The resulting hybridomas can be screened using a selection medium according to the selection marker possessed by myeloma cells used in the cell fusion. For example, HGPRT- or TK-deficient cells can be screened by culturing them in a HAT medium (a medium containing hypoxanthine, aminopterin, and thymidine). Specifically, when HAT-sensitive myeloma cells are used in cell fusion, cells successfully fused with normal cells can be selectively grown in the HAT medium. The cell culture using the above HAT medium is continued for a sufficient period of time to allow all cells except the desired hybridomas (non-fused cells) to die. Specifically, in general, the desired hybridomas can be selected by culturing the cells for several days to several weeks. Then, screening and single cloning of hybridomas that produce an antibody of interest can be carried out by performing ordinary limiting dilution methods.
[0156] Screening and single cloning of an antibody of interest can be suitably carried out by known screening methods based on antigen-antibody reaction. For example, an antigen is bound to a carrier such as beads made of polystyrene or such and commercially available 96-well microtiter plates, and then reacted with the culture supernatant of hybridoma. Next, the carrier is washed and then reacted with an enzyme-labeled secondary antibody or such. When the culture supernatant contains an antibody of interest reactive to the sensitizing antigen, the secondary antibody binds to the carrier via this antibody. Finally, the secondary antibody bound to the carrier is detected to determine whether the culture supernatant contains the antibody of interest. Hybridomas producing a desired antibody capable of binding to the antigen can be cloned by the limiting dilution method or such.
[0157] In addition to the above-described method for preparing hybridomas through immunization of a nonhuman animal with an antigen, antibodies of interest can also be obtained by sensitizing human lymphocytes with an antigen. Specifically, first, human lymphocytes are sensitized with the mutant polypeptide of the present invention in vitro. Then, the sensitized lymphocytes are fused with an appropriate fusion partner. For example, human-derived myeloma cells with the ability to divide permanently can be used as the fusion partner (see JP-B (Kokoku) H01-59878). Antibodies obtained by this method are human antibodies having an activity of binding to the mutant polypeptide of the present invention.
[0158] The nucleotide sequence encoding an antibody that binds to the mutant polypeptide of the present invention obtained by the above-described method or such, and its amino acid sequence can be obtained by methods known to those skilled in the art.
[0159] Based on the obtained sequence of the antibody that binds to the mutant polypeptide of the present invention, the antibody that binds to the mutant polypeptide of the present invention can be prepared by genetic recombination techniques known to those skilled in the art. Specifically, a polynucleotide encoding an antibody can be constructed based on the sequence of the antibody that recognizes the mutant polypeptides of the present invention, inserted into an expression vector, and then expressed in appropriate host cells (see for example, Co, M. S. et al., J. Immunol. (1994) 152, 2968-2976; Better, M. and Horwitz, A. H., Methods Enzymol. (1989) 178, 476-496; Pluckthun, A. and Skerra, A., Methods Enzymol. (1989) 178, 497-515; Lamoyi, E., Methods Enzymol. (1986) 121, 652-663; Rousseaux, J. et al., Methods Enzymol. (1986) 121, 663-669; Bird, R. E. and Walker, B. W., Trends Biotechnol. (1991) 9, 132-137).
[0160] The vectors include M13 vectors, pUC vectors, pBR322, pBluescript, and pCR-Script. Alternatively, when aiming to subclone and excise cDNA, the vectors include, for example, pGEM-T, pDIRECT, and pT7, in addition to the vectors described above. Expression vectors are particularly useful when using vectors for producing the antibodies of the present invention. For example, when aiming for expression in E. coli such as JM109, DH5.alpha., HB101, and XL1-Blue, the expression vectors not only have the above-described characteristics that allow vector amplification in E. coli, but must also carry a promoter that allows efficient expression in E. coli, for example, lacZ promoter (Ward et al., Nature (1989) 341, 544-546; FASEB J. (1992) 6, 2422-2427), araB promoter (Better et al., Science (1988) 240, 1041-1043), T7 promoter or such. Such vectors include pGEX-5X-1 (Pharmacia), "QIAexpress system" (Qiagen), pEGFP, or pET (in this case, the host is preferably BL21 that expresses T7 RNA polymerase) in addition to the vectors described above.
[0161] The vectors may contain signal sequences for antibody secretion. As a signal sequence for antibody secretion, a pelB signal sequence (Lei, S. P. et al J. Bacteriol. (1987) 169, 4379) may be used when a protein is secreted into the E. coli periplasm. The vector can be introduced into host cells by calcium chloride or electroporation methods, for example.
[0162] In addition to vectors for E. coli, the vectors for producing the antibodies of the present invention include mammalian expression vectors (for example, pcDNA3 (Invitrogen), pEF-BOS (Nucleic Acids. Res. 1990, 18(17), p5322), pEF, and pCDM8), insect cell-derived expression vectors (for example, the "Bac-to-BAC baculovirus expression system" (Gibco-BRL) and pBacPAK8), plant-derived expression vectors (for example, pMH1 and pMH2), animal virus-derived expression vectors (for example, pHSV, pMV, and pAdexLcw), retroviral expression vectors (for example, pZlPneo), yeast expression vectors (for example, "Pichia Expression Kit" (Invitrogen), pNV11, and SP-Q01), and Bacillus subtilis expression vectors (for example, pPL608 and pKTH50), for example.
[0163] When aiming for expression in animal cells such as CHO, COS, and NIH3T3 cells, the vectors must have a promoter essential for expression in cells, for example, SV40 promoter (Mulligan et al., Nature (1979) 277, 108), MMLV-LTR promoter, EFla promoter (Mizushima et al., Nucleic Acids Res. (1990) 18, 5322), and CMV promoter, and more preferably they have a gene for selecting transformed cells (for example, a drug resistance gene that allows evaluation using an agent (neomycin, G418, or such)). Vectors with such characteristics include pMAM, pDR2, pBK-RSV, pBK-CMV, pOPRSV, and pOP13, for example.
[0164] In addition, the following method can be used for stable gene expression and gene amplification in cells: CHO cells deficient in a nucleic acid synthesis pathway are introduced with a vector (for example, pSV2-dhfr ("Molecular Cloning 2.sup.nd edition", Cold Spring Harbor Laboratory Press, 1989)) that carries a DHFR gene which compensates for the deficiency, and the vector is amplified using methotrexate (MTX). Alternatively, the following method can be used for transient gene expression: COS cells with a gene expressing SV40 T antigen on their chromosome are transformed with a vector (pcD and such) with an SV40 replication origin. Replication origins derived from polyoma virus, adenovirus, bovine papilloma virus (BPV), and such can also be used. To amplify gene copy number in host cells, the expression vectors may further carry selection markers such as aminoglycoside transferase (APH) gene, thymidine kinase (TK) gene, E. coli xanthine-guanine phosphoribosyltransferase (Ecogpt) gene, and dihydrofolate reductase (dhfr) gene.
[0165] The antibodies of the present invention obtained by the methods described above can be isolated from inside host cells or from outside the cells (the medium, or such), and purified to homogeneity. The antibodies can be isolated and purified by methods routinely used for isolating and purifying antibodies, and the type of method is not limited. For example, the antibodies can be isolated and purified by appropriately selecting and combining column chromatography, filtration, ultrafiltration, salting out, solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, isoelectrofocusing, dialysis, recrystallization, and such.
[0166] The chromatographies include, for example, affinity chromatography, ion exchange chromatography, hydrophobic chromatography, gel filtration, reverse phase chromatography, and adsorption chromatography (Strategies for Protein Purification and Characterization: A Laboratory Course Manual. Ed Daniel R. Marshak et al., Cold Spring Harbor Laboratory Press, 1996). The chromatographic methods described above can be conducted using liquid chromatography, for example, HPLC and FPLC. Columns that can be used for affinity chromatography include protein A columns and protein G columns. Columns using protein A include, for example, Hyper D, POROS, and Sepharose FF (GE Amersham Biosciences). The present invention includes antibodies that are highly purified using these purification methods.
[0167] The binding activity to the mutant polypeptide of the present invention of the obtained antibodies can be determined by methods known to those skilled in the art. Methods for determining the antigen-binding activity of an antibody include, for example, ELISA (enzyme-linked immunosorbent assay), EIA (enzyme immunoassay), RIA (radioimmunoassay), and fluorescent antibody method. For example, when enzyme immunoassay is used, antibody-containing samples, such as purified antibodies and culture supernatants of antibody-producing cells, are added to antigen-coated plates. A secondary antibody labeled with an enzyme, such as alkaline phosphatase, is added and the plates are incubated. After washing, an enzyme substrate, such as p-nitrophenyl phosphate, is added, and the absorbance is measured to evaluate the antigen-binding activity.
[0168] In the present invention, "cancer" generally refers to malignant neoplasm which may be metastatic or non-metastatic. For instance, non-limiting examples of cancer that develops from epithelial tissues such as gastrointestinal tract and skin include brain tumor, skin cancer, head and neck cancer, esophageal cancer, lung cancer, gastric cancer, duodenal cancer, breast cancer, prostate cancer, cervical cancer, cancer of uterine body, pancreatic cancer, liver cancer, colorectal cancer, colon cancer, bladder cancer, and ovarian cancer. Meanwhile, non-limiting examples of sarcoma that develops from non-epithelial tissues (stroma) such as muscles include osteosarcoma, chondrosarcoma, rhabdomyosarcoma, leiomyosarcoma, liposarcoma, and angiosarcoma. Furthermore, non-limiting examples of hematological cancer derived from hematopoietic organs include malignant lymphoma including Hodgkin's lymphoma and non-Hodgkin's lymphoma, leukemia including acute myelocytic leukemia, chronic myelocytic leukemia, acute lymphatic leukemia, and chronic lymphatic leukemia, and multiple myeloma.
[0169] In the present invention, cancer includes any newly developed pathological tissue tumor (neoplasm). In the present invention, neoplasm leads to tumor formation which is characterized by partial neovascularization. Neoplasm can be benign, for example, angioma, glioma, and teratoma, or malignant, for example, cancer, sarcoma, glial tumor, astrocytoma, neuroblastoma, and retinoblastoma.
[0170] In the present invention, preferred examples of cancer include bladder cancer, brain tumor, head and neck squamous cell carcinoma, lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, skin melanoma, endometrial cancer, breast cancer, prostate cancer, colon cancer, esophageal cancer, gastric cancer, bile duct cancer, biliary tract cancer, and liver cancer.
[0171] In the present invention, "cancer tissue" refers to a tissue containing at least one cancer cell. For example, as cancer tissues contain cancer cells and blood vessels, cancer tissue refers to all cell types that contribute to the formation of tumor mass containing cancer cells and endothelial cells. Herein, tumor mass refers to foci of tumor tissue. The term "tumor" is generally used to refer to benign or malignant neoplasm.
[0172] The present invention relates to pharmaceutical compositions comprising an above-described antibody or antigen-binding fragment thereof, oligonucleotides, or a compound of the present invention.
[0173] In the present invention, the pharmaceutical composition generally refers to a pharmaceutical agent for treating, preventing, or examining/diagnosing diseases.
[0174] The pharmaceutical compositions of the present invention can be formulated by methods known to those skilled in the art. For example, they can be used parenterally, in an injectable form of sterile solutions or suspensions including water or other pharmaceutically acceptable liquid. For example, such compositions may be formulated by mixing in a unit dose form required by the generally approved pharmaceutical manufacturing practice, by appropriately combining with pharmacologically acceptable carriers or media, specifically sterile water, physiological saline, vegetable oil, emulsifier, suspension, surfactant, stabilizer, flavoring agent, excipient, vehicle, preservative, binder, or such. The amount of active ingredient in such formulations is adjusted so that an appropriate amount can be obtained within a specified range.
[0175] Sterile compositions for injection can be formulated according to general formulation practice using vehicles such as distilled water for injection. Aqueous solutions for injection include, for example, physiological saline, and isotonic solutions containing glucose or other adjuvants (e.g., D-sorbitol, D-mannnose, D-mannitol, and sodium chloride). These can be used in combination with appropriate solubilizers, for example, alcohol (ethanol, etc.), polyalcohol (propylene glycol, polyethylene glycol, etc.), and non-ionic detergents (Polysorbate 80.TM., HCO-50, etc.).
[0176] Oils include sesame oil and soybean oils. Benzyl benzoate and/or benzyl alcohol can be used in combination as solubilizers. It is also possible to combine buffers (for example, phosphate buffer and sodium acetate buffer), soothing agents (for example, procaine hydrochloride), stabilizers (for example, benzyl alcohol and phenol), and/or antioxidants. Appropriate ampules are filled with the prepared injections.
[0177] The pharmaceutical compositions of the present invention are preferably administered parenterally. For example, compositions are administered in an injectable form, or in a form for transnasal administration, transpulmonary administration, or transdermal administration. For example, they can be administered systemically or locally by intravenous injection, intramuscular injection, intraperitoneal injection, subcutaneous injection, or such.
[0178] Administration methods can be appropriately selected in consideration of the patient's age and symptoms. The dose of a pharmaceutical composition containing an antigen-binding molecule may be, for example, 0.0001 mg to 1,000 mg/kg for each administration. Alternatively, the dose may be, for example, 0.001 to 100,000 mg per patient. However, the present invention is not limited by the numeric values described above. The dosage and administration method vary according to the patient's weight, age, symptoms, and such. Those skilled in the art can set an appropriate dosage and administration method in consideration of the factors described above.
[0179] Amino acids in the amino acid sequences described herein may be modified after translation (for example, modification of N-terminal glutamine into pyroglutamic acid by pyroglutamylation is well known to those skilled in the art). As a matter of course, such posttranslationally modified amino acids are also included in the amino acid sequences of the present invention.
[0180] The present invention also relates to methods for detecting an above-described mutant polypeptide of the present invention or a polynucleotide encoding the mutant polypeptide in samples from subjects (including cancer patients and healthy persons).
[0181] The presence or absence of a mutant polypeptide of the present invention in a sample from a subject can be tested and determined, for example, using antigen-antibody reaction which is performed by contacting an above-described antibody or antigen-binding fragment thereof that binds to a mutant polypeptide of the present invention with a sample (tumor tissue, normal tissue, and various body fluid specimens containing cancer or normal cells (blood, serum, urine, saliva, ascites, pleural effusion, etc.)) collected from a subject (cancer patient, person who may be affected with cancer, person with the risk of getting cancer, or healthy person; however, it is not limited to human).
[0182] The antigen (i.e., a mutant polypeptide of the present invention) in an antigen-antibody reaction can be detected, for example, by using conventional immunoassay.
[0183] In the present invention, immunoassay refers to a method for detecting a mutant polypeptide of the present invention in a sample (tumor tissue, normal tissue, and various body fluid specimens containing cancer or normal cells (blood, serum, urine, saliva, ascites, pleural effusion, etc.)) based on the reaction mechanism between an antigen (i.e., a mutant polypeptide of the present invention) and an antibody that binds to the antigen or antigen-binding fragment thereof. Any immunoassay is included in the present invention as long as it is a method that can detect the fusion polypeptides of the present invention.
[0184] For immunoassay in the present invention, for example, the principles of various methods such as those described in "Kouso Men-eki Sokutei Hou (Enzyme immunoassay)" (3rd Ed., eds., Eiji Ishikawa et al., Igakushoin, 1987) can be applied. Specifically, these various methods can be carried out using one or more antibodies that bind to an antigen of interest to capture (trap) the antigen to be detected in a sample.
[0185] Applicable principles preferably include, for example, single antibody solid phase methods, double antibody liquid phase methods, double antibody solid phase methods, sandwich methods, and one-pot methods such as described in JP-B (Kokoku) H02-39747. Meanwhile, assays based on antigen-antibody reaction also include enzyme multiplied immunoassay technique (EMIT), enzyme channeling immunoassay, enzyme modulator mediated enzyme immunoassay (EMMIA), enzyme inhibitor immunoassay, immunoenzymometric assay, enzyme enhanced immunoassay, and proximal linkage immunoassay.
[0186] In the present invention, it is possible to select and use any appropriate immunoassay principle such as those described above depending on the objective of the test.
[0187] The immunoassays of the present invention also include sandwich methods using a biotin- or enzyme-labeled antibody, and multi-well microtiter plates having a number of wells including 96-well microplate, as well as one-pot methods using beads and antibodies labeled with biotin or enzyme such as peroxidase.
[0188] As described above, antibodies that bind to a mutant polypeptide of the present invention or antigen-binding fragments thereof, which are used in immunoassays of the present invention, may be labeled with a labeling substance that can provide a detectable signal by itself or upon reaction with other substances.
[0189] Such labeling substances include, for example, enzymes, fluorescent substances, chemiluminescent substances, biotin, avidin, and radioisotopes. More specifically, the substances include enzymes such as peroxidase (e.g., horseradish peroxidase), alkaline phosphatase, .beta.-D-galactosidase, glucose oxidase, glucose-6-phosphate dehydrogenase, alcohol dehydrogenase, malate dehydrogenase, penicillinase, catalase, apoglucoseoxidase, urease, luciferase, and acetylcholinesterase; fluorescent substances such as fluorescein isothiocyanate, phycobiliprotein, rare earth metal chelates, dansyl chloride, and tetramethylrhodamine isothiocyanate; radioisotopes such as .sup.3H, .sup.14C, .sup.125I, and .sup.131I; biotin; avidin; and chemiluminescent substances.
[0190] Such radioisotopes and fluorescent substances can provide a detectable signal by themselves.
[0191] Meanwhile, enzymes, chemiluminescent substances, biotin, and avidin cannot provide any detectable signal by themselves, but provide a detectable signal when reacting with one or more different substances.
[0192] For example, when an enzyme is used, at least a substrate is necessary. Various substrates are used according to the type of enzymatic activity assay method (colorimetric assay, fluorescent assay, bioluminescence assay, chemiluminescent assay, etc.). For example, hydrogen peroxide is used as a substrate for peroxidase. Meanwhile, biotin is generally reacted with at least avidin or enzyme-modified avidin, but substrates are not limited thereto. If needed, it is also possible to use various chromogenic substances according to the substrates.
[0193] The presence or absence of a polynucleotide encoding a mutant polypeptide of the present invention in a sample from a subject can be tested and determined, for example, according to routine methods using various oligonucleotides (a pair of oligonucleotide primers, oligonucleotide probes, etc.) of the present invention described above, and mRNA, cDNA prepared using mRNA as a template, genomic DNA, or such in a sample (tumor tissue, normal tissue, and various body fluid specimens containing cancer or normal cells (blood, serum, urine, saliva, ascites, pleural effusion, etc.)) collected from a subject (cancer patient, person who may be affected with cancer, person with the risk of getting cancer, or healthy person; however, it is not limited to human) by using various gene analysis methods. Such gene analysis methods include, for example, Northern blotting, polymerase chain reaction (PCR), Southern blotting, ligase chain reaction (LCR), strand displacement amplification (SDA), nucleic acid sequence-based amplification (NASBA), isothermal and chimeric primer-initiated amplification of nucleic acids (ICAN), loop-mediated isothermal amplification (LAMP), TMA method (Gen-Probe's TMA system), microarray, and next-generation sequencing method.
[0194] These assays utilize hybridization of oligonucleotides of the present invention to a polynucleotide encoding a mutant polypeptide of the present invention derived from a sample. Desired stringent conditions for such hybridization include, for example, the conditions of 6 M urea, 0.4% SDS, 0.5.times.SSC, and 37.degree. C.; and hybridization conditions of equivalent stringency. Depending on the objective, it is possible to use more stringent conditions, for example, 6 M urea, 0.4% SDS, and 0.1.times.SSC, and 42.degree. C.
[0195] The present invention also relates to kits for detecting an above-described mutant polypeptide of the present invention or a polynucleotide encoding the mutant polypeptide in samples from subjects described above (including cancer patients and healthy persons).
[0196] Specifically, detection kits of the present invention may contain an above-described antibody or antigen-binding fragment thereof that binds to a mutant polypeptide of the present invention (including antibodies or antigen-binding fragments thereof labeled with above-described various labeling substances). Depending on the objective of each immunoassay described above, the kits may also contain various detection reagents (enzymes, substrates, etc.) and instruction manuals.
[0197] Specifically, detection kits of the present invention may contain various oligonucleotides of the present invention described above (a pair of oligonucleotide primers, oligonucleotide probes, etc.) that hybridize to mRNA derived from a polynucleotide encoding an above-described mutant polypeptide of the present invention, cDNA prepared using the mRNA as template, or genomic DNA. According to the objective of each gene analysis, the kits may also contain various reagents (enzymes, other oligonucleotides, nucleic acid, reaction buffer, etc.) and instruction manuals.
[0198] The present invention also relates to methods of testing for the presence or absence of resistance to various FGFR inhibitors, prediction of response of a subject to treatment with FGFR inhibitors, or prediction of the effects of FGFR inhibitors in cancer treatment, based on the presence or absence of mutant polypeptides of the present invention or polynucleotides encoding those mutant polypeptides in samples isolated from the subjects.
[0199] Specifically, methods of the present invention are, for example, methods of testing and determining the presence or absence of mutant polypeptides of the present invention in samples (tumor tissues, normal tissues, or various body fluids (such as blood, serum, urine, and saliva) that contain cancer cells or normal cells) collected from subjects (cancer patients, those who may have cancer, those at risk of having cancer, or healthy persons, without being limited to humans) by using the above-described methods and kits for detecting the mutant polypeptides of the present invention, and thereby testing for the presence or absence of resistance to various FGFR inhibitors, prediction of response of the subjects to treatment with FGFR inhibitors, or prediction of effects of FGFR inhibitors in cancer treatment, based on the criteria that the presence of the mutant polypeptide indicates the presence of resistance to various FGFR inhibitors.
[0200] Furthermore, methods of the present invention are, for example, methods of testing and determining the presence or absence of polynucleotides encoding the mutant polypeptides of the present invention in samples (tumor tissues, normal tissues, or various body fluids (such as blood, serum, urine, and saliva) that contain cancer cells or normal cells) collected from subjects (cancer patients, those who may have cancer, those at risk of having cancer, or healthy persons, without being limited to humans) by using the above-described methods and kits for detecting polynucleotides encoding the mutant polypeptides of the present invention, and thereby testing for the presence or absence of resistance to various FGFR inhibitors, prediction of response of the subjects to treatment with FGFR inhibitors, or prediction of effects of FGFR inhibitors in cancer treatment, based on the criteria that the presence of the mutant polypeptide indicates the presence of resistance to various FGFR inhibitors.
[0201] The present invention also relates to methods for selecting a patient to whom an anticancer agent (as described below) containing a compound having FGFR inhibitory activity is applicable, based on the presence or absence of mutant polypeptides of the present invention or polynucleotides encoding the mutant polypeptides in samples isolated from subjects.
[0202] Specifically, methods of the present invention are, for example, methods of testing and determining the presence or absence of mutant polypeptides of the present invention in samples (tumor tissues, normal tissues, or various body fluids (such as blood, serum, urine, and saliva) that contain cancer cells or normal cells) collected from subjects (cancer patients or those who may have cancer, without being limited to humans) by using the above-described methods and kits for detecting mutant polypeptides of the present invention, and when the mutant polypeptides are detected, selecting the subject as a patient to whom an anticancer agent (or a pharmaceutical composition for cancer treatment, as described below) containing a compound having FGFR inhibitory activity is applicable. Here, the compound of formula (I) is preferred as the compound having FGFR inhibitory activity. Furthermore, methods of the present invention are, for example, methods of testing and determining the presence or absence of polynucleotides encoding the mutant polypeptides of the present invention in samples (tumor tissues, normal tissues, or various body fluids (such as blood, serum, urine, and saliva) that contain cancer cells or normal cells) collected from subjects (cancer patients or those who may have cancer, without being limited to humans) by using the above-described methods and kits for detecting polynucleotides encoding the mutant polypeptides of the present invention, and when the polynucleotides encoding the mutant polypeptides are detected, selecting the subject as a patient to whom an anticancer agent (as described below) containing a compound having FGFR inhibitory activity is applicable. Here, the compound of formula (I) is preferred as the compound having FGFR inhibitory activity.
[0203] In the present invention, "FGFR inhibitor" and "compound having FGFR inhibitory activity" are used interchangeably, and refer to a compound having the activity of inhibiting the activity of the above-mentioned FGFR, specifically, one or more arbitrary FGFRs belonging to the FGFR family comprising FGFR1, FGFR2, FGFR3, and FGFR4, which are fibroblast growth factor receptors (FGFRs) belonging to the receptor tyrosine kinase family. Preferably, they refer to a compound having the activity of inhibiting human FGFR activity, and more preferably a compound having the activity of inhibiting the activity of human FGFR3 comprising the amino acid sequence of SEQ ID NO: 1 or 2 (cDNA sequences, SEQ ID NOs: 3 and 4, respectively/GenBank Accession Nos. NM_000141.4 and NM_022970.3, respectively).
[0204] Any FGFR inhibitors are included in the FGFR inhibitors of the present invention as long as the compounds have the activity of inhibiting FGFR activity.
[0205] Specifically, the FGFR inhibitors of the present invention include any compounds, antibodies, nucleic acid pharmaceuticals (siRNA, antisense nucleic acids, ribozymes, and such) having an action mechanism of:
(1) inhibiting the FGFR kinase activity; (2) inhibiting dimerization between FGFR, TACC3, and BAIAP2L1;
[0206] (3) inhibiting FGFR-mediated signaling (MAPK pathway and PI3K/AKT pathway) (for example, MEK inhibitors, RAF inhibitors, ERK inhibitors, PI3K inhibitors, mTOR inhibitors, AKT inhibitors, PDK inhibitors, S6K inhibitors, etc.); or
(4) inhibiting FGFR expression (for example, siRNA, HSP90 inhibitors, etc.).
[0207] Antibodies having the activity of inhibiting FGFR activity, which are included as FGFR inhibitors of the present invention, comprise antibodies identified by the following code names: RG7444, FP-1039, AV370, and PRO-001.
[0208] Low-molecular-weight compounds having the activity of inhibiting FGFR activity, which are included as FGFR inhibitors of the present invention, include, for example:
(1) compounds disclosed in the following Patent Document and Non-patent Documents: Cancer Research, 2012, 72: 2045-2056; J. Med. Chem., 2011, 54: 7066-7083; International Publication WO 2011/016528; (2) compounds identified by the following generic names or code names: AZD-4547 (compound C in Table 1 described below), BGJ-398 (compound D in Table 1 described below), LY-2874455, cediranib (AZD2171; compound E in Table 1 described below), PD173074 (compound B in Table 1 described below), regorafenib, ponatinib, orantinib, nintedanib, masitinib, lenvatinib, dovitinib (TKI258), brivanib, volasertib, golvatinib, ENMD-2076, E-3810, XL-999, XL-228, ARQ087, Tivozanib, motesanib, and regorafenib; and (3) compounds exemplified below; however, FGFR inhibitors are not limited thereto:
##STR00004##
wherein R.sub.1, R.sub.2, R.sub.3, and R.sub.4 each independently represents the group listed below: R.sub.1 represents hydrogen, hydroxy, halogen, cyano, nitro, C.sub.1-4 haloalkyl, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-10 aryl C.sub.1-4 alkyl, --OR.sub.5, --NR.sub.6R.sub.7, --(CR.sub.8R.sub.9).sub.nZ.sub.1, --C(O)NR.sub.12R.sub.13, --SR.sub.14, --SO.sub.2R.sub.16, --NR.sub.17SO.sub.2R.sub.18, COOH, C.sub.6-10 aryl which is optionally substituted by one or more groups independently selected from group P, 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q, --COR.sub.19, --COOR.sub.20, --OC(O)R.sub.21, --NR.sub.22C(O)R.sub.23, --NR.sub.24C(S)R.sub.25, --C(S)NR.sub.26R.sub.27, --SO.sub.2NR.sub.28R.sub.29, --OSO.sub.2R.sub.30, --SO.sub.3R.sub.31, or --Si(R.sub.32).sub.3; R.sub.2 represents hydrogen, hydroxy, halogen, cyano, nitro, C.sub.1-4 haloalkyl, C.sub.1-6 alkyl, C.sub.26 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-10 aryl C.sub.1-4 alkyl, --OR.sub.5, --NR.sub.6R.sub.7, --(CR.sub.8R.sub.9).sub.nZ.sub.1, --C(O)NR.sub.12R.sub.13, --SR.sub.14, --SO.sub.2R.sub.16, --NR.sub.17SO.sub.2R.sub.18, COOH, C.sub.6-10 aryl which is optionally substituted by one or more groups independently selected from group P, 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q, --COR.sub.19, --COOR.sub.20, --OC(O)R.sub.21, --NR.sub.22C(O)R.sub.23, --NR.sub.24C(S)R.sub.25, --C(S)NR.sub.26R.sub.27, --SO.sub.2NR.sub.28R.sub.29, --OSO.sub.2R.sub.30, --SO.sub.3R.sub.31, or --Si(R.sub.32).sub.3; or R.sub.1 and R.sub.2, together with an atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl, wherein the heterocyclyl or heteroaryl is optionally substituted by halogen; R.sub.3 represents methyl; R.sub.4 represents hydrogen; A is indole; R.sub.5 represents C.sub.1-5 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkyl C.sub.1-3 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.1-3 alkoxy C.sub.1-4 alkyl, C.sub.1-3 alkoxy C.sub.1-4 alkoxy C.sub.1-4 alkyl, C.sub.1-4 aminoalkyl, C.sub.1-4 alkylamino C.sub.1-4 alkyl, di(C.sub.1-4 alkyl)amino C.sub.1-4 alkyl, C.sub.6-10 aryl, C.sub.6-10 aryl C.sub.1-3 alkyl, or 3- to 10-membered heterocyclyl C.sub.1-3 alkyl, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryl C.sub.1-3 alkyl, C.sub.1-6 monohydroxy alkyl, C.sub.1-6 dihydroxy alkyl, or C.sub.1-6 trihydroxy alkyl which is optionally substituted by one or more groups independently selected from group Q; R.sub.6 and R.sub.7, which can be the same or different, each represents hydrogen, C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.1-3 alkoxy C.sub.1-4 alkyl, C.sub.6-10 aryl C.sub.1-3 alkyl, 3- to 10-membered heterocyclyl C.sub.1-3 alkyl, 5- to 10-membered heteroaryl C.sub.1-3 alkyl, C.sub.1-6 monohydroxy alkyl, C.sub.1-6 dihydroxy alkyl, C.sub.1-6 trihydroxy alkyl, 3- to 10-membered heterocyclyl, C.sub.1-4 aminoalkyl, C.sub.1-4 alkylamino C.sub.1-4 alkyl, di(C.sub.1-4 alkyl)amino C.sub.1-4 alkyl, or cyano(C.sub.1-3 alkyl); or alternatively R.sub.6 and R.sub.7, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl; n represents 1 to 3; R.sub.8 and R.sub.9, which can be the same or different, each represents hydrogen, C.sub.1-4 alkyl, or halogen; or alternatively R.sub.8 and R.sub.9, together with a carbon atom linked thereto, form a cycloaliphatic ring; Z.sub.1 represents hydrogen, NR.sub.10R.sub.11, --OH, or 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl which is optionally substituted by one or more groups independently selected from group Q; R.sub.10 and R.sub.11, which can be the same or different, each represents C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.1-3 alkoxy C.sub.1-4 alkyl, cyano(C.sub.1-3 alkyl), or C.sub.1-3 alkylsulfonyl C.sub.1-4 alkyl; or alternatively R.sub.10 and R.sub.11, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl; R.sub.12 and R.sub.13, which can be the same or different, each represents hydrogen, C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.1-3 alkoxy C.sub.1-4 alkyl, C.sub.6-10 aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, C.sub.6-10 aryl C.sub.1-4 alkyl, 3- to 10-membered heterocyclyl C.sub.1-3 alkyl, 5- to 10-membered heteroaryl C.sub.1-3 alkyl, cyano(C.sub.1-3 alkyl), C.sub.1-3 alkylsulfonyl C.sub.1-4 alkyl, 3- to 10-membered cycloaliphatic ring, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; or alternatively R.sub.12 and R.sub.13, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl which is optionally substituted by one or more groups independently selected from group Q; R.sub.14 represents C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl which is optionally substituted by one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q; R.sub.15 represents C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl which is optionally substituted by one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q; R.sub.16 represents C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl which is optionally substituted by one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q; R.sub.17 represents hydrogen or C.sub.1-4 alkyl; R.sub.18 represents C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl which is optionally substituted by one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q; R.sub.19 represents hydrogen, C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, haloalkyl, C.sub.6-10 aryl, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl which is optionally substituted by one or more groups independently selected from group Q; R.sub.29 represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R.sub.21 represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R.sub.22 represents hydrogen, C.sub.1-4 alkyl, or C.sub.1-4 haloalkyl; R.sub.23 represents hydrogen, C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R.sub.24 represents hydrogen, C.sub.1-4 alkyl, or C.sub.1-4 haloalkyl; R.sub.25 represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R.sub.26 and R.sub.27, which can be the same or different, each represents hydrogen, C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.1-3 alkoxyl C.sub.1-4 alkyl, C.sub.6-10 aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, C.sub.6-10 aryl C.sub.1-4 alkyl, 3- to 10-membered heterocyclyl C.sub.1-3 alkyl, 5- to 10-membered heteroaryl C.sub.1-3 alkyl, cyano(C.sub.1-3 alkyl), C.sub.1-3 alkylsulfonyl C.sub.1-4 alkyl, or 3- to 10-membered cycloaliphatic ring; or alternatively R.sub.26 and R.sub.27, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl; R.sub.28 and R.sub.29, which can be the same or different, each represents hydrogen, C1-4 alkyl, C2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.1-3 alkoxyl C.sub.1-4 alkyl, C.sub.6-10 aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, C.sub.6-10 aryl C.sub.1-4 alkyl, 3- to 10-membered heterocyclyl C.sub.1-3 alkyl, 5- to 10-membered heteroaryl C.sub.1-3 alkyl, cyano(C.sub.1-3 alkyl), C.sub.1-3 alkylsulfonyl C.sub.1-4 alkyl, or 3- to 10-membered cycloaliphatic ring; or alternatively R.sub.28 and R.sub.29, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl; R.sub.30 represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R.sub.31represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; R.sub.32 represents C.sub.1-4 alkyl or C.sub.6-10 aryl; <group P> halogen, C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, --OH, C.sub.1-3 alkoxy, C.sub.1-3 haloalkoxy, 3- to 10-membered heterocyclylamino, --SO.sub.2R.sub.16, --CN, --NO.sub.2, and 3- to 10-membered heterocyclyl; <group Q> halogen, C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, --OH, C.sub.1-3 alkoxy, C.sub.1-6 monohydroxy alkyl, C.sub.1-6 dihydroxy alkyl, C.sub.1-6 trihydroxy alkyl, 3- to 10-membered heterocyclyl amine, --SO.sub.2R.sub.16, --CN, --NO.sub.2, C.sub.3-7 cycloalkyl, --COR.sub.19, and 3- to 10-membered heterocyclyl which is optionally substituted by C.sub.1-4 alkyl.
##STR00005##
[0209] Herein, the "alkyl" refers to a monovalent group derived from an aliphatic hydrocarbon by removing an arbitrary hydrogen atom. It contains no heteroatom or unsaturated carbon-carbon bond in the backbone, and has a subset of hydrocarbyl or hydrocarbon group structures which contain hydrogen and carbon atoms. The alkyl group includes linear and branched structures. Preferred alkyl groups include alkyl groups with one to six carbon atoms (C.sub.1-6;
[0210] hereinafter, "C.sub.p-q" means that the number of carbon atoms is p to q), C.sub.1-5 alkyl groups, C.sub.1-4 alkyl groups, and C.sub.1-3 alkyl groups.
[0211] Specifically, the alkyl includes, for example, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, s-butyl group, t-butyl group, pentyl group, isopentyl group, 2,3-dimethylpropyl group, 3,3-dimethylbutyl group, and hexyl group.
[0212] Herein, "alkenyl" refers to a monovalent hydrocarbon group having at least one double bond (two adjacent SP2 carbon atoms), and includes those of linear and branched forms. Depending on the configuration of the double bond and substituents (if any), the geometry of the double bond can be of entgegen (E) or zusammen (Z), or cis or trans configuration. Preferred alkenyl groups include C.sub.26 alkenyl groups.
[0213] Specifically, the alkenyl includes, for example, vinyl group, allyl group, 1-propenyl group, 2-propenyl group, 1-butenyl group, 2-butenyl group (including cis and trans), 3-butenyl group, pentenyl group, and hexenyl group.
[0214] Herein, "alkynyl" refers to a monovalent hydrocarbon group having at least one triple bond (two adjacent SP carbon atoms), and includes those of linear and branched forms.
[0215] Preferred alkynyl groups include C.sub.2-6 alkynyl groups.
[0216] Specifically, the alkynyl includes, for example, ethynyl group, 1-propynyl group, propargyl group, 3-butynyl group, pentynyl group, and hexynyl group.
[0217] The alkenyl and alkynyl may each have one, two or more double bonds or triple bonds.
[0218] Herein, "cycloalkyl" refers to a saturated or partially saturated cyclic monovalent aliphatic hydrocarbon group, and includes monocyclic groups, bicyclo rings, and spiro rings. Preferred cycloalkyl includes C.sub.3-7 cycloalkyl groups. Specifically, the cycloalkyl group includes, for example, cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, and cycloheptyl group.
[0219] Herein, "cycloalkylalkyl" refers to a group in which an arbitrary hydrogen atom of an "alkyl" defined above is substituted with a "cycloalkyl" defined above. Preferred cycloalkylalkyl groups include C.sub.3-7 cycloalkylC.sub.1-3 alkyl, and specifically include, for example, cyclopropylmethyl group and cyclopropylethyl group.
[0220] Herein, "hetero atom" refers to a nitrogen atom (N), oxygen atom (O), or sulfur atom (S).
[0221] Herein, "halogen" refers to a fluorine atom, chlorine atom, bromine atom, or iodine atom.
[0222] Herein, "haloalkyl" refers to a group in which preferably one to nine, more preferably one to five identical or different "halogen atoms" defined above are linked to an "alkyl" defined above.
[0223] Specifically, the haloalkyl includes, for example, chloromethyl group, dichloromethyl group, trichloromethyl group, fluoromethyl group, difluoromethyl group, perfluoroalkyl group (such as trifluoromethyl group and --CF.sub.2CF.sub.3), and 2,2,2-trifluoroethyl group.
[0224] Herein, "alkoxy" refers to an oxy group linked with an "alkyl" defined above. Preferred alkoxy includes C.sub.1-4 alkoxy groups and C.sub.1-3 alkoxy groups. Specifically, alkoxy includes, for example, methoxy group, ethoxy group, 1-propoxy group, 2-propoxy group, n-butoxy group, i-butoxy group, sec-butoxy group, and tert-butoxy group.
[0225] Herein, "haloalkoxy" refers to a group in which preferably one to nine, more preferably one to five identical or different halogen atoms defined above are linked to an "alkoxy" defined above.
[0226] Specifically, the haloalkoxy includes, for example, chloromethoxy group, trichloromethoxy group, and trifluoromethoxy group.
[0227] Herein, "aryl" refers to a monovalent aromatic hydrocarbon ring. The aryl preferably includes C.sub.6-10 aryl. Specifically, the aryl includes, for example, phenyl group and naphthyl groups (for example, 1-naphthyl group and 2-naphthyl group).
[0228] Herein, "alicyclic ring" refers to a monovalent non-aromatic hydrocarbon ring. The alicyclic ring may have unsaturated bonds within its ring, and may be a multicyclic group having two or more rings. The carbon atoms constituting the ring may be oxidized to form a carbonyl. The number of atoms constituting an alicyclic ring preferably ranges from three to ten (3- to 10-membered aliphatic ring). The alicyclic ring includes, for example, cycloalkyl rings, cycloalkenyl rings, and cycloalkynyl rings.
[0229] Herein, "heteroaryl" refers to a monovalent aromatic heterocyclic group in which the ring-constituting atoms include preferably one to five hetero atoms. The heteroaryl may be partially saturated, and may be a monocyclic or condensed ring (for example, a bicyclic heteroaryl condensed with a benzene ring or monocyclic heteroaryl ring). The number of ring-constituting atoms preferably ranges from five to ten (5- to 10-membered heteroaryl).
[0230] Specifically, the heteroaryl includes, for example, furyl group, thienyl group, pyrrolyl group, imidazolyl group, pyrazolyl group, thiazolyl group, isothiazolyl group, oxazolyl group, isooxazolyl group, oxadiazolyl group, thiadiazolyl group, triazolyl group, tetrazolyl group, pyridyl group, pyrimidyl group, pyridazinyl group, pyrazinyl group, triazinyl group, benzofuranyl group, benzothienyl group, benzothiadiazolyl group, benzothiazolyl group, benzoxazolyl group, benzoxadiazolyl group, benzoimidazolyl group, indolyl group, isoindolyl group, azaindolyl group, indazolyl group, quinolyl group, isoquinolyl group, cinnolinyl group, quinazolinyl group, quinoxalinyl group, benzodioxolyl group, indolidinyl group, and imidazopyridyl group.
[0231] Herein, "heterocyclyl" refers to a non-aromatic monovalent heterocyclic group in which the ring-constituting atoms include preferably one to five hetero atoms. The heterocyclyl may contain double or triple bonds in its ring. The carbon atoms may be oxidized to form carbonyl. The ring may be a monocyclic or condensed ring. The number of the ring-constituting atoms preferably ranges from three to ten (3- to 10-membered heterocyclyl).
[0232] Specifically, the heterocyclyl includes, for example, oxetanyl group, dihydrofuryl group, tetrahydrofuryl group, dihydropyranyl group, tetrahydropyranyl group, tetrahydropyridyl group, morpholinyl group, thiomorpholinyl group, pyrrolidinyl group, piperidinyl group, piperazinyl group, pyrazolidinyl group, imidazolinyl group, imidazolidinyl group, oxazolidinyl group, isooxazolidinyl group, thiazolidinyl group, isothiazolidinyl group, thiadiazolidinyl group, azetidinyl group, oxazolidone group, benzodioxanyl group, benzoxazolyl group, dioxolanyl group, and dioxanyl group.
[0233] Herein, "arylalkyl" refers to a group in which an arbitrary hydrogen atom in an "alkyl" defined above is substituted with an "aryl" defined above. The arylalkyl preferably includes C.sub.6-10 aryl C.sub.1-4 alkyl and C.sub.6-10 aryl C.sub.1-3 alkyl. Specifically, the arylalkyl includes, for example, benzyl group, phenethyl group, and naphthylmethyl group.
[0234] Herein, "heteroarylalkyl" refers to a group in which an arbitrary hydrogen atom in an alkyl defined above is substituted with a "heteroaryl" defined above. The heteroarylalkyl preferably includes 5- to 10-membered heteroaryl C.sub.1-3 alkyl. Specifically, the heteroarylalkyl includes, for example, pyrrolylmethyl group, imidazolylmethyl group, thienylmethyl group, pyridylmethyl group, pyrimidylmethyl group, quinolylmethyl group, and pyridylethyl group.
[0235] Herein, "heterocyclylalkyl" refers to a group in which an arbitrary hydrogen atom in an "alkyl" defined above is substituted with a "heterocyclyl" defined above. The heterocyclylalkyl preferably includes 3- to 10-membered heterocyclyl C.sub.1-3 alkyl. Specifically, the heterocyclylalkyl includes, for example, morpholinylmethyl group, morpholinylethyl group, thiomorpholinylmethyl group, pyrrolidinylmethyl group, piperidinylmethyl group, piperazinylmethyl group, piperazinylethyl group, and oxetanylmethyl group.
[0236] Herein, "monohydroxyalkyl" refers to a group in which an arbitrary hydrogen atom in an "alkyl" defined above is substituted with a hydroxyl group. The monohydroxyalkyl preferably includes C.sub.1-6 monohydroxyalkyl and C.sub.2-6 monohydroxyalkyl. Specifically, the monohydroxyalkyl includes, for example, hydroxymethyl group, 1-hydroxyethyl group, and 2-hydroxyethyl group.
[0237] Herein, "dihydroxyalkyl" refers to a group in which two arbitrary hydrogen atoms in an "alkyl" defined above are substituted with two hydroxyl groups. The dihydroxyalkyl preferably includes C.sub.1-6 dihydroxyalkyl and C.sub.2-6 dihydroxyalkyl. Specifically, the dihydroxyalkyl includes, for example, 1,2-dihydroxyethyl group, 1,2-dihydroxypropyl group, and 1,3-dihydroxypropyl group.
[0238] Herein, "trihydroxyalkyl" refers to a group in which three arbitrary hydrogen atoms in an "alkyl" defined above are substituted with three hydroxyl groups. The trihydroxyalkyl preferably includes C.sub.1-6 trihydroxyalkyl and C.sub.2-6 trihydroxyalkyl.
[0239] Herein, "alkoxyalkyl" refers to a group in which an arbitrary hydrogen atom in an "alkyl" defined above is substituted with an "alkoxy" defined above. The alkoxyalkyl preferably includes C.sub.1-3 alkoxy C.sub.1-4 alkyl and C.sub.1-3 alkoxy C.sub.2-4 alkyl. Specifically, the alkoxyalkyl includes, for example, methoxyethyl.
[0240] Herein, "alkoxyalkoxyalkyl" refers to a group in which an arbitrary hydrogen atom in the terminal alkyl of an "alkoxyalkyl" defined above is substituted with an "alkoxy" defined above. The alkoxyalkoxyalkyl preferably includes C.sub.1-3 alkoxy C.sub.1-4 alkoxy C.sub.1-4 alkyl and C.sub.1-3 alkoxy C.sub.2-4 alkoxy C.sub.2-4 alkyl.
[0241] Herein, "aminoalkyl" refers to a group in which an arbitrary hydrogen atom in an "alkyl" defined above is substituted with an amino group. The aminoalkyl group preferably includes C.sub.1-4 aminoalkyl and C.sub.2-4 aminoalkyl.
[0242] Herein, "alkylamino" refers to an amino group linked with an "alkyl" defined above. The alkylamino preferably includes C.sub.1-4 alkylamino.
[0243] Herein, "dialkylamino" refers to an amino group linked with two "alkyls" defined above. The two alkyl groups may be same or different. The dialkylamino preferably includes di(C.sub.1-4 alkyl)amino.
[0244] Herein, "alkylaminoalkyl" refers to a group in which an arbitrary hydrogen atom in an "alkyl" defined above is substituted with an "alkylamino" defined above. The alkylaminoalkyl preferably includes C.sub.1-4 alkylamino C.sub.1-4 alkyl and C.sub.1-4 alkylamino C.sub.2-4 alkyl.
[0245] Herein, "dialkylaminoalkyl" refers to a group in which an arbitrary hydrogen atom in an "alkyl" defined above is substituted with a "dialkylamino" defined above. The dialkylaminoalkyl preferably includes di(C.sub.1-4 alkyl)amino C.sub.1-4 alkyl and di(C.sub.1-4 alkyl)amino C.sub.2-4 alkyl.
[0246] Herein, "heterocyclylamino" refers to an amino group linked with a "heterocyclyl" defined above. The heterocyclylamino preferably includes 3- to 10-membered heterocyclylamino.
[0247] Herein, "cyanoalkyl" refers to a group in which an arbitrary hydrogen atom in an "alkyl" defined above is substituted with a cyano group. The cyanoalkyl preferably includes cyano(C.sub.1-3 alkyl).
[0248] Herein, "alkylsulfonyl" refers to a sulfonyl group linked with an "alkyl" defined above (i.e. alkyl-SO.sub.2--). The alkylsulfonyl preferably includes C.sub.1-3 alkylsulfonyl. Specifically, the alkylsulfonyl includes methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, and i-propylsulfonyl.
[0249] Herein, "alkylsulfonylalkyl" refers to a group in which an arbitrary hydrogen atom in an "alkyl" defined above is substituted with an "alkylsulfonyl" defined above. The alkylsulfonylalkyl preferably includes C.sub.1-3 alkylsulfonyl C.sub.1-4 alkyl and C.sub.1-3 alkylsulfonyl C2-4 alkyl.
[0250] Preferably, the compounds represented by formula (I) shown above are as follows:
[0251] R.sub.1 shown above preferably represents hydrogen, hydroxy, halogen, cyano, nitro, C.sub.1-4 haloalkyl, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-10 aryl C.sub.1-4 alkyl, --OR.sub.5, --NR.sub.6R.sub.7, --(CR.sub.8R.sub.9).sub.nZ.sub.1, --C(O)NR.sub.12R.sub.13, --SR.sub.14, --SOR.sub.15, --SO.sub.2R.sub.16, --NR.sub.17SO.sub.2R.sub.18, COOH, C.sub.6-10 aryl which is optionally substituted with one or more groups independently selected from group P, 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl each of which is optionally substituted with one or more groups independently selected from group Q, --COR.sub.19, --COOR.sub.20, --OC(O)R.sub.21, --NR.sub.22C(O)R.sub.23, --NR.sub.24C(S)R.sub.25, --C(S)NR.sub.26R.sub.27, --SO.sub.2NR.sub.28R.sub.29, --OSO.sub.2R.sub.30, --SO.sub.3R.sub.31, or --Si(R.sub.32).sub.3.
[0252] R.sub.1 shown above more preferably represents hydrogen, hydroxy, halogen, cyano, C.sub.1-4 haloalkyl, C.sub.1-6 alkyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-10 aryl C.sub.1-4 alkyl, --OR.sub.5, --NR.sub.6R.sub.7, --(CR.sub.8R.sub.9).sub.nZ.sub.1, --C(O)NR.sub.12R.sub.13, --SR.sub.14, --SO.sub.2R.sub.16, --NR.sub.17SO.sub.2R.sub.18, COOH, C.sub.6-10 aryl which is optionally substituted with one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl each of which is optionally substituted with one or more groups independently selected from group Q. Specifically, the above 5- to 10-membered heteroaryl is particularly preferably an imidazolyl group, thienyl group, pyridyl group, pyridazinyl group, or pyrazolyl group. The above 3- to 10-membered heterocyclyl is particularly preferably a morpholinyl group, tetrahydropyridyl group, or piperidinyl group.
[0253] R.sub.2 shown above preferably represents hydrogen, hydroxy, halogen, cyano, nitro, C.sub.1-4 haloalkyl, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.6-10 aryl C.sub.1-4 alkyl, --OR.sub.5, --NR.sub.6R.sub.7, --(CR.sub.8R.sub.9).sub.nZ.sub.1, --C(O)NR.sub.12R.sub.13, --SR.sub.14, --SOR.sub.15, --SO2R.sub.16, --NR.sub.17SO.sub.2R.sub.18, COOH, C.sub.6-10 aryl which is optionally substituted with one or more groups independently selected from group P, 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl each of which is optionally substituted with one or more groups independently selected from group Q, --COR.sub.19, --COOR.sub.20, --OC(O)R.sub.21, --NR.sub.22C(O)R.sub.23, --NR.sub.24C(S)R.sub.25, --C(S)NR.sub.26R.sub.27, --SO.sub.2NR.sub.28R.sub.29, --OSO.sub.2R.sub.30, --SO.sub.3R.sub.31, or --Si(R.sub.32).sub.3.
[0254] R.sub.2 shown above more preferably represents hydrogen, halogen, C.sub.1-4 haloalkyl, C.sub.1-6 alkyl, --OR.sub.5, C.sub.6-10 aryl which is optionally substituted with one or more groups independently selected from group P, or 5- to 10-membered heteroaryl which is optionally substituted with one or more groups independently selected from group Q. Specifically, this 5- to 10-membered heteroaryl is particularly preferably a pyridyl group.
[0255] R.sub.1 and R.sub.2 shown above can preferably be taken together with the atoms to which they are attached to form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl. The heterocyclyl or heteroaryl may have a halogen atom as a substituent. Specifically, the 3- to 10-membered heterocyclyl formed together with the atoms to which R.sub.1 and R.sub.2 are attached, is particularly preferably a dioxolanyl group or dioxanyl group.
[0256] R.sub.3 shown above preferably represents hydrogen, C.sub.1-5 alkyl, C.sub.6-10 aryl C.sub.1-6 alkyl, or C.sub.1-4 haloalkyl, more preferably hydrogen, C.sub.1-4 alkyl, C.sub.6-10 aryl C.sub.1-4 alkyl, or C.sub.1-3perfluoroalkyl, and particularly preferably C.sub.1 alkyl.
[0257] R.sub.4 shown above preferably represents hydrogen, halogen, C.sub.1-3 alkyl, C.sub.1-4 haloalkyl, hydroxy, cyano, nitro, C.sub.1-4 alkoxy, --(CH.sub.2).sub.nZ.sub.1, --NR.sub.6R.sub.7, --OR.sub.5, --C(O)NR.sub.12R.sub.13, --SR.sub.14, --SOR.sub.15, --SO.sub.2R.sub.16, NR.sub.17SO.sub.2R.sub.18, COOH, --COOR.sub.19, --COOR.sub.20, --OC(O)R.sub.21, --NR.sub.22C(O)R.sub.23, --NR.sub.24C(S)R.sub.25, --C(S)NR.sub.26R.sub.27, --SO.sub.2NR.sub.28R.sub.29, --OSO.sub.2R.sub.30--SO.sub.3R.sub.31, or --Si(R.sub.32).sub.3.
[0258] R.sub.4 shown above more preferably represents hydrogen, halogen, C.sub.1-3 alkyl, C.sub.1-3 perfluoroalkyl, cyano, methanesulfonyl, hydroxyl, alkoxy, or amino, and particularly preferably hydrogen or halogen.
[0259] Ring A mentioned above is preferably a 5- to 10-membered heteroaryl ring or C.sub.6-10 aryl ring, more preferably benzene, indole, azaindole, benzofuran, benzothiophene, benzothiazole, quinoline, or pyrrole, and particularly preferably indole or pyrrole.
[0260] R.sub.5 shown above preferably represents C.sub.1-5 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkyl C.sub.1-3 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.1-3 alkoxy C.sub.1-4 alkyl, C.sub.1-3 alkoxy C.sub.1-4 alkoxy C.sub.1-4 alkyl, C.sub.1-4 amino alkyl, C.sub.1-4 alkylamino C.sub.1-4 alkyl, di(C.sub.1-4 alkyl)amino C.sub.1-4 alkyl, C.sub.6-10 aryl, C.sub.6-10 aryl C.sub.1-3 alkyl, or 3- to 10-membered heterocyclyl C.sub.1-3 alkyl, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, or 5- to 10-membered heteroaryl C.sub.1-3 alkyl, each of which is optionally substituted with one or more groups independently selected from group Q, C.sub.1-6 monohydroxyalkyl, C.sub.1-6 dihydroxyalkyl, or C.sub.1-6 trihydroxyalkyl.
[0261] R.sub.5 shown above more preferably represents C.sub.1-5 alkyl, C.sub.3-7 cycloalkyl C.sub.1-3 alkyl, C.sub.1-4 haloalkyl, C.sub.1-3 alkoxy C.sub.1-4 alkyl, C.sub.6-10 aryl , C.sub.6-10 aryl C.sub.1-3 alkyl, or 3- to 10-membered heterocyclyl C.sub.1-3 alkyl or 3- to 10-membered heterocyclyl each of which is optionally substituted with one or more groups independently selected from group Q. Specifically, the above 3- to 10-membered heterocyclylalkyl is particularly preferably a piperazinylethyl group, oxetanylmethyl group, or morpholinylethyl group. The above 3- to 10-membered heterocyclyl is particularly preferably an oxetanyl group or tetrahydropyranyl group.
[0262] R.sub.6 and R.sub.7 shown above may be the same or different, and each preferably represents hydrogen, C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.1-3 alkoxy C.sub.2-4 alkyl, C.sub.6-10 aryl C.sub.1-3 alkyl, 3- to 10-membered heterocyclyl C.sub.1-3 alkyl, 5- to 10-membered heteroaryl C.sub.1-3 alkyl, C.sub.1-6 monohydroxyalkyl, C.sub.1-6 dihydroxyalkyl, C.sub.1-6 trihydroxyalkyl, 3- to 10-membered heterocyclyl, C.sub.1-4 aminoalkyl, C.sub.1-4 alkylamino C.sub.1- 4 alkyl, di(C.sub.1-4 alkyl)amino C.sub.1-4 alkyl, or cyano(C.sub.1-3 alkyl).
[0263] R.sub.6 and R.sub.7 shown above more preferably each independently represent hydrogen, C.sub.1-3 alkoxy C.sub.1-4 alkyl, 3- to 10-membered heterocyclyl C.sub.1-3 alkyl, 5- to 10-membered heteroaryl C.sub.1-3 alkyl, or C.sub.1-6 dihydroxyalkyl. Specifically, the 3- to 10-membered heterocyclylalkyl is particularly preferably a morpholinylethyl group, and the 5- to 10-membered heteroarylalkyl is particularly preferably a pyridylethyl group.
[0264] Alternatively, R6 and R7 shown above can preferably be taken together with the nitrogen atoms to which they are attached to form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl.
[0265] "n" shown above represents an integer from 1 to 3. Preferably, n is 1.
[0266] R.sub.8 and R.sub.9 shown above preferably may be the same or different, and each represents hydrogen, C.sub.1-4 alkyl, or halogen, and more preferably hydrogen.
[0267] Alternatively, R.sub.8 and R.sub.9 shown above can preferably be taken together with the carbon atoms to which they are attached to form an alicyclic ring.
[0268] Z.sub.1 shown above preferably represents hydrogen, NR.sub.10R.sub.11, --OH, or 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl each of which is optionally substituted with one or more groups independently selected from group Q, more preferably NR.sub.10R.sub.11 or --OH, or 3- to 10-membered heterocyclyl which is optionally substituted with one or more groups independently selected from group Q. Specifically, the above 3- to 10-membered heterocyclyl is particularly preferably a pyrrolidinyl group, piperazinyl group, piperidinyl group, or morpholinyl group.
[0269] R.sub.10 and R.sub.11 shown above preferably may be the same or different, and each preferably represents C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.1-3 alkoxy C.sub.1-4 alkyl, cyano(C.sub.1-3 alkyl), or C.sub.1-3 alkylsulfonyl C.sub.1-4 alkyl, more preferably C.sub.1-4 alkyl, C.sub.2-6 alkynyl, or C.sub.1-3 alkoxy C.sub.2-4 alkyl.
[0270] Alternatively, R.sub.10 and R.sub.11 shown above can preferably be taken together with the nitrogen atoms to which they are attached to form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl.
[0271] R.sub.12 and R.sub.13 shown above preferably may be the same or different, and each represents hydrogen, C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.1-3 alkoxy C.sub.1-4 alkyl, C.sub.6-19 aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, C.sub.6-19 aryl C.sub.1-4 alkyl, 3- to 10-membered heterocyclyl C.sub.1-3 alkyl, 5- to 10-membered heteroaryl C1-3 alkyl, cyano(C1-3 alkyl), C.sub.1-3 alkylsulfonyl C.sub.1-4 alkyl, or 3- to 10-membered alicyclic ring, more preferably hydrogen, C.sub.1-4 alkyl, or C.sub.1-4 haloalkyl.
[0272] Alternatively, R.sub.12 and R.sub.13 shown above preferably can be taken together with the nitrogen atoms to which they are attached to form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl each of which is optionally substituted with one or more groups independently selected from group Q, and particularly preferably 3- to 10-membered heterocyclylalkyl. Specifically, piperazinyl group, morpholinyl group, pyrrolidinyl group, and piperidinyl group are more preferred.
[0273] R.sub.14 shown above preferably represents C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl which is optionally substituted with one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl each of which is optionally substituted with one or more groups independently selected from group Q, and more preferably represents C.sub.1-4 alkyl or C.sub.1-4 haloalkyl.
[0274] R15 shown above preferably represents C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl which is optionally substituted with one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl each of which is optionally substituted with one or more groups independently selected from group Q.
[0275] R.sub.16 shown above preferably represents C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl which is optionally substituted with one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl each of which is optionally substituted with one or more groups independently selected from group Q, and more preferably represents C.sub.1-4 alkyl.
[0276] R.sub.17 shown above preferably represents hydrogen or C.sub.1-4 alkyl, and more preferably hydrogen.
[0277] R.sub.18 shown above preferably represents C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl which is optionally substituted with one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl each of which is optionally substituted with one or more groups independently selected from group Q, and more preferably represents C.sub.1-4 alkyl.
[0278] R.sub.19 shown above preferably represents hydrogen, C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl each of which is optionally substituted with one or more groups independently selected from group Q, and more preferably represents hydrogen, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocyclyl each of which is optionally substituted with one or more groups independently selected from group Q. Specifically, this 3- to 10-membered heterocyclyl is more preferably a piperazinyl group, morpholinyl group, pyrrolidinyl group, or piperidinyl group.
[0279] R.sub.20 shown above preferably represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl.
[0280] R.sub.21 shown above preferably represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl.
[0281] R.sub.22 shown above preferably represents hydrogen, C.sub.1-4 alkyl, or C.sub.1-4 haloalkyl.
[0282] R.sub.23 shown above preferably represents hydrogen, C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl.
[0283] R.sub.24 shown above preferably represents hydrogen, C.sub.1-4 alkyl, or C.sub.1-4 haloalkyl.
[0284] R.sub.25 shown above preferably represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl.
[0285] R.sub.26 and R.sub.27 shown above preferably may be the same or different, and each represents hydrogen, C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.1-3 alkoxy C.sub.1-4 alkyl, C.sub.6-10 aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, C.sub.6-10 aryl C.sub.1-4 alkyl, 3- to 10-membered heterocyclyl C.sub.1-3 alkyl, 5- to 10-membered heteroaryl C.sub.1-3 alkyl, cyano(C.sub.1-3 alkyl), C.sub.1-3 alkylsulfonyl C.sub.14 alkyl, or 3- to 10-membered alicyclic ring.
[0286] Alternatively, R.sub.26 and R.sub.27 shown above can preferably be taken together with the nitrogen atoms to which they are attached to form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl.
[0287] R.sub.28 and R.sub.29 shown above preferably may be the same or different, and each represents hydrogen, C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-4 haloalkyl, C.sub.1-3 alkoxy C.sub.1-4 alkyl, C.sub.6-10 aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, C.sub.6-10 aryl C.sub.1-4 alkyl, 3- to 10-membered heterocyclyl C.sub.1-3 alkyl, 5- to 10-membered heteroaryl C.sub.1-3 alkyl, cyano(C.sub.1-3 alkyl), C.sub.1-3 alkylsulfonyl C.sub.1-4 alkyl, or 3- to 10-membered alicyclic ring.
[0288] Alternatively, R.sub.28 and R.sub.29 shown above preferably can be taken together with the nitrogen atoms to which they are attached to form 3- to 10-membered heterocyclyl or 5- to 10-membered heteroaryl.
[0289] R.sub.30 shown above preferably represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl.
[0290] R.sub.31 shown above preferably represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, C.sub.1-4 haloalkyl, C.sub.6-10 aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl.
[0291] R.sub.32 shown above preferably represents C.sub.1-4 alkyl, or C.sub.6-10 aryl.
[0292] Preferred substituents included in group P defined above are halogen, C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, --OH, C.sub.1-3 alkoxy, C.sub.1-3 haloalkoxy, 3- to 10-membered heterocyclylamino, --SO.sub.2R, --CN, --NO.sub.2, and 3- to 10-membered heterocyclyl; and more preferably halogen, C.sub.1-4 haloalkyl, C.sub.1-3 alkoxy, C.sub.1-3 haloalkoxy, and 3- to 10-membered heterocyclyl. Specifically, this 3- to 10-membered heterocyclyl is particularly preferably a morpholinyl group.
[0293] Preferred substituents included in group Q defined above are halogen, C.sub.1-4 alkyl, C1-4 haloalkyl, --OH, C.sub.1-3 alkoxy, C.sub.1-6 monohydroxyalkyl, C.sub.1-6 dihydroxyalkyl, C.sub.1-6 trihydroxyalkyl, 3- to 10-membered heterocyclylamino, --SO.sub.2R, --CN, --NO.sub.2, C.sub.3-7 cycloalkyl, -COR19, and 3- to 10-membered heterocyclyl which is optionally substituted with C.sub.1-4 alkyl; and more preferably halogen, C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, --OH, C.sub.1-3 alkoxy, C.sub.1-6 monohydroxyalkyl, --SO.sub.2R.sub.16, C.sub.3-7 cycloalkyl, --COR.sub.19, and 3- to 10-membered heterocyclyl which is optionally substituted with C.sub.1-4 alkyl. Specifically, this 3- to 10-membered heterocyclyl is more preferably a piperazinyl group, piperidinyl group, or morpholinyl group.
[0294] Specific examples of the compounds include:
(1) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-indol- -2-yl)-methanone; (2) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-pyrrolidin- -1-ylmethyl-1H-indol-2-yl)-methanone; (3) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-hydroxy- -piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone; (4) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-pyrrolo[3- ,2-c]pyridin-2-yl)-methanone; (5) [5-amino-1-(2-methyl-1H-benzimi dazol-5-yl)-1H-pyrazol-4-yl]-(6-piperazin-1-ylmethyl-1H-indol-2-yl)-metha- none; (6) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(- 2-morpholin-4-yl-ethoxy)-1H-indol-2-yl]-methanone; (7) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(tetrahydr- o-pyran-4-yloxy)-1H-indol-2-yl]-methanone; (8) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-chloro-1H-- indol-2-yl)-methanone; (9) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-bromo-1H-i- ndol-2-yl)-methanone; (10) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-iodo-1H-in- dol-2-yl)-methanone; (11) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-i- ndole-5-carbonitrile; (12) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl] -(6-bromo-5-fluoro-1H-indol-2-yl)-methanone; (13) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-ethynyl-1H- -indo1-2-yl)-methanone; (14) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-fluoro-- phenyl)-1H-indol-2-yl]-methanone; (15) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-fluoro-- phenyl)-1H-indol-2-yl]-methanone; (16) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-fluoro-- phenyl)-1H-indol-2-yl]-methanone; (17) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-chloro-- phenyl)-1H-indol-2-yl]-methanone; (18) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-chloro-- phenyl)-1H-indol-2-yl]-methanone; (19) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-chloro-- phenyl)-1H-indol-2-yl]-methanone; (20) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-trifluo- romethyl-phenyl)-1H-indol-2-yl]-methanone; (21) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-trifluo- romethyl-phenyl)-1H-indol-2-yl]-methanone; (22) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-trifluo- romethyl-phenyl)-1H-indol-2-yl]-methanone; (23) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-bromo-1H-i- ndol-2-yl)-methanone; (24) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-fluoro-- pyridin-2-yl)-1H-indol-2-yl]-methanone; (25) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-methyl-1H-- indol-2-yl)-methanone; (26) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4,4-diflu- oro-piperidine-1-carbonyl)-1H-indol-2-yl]-methanone; (27) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3-diflu- oro-piperidine-1-carbonyl)-1H-indol-2-yl]-methanone; (28) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-i- ndole-5-carboxylic acid (2,2,2-trifluoro-ethyl)-amide; (29) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-trifluo- romethyl-pyridin-2-yl)-1H-indol-2-yl]-methanone; (30) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-trifluo- romethyl-pyridin-2-yl)-1H-indol-2-yl]-methanone; (31) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-chloro-- pyridin-2-yl)-1H-indol-2-yl]-methanone; (32) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-methyl-- pyridin-2-yl)-1H-indol-2-yl]methanone; (33) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-chloro-- 4-fluoro-phenyl)-1H-indol-2-yl]-methanone; (34) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-trifluo- romethyl-pyridin-2-yl)-1H-indol-2-yl]-methanone; (35) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-trifluo- romethyl-pyridin-2-yl)-1H-indol-2-yl]methanone; (36) [5-amino-1-(6-fluoro-2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-- indol-2-yl)-methanone; (37) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-i- ndole-6-carboxylic acid; (38) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-hydroxymet- hyl-1H-indol-2-yl)-methanone; (39) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-{6-[2-(4-meth- yl-piperazin-1-yl)-ethoxy]-1H-indol-2-yl}- methanone; (40) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-methyl-- oxetan-3-ylmethoxy)-1H-indol-2-yl]-methanone; (41) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-fluoro-- piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone; (42) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-{[bis(2-me- thoxy-ethyl)-amino]-methyl}-1H-indol-2-yl)-methanone; (43) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-{6-[(methyl-p- rop-2-ynyl-amino)-methyl]-1H-indol-2-yl}-methanone; (44) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3,3-diflu- oro-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone; (45) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2,5-dimet- hyl-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone; (46) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3,3-diflu- oro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone; (47) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-((S)-3-met- hyl-morpholin-4-ylmethyl)-1H-indol-2-yl]-methanone; (48) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-bromo-1H-i- ndol-2-yl)-methanone; (49) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-iodo-1H-in- do1-2-yl)-methanone; (50) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-pyrrolo[3- ,2-b]pyridin-2-yl)-methanone; (51) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-bromo-6-tr- ifluoromethyl-1H-indol-2-yl)-methanone; (52) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-iodo-1H-in- dol-2-yl)-methanone; (53) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-methyl-1H-- indol-2-yl)-methanone; (54) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-isopropyl-- 1H-indol-2-yl)-methanone; (55) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2-fluoro-- phenyl)-1H-indol-2-yl]-methanone; (56) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-benzyl-1H-- indol-2-yl)-methanone; (57) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2-trifluo- romethyl-phenyl)-1H-indol-2-yl]-methanone; (58) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3-fluorop- henyl)-1H-indol-2-yl]-methanone; (59) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3-trifluo- romethyl-phenyl)-1H-indol-2-yl]-methanone; (60) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-ethynyl-1H- -indol-2-yl)-methanone; (61) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5H[1,3]dioxo- lo[4,5-f]indol-6-yl)-methanone; (62) [5-amino-1-(7-fluoro-2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-- indol-2-yl)-methanone; (63) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-trifluo- romethyl-phenyl)-1H-indol-2-yl]-methanone; (64) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-butoxy-1H-- indol-2-yl)-methanone; (65) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-methyl-- piperidin-4-yl)-1H-indol-2-yl]methanone; (66) N-{2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1- H-indol-6-yl}-methanesulfonamide; (67) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-morphol- in-4-yl-pyridin-3-yl)-1H-indol-2-yl]-methanone; (68) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-butyl-1H-i- ndol-2-yl)-methanone; (69) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(1-methyl-- 1H-pyrazol-4-yl)-1H-indol-2-yl]-methanone; (70) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-methoxy- -pyridin-3-yl)-1H-indol-2-yl]-methanone; (71) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-methoxy- -pyridin-3-yl)-1H-indol-2-yl]-methanone; (72) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-cyclopropy- l-1H-indol-2-yl)-methanone; (73) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-methoxy- -phenyl)-1H-indol-2-yl]-methanone; (74) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-phenyl-1H-- indol-2-yl)-methanone; (75) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-methane- sulfonyl-pyridin-3-yl)-1H-indol-2-yl]-methanone; (76) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-isopropyl-- 1H-indol-2-yl)-methanone; (77) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-pyridin-2-- yl-1H-indol-2-yl)-methanone; (78) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-cyclopropy- l-1H-indol-2-yl)-methanone; (79) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-pyridazin-- 3-yl-1H-indol-2-yl)-methanone; (80) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-isopropoxy- -1H-indol-2-yl)-methanone; (81) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2-methoxy- -ethoxy)-1H-indol-2-yl]-methanone; (82) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-cyclopropy- lmethoxy-1H-indol-2-yl)-methanone; (83) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(2,2-difluoro- -5H-[1,3]dioxolo[4,5-f]indol-6-yl)-methanone; (84) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-chloro-- pyridin-2-yl)-1H-indol-2-yl]-methanone; (85) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-fluoro-- pyridin-2-yl)-1H-indol-2-yl]-methanone; (86) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-morphol- in-4-yl-pyridazin-3-yl)-1H-indol-2-yl]-methanone; (87) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-chloro-6-c- yclopropylmethoxy-1H-indol-2-yl)-methanone; (88) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2,4-diflu- oro-phenyl)-1H-indo1-2-yl]-methanone; (89) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-pyridazin-- 4-yl-1H-indol-2-yl)-methanone; (90) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(3-fluoro-1H-- indol-2-yl)-methanone; (91) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-isoprop- yl-piperidin-4-yl)-6-trifluoromethyl-1H-indl-2-yl]- methanone; (92) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-i- ndole-6-carbonitrile; (93) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1,2,3,6-t- etrahydro-pyridin-4-yl)-1H-indol-2-yl]-methanone; (94) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-piperidin-- 4-yl-1H-indol-2-yl)-methanone; (95) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-((R)-3-flu- oro-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone; (96) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-fluoro-5-p- iperidin-4-yl-1H-indol-2-yl)-methanone; (97) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-(- 1-methyl-piperidin-4-yl)-1H-indol-2-yl]-methanone; (98) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-isoprop- yl-piperidin-4-yl)-1H-indol-2-yl]-methanone; (99) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-(- 1-isopropyl-piperidin-4-yl)-1H-indol-2-yl]-methanone; (100) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-pyridin-3-- yl-1H-indol-2-yl)-methanone; (101) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-morphol- in-4-yl-pyridin-3-yl)-1H-indol-2-yl]-methanone; (102) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-pyridin-3-- yl-1H-indol-2-yl)-methanone; (103) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-piperaz- in-1-yl-pyridin-3-yl)-1H-indol-2-yl]-methanone; (104) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-hydroxy- -pyridin-3-yl)-1H-indol-2-yl]-methanone; (105) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-(- 4-methyl-piperazin-1-ylmethyl)-1H-indol-2-yl]- methanone; (106) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-fluoro-5-p- yrrolidin-1-ylmethyl-1H-indol-2-yl)-methanone; (107) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(1-methyl-- piperidin-4-yl)-1H-indol-2-yl]-methanone; (108) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-morphol- in-4-yl-phenyl)-1H-indol-2-yl]-methanone; (109) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3,4,5,6-t- etrahydro-2H-[1,2']bipyridin-5'-yl)-1H-indol- 2-yl]-methanone; (110) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-piperaz- in-1-yl-pyridin-3-yl)-1H-indo1-2-yl]-methanone; (111) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-methoxy- -pyridin-3-yl)-1H-indol-2-yl]-methanone; (112) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-((S)-3-met- hyl-morpholin-4-ylmethyl)-1H-indol-2-yl]-methanone; (113) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-((R)-3-flu- oro-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone; (114) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2,5-dimet- hyl-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone; (115) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3-fluoro-- piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone; (116) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3-diflu- oro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone; (117) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-{6-[2-(4-meth- yl-piperazin-1-yl)pyridin-4-yl]-1H-indol-2- yl}-methanone; (118) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-pyridin-4-- yl-1H-indol-2-yl)-methanone; (119) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-fluorop- iperidin-1-ylmethyl)-1H-indol-2-yl]-methanone; (120) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4,4-diflu- oro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone; (121) [5-amino-1-(2-difluoromethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1- -methyl-piperidin-4-yl)-1H-indol-2-yl]-methanone; (122) [5-amino-1-(2-difluoromethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-i- ndol-2-yl)-methanone; (123) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3-diflu- oro-pyrrolidin-1-ylmethyl)-1H-indo1-2-yl]-methanone; (124) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-cyclope- ntyl-piperidin-4-yl)-1H-indol-2-yl]-methanone; (125) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[45-(1-cycloh- exyl-piperidin-4-yl)-1H-indol-2-yl]-methanone; (126) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-bromo-1H-p- yrrol-2-yl)-methanone; (127)
[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-pyrrol-2-- yl)-methanone; (128) [5-amino-1-(2-methyl-1H-benzimi dazol-5-yl)-1H-pyrazol-4-yl]-(4-phenyl-1H-pyrrol-2-yl)-methanone; (129) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(3-chloro-- phenyl)-1H-pyrrol-2-yl]-methanone; (130) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(4-fluoro-- phenyl)-1H-pyrrol-2-yl]-methanone; (131) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(3-fluoro-- phenyl)-1H-pyrrol-2-yl]-methanone; (132) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-morpholin-- 4-ylmethyl-1H-indol-2-yl)-methanone; (133) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-morphol- in-4-yl-ethylamino)-1H-indol-2-yl]-methanone; (134) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-methyl-- piperazine-1-carbonyl)-1H-indol-2-yl]-methanone; (135) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-morphol- in-4-yl-ethylamino)-1H-indol-2-yl]-methanone; (136) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(piperazin- e-1-carbonyl)-1H-indol-2-yl]-methanone; (137) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-methoxy- -ethylamino)-1H-indol-2-yl]-methanone; (138) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-hydroxy- -1-hydroxymethyl-ethylamino)-1H-indol-2-yl]-methanone; (139) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-pyridin- -4-yl-ethylamino)-1H-indol-2-yl]-methanone; (140) [5-amino-1-(2-methyl-1H-benzimi dazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-methoxy-ethylamino)-1H-indol-2-yl]-met- hanone; (141) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-morpholin-- 4-yl-1H-indol-2-yl)-methanone; (142) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-morpholin-- 4-yl-1H-indol-2-yl)-methanone; (143) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-morpholin-- 4-ylmethyl-1H-indol-2-yl)-methanone; (144) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-morpholin-- 4-ylmethyl-1H-indol-2-yl)-methanone; (145) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(morpholin- e-4-carbonyl)-1H-indol-2-yl]-methanone; (146) [5-amino-1-(2-isopropyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-indol-- 2-yl)-methanone; (147) [5-amino-1-(2-propyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-indol-2-y- l)-methanone; (148) [5-amino-1-(1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-indol-2-yl)-methan- one; (149) [5-amino-1-(2-trifluoromethyl-1H-benzimidazol-5-yl)-1H-pyrazol-- 4-yl]-(1H-indol-2-yl)-methanone; (150) [5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl] -(1H-indol-2-yl)-methanone; (151) [5-amino-1-(2-benzyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-indol-2-y- l)methanone; (152) 1-(4-{2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl- ]-1H-indol-5-ylmethyl}-piperazin-1-yl)-ethanone; (153) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-methane- sulfonyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-methanone; (154) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[(5-piperazin- -1-ylmethyl-1H-indol-2-yl]-methanone; (155) 1-(4-{2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl- ]-1H-indol-6-ylmethyl}-piperazin-1-yl)-ethanone; (156) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-methyl-- piperazin-1-ylmethyl)-1H-indol-2-yl]-methanone; (157) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-methyl-- piperazin-1-ylmethyl)-1H-indol-2-yl]-methanone; (158) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-pyrrolidin- -1-ylmethyl-1H-indol-2-yl)-methanone; (159) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-fluoro-1H-- indol-2-yl)-methanone; (160) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-fluoro-1H-- indol-2-yl)-methanone; (161) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-fluoro-1H-- indol-2-yl)-methanone; (162) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-pyrrolo [2,3-b]pyridin-2-yl)-methanone; (163) [5-amino-1-(2-methyl-1H-benzimi dazol-5-yl)-1H-pyrazol-4-yl]-(5-fluoro-6-morpholin-4-ylmethyl-1H-indol-2-- yl)-methanone; (164) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-i- ndole-5-carboxylic acid; (165) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-methoxy-1H- -indol-2-yl)-methanone; (166) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4,6-dimethox- y-1H-indol-2-yl)-methanone; (167) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-methoxy-1H- -indol-2-yl)-methanone; (168) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-methoxy-1H- -indol-2-yl)-methanone; (169) [5-amino-1-(2-methyl-1H-benzimi dazol-5-yl)-1H-pyrazol-4-yl]-(4,6-dimethyl-1H-indol-2-yl)-methanone; (170) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-tert- -butyl-1H-indol-2-yl)-methanone; (171) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-isopropyl-- 1H-indol-2-yl)-methanone; (172) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-benzyloxy-- 1H-indol-2-yl)-methanone; (173) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-benzyloxy-- 1H-indol-2-yl)-methanone; (174) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5,6-dimethox- y-1H-indol-2-yl)-methanone; (175) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-tert-butyl- -1H-indol-2-yl)-methanone; (176) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-fluoro-4-t- rifluoromethyl-1H-indol-2-yl)-methanone; (177) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-phenoxy-1H- -indol-2-yl)-methanone; (178) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-methylsulf- anyl-1H-indol-2-yl)-methanone; (179) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-tert-butyl- -1H-indol-2-yl)-methanone; (180) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-methyl-1H-- indol-2-yl)-methanone; (181) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-ethyl-1H-i- ndol-2-yl)-methanone; (182) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-fluoro-6-t- rifluoromethyl-1H-indol-2-yl)-methanone; (183) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-fluoro-5-m- ethoxy-1H-indol-2-yl)-methanone; (184) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-chloro-5-m- ethoxy-1H-indol-2-yl)-methanone; (185) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-chloro-6-m- ethoxy-1H-indol-2-yl)-methanone; (186) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-isopropoxy- -1H-indol-2-yl)-methanone; (187) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-benzyloxy-- 1H-indol-2-yl)-methanone; (188) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-isopropoxy- -1H-indol-2-yl)-methanone; (189) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(2,3-dihydro-- 6H-[1,4]dioxino [2,3-f]indol-7-yl)-methanone; (190) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4,6-di-tert-- butyl-1H-indol-2-yl)-methanone; (191) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-i- ndole-4-carbonitrile; (192) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-imidazol-1- -yl-1H-indol-2-yl)-methanone; (193) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-trifluorom- ethylsulfanyl-1H-indol-2-yl)-methanone; (194) [5-amino-1-(2-methyl-1H-benzimi dazol-5-yl)-1H-pyrazol-4-yl]-(5-methylsulfanyl-1H-indol-2-yl)-methanone; (195) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-meth- anesulfonyl-1H-indol-2-yl)-methanone; (196) [5-amino-1-(2-methyl-1H-benzimi dazol-5-yl)-1H-pyrazol-4-yl]-[6-(4,4-difluoro-piperidin-1-ylmethyl)-1H-in- dol-2-yl]-methanone; (197) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-fluoro-- piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone; (198) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(oxetan-3-- yloxy)-1H-indol-2-yl]-methanone; (199) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-hydroxy-1H- -indol-2-yl)-methanone; (200) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-methanesul- fonyl-1H-indol-2-yl)-methanone; (201) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4,5-dibromo-- 1H-pyrrol-2-yl)-methanone; (202) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4,5-diphenyl- -1H-pyrrol-2-yl)-methanone; and (203) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4,5-dipyridi- n-3-yl-1H-pyrrol-2-yl)-methanone. (204) [5-amino-1-(2-methyl-3H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-chloro-1H-- indol-2-yl)-methanone; (205) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-chloro-1H-- indol-2-yl)-methanone; (206) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-indol-3-y- l)-methanone; (207) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-indol-6-y- l)-methanone; (208) [5-amino-1-(2-methyl-1H-benzimi dazol-5-yl)-1H-pyrazol-4-yl]-(5-bromo-6-fluoro-1H-indol-2-yl)-methanone; (209) [5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-bromo- -6-fluoro-1H-indol-2-yl)-methanone; (210) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-trifluorom- ethyl-1H-indol-2-yl)-methanone; (211) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-trifluorom- ethoxy-1H-indol-2-yl)-methanone; (212) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4,6-dichloro- -1H-indo1-2-yl)-methanone; (213) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-bromo-4-fl- uoro-1H-indol-2-yl)-methanone; (214) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-trifluorom- ethoxy-1H-indol-2-yl)-methanone; (215) [5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-trifluorome- thoxy-1H-indol-2-yl)-methanone; (216) [5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-trifluorome- thyl-1H-indol-2-yl)-methanone; (217) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5,6-dichloro- -1H-indol-2-yl)-methanone; (218) [5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-bromo-5-flu- oro-1H-indol-2-yl)-methanone; (219) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4,5-dichloro- -1H-indol-2-yl)-methanone; (220) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4,6-difluoro- -1H-indo1-2-yl)-methanone; (221) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-chloro-- pyridin-4-yl)-1H-indol-2-yl]-methanone; (222) [5-amino-1-(2-methyl-1H-benzimi dazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-methyl-pyridine-3-yl)-1H-indol-2-yl]-m- ethanone; (223) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-fluoro-- pyridin-3-yl)-1H-indol-2-yl]-methanone; (224) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-trifluo- romethyl-pyridin-3-yl)-1H-indol-2-yl]-methanone; (225) [5-amino-1-(2-methyl-1H-benzimi dazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-chloro-2-methoxy-pyridin-3-yl)-1H-indo- l-2-yl]-methanone; (226) [5-amino-1-(2-methyl-1H-benzimi dazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-chloro-pyridin-3-yl)-1H-indol-2-yl]-me- thanone; (227) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-thiophen-3- -yl-1H-indol-2-yl)-methanone; (228) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-chlorop- yridin-3-yl)-1H-indol-2-yl]-methanone; (229) [5-amino-1-(2-methyl-1H-benzimi dazol-5-yl)-1H-pyrazol-4-yl]-(6-thiophen-2-yl-1H-indol-2-yl)-methanone; (230) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-f- luoro-pyridin-4-yl)-1H-indol-2-yl]-methanone; (231) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-trifluo- romethyl-pyridin-4-yl)-1H-indol-2-yl]-methanone; (232) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3-diflu- oro-pyrrolidine-1-carbonyl)-1H-indol-2-yl]-methanone; (233) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2,6-dimet- hyl-morpholine-4-carbonyl)-1H-indol-2-yl]-methanone; (234) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-([1,4] bipiperidinyl-1'-carbonyl)-1H-indol-2-yl]-methanone; (235) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-{5-[4-(2,2,2-- trifluoro-ethyl)-piperazine-1-carbonyl]-1H-indol-2- yl}-methanone; (236) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-{5-[4-(2-hydr- oxy-ethyl)-piperazine-1-carbonyl]-1H-indol-2-yl}-methanone; (237) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3,4,4-t- etrafluoro-pyrrolidine-1-carbonyl)-1H-indol-2-yl]- methanone; (238) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-((R)-3-flu- oro-pyrrolidine-1-carbonyl)-1H-indol-2-yl]-methanone; (239) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-((S)-3-flu- roro-pyrrolidine-1-carbonyl)-1H-indol-2-yl]-methanone; (240) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(4-methoxy- -phenyl)-1H-pyrrol-2-yl]-methanone; (241) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(3-methoxy- -phenyl)-1H-pyrrol-2-yl]-methanone; (242) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-bis-(3-f- luoro-phenyl)-1H-pyrrol-2-yl]-methanone; (243) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-bis-(4-m- ethoxy-phenyl)-1H-pyrrol-2-yl]-methanone; (244) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2,4-diflu- oro-phenyl)-1H-pyrrol-2-yl]-methanone; (245) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(4-trifluo- romethoxy-phenyl)-1H-pyrrol-2-yl]-methanone; (246) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-bis-(3-m- ethoxy-phenyl)-1H-pyrrol-2-yl]-methanone; (247) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-benzofuran-2-- yl-methanone; (248) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-benzo[b] thiophen-2-yl-methanone; (249) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-benzothiazol-- 2-yl-methanone; (250) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(4-fluoro-phe- nyl)-methanone; (251) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(3-chloro-phe- nyl)-methanone; (252) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-quinolin-3-yl-
-methanone; (253) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-quinolin-7-yl- -methanone; and (254) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-quinolin-6-yl- -methanone.
[0295] More specific examples include compounds in which A is indole, R3 is methyl, and R4 is hydrogen in formula (I) described above, and compounds shown in Table 1 can be included as examples.
TABLE-US-00002 TABLE 1 CODE STRUCTURAL FORMULA/CHEMICAL NAME A ##STR00006## B ##STR00007## C ##STR00008## D ##STR00009## E ##STR00010##
[0296] The above-mentioned compounds can be produced according to the production method described in International Publication WO 2011/016528.
[0297] In the present invention, compounds having FGFR inhibitory activity as describe above include not only free forms but also pharmaceutically acceptable salts thereof.
[0298] Such "salts" include, for example, inorganic acid salts, organic salts, inorganic base salts, organic base salts, and acidic or basic amino acid salts. Preferred inorganic acid salts include, for example, hydrochloride, hydrobromide, sulfate, nitrate, and phosphate. Preferred organic salts include, for example, acetate, succinate, fumarate, maleate, tartrate, citrate, lactate, malate, stearate, benzoate, methanesulfonate, and p-toluenesulfonate. A particularly preferred salt in the present invention is malate.
[0299] Preferred inorganic base salts include, for example, alkali metal salts such as sodium salts and potassium salts; alkali earth metal salts such as calcium salts and magnesium salts; aluminum salts; and ammonium salts. Preferred organic base salts include, for example, diethylamine salts, diethanolamine salts, meglumine salts, and N,N-dibenzylethylenediamine salts.
[0300] Preferred acidic amino acid salts include, for example, aspartate and glutamate. Preferred basic amino acid salts include, for example, arginine salts, lysine salts, and ornithine salts.
[0301] In the present invention, compounds having FGFR inhibitory activity also include hydrates thereof Furthermore, in the present invention, compounds having FGFR inhibitory activity may absorb some type of solvents to form solvates. Such solvates are also included.
[0302] In addition, compounds having FGFR inhibitory activity in the present invention include all possible structural isomers (geometric isomers, optical isomers, stereoisomers, tautomers, etc.), and mixtures of isomers.
[0303] Compounds having FGFR inhibitory activity in the present invention also include any crystalline polymorphism thereof.
[0304] In the present invention, compounds having FGFR inhibitory activity also include prodrugs thereof "Prodrug" refers to derivatives of the compounds of the present invention which have a chemically or metabolically degradable group, and upon administration to the living body, revert to the original compounds and exhibit the original drug efficacy. The prodrugs include non-covalent complexes and salts. In the present invention, compounds having FGFR inhibitory activity include those in which one or more atoms within the molecule have been replaced with isotopes. Herein, "isotope" refers to an atom which has the same atomic number (proton number) but different mass number (sum of protons and neutrons). The target atoms to be replaced with an isotope in the compounds of the present invention include, for example, hydrogen atom, carbon atom, nitrogen atom, oxygen atom, phosphorus atom, sulfur atom, fluorine atom, and chlorine atom. Their isotopes include .sup.2H, .sup.3H, .sup.13C, .sup.14C, .sup.15N, .sup.17O, .sup.18O, .sup.31P, .sup.32P, .sup.35S, .sup.18F, and .sup.36Cl. In particular, radioisotopes such as .sup.3H and .sup.14C, which emit radiation and decay, are useful in in vivo tissue distribution studies or such of pharmaceuticals or compounds. Stable isotopes do not decay, and thus their quantity rarely changes; and since there is no emission of radiation, stable isotopes can be used safely. The compounds of the present invention can be converted into isotope-substituted compounds according to routine methods by replacing reagents used in synthesis with reagents containing corresponding isotopes.
[0305] Herein, "anticancer agent" or "pharmaceutical composition for treating cancer" which comprises an FGFR inhibitor are used interchangeably, and refers to a cancer therapeutic composition that comprises an above-described compound having FGFR inhibitory activity and pharmaceutically acceptable carriers.
[0306] The compounds having FGFR inhibitory activity of the present invention can be formulated into tablets, powders, fine granules, granules, coated tablets, capsules, syrups, troches, inhalants, suppositories, injections, ointments, eye ointments, eye drops, nasal drops, ear drops, cataplasms, lotions, and such by routine methods. For the formulation, conventional excipients, binders, lubricants, colorants, flavoring agents, and if needed, stabilizers, emulsifiers, absorbefacients, surfactants, pH adjusting agents, preservatives, antioxidants, and such can be used. The compounds of the present invention are formulated using routine methods, by combining ingredients that are generally used as materials for pharmaceutical preparations.
[0307] For example, to produce oral formulations, the compounds of the present invention or pharmacologically acceptable salts thereof are combined with excipients, and if needed, binders, disintegrating agents, lubricants, coloring agents, flavoring agents, and the like; and then formulated into powders, fine granules, granules, tablets, coated tablets, capsules, and such by routine methods.
[0308] The ingredients include, for example, animal and vegetable oils such as soybean oils, beef tallow, and synthetic glycerides; hydrocarbons such as liquid paraffin, squalane, and solid paraffin; ester oils such as octyldodecyl myristate and isopropyl myristate; higher alcohols such as cetostearyl alcohol and behenyl alcohol; silicon resins; silicon oils; surfactants such as polyoxyethylene fatty acid esters, sorbitan fatty acid esters, glycerin fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene hydrogenated castor oils, and polyoxyethylene/polyoxypropylene block copolymers; water-soluble polymers such as hydroxyethyl cellulose, polyacrylic acids, carboxyvinyl polymers, polyethylene glycol, polyvinylpyrrolidone, and methyl cellulose; lower alcohols such as ethanol and isopropanol; polyalcohols such as glycerin, propylene glycol, dipropylene glycol, and sorbitol; saccharides such as glucose and sucrose; inorganic powders such as silicic anhydride, magnesium aluminum silicate, and aluminum silicate; and purified water.
[0309] Excipients include, for example, lactose, cornstarch, sucrose, glucose, mannitol, sorbit, crystalline cellulose, and silicon dioxide.
[0310] Binders include, for example, polyvinyl alcohol, polyvinyl ether, methyl cellulose, ethyl cellulose, Arabic gum, tragacanth, gelatin, shellac, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, polypropylene glycol/polyoxyethylene block polymer, and meglumine.
[0311] Disintegrating agents include, for example, starch, agar, gelatin powder, crystalline cellulose, calcium carbonate, sodium bicarbonate, calcium citrate, dextran, pectin, and calcium carboxymethyl cellulose.
[0312] Lubricants include, for example, magnesium stearate, talc, polyethylene glycol, silica, and hardened vegetable oil.
[0313] Coloring agents approved for use as additives for pharmaceuticals are used. Flavoring agents used include, for example, cacao powder, menthol, aromatic powder, peppermint oil, borneol, and cinnamon powder.
[0314] Of course, these tablets and granules may be coated with sugar, or if needed, other appropriate coatings. Alternatively, when liquid preparations such as syrups and injections are produced, the compounds of the present invention or pharmacologically acceptable salts thereof are combined with pH adjusting agents, solubilizers, isotonizing agents, or such, and if needed, solubilizing agents, stabilizers, and such, and then formulated using routine methods.
[0315] Methods for producing external preparations are not limited, and they can be produced by conventional methods. Various conventional materials for pharmaceuticals, quasi-drugs, cosmetics, and such can be used as base materials in the production. Specifically, the base materials used include, for example, animal and vegetable oils, mineral oils, ester oils, waxes, higher alcohols, fatty acids, silicon oils, surfactants, phospholipids, alcohols, polyalcohols, water-soluble polymers, clay minerals, and purified water. Furthermore, as necessary, it is possible to add pH-adjusting agents, antioxidants, chelating agents, preservatives, colorants, flavoring agents, and such. However, the base materials for external preparations of the present invention are not limited thereto.
[0316] Furthermore, if needed, the preparations may be combined with components that have an activity of inducing differentiation, or components such as blood flow-enhancing agents, antimicrobial agents, antiphlogistic agents, cell-activating agents, vitamins, amino acids, humectants, and keratolytic agents. The amount of above-described base materials added is a quantity that provides a concentration typically selected in the production of external preparations.
[0317] The anticancer agents (granular pharmaceutical compositions for treating cancer) for administering a compound having FGFR inhibitory activity in the present invention are not particularly limited in their dosage form; and the agents may be administered orally or parenterally by commonly used methods. They can be formulated and administered as, for example, tablets, powders, granules, capsules, syrups, troches, inhalants, suppositories, injections, ointments, eye ointments, eye drops, nose drops, ear drops, cataplasms, lotions, etc.
[0318] In the present invention, the dosage of an FGFR inhibitor contained in an anticancer agent or a pharmaceutical composition for treating cancer can be appropriately selected according to the severity of symptoms, age, sex, weight, dosage form, salt type, specific type of disease, and such.
[0319] The dosage varies considerably depending on the patient's disease type, symptom severity, age, sex, sensitivity to the agent, and such. Typically, the agent is administered to an adult once or several times a day at a daily dose of about 0.03 to 1,000 mg, preferably 0.1 to 500 mg, and more preferably 0.1 to 100 mg. The agents or compositions of the present invention are administered once or several times a day. When an injection is used, the daily dose is generally about 1 .mu.g/kg to 3,000 .mu.g/kg, and preferably about 3 .mu.g/kg to 1,000 .mu.g/kg.
[0320] The present invention also relates to pharmaceutical compositions for treating cancer which comprise an above-described compound having FGFR inhibitory activity, and are characterized by their use of being administered to patients expressing a mutant polypeptide of the present invention or carrying a polynucleotide encoding the mutant polypeptide.
[0321] The present invention further relates to methods for treating or preventing cancer which comprise administering an effective amount of the above-mentioned compounds having FGFR inhibitory activity or pharmaceutically acceptable salts thereof to patients expressing the mutant polypeptides or carrying the polynucleotides; use of compounds having FGFR inhibitory activity or pharmaceutically acceptable salts thereof in the production of pharmaceutical compositions for cancer treatment for administration to patients expressing the fusion polypeptides or carrying the polynucleotides; compounds having FGFR inhibitory activity or pharmaceutically acceptable salts thereof for use in treatment or prevention for patients expressing the mutant polypeptides or carrying the polynucleotides; and such.
[0322] Specifically, use of the pharmaceutical compositions for treating cancer is characterized in that whether a patient expresses the mutant polypeptide or carries a polynucleotide encoding the mutant polypeptide is tested using a mutant polypeptide of the present invention as a biomarker before an above-described anticancer agent comprising an FGFR inhibitor is administered to the patient, and the anticancer agent containing an FGFR inhibitor is administered to the patient only if the patient expresses the mutant polypeptide or carries a polynucleotide encoding the mutant polypeptide. This enables one to avoid side effects in therapies using the agent and control the therapeutic condition to produce the best therapeutic effect, thus enabling personalized medicine.
[0323] Whether a patient expresses a mutant polypeptide of the present invention or carries a polynucleotide encoding the mutant polypeptide can be tested by using methods of the present invention described above.
[0324] The present invention also relates to methods for identifying compounds having FGFR inhibitory activity.
[0325] Specifically, methods for identifying compounds having FGFR inhibitory activity in the present invention include methods comprising the steps of:
(a) culturing cells that express an above-described mutant polypeptide of the present invention in the presence or absence of a test compound and determining the level of cell proliferation; (b) comparing the proliferation level of cultured cell between in the presence and absence of the test compound; and (c) judging that the test compound has FGFR inhibitory activity when the proliferation level of the cell cultured in the presence of the test compound is lower than that of the cell cultured in the absence of the test compound.
[0326] Cells used for the above method may be primary cultured cells, established cell lines, or recombinant cells, as long as they express a mutant polypeptide of the present invention. Such recombinant cells include those introduced with an above-described vector carrying a polynucleotide encoding a mutant polypeptide of the present invention.
[0327] Meanwhile, the primary cultured cells include cells collected from cancer patients. The established cell lines include cancer cell lines established from cancer cells collected from cancer patients.
[0328] In the present invention, cancer includes any cancer described above.
[0329] Methods for identifying compounds having FGFR inhibitory activity in the present invention also include those comprising the steps of:
(a) administering a test compound to a non-human mammal transplanted with cells that express an above-described mutant polypeptide of the present invention and determining the proliferation level of the cells; (b) comparing the cell proliferation level determined in step (a) with that determined using a non-human mammal transplanted with the cells but not administered with the test compound; and (c) judging that the test compound has FGFR inhibitory activity when the cell proliferation level determined in step (a) is lower than that determined using a non-human mammal transplanted with the cells but not administered with the test compound.
[0330] Cells used for the above method may be primary cultured cells, established cell lines, or recombinant cells, as long as they express a mutant polypeptide of the present invention. Such recombinant cells include those introduced with an above-described vector carrying a polynucleotide encoding a mutant polypeptide of the present invention.
[0331] Meanwhile, the primary cultured cells include cells collected from cancer patients. The established cell lines include cancer cell lines established from cancer cells collected from cancer patients.
[0332] In the present invention, cancer includes any cancer described above.
[0333] In the methods of the present invention, the cell proliferation level can be tested according to routine methods, for example, by colorimetric methods that measure the enzyme activity of reducing a dye (MTT, XTT, MTS, WST, etc.) to formazan dye (purple).
[0334] When the above-described cells are cancer cells, the cell proliferation level can also be determined by measuring the volume or weight of tumor formed as a result of cell proliferation.
[0335] In the present invention, methods for identifying compounds having FGFR inhibitory activity also comprise embodiments that use reporter gene assays.
[0336] Reporter genes include commonly-used genes encoding arbitrary fluorescent proteins, for example, the green fluorescent protein (GFP) derived from Aequorea coerulescens , luciferase derived from Renilla reniformis or such, reef coral fluorescent proteins (RCFPs) derived from hermatypic coral, fruit fluorescent proteins, and variants thereof.
[0337] In the present invention, reporter gene assay can be carried out, for example, as follows.
[0338] Recombinant cells are prepared by transforming cells that are typically used for producing recombinant proteins with an expression vector inserted with a polynucleotide encoding the mutant polypeptide of the present invention and a gene encoding a reporter protein, so that the reporter protein-encoding gene is transcribed into mRNA dependently on the signal that transcribes the mutant polypeptide-encoding polynucleotide into mRNA. A test compound is contacted with the obtained transformed cells. Whether the compound affects the expression of the mutant polypeptide is indirectly analyzed by determining the expression level of the mutant polypeptide, which depends on the compound activity, by measuring the intensity of fluorescence emitted by the reporter protein simultaneously expressed with the mutant polypeptide (for example, U.S. Pat. Nos. 5,436,128; 5,401,629).
[0339] Identification of the compounds using the above-described assay can be achieved by manual operation; however, it can also be done readily and simply by so-called "high-throughput screening" using robots automatically (Soshiki Baiyou Kougaku (The Tissue Culture Engineering), Vol. 23, No. 13, p.521-524; U.S. Pat. No. 5,670,113).
[0340] Hereinbelow, the present invention is specifically described using the Examples, but it is not to be construed as being limited thereto.
[0341] Unless otherwise specified, each assay step can be performed according to known methods.
[0342] Meanwhile, when using commercially available reagents, kits, or such, assays can be performed according to manuals included in the commercial products.
[0343] All prior art documents cited herein are incorporated by reference in their entirety.
EXAMPLES
[Example 1] Examination of the V564F Mutant and the V562L Mutant of FGFR2
(1) Evaluation of Phosphorylation-Inhibiting Actions by FGFR Inhibitors
[0344] The polynucleotide (SEQ ID NO: 6) encoding the FGFR2 V564F mutant (SEQ ID NO: 9) and the polynucleotide (SEQ ID NO: 7) encoding the FGFR2 V562L mutant (SEQ ID NO: 10) were prepared from the ORF polynucleotide (SEQ ID NO: 5) of the wild-type FGFR2 (SEQ ID NO: 8) by a PCR-based site-directed mutagenesis method. The wild-type FGFR2 ORF polynucleotide and a polynucleotide encoding the FGFR2 V564F mutant or the FGFR2 V562L mutant were subcloned into the pCXND3 vector (Kaketsuken) to prepare vectors for expressing each of the polypeptides. Each of the prepared vectors were introduced into HCT 116 human colon adenocarcinoma cells (ATCC) using a transfection reagent FuGENE.RTM. HD (Promega) to transiently express the wild-type FGFR2 polypeptide (SEQ ID NO: 8), the FGFR2 V564F mutant polypeptide (SEQ ID NO: 9), and the FGFR2 V562L mutant polypeptide (SEQ ID NO: 10), respectively. Either Compound A or Compound C was made to act on each of the cells in the presence of 0.1% DMSO, and then the cell lysates from each of the cells were collected by using Cell Lysis Buffer (Cell Signaling Technology). Analysis of each of the cell lysates by Western blotting using the Phospho-FGF Receptor (Tyr653/654) Antibody (Cell Signaling Technology) or the FGFR-2 Antibody (Sigma) revealed that the phosphorylation inhibitory effects of each compound on the FGFR2 V564F mutant polypeptide and the FGFR2 V562L mutant polypeptide showed a great reduction with Compound C, while the effects did not reduce much with Compound A, compared to the phosphorylation inhibitory effects on the wild-type FGFR2 polypeptide, as shown in FIG. 1.
(2) Evaluation of In Vitro Cell Proliferation-Inhibiting Effects by FGFR Inhibitors
[0345] Each polypeptide expression vector for the wild-type FGFR2, the FGFR2 V564F mutant, or the V562L mutant prepared in (1) of Example 1 was introduced into IL-3-dependent mouse pro-B cells Ba/F3 (Riken) by electroporation, the cells were cultured in the absence of IL-3 under conditions in which selection marker G-418 (Life Technology), and FGF1 (Sigma) and heparin (Sigma) was added, and then a Ba/F3 strain that can stably express the wild-type FGFR2 polypeptide, FGFR2 V564F mutant polypeptide, or FGFR2 V562L mutant polypeptide and can proliferate independently from IL-3 was established. Each of the strains seeded onto 96-well plates was added with each compound (Compound A, B, or C) made into a nine-step four-fold dilution series with the maximum concentration of 20 .mu.M, or DMSO (used as the control), and cultured for four days. Cell proliferation after culturing for four days was measured using WST-8 (Dojindo Laboratories). Cell proliferation-inhibiting activity of each compound on each cell was calculated using the equation (1-T/C).times.100 (%), where T is the absorbance value at 450 nm for a well wherein the cells were added with the compound of each concentration and cultured, and C is the absorbance value at 450 nm wherein the cells were added with DMSO and cultured, and the IC50 was calculated by the least-square method. As a result, the cell proliferation-inhibiting activities of each of the compounds on the strain stably expressing the FGFR2 V564F mutant polypeptide or the FGFR2 V562L mutant polypeptide was greatly weakened with Compound B and Compound C, while the activities showed hardly any change with Compound A, compared to their cell proliferation-inhibiting activities on the strain stably expressing the wild-type FGFR2 polypeptide, as shown in FIG. 2 and Table 2.
TABLE-US-00003 TABLE 2 IC50 RATIO RELATIVE TO WT FGFR2 COMPOUND COMPOUND COMPOUND MUTATION A B C V564F 1.9 90 37 V562L 0.58 3.2 3.5
[Example 2] Examination of the TEL-Fused FGFR2 V564F Mutant
(1) Evaluation of In Vitro Cell Proliferation-Inhibiting Effects by FGFR Inhibitors
[0346] A polynucleotide encoding the dimerization domain of wild-type TEL (SEQ ID NO: 33) and a polynucleotide encoding the intracellular domain of wild-type FGFR2 (SEQ ID NO: 1) were fused by a PCR-based site-directed mutagenesis method to produce a polynucleotide (SEQ ID NO: 11) encoding the TEL-fused wild-type FGFR2 (SEQ ID NO: 34). Using the polynucleotide encoding the TEL-fused wild-type FGFR2 as a template, a polynucleotide (SEQ ID NO: 12) encoding the TEL-fused FGFR2 V564F mutant (SEQ ID NO: 35) was prepared by a PCR-based site-directed mutagenesis method. The polynucleotides encoding the TEL-fused wild-type FGFR2 and the TEL-fused FGFR2 V564F mutant were subcloned into a pCXND3 vector (Kaketsuken) to prepare vectors for expressing each of the polypeptides. Each polypeptide expression vector for the TEL-fused wild-type FGFR2 or the TEL-fused FGFR2 V564F mutant was introduced into IL-3-dependent mouse pro-B cells Ba/F3 by electroporation, and the cells were cultured in the absence of IL-3 with addition of selection marker G-418 to establish a Ba/F3 strain that can stably express the TEL-fused wild-type FGFR2 polypeptide or TEL-fused FGFR2 V564F mutant polypeptide and can proliferate independently of IL-3. Each of the strains seeded onto 96-well plates was added with each compound (Compound A, B, C, or E) made into an 18-step four-fold dilution series with the maximum concentration of 50 .mu.M, a compound (Compound D) made into an 18-step four-fold dilution series with the maximum concentration of 10 .mu.M, or DMSO (used as the control), and cultured for four days. Cell proliferation after culturing for four days was measured using WST-8 (Dojindo Laboratories). Cell proliferation-inhibiting activity of each compound on each cell was calculated using the equation (1-T/C).times.100 (%), where T is the absorbance value at 450 nm for a well wherein the cells were added with the compound of each concentration and cultured, and C is the absorbance value at 450 nm wherein the cells were added with DMSO and cultured. As a result, the cell proliferation-inhibiting activities of each of the compounds on the strain stably expressing the TEL-fused FGFR2 V564F mutant polypeptide were greatly weakened with Compounds B, C, D, and E, while the activities showed hardly any change with Compound A, compared to their cell proliferation-inhibiting activities on the strain stably expressing the TEL-fused wild-type FGFR2 polypeptide, as shown in FIG. 3.
(2) Evaluation of In Vivo Tumor Increase-Inhibiting Effects by FGFR Inhibitors
[0347] The Ba/F3 strain established in (1) of Example 2 that can stably express the TEL-fused wild-type FGFR2 polypeptide or the TEL-fused FGFR2 V564F mutant polypeptide and which can proliferate independently of IL-3, was inoculated subcutaneously in the inguinal region of BALB/c nude mice (Japan Charles River) with 5.0.times.10.sup.6 to 5.2.times.10.sup.6 cells per inoculation. From nine days after the inoculation, Compound A or Compound C suspended in a solution containing 10% DMSO, 10% Cremophor EL, 15% PEG400, and 15% HPCD, was administered orally once every day to the mice at a concentration of 20 mL/kg. As shown in FIG. 4, the tumor proliferation-inhibiting activities of each of the compounds in mice carrying tumor cells that express the TEL-fused FGFR2 V564F mutant polypeptide showed a great reduction with Compound C, while the activities showed hardly any change with Compound A, compared to the activities in mice carrying tumor cells expressing the TEL-fused wild-type FGFR2 polypeptide.
[0348] Furthermore, tumor lysates were collected from tumor samples that have undergone the testing, by using a Cell Lysis Buffer (Cell Signaling Technology), and each of the tumor lysates were analyzed by Western blotting using Phospho-FGF Receptor (Tyr653/654) Antibody (Cell Signaling Technology) or FGFR-2 Antibody (Sigma). As shown in FIG. 5, the inhibitory effects of each of the compounds on phosphorylation in tumors in mice carrying tumor cells that express the TEL-fused FGFR2 V564F mutant polypeptide showed a great reduction with Compound C, while the activities showed hardly any change with Compound A, compared to the activities in mice carrying tumor cells expressing the TEL-fused wild-type FGFR2 polypeptide.
INDUSTRIAL APPLICABILITY
[0349] The mutant FGFR polypeptides of the present invention demonstrate resistance to known FGFR inhibitors such as AZD4547, and at the same time demonstrate sensitivity to specific compounds. Therefore, the mutant polypeptides may be used as biomarkers in cancer treatment by various FGFR inhibitors to determine applicability of each type of FGFR inhibitor to each individual patient, to prevent the development of side effects in therapy using conventional FGFR inhibitors, and to control the therapeutic mode for receiving the best therapeutic effect, thus making individualized treatment possible.
Sequence CWU
1
1
541821PRTHomo sapiens 1Met Val Ser Trp Gly Arg Phe Ile Cys Leu Val Val Val
Thr Met Ala1 5 10 15Thr
Leu Ser Leu Ala Arg Pro Ser Phe Ser Leu Val Glu Asp Thr Thr 20
25 30Leu Glu Pro Glu Glu Pro Pro Thr
Lys Tyr Gln Ile Ser Gln Pro Glu 35 40
45Val Tyr Val Ala Ala Pro Gly Glu Ser Leu Glu Val Arg Cys Leu Leu
50 55 60Lys Asp Ala Ala Val Ile Ser Trp
Thr Lys Asp Gly Val His Leu Gly65 70 75
80Pro Asn Asn Arg Thr Val Leu Ile Gly Glu Tyr Leu Gln
Ile Lys Gly 85 90 95Ala
Thr Pro Arg Asp Ser Gly Leu Tyr Ala Cys Thr Ala Ser Arg Thr
100 105 110Val Asp Ser Glu Thr Trp Tyr
Phe Met Val Asn Val Thr Asp Ala Ile 115 120
125Ser Ser Gly Asp Asp Glu Asp Asp Thr Asp Gly Ala Glu Asp Phe
Val 130 135 140Ser Glu Asn Ser Asn Asn
Lys Arg Ala Pro Tyr Trp Thr Asn Thr Glu145 150
155 160Lys Met Glu Lys Arg Leu His Ala Val Pro Ala
Ala Asn Thr Val Lys 165 170
175Phe Arg Cys Pro Ala Gly Gly Asn Pro Met Pro Thr Met Arg Trp Leu
180 185 190Lys Asn Gly Lys Glu Phe
Lys Gln Glu His Arg Ile Gly Gly Tyr Lys 195 200
205Val Arg Asn Gln His Trp Ser Leu Ile Met Glu Ser Val Val
Pro Ser 210 215 220Asp Lys Gly Asn Tyr
Thr Cys Val Val Glu Asn Glu Tyr Gly Ser Ile225 230
235 240Asn His Thr Tyr His Leu Asp Val Val Glu
Arg Ser Pro His Arg Pro 245 250
255Ile Leu Gln Ala Gly Leu Pro Ala Asn Ala Ser Thr Val Val Gly Gly
260 265 270Asp Val Glu Phe Val
Cys Lys Val Tyr Ser Asp Ala Gln Pro His Ile 275
280 285Gln Trp Ile Lys His Val Glu Lys Asn Gly Ser Lys
Tyr Gly Pro Asp 290 295 300Gly Leu Pro
Tyr Leu Lys Val Leu Lys Ala Ala Gly Val Asn Thr Thr305
310 315 320Asp Lys Glu Ile Glu Val Leu
Tyr Ile Arg Asn Val Thr Phe Glu Asp 325
330 335Ala Gly Glu Tyr Thr Cys Leu Ala Gly Asn Ser Ile
Gly Ile Ser Phe 340 345 350His
Ser Ala Trp Leu Thr Val Leu Pro Ala Pro Gly Arg Glu Lys Glu 355
360 365Ile Thr Ala Ser Pro Asp Tyr Leu Glu
Ile Ala Ile Tyr Cys Ile Gly 370 375
380Val Phe Leu Ile Ala Cys Met Val Val Thr Val Ile Leu Cys Arg Met385
390 395 400Lys Asn Thr Thr
Lys Lys Pro Asp Phe Ser Ser Gln Pro Ala Val His 405
410 415Lys Leu Thr Lys Arg Ile Pro Leu Arg Arg
Gln Val Thr Val Ser Ala 420 425
430Glu Ser Ser Ser Ser Met Asn Ser Asn Thr Pro Leu Val Arg Ile Thr
435 440 445Thr Arg Leu Ser Ser Thr Ala
Asp Thr Pro Met Leu Ala Gly Val Ser 450 455
460Glu Tyr Glu Leu Pro Glu Asp Pro Lys Trp Glu Phe Pro Arg Asp
Lys465 470 475 480Leu Thr
Leu Gly Lys Pro Leu Gly Glu Gly Cys Phe Gly Gln Val Val
485 490 495Met Ala Glu Ala Val Gly Ile
Asp Lys Asp Lys Pro Lys Glu Ala Val 500 505
510Thr Val Ala Val Lys Met Leu Lys Asp Asp Ala Thr Glu Lys
Asp Leu 515 520 525Ser Asp Leu Val
Ser Glu Met Glu Met Met Lys Met Ile Gly Lys His 530
535 540Lys Asn Ile Ile Asn Leu Leu Gly Ala Cys Thr Gln
Asp Gly Pro Leu545 550 555
560Tyr Val Ile Val Glu Tyr Ala Ser Lys Gly Asn Leu Arg Glu Tyr Leu
565 570 575Arg Ala Arg Arg Pro
Pro Gly Met Glu Tyr Ser Tyr Asp Ile Asn Arg 580
585 590Val Pro Glu Glu Gln Met Thr Phe Lys Asp Leu Val
Ser Cys Thr Tyr 595 600 605Gln Leu
Ala Arg Gly Met Glu Tyr Leu Ala Ser Gln Lys Cys Ile His 610
615 620Arg Asp Leu Ala Ala Arg Asn Val Leu Val Thr
Glu Asn Asn Val Met625 630 635
640Lys Ile Ala Asp Phe Gly Leu Ala Arg Asp Ile Asn Asn Ile Asp Tyr
645 650 655Tyr Lys Lys Thr
Thr Asn Gly Arg Leu Pro Val Lys Trp Met Ala Pro 660
665 670Glu Ala Leu Phe Asp Arg Val Tyr Thr His Gln
Ser Asp Val Trp Ser 675 680 685Phe
Gly Val Leu Met Trp Glu Ile Phe Thr Leu Gly Gly Ser Pro Tyr 690
695 700Pro Gly Ile Pro Val Glu Glu Leu Phe Lys
Leu Leu Lys Glu Gly His705 710 715
720Arg Met Asp Lys Pro Ala Asn Cys Thr Asn Glu Leu Tyr Met Met
Met 725 730 735Arg Asp Cys
Trp His Ala Val Pro Ser Gln Arg Pro Thr Phe Lys Gln 740
745 750Leu Val Glu Asp Leu Asp Arg Ile Leu Thr
Leu Thr Thr Asn Glu Glu 755 760
765Tyr Leu Asp Leu Ser Gln Pro Leu Glu Gln Tyr Ser Pro Ser Tyr Pro 770
775 780Asp Thr Arg Ser Ser Cys Ser Ser
Gly Asp Asp Ser Val Phe Ser Pro785 790
795 800Asp Pro Met Pro Tyr Glu Pro Cys Leu Pro Gln Tyr
Pro His Ile Asn 805 810
815Gly Ser Val Lys Thr 8202822PRTHomo sapiens 2Met Val Ser Trp
Gly Arg Phe Ile Cys Leu Val Val Val Thr Met Ala1 5
10 15Thr Leu Ser Leu Ala Arg Pro Ser Phe Ser
Leu Val Glu Asp Thr Thr 20 25
30Leu Glu Pro Glu Glu Pro Pro Thr Lys Tyr Gln Ile Ser Gln Pro Glu
35 40 45Val Tyr Val Ala Ala Pro Gly Glu
Ser Leu Glu Val Arg Cys Leu Leu 50 55
60Lys Asp Ala Ala Val Ile Ser Trp Thr Lys Asp Gly Val His Leu Gly65
70 75 80Pro Asn Asn Arg Thr
Val Leu Ile Gly Glu Tyr Leu Gln Ile Lys Gly 85
90 95Ala Thr Pro Arg Asp Ser Gly Leu Tyr Ala Cys
Thr Ala Ser Arg Thr 100 105
110Val Asp Ser Glu Thr Trp Tyr Phe Met Val Asn Val Thr Asp Ala Ile
115 120 125Ser Ser Gly Asp Asp Glu Asp
Asp Thr Asp Gly Ala Glu Asp Phe Val 130 135
140Ser Glu Asn Ser Asn Asn Lys Arg Ala Pro Tyr Trp Thr Asn Thr
Glu145 150 155 160Lys Met
Glu Lys Arg Leu His Ala Val Pro Ala Ala Asn Thr Val Lys
165 170 175Phe Arg Cys Pro Ala Gly Gly
Asn Pro Met Pro Thr Met Arg Trp Leu 180 185
190Lys Asn Gly Lys Glu Phe Lys Gln Glu His Arg Ile Gly Gly
Tyr Lys 195 200 205Val Arg Asn Gln
His Trp Ser Leu Ile Met Glu Ser Val Val Pro Ser 210
215 220Asp Lys Gly Asn Tyr Thr Cys Val Val Glu Asn Glu
Tyr Gly Ser Ile225 230 235
240Asn His Thr Tyr His Leu Asp Val Val Glu Arg Ser Pro His Arg Pro
245 250 255Ile Leu Gln Ala Gly
Leu Pro Ala Asn Ala Ser Thr Val Val Gly Gly 260
265 270Asp Val Glu Phe Val Cys Lys Val Tyr Ser Asp Ala
Gln Pro His Ile 275 280 285Gln Trp
Ile Lys His Val Glu Lys Asn Gly Ser Lys Tyr Gly Pro Asp 290
295 300Gly Leu Pro Tyr Leu Lys Val Leu Lys His Ser
Gly Ile Asn Ser Ser305 310 315
320Asn Ala Glu Val Leu Ala Leu Phe Asn Val Thr Glu Ala Asp Ala Gly
325 330 335Glu Tyr Ile Cys
Lys Val Ser Asn Tyr Ile Gly Gln Ala Asn Gln Ser 340
345 350Ala Trp Leu Thr Val Leu Pro Lys Gln Gln Ala
Pro Gly Arg Glu Lys 355 360 365Glu
Ile Thr Ala Ser Pro Asp Tyr Leu Glu Ile Ala Ile Tyr Cys Ile 370
375 380Gly Val Phe Leu Ile Ala Cys Met Val Val
Thr Val Ile Leu Cys Arg385 390 395
400Met Lys Asn Thr Thr Lys Lys Pro Asp Phe Ser Ser Gln Pro Ala
Val 405 410 415His Lys Leu
Thr Lys Arg Ile Pro Leu Arg Arg Gln Val Thr Val Ser 420
425 430Ala Glu Ser Ser Ser Ser Met Asn Ser Asn
Thr Pro Leu Val Arg Ile 435 440
445Thr Thr Arg Leu Ser Ser Thr Ala Asp Thr Pro Met Leu Ala Gly Val 450
455 460Ser Glu Tyr Glu Leu Pro Glu Asp
Pro Lys Trp Glu Phe Pro Arg Asp465 470
475 480Lys Leu Thr Leu Gly Lys Pro Leu Gly Glu Gly Cys
Phe Gly Gln Val 485 490
495Val Met Ala Glu Ala Val Gly Ile Asp Lys Asp Lys Pro Lys Glu Ala
500 505 510Val Thr Val Ala Val Lys
Met Leu Lys Asp Asp Ala Thr Glu Lys Asp 515 520
525Leu Ser Asp Leu Val Ser Glu Met Glu Met Met Lys Met Ile
Gly Lys 530 535 540His Lys Asn Ile Ile
Asn Leu Leu Gly Ala Cys Thr Gln Asp Gly Pro545 550
555 560Leu Tyr Val Ile Val Glu Tyr Ala Ser Lys
Gly Asn Leu Arg Glu Tyr 565 570
575Leu Arg Ala Arg Arg Pro Pro Gly Met Glu Tyr Ser Tyr Asp Ile Asn
580 585 590Arg Val Pro Glu Glu
Gln Met Thr Phe Lys Asp Leu Val Ser Cys Thr 595
600 605Tyr Gln Leu Ala Arg Gly Met Glu Tyr Leu Ala Ser
Gln Lys Cys Ile 610 615 620His Arg Asp
Leu Ala Ala Arg Asn Val Leu Val Thr Glu Asn Asn Val625
630 635 640Met Lys Ile Ala Asp Phe Gly
Leu Ala Arg Asp Ile Asn Asn Ile Asp 645
650 655Tyr Tyr Lys Lys Thr Thr Asn Gly Arg Leu Pro Val
Lys Trp Met Ala 660 665 670Pro
Glu Ala Leu Phe Asp Arg Val Tyr Thr His Gln Ser Asp Val Trp 675
680 685Ser Phe Gly Val Leu Met Trp Glu Ile
Phe Thr Leu Gly Gly Ser Pro 690 695
700Tyr Pro Gly Ile Pro Val Glu Glu Leu Phe Lys Leu Leu Lys Glu Gly705
710 715 720His Arg Met Asp
Lys Pro Ala Asn Cys Thr Asn Glu Leu Tyr Met Met 725
730 735Met Arg Asp Cys Trp His Ala Val Pro Ser
Gln Arg Pro Thr Phe Lys 740 745
750Gln Leu Val Glu Asp Leu Asp Arg Ile Leu Thr Leu Thr Thr Asn Glu
755 760 765Glu Tyr Leu Asp Leu Ser Gln
Pro Leu Glu Gln Tyr Ser Pro Ser Tyr 770 775
780Pro Asp Thr Arg Ser Ser Cys Ser Ser Gly Asp Asp Ser Val Phe
Ser785 790 795 800Pro Asp
Pro Met Pro Tyr Glu Pro Cys Leu Pro Gln Tyr Pro His Ile
805 810 815Asn Gly Ser Val Lys Thr
82032466DNAHomo sapiens 3atggtcagct ggggtcgttt catctgcctg gtcgtggtca
ccatggcaac cttgtccctg 60gcccggccct ccttcagttt agttgaggat accacattag
agccagaaga gccaccaacc 120aaataccaaa tctctcaacc agaagtgtac gtggctgcgc
caggggagtc gctagaggtg 180cgctgcctgt tgaaagatgc cgccgtgatc agttggacta
aggatggggt gcacttgggg 240cccaacaata ggacagtgct tattggggag tacttgcaga
taaagggcgc cacgcctaga 300gactccggcc tctatgcttg tactgccagt aggactgtag
acagtgaaac ttggtacttc 360atggtgaatg tcacagatgc catctcatcc ggagatgatg
aggatgacac cgatggtgcg 420gaagattttg tcagtgagaa cagtaacaac aagagagcac
catactggac caacacagaa 480aagatggaaa agcggctcca tgctgtgcct gcggccaaca
ctgtcaagtt tcgctgccca 540gccgggggga acccaatgcc aaccatgcgg tggctgaaaa
acgggaagga gtttaagcag 600gagcatcgca ttggaggcta caaggtacga aaccagcact
ggagcctcat tatggaaagt 660gtggtcccat ctgacaaggg aaattatacc tgtgtagtgg
agaatgaata cgggtccatc 720aatcacacgt accacctgga tgttgtggag cgatcgcctc
accggcccat cctccaagcc 780ggactgccgg caaatgcctc cacagtggtc ggaggagacg
tagagtttgt ctgcaaggtt 840tacagtgatg cccagcccca catccagtgg atcaagcacg
tggaaaagaa cggcagtaaa 900tacgggcccg acgggctgcc ctacctcaag gttctcaagg
ccgccggtgt taacaccacg 960gacaaagaga ttgaggttct ctatattcgg aatgtaactt
ttgaggacgc tggggaatat 1020acgtgcttgg cgggtaattc tattgggata tcctttcact
ctgcatggtt gacagttctg 1080ccagcgcctg gaagagaaaa ggagattaca gcttccccag
actacctgga gatagccatt 1140tactgcatag gggtcttctt aatcgcctgt atggtggtaa
cagtcatcct gtgccgaatg 1200aagaacacga ccaagaagcc agacttcagc agccagccgg
ctgtgcacaa gctgaccaaa 1260cgtatccccc tgcggagaca ggtaacagtt tcggctgagt
ccagctcctc catgaactcc 1320aacaccccgc tggtgaggat aacaacacgc ctctcttcaa
cggcagacac ccccatgctg 1380gcaggggtct ccgagtatga acttccagag gacccaaaat
gggagtttcc aagagataag 1440ctgacactgg gcaagcccct gggagaaggt tgctttgggc
aagtggtcat ggcggaagca 1500gtgggaattg acaaagacaa gcccaaggag gcggtcaccg
tggccgtgaa gatgttgaaa 1560gatgatgcca cagagaaaga cctttctgat ctggtgtcag
agatggagat gatgaagatg 1620attgggaaac acaagaatat cataaatctt cttggagcct
gcacacagga tgggcctctc 1680tatgtcatag ttgagtatgc ctctaaaggc aacctccgag
aatacctccg agcccggagg 1740ccacccggga tggagtactc ctatgacatt aaccgtgttc
ctgaggagca gatgaccttc 1800aaggacttgg tgtcatgcac ctaccagctg gccagaggca
tggagtactt ggcttcccaa 1860aaatgtattc atcgagattt agcagccaga aatgttttgg
taacagaaaa caatgtgatg 1920aaaatagcag actttggact cgccagagat atcaacaata
tagactatta caaaaagacc 1980accaatgggc ggcttccagt caagtggatg gctccagaag
ccctgtttga tagagtatac 2040actcatcaga gtgatgtctg gtccttcggg gtgttaatgt
gggagatctt cactttaggg 2100ggctcgccct acccagggat tcccgtggag gaacttttta
agctgctgaa ggaaggacac 2160agaatggata agccagccaa ctgcaccaac gaactgtaca
tgatgatgag ggactgttgg 2220catgcagtgc cctcccagag accaacgttc aagcagttgg
tagaagactt ggatcgaatt 2280ctcactctca caaccaatga ggaatacttg gacctcagcc
aacctctcga acagtattca 2340cctagttacc ctgacacaag aagttcttgt tcttcaggag
atgattctgt tttttctcca 2400gaccccatgc cttacgaacc atgccttcct cagtatccac
acataaacgg cagtgttaaa 2460acatga
246642469DNAHomo sapiens 4atggtcagct ggggtcgttt
catctgcctg gtcgtggtca ccatggcaac cttgtccctg 60gcccggccct ccttcagttt
agttgaggat accacattag agccagaaga gccaccaacc 120aaataccaaa tctctcaacc
agaagtgtac gtggctgcgc caggggagtc gctagaggtg 180cgctgcctgt tgaaagatgc
cgccgtgatc agttggacta aggatggggt gcacttgggg 240cccaacaata ggacagtgct
tattggggag tacttgcaga taaagggcgc cacgcctaga 300gactccggcc tctatgcttg
tactgccagt aggactgtag acagtgaaac ttggtacttc 360atggtgaatg tcacagatgc
catctcatcc ggagatgatg aggatgacac cgatggtgcg 420gaagattttg tcagtgagaa
cagtaacaac aagagagcac catactggac caacacagaa 480aagatggaaa agcggctcca
tgctgtgcct gcggccaaca ctgtcaagtt tcgctgccca 540gccgggggga acccaatgcc
aaccatgcgg tggctgaaaa acgggaagga gtttaagcag 600gagcatcgca ttggaggcta
caaggtacga aaccagcact ggagcctcat tatggaaagt 660gtggtcccat ctgacaaggg
aaattatacc tgtgtagtgg agaatgaata cgggtccatc 720aatcacacgt accacctgga
tgttgtggag cgatcgcctc accggcccat cctccaagcc 780ggactgccgg caaatgcctc
cacagtggtc ggaggagacg tagagtttgt ctgcaaggtt 840tacagtgatg cccagcccca
catccagtgg atcaagcacg tggaaaagaa cggcagtaaa 900tacgggcccg acgggctgcc
ctacctcaag gttctcaagc actcggggat aaatagttcc 960aatgcagaag tgctggctct
gttcaatgtg accgaggcgg atgctgggga atatatatgt 1020aaggtctcca attatatagg
gcaggccaac cagtctgcct ggctcactgt cctgccaaaa 1080cagcaagcgc ctggaagaga
aaaggagatt acagcttccc cagactacct ggagatagcc 1140atttactgca taggggtctt
cttaatcgcc tgtatggtgg taacagtcat cctgtgccga 1200atgaagaaca cgaccaagaa
gccagacttc agcagccagc cggctgtgca caagctgacc 1260aaacgtatcc ccctgcggag
acaggtaaca gtttcggctg agtccagctc ctccatgaac 1320tccaacaccc cgctggtgag
gataacaaca cgcctctctt caacggcaga cacccccatg 1380ctggcagggg tctccgagta
tgaacttcca gaggacccaa aatgggagtt tccaagagat 1440aagctgacac tgggcaagcc
cctgggagaa ggttgctttg ggcaagtggt catggcggaa 1500gcagtgggaa ttgacaaaga
caagcccaag gaggcggtca ccgtggccgt gaagatgttg 1560aaagatgatg ccacagagaa
agacctttct gatctggtgt cagagatgga gatgatgaag 1620atgattggga aacacaagaa
tatcataaat cttcttggag cctgcacaca ggatgggcct 1680ctctatgtca tagttgagta
tgcctctaaa ggcaacctcc gagaatacct ccgagcccgg 1740aggccacccg ggatggagta
ctcctatgac attaaccgtg ttcctgagga gcagatgacc 1800ttcaaggact tggtgtcatg
cacctaccag ctggccagag gcatggagta cttggcttcc 1860caaaaatgta ttcatcgaga
tttagcagcc agaaatgttt tggtaacaga aaacaatgtg 1920atgaaaatag cagactttgg
actcgccaga gatatcaaca atatagacta ttacaaaaag 1980accaccaatg ggcggcttcc
agtcaagtgg atggctccag aagccctgtt tgatagagta 2040tacactcatc agagtgatgt
ctggtccttc ggggtgttaa tgtgggagat cttcacttta 2100gggggctcgc cctacccagg
gattcccgtg gaggaacttt ttaagctgct gaaggaagga 2160cacagaatgg ataagccagc
caactgcacc aacgaactgt acatgatgat gagggactgt 2220tggcatgcag tgccctccca
gagaccaacg ttcaagcagt tggtagaaga cttggatcga 2280attctcactc tcacaaccaa
tgaggaatac ttggacctca gccaacctct cgaacagtat 2340tcacctagtt accctgacac
aagaagttct tgttcttcag gagatgattc tgttttttct 2400ccagacccca tgccttacga
accatgcctt cctcagtatc cacacataaa cggcagtgtt 2460aaaacatga
246952466DNAHomo sapiens
5atggtcagct ggggtcgttt catctgcctg gtcgtggtca ccatggcaac cttgtccctg
60gcccggccct ccttcagttt agttgaggat accacattag agccagaaga gccaccaacc
120aaataccaaa tctctcaacc agaagtgtac gtggctgcgc caggggagtc gctagaggtg
180cgctgcctgt tgaaagatgc cgccgtgatc agttggacta aggatggggt gcacttgggg
240cccaacaata ggacagtgct tattggggag tacttgcaga taaagggcgc cacgcctaga
300gactccggcc tctatgcttg tactgccagt aggactgtag acagtgaaac ttggtacttc
360atggtgaatg tcacagatgc catctcatcc ggagatgatg aggatgacac cgatggtgcg
420gaagattttg tcagtgagaa cagtaacaac aagagagcac catactggac caacacagaa
480aagatggaaa agcggctcca tgctgtgcct gcggccaaca ctgtcaagtt tcgctgccca
540gccgggggga acccaatgcc aaccatgcgg tggctgaaaa acgggaagga gtttaagcag
600gagcatcgca ttggaggcta caaggtacga aaccagcact ggagcctcat tatggaaagt
660gtggtcccat ctgacaaggg aaattatacc tgtgtagtgg agaatgaata cgggtccatc
720aatcacacgt accacctgga tgttgtggag cgatcgcctc accggcccat cctccaagcc
780ggactgccgg caaatgcctc cacagtggtc ggaggagacg tagagtttgt ctgcaaggtt
840tacagtgatg cccagcccca catccagtgg atcaagcacg tggaaaagaa cggcagtaaa
900tacgggcccg acgggctgcc ctacctcaag gttctcaagg ccgccggtgt taacaccacg
960gacaaagaga ttgaggttct ctatattcgg aatgtaactt ttgaggacgc tggggaatat
1020acgtgcttgg cgggtaattc tattgggata tcctttcact ctgcatggtt gacagttctg
1080ccagcgcctg gaagagaaaa ggagattaca gcttccccag actacctgga gatagccatt
1140tactgcatag gggtcttctt aatcgcctgt atggtggtaa cagtcatcct gtgccgaatg
1200aagaacacga ccaagaagcc agacttcagc agccagccgg ctgtgcacaa gctgaccaaa
1260cgtatccccc tgcggagaca ggtaacagtt tcggctgagt ccagctcctc catgaactcc
1320aacaccccgc tggtgaggat aacaacacgc ctctcttcaa cggcagacac ccccatgctg
1380gcaggggtct ccgagtatga acttccagag gacccaaaat gggagtttcc aagagataag
1440ctgacactgg gcaagcccct gggagaaggt tgctttgggc aagtggtcat ggcggaagca
1500gtgggaattg acaaagacaa gcccaaggag gcggtcaccg tggccgtgaa gatgttgaaa
1560gatgatgcca cagagaaaga cctttctgat ctggtgtcag agatggagat gatgaagatg
1620attgggaaac acaagaatat cataaatctt cttggagcct gcacacagga tgggcctctc
1680tatgtcatag ttgagtatgc ctctaaaggc aacctccgag aatacctccg agcccggagg
1740ccacccggga tggagtactc ctatgacatt aaccgtgttc ctgaggagca gatgaccttc
1800aaggacttgg tgtcatgcac ctaccagctg gccagaggca tggagtactt ggcttcccaa
1860aaatgtattc atcgagattt agcagccaga aatgttttgg taacagaaaa caatgtgatg
1920aaaatagcag actttggact cgccagagat atcaacaata tagactatta caaaaagacc
1980accaatgggc ggcttccagt caagtggatg gctccagaag ccctgtttga tagagtatac
2040actcatcaga gtgatgtctg gtccttcggg gtgttaatgt gggagatctt cactttaggg
2100ggctcgccct acccagggat tcccgtggag gaacttttta agctgctgaa ggaaggacac
2160agaatggata agccagccaa ctgcaccaac gaactgtaca tgatgatgag ggactgttgg
2220catgcagtgc cctcccagag accaacgttc aagcagttgg tagaagactt ggatcgaatt
2280ctcactctca caaccaatga ggaatacttg gacctcagcc aacctctcga acagtattca
2340cctagttacc ctgacacaag aagttcttgt tcttcaggag atgattctgt tttttctcca
2400gaccccatgc cttacgaacc atgccttcct cagtatccac acataaacgg cagtgttaaa
2460acatag
246662466DNAHomo sapiens 6atggtcagct ggggtcgttt catctgcctg gtcgtggtca
ccatggcaac cttgtccctg 60gcccggccct ccttcagttt agttgaggat accacattag
agccagaaga gccaccaacc 120aaataccaaa tctctcaacc agaagtgtac gtggctgcgc
caggggagtc gctagaggtg 180cgctgcctgt tgaaagatgc cgccgtgatc agttggacta
aggatggggt gcacttgggg 240cccaacaata ggacagtgct tattggggag tacttgcaga
taaagggcgc cacgcctaga 300gactccggcc tctatgcttg tactgccagt aggactgtag
acagtgaaac ttggtacttc 360atggtgaatg tcacagatgc catctcatcc ggagatgatg
aggatgacac cgatggtgcg 420gaagattttg tcagtgagaa cagtaacaac aagagagcac
catactggac caacacagaa 480aagatggaaa agcggctcca tgctgtgcct gcggccaaca
ctgtcaagtt tcgctgccca 540gccgggggga acccaatgcc aaccatgcgg tggctgaaaa
acgggaagga gtttaagcag 600gagcatcgca ttggaggcta caaggtacga aaccagcact
ggagcctcat tatggaaagt 660gtggtcccat ctgacaaggg aaattatacc tgtgtagtgg
agaatgaata cgggtccatc 720aatcacacgt accacctgga tgttgtggag cgatcgcctc
accggcccat cctccaagcc 780ggactgccgg caaatgcctc cacagtggtc ggaggagacg
tagagtttgt ctgcaaggtt 840tacagtgatg cccagcccca catccagtgg atcaagcacg
tggaaaagaa cggcagtaaa 900tacgggcccg acgggctgcc ctacctcaag gttctcaagg
ccgccggtgt taacaccacg 960gacaaagaga ttgaggttct ctatattcgg aatgtaactt
ttgaggacgc tggggaatat 1020acgtgcttgg cgggtaattc tattgggata tcctttcact
ctgcatggtt gacagttctg 1080ccagcgcctg gaagagaaaa ggagattaca gcttccccag
actacctgga gatagccatt 1140tactgcatag gggtcttctt aatcgcctgt atggtggtaa
cagtcatcct gtgccgaatg 1200aagaacacga ccaagaagcc agacttcagc agccagccgg
ctgtgcacaa gctgaccaaa 1260cgtatccccc tgcggagaca ggtaacagtt tcggctgagt
ccagctcctc catgaactcc 1320aacaccccgc tggtgaggat aacaacacgc ctctcttcaa
cggcagacac ccccatgctg 1380gcaggggtct ccgagtatga acttccagag gacccaaaat
gggagtttcc aagagataag 1440ctgacactgg gcaagcccct gggagaaggt tgctttgggc
aagtggtcat ggcggaagca 1500gtgggaattg acaaagacaa gcccaaggag gcggtcaccg
tggccgtgaa gatgttgaaa 1560gatgatgcca cagagaaaga cctttctgat ctggtgtcag
agatggagat gatgaagatg 1620attgggaaac acaagaatat cataaatctt cttggagcct
gcacacagga tgggcctctc 1680tatgtcatat ttgagtatgc ctctaaaggc aacctccgag
aatacctccg agcccggagg 1740ccacccggga tggagtactc ctatgacatt aaccgtgttc
ctgaggagca gatgaccttc 1800aaggacttgg tgtcatgcac ctaccagctg gccagaggca
tggagtactt ggcttcccaa 1860aaatgtattc atcgagattt agcagccaga aatgttttgg
taacagaaaa caatgtgatg 1920aaaatagcag actttggact cgccagagat atcaacaata
tagactatta caaaaagacc 1980accaatgggc ggcttccagt caagtggatg gctccagaag
ccctgtttga tagagtatac 2040actcatcaga gtgatgtctg gtccttcggg gtgttaatgt
gggagatctt cactttaggg 2100ggctcgccct acccagggat tcccgtggag gaacttttta
agctgctgaa ggaaggacac 2160agaatggata agccagccaa ctgcaccaac gaactgtaca
tgatgatgag ggactgttgg 2220catgcagtgc cctcccagag accaacgttc aagcagttgg
tagaagactt ggatcgaatt 2280ctcactctca caaccaatga ggaatacttg gacctcagcc
aacctctcga acagtattca 2340cctagttacc ctgacacaag aagttcttgt tcttcaggag
atgattctgt tttttctcca 2400gaccccatgc cttacgaacc atgccttcct cagtatccac
acataaacgg cagtgttaaa 2460acatag
246672466DNAHomo sapiens 7atggtcagct ggggtcgttt
catctgcctg gtcgtggtca ccatggcaac cttgtccctg 60gcccggccct ccttcagttt
agttgaggat accacattag agccagaaga gccaccaacc 120aaataccaaa tctctcaacc
agaagtgtac gtggctgcgc caggggagtc gctagaggtg 180cgctgcctgt tgaaagatgc
cgccgtgatc agttggacta aggatggggt gcacttgggg 240cccaacaata ggacagtgct
tattggggag tacttgcaga taaagggcgc cacgcctaga 300gactccggcc tctatgcttg
tactgccagt aggactgtag acagtgaaac ttggtacttc 360atggtgaatg tcacagatgc
catctcatcc ggagatgatg aggatgacac cgatggtgcg 420gaagattttg tcagtgagaa
cagtaacaac aagagagcac catactggac caacacagaa 480aagatggaaa agcggctcca
tgctgtgcct gcggccaaca ctgtcaagtt tcgctgccca 540gccgggggga acccaatgcc
aaccatgcgg tggctgaaaa acgggaagga gtttaagcag 600gagcatcgca ttggaggcta
caaggtacga aaccagcact ggagcctcat tatggaaagt 660gtggtcccat ctgacaaggg
aaattatacc tgtgtagtgg agaatgaata cgggtccatc 720aatcacacgt accacctgga
tgttgtggag cgatcgcctc accggcccat cctccaagcc 780ggactgccgg caaatgcctc
cacagtggtc ggaggagacg tagagtttgt ctgcaaggtt 840tacagtgatg cccagcccca
catccagtgg atcaagcacg tggaaaagaa cggcagtaaa 900tacgggcccg acgggctgcc
ctacctcaag gttctcaagg ccgccggtgt taacaccacg 960gacaaagaga ttgaggttct
ctatattcgg aatgtaactt ttgaggacgc tggggaatat 1020acgtgcttgg cgggtaattc
tattgggata tcctttcact ctgcatggtt gacagttctg 1080ccagcgcctg gaagagaaaa
ggagattaca gcttccccag actacctgga gatagccatt 1140tactgcatag gggtcttctt
aatcgcctgt atggtggtaa cagtcatcct gtgccgaatg 1200aagaacacga ccaagaagcc
agacttcagc agccagccgg ctgtgcacaa gctgaccaaa 1260cgtatccccc tgcggagaca
ggtaacagtt tcggctgagt ccagctcctc catgaactcc 1320aacaccccgc tggtgaggat
aacaacacgc ctctcttcaa cggcagacac ccccatgctg 1380gcaggggtct ccgagtatga
acttccagag gacccaaaat gggagtttcc aagagataag 1440ctgacactgg gcaagcccct
gggagaaggt tgctttgggc aagtggtcat ggcggaagca 1500gtgggaattg acaaagacaa
gcccaaggag gcggtcaccg tggccgtgaa gatgttgaaa 1560gatgatgcca cagagaaaga
cctttctgat ctggtgtcag agatggagat gatgaagatg 1620attgggaaac acaagaatat
cataaatctt cttggagcct gcacacagga tgggcctctc 1680tatctcatag ttgagtatgc
ctctaaaggc aacctccgag aatacctccg agcccggagg 1740ccacccggga tggagtactc
ctatgacatt aaccgtgttc ctgaggagca gatgaccttc 1800aaggacttgg tgtcatgcac
ctaccagctg gccagaggca tggagtactt ggcttcccaa 1860aaatgtattc atcgagattt
agcagccaga aatgttttgg taacagaaaa caatgtgatg 1920aaaatagcag actttggact
cgccagagat atcaacaata tagactatta caaaaagacc 1980accaatgggc ggcttccagt
caagtggatg gctccagaag ccctgtttga tagagtatac 2040actcatcaga gtgatgtctg
gtccttcggg gtgttaatgt gggagatctt cactttaggg 2100ggctcgccct acccagggat
tcccgtggag gaacttttta agctgctgaa ggaaggacac 2160agaatggata agccagccaa
ctgcaccaac gaactgtaca tgatgatgag ggactgttgg 2220catgcagtgc cctcccagag
accaacgttc aagcagttgg tagaagactt ggatcgaatt 2280ctcactctca caaccaatga
ggaatacttg gacctcagcc aacctctcga acagtattca 2340cctagttacc ctgacacaag
aagttcttgt tcttcaggag atgattctgt tttttctcca 2400gaccccatgc cttacgaacc
atgccttcct cagtatccac acataaacgg cagtgttaaa 2460acatag
24668821PRTHomo sapiens 8Met
Val Ser Trp Gly Arg Phe Ile Cys Leu Val Val Val Thr Met Ala1
5 10 15Thr Leu Ser Leu Ala Arg Pro
Ser Phe Ser Leu Val Glu Asp Thr Thr 20 25
30Leu Glu Pro Glu Glu Pro Pro Thr Lys Tyr Gln Ile Ser Gln
Pro Glu 35 40 45Val Tyr Val Ala
Ala Pro Gly Glu Ser Leu Glu Val Arg Cys Leu Leu 50 55
60Lys Asp Ala Ala Val Ile Ser Trp Thr Lys Asp Gly Val
His Leu Gly65 70 75
80Pro Asn Asn Arg Thr Val Leu Ile Gly Glu Tyr Leu Gln Ile Lys Gly
85 90 95Ala Thr Pro Arg Asp Ser
Gly Leu Tyr Ala Cys Thr Ala Ser Arg Thr 100
105 110Val Asp Ser Glu Thr Trp Tyr Phe Met Val Asn Val
Thr Asp Ala Ile 115 120 125Ser Ser
Gly Asp Asp Glu Asp Asp Thr Asp Gly Ala Glu Asp Phe Val 130
135 140Ser Glu Asn Ser Asn Asn Lys Arg Ala Pro Tyr
Trp Thr Asn Thr Glu145 150 155
160Lys Met Glu Lys Arg Leu His Ala Val Pro Ala Ala Asn Thr Val Lys
165 170 175Phe Arg Cys Pro
Ala Gly Gly Asn Pro Met Pro Thr Met Arg Trp Leu 180
185 190Lys Asn Gly Lys Glu Phe Lys Gln Glu His Arg
Ile Gly Gly Tyr Lys 195 200 205Val
Arg Asn Gln His Trp Ser Leu Ile Met Glu Ser Val Val Pro Ser 210
215 220Asp Lys Gly Asn Tyr Thr Cys Val Val Glu
Asn Glu Tyr Gly Ser Ile225 230 235
240Asn His Thr Tyr His Leu Asp Val Val Glu Arg Ser Pro His Arg
Pro 245 250 255Ile Leu Gln
Ala Gly Leu Pro Ala Asn Ala Ser Thr Val Val Gly Gly 260
265 270Asp Val Glu Phe Val Cys Lys Val Tyr Ser
Asp Ala Gln Pro His Ile 275 280
285Gln Trp Ile Lys His Val Glu Lys Asn Gly Ser Lys Tyr Gly Pro Asp 290
295 300Gly Leu Pro Tyr Leu Lys Val Leu
Lys Ala Ala Gly Val Asn Thr Thr305 310
315 320Asp Lys Glu Ile Glu Val Leu Tyr Ile Arg Asn Val
Thr Phe Glu Asp 325 330
335Ala Gly Glu Tyr Thr Cys Leu Ala Gly Asn Ser Ile Gly Ile Ser Phe
340 345 350His Ser Ala Trp Leu Thr
Val Leu Pro Ala Pro Gly Arg Glu Lys Glu 355 360
365Ile Thr Ala Ser Pro Asp Tyr Leu Glu Ile Ala Ile Tyr Cys
Ile Gly 370 375 380Val Phe Leu Ile Ala
Cys Met Val Val Thr Val Ile Leu Cys Arg Met385 390
395 400Lys Asn Thr Thr Lys Lys Pro Asp Phe Ser
Ser Gln Pro Ala Val His 405 410
415Lys Leu Thr Lys Arg Ile Pro Leu Arg Arg Gln Val Thr Val Ser Ala
420 425 430Glu Ser Ser Ser Ser
Met Asn Ser Asn Thr Pro Leu Val Arg Ile Thr 435
440 445Thr Arg Leu Ser Ser Thr Ala Asp Thr Pro Met Leu
Ala Gly Val Ser 450 455 460Glu Tyr Glu
Leu Pro Glu Asp Pro Lys Trp Glu Phe Pro Arg Asp Lys465
470 475 480Leu Thr Leu Gly Lys Pro Leu
Gly Glu Gly Cys Phe Gly Gln Val Val 485
490 495Met Ala Glu Ala Val Gly Ile Asp Lys Asp Lys Pro
Lys Glu Ala Val 500 505 510Thr
Val Ala Val Lys Met Leu Lys Asp Asp Ala Thr Glu Lys Asp Leu 515
520 525Ser Asp Leu Val Ser Glu Met Glu Met
Met Lys Met Ile Gly Lys His 530 535
540Lys Asn Ile Ile Asn Leu Leu Gly Ala Cys Thr Gln Asp Gly Pro Leu545
550 555 560Tyr Val Ile Val
Glu Tyr Ala Ser Lys Gly Asn Leu Arg Glu Tyr Leu 565
570 575Arg Ala Arg Arg Pro Pro Gly Met Glu Tyr
Ser Tyr Asp Ile Asn Arg 580 585
590Val Pro Glu Glu Gln Met Thr Phe Lys Asp Leu Val Ser Cys Thr Tyr
595 600 605Gln Leu Ala Arg Gly Met Glu
Tyr Leu Ala Ser Gln Lys Cys Ile His 610 615
620Arg Asp Leu Ala Ala Arg Asn Val Leu Val Thr Glu Asn Asn Val
Met625 630 635 640Lys Ile
Ala Asp Phe Gly Leu Ala Arg Asp Ile Asn Asn Ile Asp Tyr
645 650 655Tyr Lys Lys Thr Thr Asn Gly
Arg Leu Pro Val Lys Trp Met Ala Pro 660 665
670Glu Ala Leu Phe Asp Arg Val Tyr Thr His Gln Ser Asp Val
Trp Ser 675 680 685Phe Gly Val Leu
Met Trp Glu Ile Phe Thr Leu Gly Gly Ser Pro Tyr 690
695 700Pro Gly Ile Pro Val Glu Glu Leu Phe Lys Leu Leu
Lys Glu Gly His705 710 715
720Arg Met Asp Lys Pro Ala Asn Cys Thr Asn Glu Leu Tyr Met Met Met
725 730 735Arg Asp Cys Trp His
Ala Val Pro Ser Gln Arg Pro Thr Phe Lys Gln 740
745 750Leu Val Glu Asp Leu Asp Arg Ile Leu Thr Leu Thr
Thr Asn Glu Glu 755 760 765Tyr Leu
Asp Leu Ser Gln Pro Leu Glu Gln Tyr Ser Pro Ser Tyr Pro 770
775 780Asp Thr Arg Ser Ser Cys Ser Ser Gly Asp Asp
Ser Val Phe Ser Pro785 790 795
800Asp Pro Met Pro Tyr Glu Pro Cys Leu Pro Gln Tyr Pro His Ile Asn
805 810 815Gly Ser Val Lys
Thr 8209821PRTHomo sapiens 9Met Val Ser Trp Gly Arg Phe Ile
Cys Leu Val Val Val Thr Met Ala1 5 10
15Thr Leu Ser Leu Ala Arg Pro Ser Phe Ser Leu Val Glu Asp
Thr Thr 20 25 30Leu Glu Pro
Glu Glu Pro Pro Thr Lys Tyr Gln Ile Ser Gln Pro Glu 35
40 45Val Tyr Val Ala Ala Pro Gly Glu Ser Leu Glu
Val Arg Cys Leu Leu 50 55 60Lys Asp
Ala Ala Val Ile Ser Trp Thr Lys Asp Gly Val His Leu Gly65
70 75 80Pro Asn Asn Arg Thr Val Leu
Ile Gly Glu Tyr Leu Gln Ile Lys Gly 85 90
95Ala Thr Pro Arg Asp Ser Gly Leu Tyr Ala Cys Thr Ala
Ser Arg Thr 100 105 110Val Asp
Ser Glu Thr Trp Tyr Phe Met Val Asn Val Thr Asp Ala Ile 115
120 125Ser Ser Gly Asp Asp Glu Asp Asp Thr Asp
Gly Ala Glu Asp Phe Val 130 135 140Ser
Glu Asn Ser Asn Asn Lys Arg Ala Pro Tyr Trp Thr Asn Thr Glu145
150 155 160Lys Met Glu Lys Arg Leu
His Ala Val Pro Ala Ala Asn Thr Val Lys 165
170 175Phe Arg Cys Pro Ala Gly Gly Asn Pro Met Pro Thr
Met Arg Trp Leu 180 185 190Lys
Asn Gly Lys Glu Phe Lys Gln Glu His Arg Ile Gly Gly Tyr Lys 195
200 205Val Arg Asn Gln His Trp Ser Leu Ile
Met Glu Ser Val Val Pro Ser 210 215
220Asp Lys Gly Asn Tyr Thr Cys Val Val Glu Asn Glu Tyr Gly Ser Ile225
230 235 240Asn His Thr Tyr
His Leu Asp Val Val Glu Arg Ser Pro His Arg Pro 245
250 255Ile Leu Gln Ala Gly Leu Pro Ala Asn Ala
Ser Thr Val Val Gly Gly 260 265
270Asp Val Glu Phe Val Cys Lys Val Tyr Ser Asp Ala Gln Pro His Ile
275 280 285Gln Trp Ile Lys His Val Glu
Lys Asn Gly Ser Lys Tyr Gly Pro Asp 290 295
300Gly Leu Pro Tyr Leu Lys Val Leu Lys Ala Ala Gly Val Asn Thr
Thr305 310 315 320Asp Lys
Glu Ile Glu Val Leu Tyr Ile Arg Asn Val Thr Phe Glu Asp
325 330 335Ala Gly Glu Tyr Thr Cys Leu
Ala Gly Asn Ser Ile Gly Ile Ser Phe 340 345
350His Ser Ala Trp Leu Thr Val Leu Pro Ala Pro Gly Arg Glu
Lys Glu 355 360 365Ile Thr Ala Ser
Pro Asp Tyr Leu Glu Ile Ala Ile Tyr Cys Ile Gly 370
375 380Val Phe Leu Ile Ala Cys Met Val Val Thr Val Ile
Leu Cys Arg Met385 390 395
400Lys Asn Thr Thr Lys Lys Pro Asp Phe Ser Ser Gln Pro Ala Val His
405 410 415Lys Leu Thr Lys Arg
Ile Pro Leu Arg Arg Gln Val Thr Val Ser Ala 420
425 430Glu Ser Ser Ser Ser Met Asn Ser Asn Thr Pro Leu
Val Arg Ile Thr 435 440 445Thr Arg
Leu Ser Ser Thr Ala Asp Thr Pro Met Leu Ala Gly Val Ser 450
455 460Glu Tyr Glu Leu Pro Glu Asp Pro Lys Trp Glu
Phe Pro Arg Asp Lys465 470 475
480Leu Thr Leu Gly Lys Pro Leu Gly Glu Gly Cys Phe Gly Gln Val Val
485 490 495Met Ala Glu Ala
Val Gly Ile Asp Lys Asp Lys Pro Lys Glu Ala Val 500
505 510Thr Val Ala Val Lys Met Leu Lys Asp Asp Ala
Thr Glu Lys Asp Leu 515 520 525Ser
Asp Leu Val Ser Glu Met Glu Met Met Lys Met Ile Gly Lys His 530
535 540Lys Asn Ile Ile Asn Leu Leu Gly Ala Cys
Thr Gln Asp Gly Pro Leu545 550 555
560Tyr Val Ile Phe Glu Tyr Ala Ser Lys Gly Asn Leu Arg Glu Tyr
Leu 565 570 575Arg Ala Arg
Arg Pro Pro Gly Met Glu Tyr Ser Tyr Asp Ile Asn Arg 580
585 590Val Pro Glu Glu Gln Met Thr Phe Lys Asp
Leu Val Ser Cys Thr Tyr 595 600
605Gln Leu Ala Arg Gly Met Glu Tyr Leu Ala Ser Gln Lys Cys Ile His 610
615 620Arg Asp Leu Ala Ala Arg Asn Val
Leu Val Thr Glu Asn Asn Val Met625 630
635 640Lys Ile Ala Asp Phe Gly Leu Ala Arg Asp Ile Asn
Asn Ile Asp Tyr 645 650
655Tyr Lys Lys Thr Thr Asn Gly Arg Leu Pro Val Lys Trp Met Ala Pro
660 665 670Glu Ala Leu Phe Asp Arg
Val Tyr Thr His Gln Ser Asp Val Trp Ser 675 680
685Phe Gly Val Leu Met Trp Glu Ile Phe Thr Leu Gly Gly Ser
Pro Tyr 690 695 700Pro Gly Ile Pro Val
Glu Glu Leu Phe Lys Leu Leu Lys Glu Gly His705 710
715 720Arg Met Asp Lys Pro Ala Asn Cys Thr Asn
Glu Leu Tyr Met Met Met 725 730
735Arg Asp Cys Trp His Ala Val Pro Ser Gln Arg Pro Thr Phe Lys Gln
740 745 750Leu Val Glu Asp Leu
Asp Arg Ile Leu Thr Leu Thr Thr Asn Glu Glu 755
760 765Tyr Leu Asp Leu Ser Gln Pro Leu Glu Gln Tyr Ser
Pro Ser Tyr Pro 770 775 780Asp Thr Arg
Ser Ser Cys Ser Ser Gly Asp Asp Ser Val Phe Ser Pro785
790 795 800Asp Pro Met Pro Tyr Glu Pro
Cys Leu Pro Gln Tyr Pro His Ile Asn 805
810 815Gly Ser Val Lys Thr 82010821PRTHomo
sapiens 10Met Val Ser Trp Gly Arg Phe Ile Cys Leu Val Val Val Thr Met
Ala1 5 10 15Thr Leu Ser
Leu Ala Arg Pro Ser Phe Ser Leu Val Glu Asp Thr Thr 20
25 30Leu Glu Pro Glu Glu Pro Pro Thr Lys Tyr
Gln Ile Ser Gln Pro Glu 35 40
45Val Tyr Val Ala Ala Pro Gly Glu Ser Leu Glu Val Arg Cys Leu Leu 50
55 60Lys Asp Ala Ala Val Ile Ser Trp Thr
Lys Asp Gly Val His Leu Gly65 70 75
80Pro Asn Asn Arg Thr Val Leu Ile Gly Glu Tyr Leu Gln Ile
Lys Gly 85 90 95Ala Thr
Pro Arg Asp Ser Gly Leu Tyr Ala Cys Thr Ala Ser Arg Thr 100
105 110Val Asp Ser Glu Thr Trp Tyr Phe Met
Val Asn Val Thr Asp Ala Ile 115 120
125Ser Ser Gly Asp Asp Glu Asp Asp Thr Asp Gly Ala Glu Asp Phe Val
130 135 140Ser Glu Asn Ser Asn Asn Lys
Arg Ala Pro Tyr Trp Thr Asn Thr Glu145 150
155 160Lys Met Glu Lys Arg Leu His Ala Val Pro Ala Ala
Asn Thr Val Lys 165 170
175Phe Arg Cys Pro Ala Gly Gly Asn Pro Met Pro Thr Met Arg Trp Leu
180 185 190Lys Asn Gly Lys Glu Phe
Lys Gln Glu His Arg Ile Gly Gly Tyr Lys 195 200
205Val Arg Asn Gln His Trp Ser Leu Ile Met Glu Ser Val Val
Pro Ser 210 215 220Asp Lys Gly Asn Tyr
Thr Cys Val Val Glu Asn Glu Tyr Gly Ser Ile225 230
235 240Asn His Thr Tyr His Leu Asp Val Val Glu
Arg Ser Pro His Arg Pro 245 250
255Ile Leu Gln Ala Gly Leu Pro Ala Asn Ala Ser Thr Val Val Gly Gly
260 265 270Asp Val Glu Phe Val
Cys Lys Val Tyr Ser Asp Ala Gln Pro His Ile 275
280 285Gln Trp Ile Lys His Val Glu Lys Asn Gly Ser Lys
Tyr Gly Pro Asp 290 295 300Gly Leu Pro
Tyr Leu Lys Val Leu Lys Ala Ala Gly Val Asn Thr Thr305
310 315 320Asp Lys Glu Ile Glu Val Leu
Tyr Ile Arg Asn Val Thr Phe Glu Asp 325
330 335Ala Gly Glu Tyr Thr Cys Leu Ala Gly Asn Ser Ile
Gly Ile Ser Phe 340 345 350His
Ser Ala Trp Leu Thr Val Leu Pro Ala Pro Gly Arg Glu Lys Glu 355
360 365Ile Thr Ala Ser Pro Asp Tyr Leu Glu
Ile Ala Ile Tyr Cys Ile Gly 370 375
380Val Phe Leu Ile Ala Cys Met Val Val Thr Val Ile Leu Cys Arg Met385
390 395 400Lys Asn Thr Thr
Lys Lys Pro Asp Phe Ser Ser Gln Pro Ala Val His 405
410 415Lys Leu Thr Lys Arg Ile Pro Leu Arg Arg
Gln Val Thr Val Ser Ala 420 425
430Glu Ser Ser Ser Ser Met Asn Ser Asn Thr Pro Leu Val Arg Ile Thr
435 440 445Thr Arg Leu Ser Ser Thr Ala
Asp Thr Pro Met Leu Ala Gly Val Ser 450 455
460Glu Tyr Glu Leu Pro Glu Asp Pro Lys Trp Glu Phe Pro Arg Asp
Lys465 470 475 480Leu Thr
Leu Gly Lys Pro Leu Gly Glu Gly Cys Phe Gly Gln Val Val
485 490 495Met Ala Glu Ala Val Gly Ile
Asp Lys Asp Lys Pro Lys Glu Ala Val 500 505
510Thr Val Ala Val Lys Met Leu Lys Asp Asp Ala Thr Glu Lys
Asp Leu 515 520 525Ser Asp Leu Val
Ser Glu Met Glu Met Met Lys Met Ile Gly Lys His 530
535 540Lys Asn Ile Ile Asn Leu Leu Gly Ala Cys Thr Gln
Asp Gly Pro Leu545 550 555
560Tyr Leu Ile Val Glu Tyr Ala Ser Lys Gly Asn Leu Arg Glu Tyr Leu
565 570 575Arg Ala Arg Arg Pro
Pro Gly Met Glu Tyr Ser Tyr Asp Ile Asn Arg 580
585 590Val Pro Glu Glu Gln Met Thr Phe Lys Asp Leu Val
Ser Cys Thr Tyr 595 600 605Gln Leu
Ala Arg Gly Met Glu Tyr Leu Ala Ser Gln Lys Cys Ile His 610
615 620Arg Asp Leu Ala Ala Arg Asn Val Leu Val Thr
Glu Asn Asn Val Met625 630 635
640Lys Ile Ala Asp Phe Gly Leu Ala Arg Asp Ile Asn Asn Ile Asp Tyr
645 650 655Tyr Lys Lys Thr
Thr Asn Gly Arg Leu Pro Val Lys Trp Met Ala Pro 660
665 670Glu Ala Leu Phe Asp Arg Val Tyr Thr His Gln
Ser Asp Val Trp Ser 675 680 685Phe
Gly Val Leu Met Trp Glu Ile Phe Thr Leu Gly Gly Ser Pro Tyr 690
695 700Pro Gly Ile Pro Val Glu Glu Leu Phe Lys
Leu Leu Lys Glu Gly His705 710 715
720Arg Met Asp Lys Pro Ala Asn Cys Thr Asn Glu Leu Tyr Met Met
Met 725 730 735Arg Asp Cys
Trp His Ala Val Pro Ser Gln Arg Pro Thr Phe Lys Gln 740
745 750Leu Val Glu Asp Leu Asp Arg Ile Leu Thr
Leu Thr Thr Asn Glu Glu 755 760
765Tyr Leu Asp Leu Ser Gln Pro Leu Glu Gln Tyr Ser Pro Ser Tyr Pro 770
775 780Asp Thr Arg Ser Ser Cys Ser Ser
Gly Asp Asp Ser Val Phe Ser Pro785 790
795 800Asp Pro Met Pro Tyr Glu Pro Cys Leu Pro Gln Tyr
Pro His Ile Asn 805 810
815Gly Ser Val Lys Thr 820111722DNAArtificial sequenceAn
artificially synthesized polynucleotide sequence 11atgtctgaga
ctcctgctca gtgtagcatt aagcaggaac gaatttcata tacacctcca 60gagagcccag
tgccgagtta cgcttcctcg acgccacttc atgttccagt gcctagagcg 120ctcaggatgg
aggaagactc gatccgcctg cctgcgcacc tgcgcttgca gccaatttac 180tggagcaggg
atgacgtagc ccagtggctc aagtgggctg aaaatgagtt ttctttaagg 240ccaattgaca
gcaacacgtt tgaaatgaat ggcaaagctc tcctgctgct gaccaaagag 300gactttcgct
atcgatctcc tcattcaggt gatgtgctct atgaactcct tcagcatatt 360ctgaagcaga
ggaaacctcg gattcttttt tcaccattct tccaccctgg aaactctata 420cacacacagc
cggaggtcat actgcatcag aaccatgaag aagataactg tgtccagagg 480acccccaggc
catccgtgga taatgtgcac cataaccctc ccaccattga actgttgcac 540cgcgtttcgg
ctgagtccag ctcctccatg aactccaaca ccccgctggt gaggataaca 600acacgcctct
cttcaacggc agacaccccc atgctggcag gggtctccga gtatgaactt 660ccagaggacc
caaaatggga gtttccaaga gataagctga cactgggcaa gcccctggga 720gaaggttgct
ttgggcaagt ggtcatggcg gaagcagtgg gaattgacaa agacaagccc 780aaggaggcgg
tcaccgtggc cgtgaagatg ttgaaagatg atgccacaga gaaagacctt 840tctgatctgg
tgtcagagat ggagatgatg aagatgattg ggaaacacaa gaatatcata 900aatcttcttg
gagcctgcac acaggatggg cctctctatg tcatagttga gtatgcctct 960aaaggcaacc
tccgagaata cctccgagcc cggaggccac ccgggatgga gtactcctat 1020gacattaacc
gtgttcctga ggagcagatg accttcaagg acttggtgtc atgcacctac 1080cagctggcca
gaggcatgga gtacttggct tcccaaaaat gtattcatcg agatttagca 1140gccagaaatg
ttttggtaac agaaaacaat gtgatgaaaa tagcagactt tggactcgcc 1200agagatatca
acaatataga ctattacaaa aagaccacca atgggcggct tccagtcaag 1260tggatggctc
cagaagccct gtttgataga gtatacactc atcagagtga tgtctggtcc 1320ttcggggtgt
taatgtggga gatcttcact ttagggggct cgccctaccc agggattccc 1380gtggaggaac
tttttaagct gctgaaggaa ggacacagaa tggataagcc agccaactgc 1440accaacgaac
tgtacatgat gatgagggac tgttggcatg cagtgccctc ccagagacca 1500acgttcaagc
agttggtaga agacttggat cgaattctca ctctcacaac caatgaggaa 1560tacttggacc
tcagccaacc tctcgaacag tattcaccta gttaccctga cacaagaagt 1620tcttgttctt
caggagatga ttctgttttt tctccagacc ccatgcctta cgaaccatgc 1680cttcctcagt
atccacacat aaacggcagt gttaaaacat ag
1722121722DNAArtificial sequenceAn artificially synthesized
polynucleotide sequence 12atgtctgaga ctcctgctca gtgtagcatt
aagcaggaac gaatttcata tacacctcca 60gagagcccag tgccgagtta cgcttcctcg
acgccacttc atgttccagt gcctagagcg 120ctcaggatgg aggaagactc gatccgcctg
cctgcgcacc tgcgcttgca gccaatttac 180tggagcaggg atgacgtagc ccagtggctc
aagtgggctg aaaatgagtt ttctttaagg 240ccaattgaca gcaacacgtt tgaaatgaat
ggcaaagctc tcctgctgct gaccaaagag 300gactttcgct atcgatctcc tcattcaggt
gatgtgctct atgaactcct tcagcatatt 360ctgaagcaga ggaaacctcg gattcttttt
tcaccattct tccaccctgg aaactctata 420cacacacagc cggaggtcat actgcatcag
aaccatgaag aagataactg tgtccagagg 480acccccaggc catccgtgga taatgtgcac
cataaccctc ccaccattga actgttgcac 540cgcgtttcgg ctgagtccag ctcctccatg
aactccaaca ccccgctggt gaggataaca 600acacgcctct cttcaacggc agacaccccc
atgctggcag gggtctccga gtatgaactt 660ccagaggacc caaaatggga gtttccaaga
gataagctga cactgggcaa gcccctggga 720gaaggttgct ttgggcaagt ggtcatggcg
gaagcagtgg gaattgacaa agacaagccc 780aaggaggcgg tcaccgtggc cgtgaagatg
ttgaaagatg atgccacaga gaaagacctt 840tctgatctgg tgtcagagat ggagatgatg
aagatgattg ggaaacacaa gaatatcata 900aatcttcttg gagcctgcac acaggatggg
cctctctatg tcatatttga gtatgcctct 960aaaggcaacc tccgagaata cctccgagcc
cggaggccac ccgggatgga gtactcctat 1020gacattaacc gtgttcctga ggagcagatg
accttcaagg acttggtgtc atgcacctac 1080cagctggcca gaggcatgga gtacttggct
tcccaaaaat gtattcatcg agatttagca 1140gccagaaatg ttttggtaac agaaaacaat
gtgatgaaaa tagcagactt tggactcgcc 1200agagatatca acaatataga ctattacaaa
aagaccacca atgggcggct tccagtcaag 1260tggatggctc cagaagccct gtttgataga
gtatacactc atcagagtga tgtctggtcc 1320ttcggggtgt taatgtggga gatcttcact
ttagggggct cgccctaccc agggattccc 1380gtggaggaac tttttaagct gctgaaggaa
ggacacagaa tggataagcc agccaactgc 1440accaacgaac tgtacatgat gatgagggac
tgttggcatg cagtgccctc ccagagacca 1500acgttcaagc agttggtaga agacttggat
cgaattctca ctctcacaac caatgaggaa 1560tacttggacc tcagccaacc tctcgaacag
tattcaccta gttaccctga cacaagaagt 1620tcttgttctt caggagatga ttctgttttt
tctccagacc ccatgcctta cgaaccatgc 1680cttcctcagt atccacacat aaacggcagt
gttaaaacat ag 1722134PRTArtificial sequencePeptide
linker sequence 13Gly Gly Gly Ser1144PRTArtificial sequencePeptide linker
sequence 14Ser Gly Gly Gly1155PRTArtificial sequencePeptide linker
sequence 15Gly Gly Gly Gly Ser1 5165PRTArtificial
sequencePeptide linker sequence 16Ser Gly Gly Gly Gly1
5176PRTArtificial sequencePeptide linker sequence 17Gly Gly Gly Gly Gly
Ser1 5186PRTArtificial sequencePeptide linker sequence
18Ser Gly Gly Gly Gly Gly1 5197PRTArtificial
sequencePeptide linker sequence 19Gly Gly Gly Gly Gly Gly Ser1
5207PRTArtificial sequencePeptide linker sequence 20Ser Gly Gly Gly
Gly Gly Gly1 521820PRTHomo sapiens 21Met Trp Ser Trp Lys
Cys Leu Leu Phe Trp Ala Val Leu Val Thr Ala1 5
10 15Thr Leu Cys Thr Ala Arg Pro Ser Pro Thr Leu
Pro Glu Gln Ala Gln 20 25
30Pro Trp Gly Ala Pro Val Glu Val Glu Ser Phe Leu Val His Pro Gly
35 40 45Asp Leu Leu Gln Leu Arg Cys Arg
Leu Arg Asp Asp Val Gln Ser Ile 50 55
60Asn Trp Leu Arg Asp Gly Val Gln Leu Ala Glu Ser Asn Arg Thr Arg65
70 75 80Ile Thr Gly Glu Glu
Val Glu Val Gln Asp Ser Val Pro Ala Asp Ser 85
90 95Gly Leu Tyr Ala Cys Val Thr Ser Ser Pro Ser
Gly Ser Asp Thr Thr 100 105
110Tyr Phe Ser Val Asn Val Ser Asp Ala Leu Pro Ser Ser Glu Asp Asp
115 120 125Asp Asp Asp Asp Asp Ser Ser
Ser Glu Glu Lys Glu Thr Asp Asn Thr 130 135
140Lys Pro Asn Pro Val Ala Pro Tyr Trp Thr Ser Pro Glu Lys Met
Glu145 150 155 160Lys Lys
Leu His Ala Val Pro Ala Ala Lys Thr Val Lys Phe Lys Cys
165 170 175Pro Ser Ser Gly Thr Pro Asn
Pro Thr Leu Arg Trp Leu Lys Asn Gly 180 185
190Lys Glu Phe Lys Pro Asp His Arg Ile Gly Gly Tyr Lys Val
Arg Tyr 195 200 205Ala Thr Trp Ser
Ile Ile Met Asp Ser Val Val Pro Ser Asp Lys Gly 210
215 220Asn Tyr Thr Cys Ile Val Glu Asn Glu Tyr Gly Ser
Ile Asn His Thr225 230 235
240Tyr Gln Leu Asp Val Val Glu Arg Ser Pro His Arg Pro Ile Leu Gln
245 250 255Ala Gly Leu Pro Ala
Asn Lys Thr Val Ala Leu Gly Ser Asn Val Glu 260
265 270Phe Met Cys Lys Val Tyr Ser Asp Pro Gln Pro His
Ile Gln Trp Leu 275 280 285Lys His
Ile Glu Val Asn Gly Ser Lys Ile Gly Pro Asp Asn Leu Pro 290
295 300Tyr Val Gln Ile Leu Lys Thr Ala Gly Val Asn
Thr Thr Asp Lys Glu305 310 315
320Met Glu Val Leu His Leu Arg Asn Val Ser Phe Glu Asp Ala Gly Glu
325 330 335Tyr Thr Cys Leu
Ala Gly Asn Ser Ile Gly Leu Ser His His Ser Ala 340
345 350Trp Leu Thr Val Leu Glu Ala Leu Glu Glu Arg
Pro Ala Val Met Thr 355 360 365Ser
Pro Leu Tyr Leu Glu Ile Ile Ile Tyr Cys Thr Gly Ala Phe Leu 370
375 380Ile Ser Cys Met Val Gly Ser Val Ile Val
Tyr Lys Met Lys Ser Gly385 390 395
400Thr Lys Lys Ser Asp Phe His Ser Gln Met Ala Val His Lys Leu
Ala 405 410 415Lys Ser Ile
Pro Leu Arg Arg Gln Val Thr Val Ser Ala Asp Ser Ser 420
425 430Ala Ser Met Asn Ser Gly Val Leu Leu Val
Arg Pro Ser Arg Leu Ser 435 440
445Ser Ser Gly Thr Pro Met Leu Ala Gly Val Ser Glu Tyr Glu Leu Pro 450
455 460Glu Asp Pro Arg Trp Glu Leu Pro
Arg Asp Arg Leu Val Leu Gly Lys465 470
475 480Pro Leu Gly Glu Gly Cys Phe Gly Gln Val Val Leu
Ala Glu Ala Ile 485 490
495Gly Leu Asp Lys Asp Lys Pro Asn Arg Val Thr Lys Val Ala Val Lys
500 505 510Met Leu Lys Ser Asp Ala
Thr Glu Lys Asp Leu Ser Asp Leu Ile Ser 515 520
525Glu Met Glu Met Met Lys Met Ile Gly Lys His Lys Asn Ile
Ile Asn 530 535 540Leu Leu Gly Ala Cys
Thr Gln Asp Gly Pro Leu Tyr Val Ile Val Glu545 550
555 560Tyr Ala Ser Lys Gly Asn Leu Arg Glu Tyr
Leu Gln Ala Arg Arg Pro 565 570
575Pro Gly Leu Glu Tyr Cys Tyr Asn Pro Ser His Asn Pro Glu Glu Gln
580 585 590Leu Ser Ser Lys Asp
Leu Val Ser Cys Ala Tyr Gln Val Ala Arg Gly 595
600 605Met Glu Tyr Leu Ala Ser Lys Lys Cys Ile His Arg
Asp Leu Ala Ala 610 615 620Arg Asn Val
Leu Val Thr Glu Asp Asn Val Met Lys Ile Ala Asp Phe625
630 635 640Gly Leu Ala Arg Asp Ile His
His Ile Asp Tyr Tyr Lys Lys Thr Thr 645
650 655Asn Gly Arg Leu Pro Val Lys Trp Met Ala Pro Glu
Ala Leu Phe Asp 660 665 670Arg
Ile Tyr Thr His Gln Ser Asp Val Trp Ser Phe Gly Val Leu Leu 675
680 685Trp Glu Ile Phe Thr Leu Gly Gly Ser
Pro Tyr Pro Gly Val Pro Val 690 695
700Glu Glu Leu Phe Lys Leu Leu Lys Glu Gly His Arg Met Asp Lys Pro705
710 715 720Ser Asn Cys Thr
Asn Glu Leu Tyr Met Met Met Arg Asp Cys Trp His 725
730 735Ala Val Pro Ser Gln Arg Pro Thr Phe Lys
Gln Leu Val Glu Asp Leu 740 745
750Asp Arg Ile Val Ala Leu Thr Ser Asn Gln Glu Tyr Leu Asp Leu Ser
755 760 765Met Pro Leu Asp Gln Tyr Ser
Pro Ser Phe Pro Asp Thr Arg Ser Ser 770 775
780Thr Cys Ser Ser Gly Glu Asp Ser Val Phe Ser His Glu Pro Leu
Pro785 790 795 800Glu Glu
Pro Cys Leu Pro Arg His Pro Ala Gln Leu Ala Asn Gly Gly
805 810 815Leu Lys Arg Arg
82022806PRTHomo sapiens 22Met Gly Ala Pro Ala Cys Ala Leu Ala Leu Cys Val
Ala Val Ala Ile1 5 10
15Val Ala Gly Ala Ser Ser Glu Ser Leu Gly Thr Glu Gln Arg Val Val
20 25 30Gly Arg Ala Ala Glu Val Pro
Gly Pro Glu Pro Gly Gln Gln Glu Gln 35 40
45Leu Val Phe Gly Ser Gly Asp Ala Val Glu Leu Ser Cys Pro Pro
Pro 50 55 60Gly Gly Gly Pro Met Gly
Pro Thr Val Trp Val Lys Asp Gly Thr Gly65 70
75 80Leu Val Pro Ser Glu Arg Val Leu Val Gly Pro
Gln Arg Leu Gln Val 85 90
95Leu Asn Ala Ser His Glu Asp Ser Gly Ala Tyr Ser Cys Arg Gln Arg
100 105 110Leu Thr Gln Arg Val Leu
Cys His Phe Ser Val Arg Val Thr Asp Ala 115 120
125Pro Ser Ser Gly Asp Asp Glu Asp Gly Glu Asp Glu Ala Glu
Asp Thr 130 135 140Gly Val Asp Thr Gly
Ala Pro Tyr Trp Thr Arg Pro Glu Arg Met Asp145 150
155 160Lys Lys Leu Leu Ala Val Pro Ala Ala Asn
Thr Val Arg Phe Arg Cys 165 170
175Pro Ala Ala Gly Asn Pro Thr Pro Ser Ile Ser Trp Leu Lys Asn Gly
180 185 190Arg Glu Phe Arg Gly
Glu His Arg Ile Gly Gly Ile Lys Leu Arg His 195
200 205Gln Gln Trp Ser Leu Val Met Glu Ser Val Val Pro
Ser Asp Arg Gly 210 215 220Asn Tyr Thr
Cys Val Val Glu Asn Lys Phe Gly Ser Ile Arg Gln Thr225
230 235 240Tyr Thr Leu Asp Val Leu Glu
Arg Ser Pro His Arg Pro Ile Leu Gln 245
250 255Ala Gly Leu Pro Ala Asn Gln Thr Ala Val Leu Gly
Ser Asp Val Glu 260 265 270Phe
His Cys Lys Val Tyr Ser Asp Ala Gln Pro His Ile Gln Trp Leu 275
280 285Lys His Val Glu Val Asn Gly Ser Lys
Val Gly Pro Asp Gly Thr Pro 290 295
300Tyr Val Thr Val Leu Lys Thr Ala Gly Ala Asn Thr Thr Asp Lys Glu305
310 315 320Leu Glu Val Leu
Ser Leu His Asn Val Thr Phe Glu Asp Ala Gly Glu 325
330 335Tyr Thr Cys Leu Ala Gly Asn Ser Ile Gly
Phe Ser His His Ser Ala 340 345
350Trp Leu Val Val Leu Pro Ala Glu Glu Glu Leu Val Glu Ala Asp Glu
355 360 365Ala Gly Ser Val Tyr Ala Gly
Ile Leu Ser Tyr Gly Val Gly Phe Phe 370 375
380Leu Phe Ile Leu Val Val Ala Ala Val Thr Leu Cys Arg Leu Arg
Ser385 390 395 400Pro Pro
Lys Lys Gly Leu Gly Ser Pro Thr Val His Lys Ile Ser Arg
405 410 415Phe Pro Leu Lys Arg Gln Val
Ser Leu Glu Ser Asn Ala Ser Met Ser 420 425
430Ser Asn Thr Pro Leu Val Arg Ile Ala Arg Leu Ser Ser Gly
Glu Gly 435 440 445Pro Thr Leu Ala
Asn Val Ser Glu Leu Glu Leu Pro Ala Asp Pro Lys 450
455 460Trp Glu Leu Ser Arg Ala Arg Leu Thr Leu Gly Lys
Pro Leu Gly Glu465 470 475
480Gly Cys Phe Gly Gln Val Val Met Ala Glu Ala Ile Gly Ile Asp Lys
485 490 495Asp Arg Ala Ala Lys
Pro Val Thr Val Ala Val Lys Met Leu Lys Asp 500
505 510Asp Ala Thr Asp Lys Asp Leu Ser Asp Leu Val Ser
Glu Met Glu Met 515 520 525Met Lys
Met Ile Gly Lys His Lys Asn Ile Ile Asn Leu Leu Gly Ala 530
535 540Cys Thr Gln Gly Gly Pro Leu Tyr Val Leu Val
Glu Tyr Ala Ala Lys545 550 555
560Gly Asn Leu Arg Glu Phe Leu Arg Ala Arg Arg Pro Pro Gly Leu Asp
565 570 575Tyr Ser Phe Asp
Thr Cys Lys Pro Pro Glu Glu Gln Leu Thr Phe Lys 580
585 590Asp Leu Val Ser Cys Ala Tyr Gln Val Ala Arg
Gly Met Glu Tyr Leu 595 600 605Ala
Ser Gln Lys Cys Ile His Arg Asp Leu Ala Ala Arg Asn Val Leu 610
615 620Val Thr Glu Asp Asn Val Met Lys Ile Ala
Asp Phe Gly Leu Ala Arg625 630 635
640Asp Val His Asn Leu Asp Tyr Tyr Lys Lys Thr Thr Asn Gly Arg
Leu 645 650 655Pro Val Lys
Trp Met Ala Pro Glu Ala Leu Phe Asp Arg Val Tyr Thr 660
665 670His Gln Ser Asp Val Trp Ser Phe Gly Val
Leu Leu Trp Glu Ile Phe 675 680
685Thr Leu Gly Gly Ser Pro Tyr Pro Gly Ile Pro Val Glu Glu Leu Phe 690
695 700Lys Leu Leu Lys Glu Gly His Arg
Met Asp Lys Pro Ala Asn Cys Thr705 710
715 720His Asp Leu Tyr Met Ile Met Arg Glu Cys Trp His
Ala Ala Pro Ser 725 730
735Gln Arg Pro Thr Phe Lys Gln Leu Val Glu Asp Leu Asp Arg Val Leu
740 745 750Thr Val Thr Ser Thr Asp
Glu Tyr Leu Asp Leu Ser Ala Pro Phe Glu 755 760
765Gln Tyr Ser Pro Gly Gly Gln Asp Thr Pro Ser Ser Ser Ser
Ser Gly 770 775 780Asp Asp Ser Val Phe
Ala His Asp Leu Leu Pro Pro Ala Pro Pro Ser785 790
795 800Ser Gly Gly Ser Arg Thr
805232463DNAHomo sapiens 23atgtggagct ggaagtgcct cctcttctgg gctgtgctgg
tcacagccac actctgcacc 60gctaggccgt ccccgacctt gcctgaacaa gcccagccct
ggggagcccc tgtggaagtg 120gagtccttcc tggtccaccc cggtgacctg ctgcagcttc
gctgtcggct gcgggacgat 180gtgcagagca tcaactggct gcgggacggg gtgcagctgg
cggaaagcaa ccgcacccgc 240atcacagggg aggaggtgga ggtgcaggac tccgtgcccg
cagactccgg cctctatgct 300tgcgtaacca gcagcccctc gggcagtgac accacctact
tctccgtcaa tgtttcagat 360gctctcccct cctcggagga tgatgatgat gatgatgact
cctcttcaga ggagaaagaa 420acagataaca ccaaaccaaa ccccgtagct ccatattgga
catccccaga aaagatggaa 480aagaaattgc atgcagtgcc ggctgccaag acagtgaagt
tcaaatgccc ttccagtggg 540accccaaacc ccacactgcg ctggttgaaa aatggcaaag
aattcaaacc tgaccacaga 600attggaggct acaaggtccg ttatgccacc tggagcatca
taatggactc tgtggtgccc 660tctgacaagg gcaactacac ctgcattgtg gagaatgagt
acggcagcat caaccacaca 720taccagctgg atgtcgtgga gcggtcccct caccggccca
tcctgcaagc agggttgccc 780gccaacaaaa cagtggccct gggtagcaac gtggagttca
tgtgtaaggt gtacagtgac 840ccgcagccgc acatccagtg gctaaagcac atcgaggtga
atgggagcaa gattggccca 900gacaacctgc cttatgtcca gatcttgaag actgctggag
ttaataccac cgacaaagag 960atggaggtgc ttcacttaag aaatgtctcc tttgaggacg
caggggagta tacgtgcttg 1020gcgggtaact ctatcggact ctcccatcac tctgcatggt
tgaccgttct ggaagccctg 1080gaagagaggc cggcagtgat gacctcgccc ctgtacctgg
agatcatcat ctattgcaca 1140ggggccttcc tcatctcctg catggtgggg tcggtcatcg
tctacaagat gaagagtggt 1200accaagaaga gtgacttcca cagccagatg gctgtgcaca
agctggccaa gagcatccct 1260ctgcgcagac aggtaacagt gtctgctgac tccagtgcat
ccatgaactc tggggttctt 1320ctggttcggc catcacggct ctcctccagt gggactccca
tgctagcagg ggtctctgag 1380tatgagcttc ccgaagaccc tcgctgggag ctgcctcggg
acagactggt cttaggcaaa 1440cccctgggag agggctgctt tgggcaggtg gtgttggcag
aggctatcgg gctggacaag 1500gacaaaccca accgtgtgac caaagtggct gtgaagatgt
tgaagtcgga cgcaacagag 1560aaagacttgt cagacctgat ctcagaaatg gagatgatga
agatgatcgg gaagcataag 1620aatatcatca acctgctggg ggcctgcacg caggatggtc
ccttgtatgt catcgtggag 1680tatgcctcca agggcaacct gcgggagtac ctgcaggccc
ggaggccccc agggctggaa 1740tactgctaca accccagcca caacccagag gagcagctct
cctccaagga cctggtgtcc 1800tgcgcctacc aggtggcccg aggcatggag tatctggcct
ccaagaagtg catacaccga 1860gacctggcag ccaggaatgt cctggtgaca gaggacaatg
tgatgaagat agcagacttt 1920ggcctcgcac gggacattca ccacatcgac tactataaaa
agacaaccaa cggccgactg 1980cctgtgaagt ggatggcacc cgaggcatta tttgaccgga
tctacaccca ccagagtgat 2040gtgtggtctt tcggggtgct cctgtgggag atcttcactc
tgggcggctc cccatacccc 2100ggtgtgcctg tggaggaact tttcaagctg ctgaaggagg
gtcaccgcat ggacaagccc 2160agtaactgca ccaacgagct gtacatgatg atgcgggact
gctggcatgc agtgccctca 2220cagagaccca ccttcaagca gctggtggaa gacctggacc
gcatcgtggc cttgacctcc 2280aaccaggagt acctggacct gtccatgccc ctggaccagt
actcccccag ctttcccgac 2340acccggagct ctacgtgctc ctcaggggag gattccgtct
tctctcatga gccgctgccc 2400gaggagccct gcctgccccg acacccagcc cagcttgcca
atggcggact caaacgccgc 2460tga
2463242421DNAHomo sapiens 24atgggcgccc ctgcctgcgc
cctcgcgctc tgcgtggccg tggccatcgt ggccggcgcc 60tcctcggagt ccttggggac
ggagcagcgc gtcgtggggc gagcggcaga agtcccgggc 120ccagagcccg gccagcagga
gcagttggtc ttcggcagcg gggatgctgt ggagctgagc 180tgtcccccgc ccgggggtgg
tcccatgggg cccactgtct gggtcaagga tggcacaggg 240ctggtgccct cggagcgtgt
cctggtgggg ccccagcggc tgcaggtgct gaatgcctcc 300cacgaggact ccggggccta
cagctgccgg cagcggctca cgcagcgcgt actgtgccac 360ttcagtgtgc gggtgacaga
cgctccatcc tcgggagatg acgaagacgg ggaggacgag 420gctgaggaca caggtgtgga
cacaggggcc ccttactgga cacggcccga gcggatggac 480aagaagctgc tggccgtgcc
ggccgccaac accgtccgct tccgctgccc agccgctggc 540aaccccactc cctccatctc
ctggctgaag aacggcaggg agttccgcgg cgagcaccgc 600attggaggca tcaagctgcg
gcatcagcag tggagcctgg tcatggaaag cgtggtgccc 660tcggaccgcg gcaactacac
ctgcgtcgtg gagaacaagt ttggcagcat ccggcagacg 720tacacgctgg acgtgctgga
gcgctccccg caccggccca tcctgcaggc ggggctgccg 780gccaaccaga cggcggtgct
gggcagcgac gtggagttcc actgcaaggt gtacagtgac 840gcacagcccc acatccagtg
gctcaagcac gtggaggtga atggcagcaa ggtgggcccg 900gacggcacac cctacgttac
cgtgctcaag acggcgggcg ctaacaccac cgacaaggag 960ctagaggttc tctccttgca
caacgtcacc tttgaggacg ccggggagta cacctgcctg 1020gcgggcaatt ctattgggtt
ttctcatcac tctgcgtggc tggtggtgct gccagccgag 1080gaggagctgg tggaggctga
cgaggcgggc agtgtgtatg caggcatcct cagctacggg 1140gtgggcttct tcctgttcat
cctggtggtg gcggctgtga cgctctgccg cctgcgcagc 1200ccccccaaga aaggcctggg
ctcccccacc gtgcacaaga tctcccgctt cccgctcaag 1260cgacaggtgt ccctggagtc
caacgcgtcc atgagctcca acacaccact ggtgcgcatc 1320gcaaggctgt cctcagggga
gggccccacg ctggccaatg tctccgagct cgagctgcct 1380gccgacccca aatgggagct
gtctcgggcc cggctgaccc tgggcaagcc ccttggggag 1440ggctgcttcg gccaggtggt
catggcggag gccatcggca ttgacaagga ccgggccgcc 1500aagcctgtca ccgtagccgt
gaagatgctg aaagacgatg ccactgacaa ggacctgtcg 1560gacctggtgt ctgagatgga
gatgatgaag atgatcggga aacacaaaaa catcatcaac 1620ctgctgggcg cctgcacgca
gggcgggccc ctgtacgtgc tggtggagta cgcggccaag 1680ggtaacctgc gggagtttct
gcgggcgcgg cggcccccgg gcctggacta ctccttcgac 1740acctgcaagc cgcccgagga
gcagctcacc ttcaaggacc tggtgtcctg tgcctaccag 1800gtggcccggg gcatggagta
cttggcctcc cagaagtgca tccacaggga cctggctgcc 1860cgcaatgtgc tggtgaccga
ggacaacgtg atgaagatcg cagacttcgg gctggcccgg 1920gacgtgcaca acctcgacta
ctacaagaag acaaccaacg gccggctgcc cgtgaagtgg 1980atggcgcctg aggccttgtt
tgaccgagtc tacactcacc agagtgacgt ctggtccttt 2040ggggtcctgc tctgggagat
cttcacgctg gggggctccc cgtaccccgg catccctgtg 2100gaggagctct tcaagctgct
gaaggagggc caccgcatgg acaagcccgc caactgcaca 2160cacgacctgt acatgatcat
gcgggagtgc tggcatgccg cgccctccca gaggcccacc 2220ttcaagcagc tggtggagga
cctggaccgt gtccttaccg tgacgtccac cgacgagtac 2280ctggacctgt cggcgccttt
cgagcagtac tccccgggtg gccaggacac ccccagctcc 2340agctcctcag gggacgactc
cgtgtttgcc cacgacctgc tgcccccggc cccacccagc 2400agtgggggct cgcggacgtg a
242125820PRTHomo sapiens
25Met Trp Ser Trp Lys Cys Leu Leu Phe Trp Ala Val Leu Val Thr Ala1
5 10 15Thr Leu Cys Thr Ala Arg
Pro Ser Pro Thr Leu Pro Glu Gln Ala Gln 20 25
30Pro Trp Gly Ala Pro Val Glu Val Glu Ser Phe Leu Val
His Pro Gly 35 40 45Asp Leu Leu
Gln Leu Arg Cys Arg Leu Arg Asp Asp Val Gln Ser Ile 50
55 60Asn Trp Leu Arg Asp Gly Val Gln Leu Ala Glu Ser
Asn Arg Thr Arg65 70 75
80Ile Thr Gly Glu Glu Val Glu Val Gln Asp Ser Val Pro Ala Asp Ser
85 90 95Gly Leu Tyr Ala Cys Val
Thr Ser Ser Pro Ser Gly Ser Asp Thr Thr 100
105 110Tyr Phe Ser Val Asn Val Ser Asp Ala Leu Pro Ser
Ser Glu Asp Asp 115 120 125Asp Asp
Asp Asp Asp Ser Ser Ser Glu Glu Lys Glu Thr Asp Asn Thr 130
135 140Lys Pro Asn Pro Val Ala Pro Tyr Trp Thr Ser
Pro Glu Lys Met Glu145 150 155
160Lys Lys Leu His Ala Val Pro Ala Ala Lys Thr Val Lys Phe Lys Cys
165 170 175Pro Ser Ser Gly
Thr Pro Asn Pro Thr Leu Arg Trp Leu Lys Asn Gly 180
185 190Lys Glu Phe Lys Pro Asp His Arg Ile Gly Gly
Tyr Lys Val Arg Tyr 195 200 205Ala
Thr Trp Ser Ile Ile Met Asp Ser Val Val Pro Ser Asp Lys Gly 210
215 220Asn Tyr Thr Cys Ile Val Glu Asn Glu Tyr
Gly Ser Ile Asn His Thr225 230 235
240Tyr Gln Leu Asp Val Val Glu Arg Ser Pro His Arg Pro Ile Leu
Gln 245 250 255Ala Gly Leu
Pro Ala Asn Lys Thr Val Ala Leu Gly Ser Asn Val Glu 260
265 270Phe Met Cys Lys Val Tyr Ser Asp Pro Gln
Pro His Ile Gln Trp Leu 275 280
285Lys His Ile Glu Val Asn Gly Ser Lys Ile Gly Pro Asp Asn Leu Pro 290
295 300Tyr Val Gln Ile Leu Lys Thr Ala
Gly Val Asn Thr Thr Asp Lys Glu305 310
315 320Met Glu Val Leu His Leu Arg Asn Val Ser Phe Glu
Asp Ala Gly Glu 325 330
335Tyr Thr Cys Leu Ala Gly Asn Ser Ile Gly Leu Ser His His Ser Ala
340 345 350Trp Leu Thr Val Leu Glu
Ala Leu Glu Glu Arg Pro Ala Val Met Thr 355 360
365Ser Pro Leu Tyr Leu Glu Ile Ile Ile Tyr Cys Thr Gly Ala
Phe Leu 370 375 380Ile Ser Cys Met Val
Gly Ser Val Ile Val Tyr Lys Met Lys Ser Gly385 390
395 400Thr Lys Lys Ser Asp Phe His Ser Gln Met
Ala Val His Lys Leu Ala 405 410
415Lys Ser Ile Pro Leu Arg Arg Gln Val Thr Val Ser Ala Asp Ser Ser
420 425 430Ala Ser Met Asn Ser
Gly Val Leu Leu Val Arg Pro Ser Arg Leu Ser 435
440 445Ser Ser Gly Thr Pro Met Leu Ala Gly Val Ser Glu
Tyr Glu Leu Pro 450 455 460Glu Asp Pro
Arg Trp Glu Leu Pro Arg Asp Arg Leu Val Leu Gly Lys465
470 475 480Pro Leu Gly Glu Gly Cys Phe
Gly Gln Val Val Leu Ala Glu Ala Ile 485
490 495Gly Leu Asp Lys Asp Lys Pro Asn Arg Val Thr Lys
Val Ala Val Lys 500 505 510Met
Leu Lys Ser Asp Ala Thr Glu Lys Asp Leu Ser Asp Leu Ile Ser 515
520 525Glu Met Glu Met Met Lys Met Ile Gly
Lys His Lys Asn Ile Ile Asn 530 535
540Leu Leu Gly Ala Cys Thr Gln Asp Gly Pro Leu Tyr Val Ile Phe Glu545
550 555 560Tyr Ala Ser Lys
Gly Asn Leu Arg Glu Tyr Leu Gln Ala Arg Arg Pro 565
570 575Pro Gly Leu Glu Tyr Cys Tyr Asn Pro Ser
His Asn Pro Glu Glu Gln 580 585
590Leu Ser Ser Lys Asp Leu Val Ser Cys Ala Tyr Gln Val Ala Arg Gly
595 600 605Met Glu Tyr Leu Ala Ser Lys
Lys Cys Ile His Arg Asp Leu Ala Ala 610 615
620Arg Asn Val Leu Val Thr Glu Asp Asn Val Met Lys Ile Ala Asp
Phe625 630 635 640Gly Leu
Ala Arg Asp Ile His His Ile Asp Tyr Tyr Lys Lys Thr Thr
645 650 655Asn Gly Arg Leu Pro Val Lys
Trp Met Ala Pro Glu Ala Leu Phe Asp 660 665
670Arg Ile Tyr Thr His Gln Ser Asp Val Trp Ser Phe Gly Val
Leu Leu 675 680 685Trp Glu Ile Phe
Thr Leu Gly Gly Ser Pro Tyr Pro Gly Val Pro Val 690
695 700Glu Glu Leu Phe Lys Leu Leu Lys Glu Gly His Arg
Met Asp Lys Pro705 710 715
720Ser Asn Cys Thr Asn Glu Leu Tyr Met Met Met Arg Asp Cys Trp His
725 730 735Ala Val Pro Ser Gln
Arg Pro Thr Phe Lys Gln Leu Val Glu Asp Leu 740
745 750Asp Arg Ile Val Ala Leu Thr Ser Asn Gln Glu Tyr
Leu Asp Leu Ser 755 760 765Met Pro
Leu Asp Gln Tyr Ser Pro Ser Phe Pro Asp Thr Arg Ser Ser 770
775 780Thr Cys Ser Ser Gly Glu Asp Ser Val Phe Ser
His Glu Pro Leu Pro785 790 795
800Glu Glu Pro Cys Leu Pro Arg His Pro Ala Gln Leu Ala Asn Gly Gly
805 810 815Leu Lys Arg Arg
82026820PRTHomo sapiens 26Met Trp Ser Trp Lys Cys Leu Leu Phe
Trp Ala Val Leu Val Thr Ala1 5 10
15Thr Leu Cys Thr Ala Arg Pro Ser Pro Thr Leu Pro Glu Gln Ala
Gln 20 25 30Pro Trp Gly Ala
Pro Val Glu Val Glu Ser Phe Leu Val His Pro Gly 35
40 45Asp Leu Leu Gln Leu Arg Cys Arg Leu Arg Asp Asp
Val Gln Ser Ile 50 55 60Asn Trp Leu
Arg Asp Gly Val Gln Leu Ala Glu Ser Asn Arg Thr Arg65 70
75 80Ile Thr Gly Glu Glu Val Glu Val
Gln Asp Ser Val Pro Ala Asp Ser 85 90
95Gly Leu Tyr Ala Cys Val Thr Ser Ser Pro Ser Gly Ser Asp
Thr Thr 100 105 110Tyr Phe Ser
Val Asn Val Ser Asp Ala Leu Pro Ser Ser Glu Asp Asp 115
120 125Asp Asp Asp Asp Asp Ser Ser Ser Glu Glu Lys
Glu Thr Asp Asn Thr 130 135 140Lys Pro
Asn Pro Val Ala Pro Tyr Trp Thr Ser Pro Glu Lys Met Glu145
150 155 160Lys Lys Leu His Ala Val Pro
Ala Ala Lys Thr Val Lys Phe Lys Cys 165
170 175Pro Ser Ser Gly Thr Pro Asn Pro Thr Leu Arg Trp
Leu Lys Asn Gly 180 185 190Lys
Glu Phe Lys Pro Asp His Arg Ile Gly Gly Tyr Lys Val Arg Tyr 195
200 205Ala Thr Trp Ser Ile Ile Met Asp Ser
Val Val Pro Ser Asp Lys Gly 210 215
220Asn Tyr Thr Cys Ile Val Glu Asn Glu Tyr Gly Ser Ile Asn His Thr225
230 235 240Tyr Gln Leu Asp
Val Val Glu Arg Ser Pro His Arg Pro Ile Leu Gln 245
250 255Ala Gly Leu Pro Ala Asn Lys Thr Val Ala
Leu Gly Ser Asn Val Glu 260 265
270Phe Met Cys Lys Val Tyr Ser Asp Pro Gln Pro His Ile Gln Trp Leu
275 280 285Lys His Ile Glu Val Asn Gly
Ser Lys Ile Gly Pro Asp Asn Leu Pro 290 295
300Tyr Val Gln Ile Leu Lys Thr Ala Gly Val Asn Thr Thr Asp Lys
Glu305 310 315 320Met Glu
Val Leu His Leu Arg Asn Val Ser Phe Glu Asp Ala Gly Glu
325 330 335Tyr Thr Cys Leu Ala Gly Asn
Ser Ile Gly Leu Ser His His Ser Ala 340 345
350Trp Leu Thr Val Leu Glu Ala Leu Glu Glu Arg Pro Ala Val
Met Thr 355 360 365Ser Pro Leu Tyr
Leu Glu Ile Ile Ile Tyr Cys Thr Gly Ala Phe Leu 370
375 380Ile Ser Cys Met Val Gly Ser Val Ile Val Tyr Lys
Met Lys Ser Gly385 390 395
400Thr Lys Lys Ser Asp Phe His Ser Gln Met Ala Val His Lys Leu Ala
405 410 415Lys Ser Ile Pro Leu
Arg Arg Gln Val Thr Val Ser Ala Asp Ser Ser 420
425 430Ala Ser Met Asn Ser Gly Val Leu Leu Val Arg Pro
Ser Arg Leu Ser 435 440 445Ser Ser
Gly Thr Pro Met Leu Ala Gly Val Ser Glu Tyr Glu Leu Pro 450
455 460Glu Asp Pro Arg Trp Glu Leu Pro Arg Asp Arg
Leu Val Leu Gly Lys465 470 475
480Pro Leu Gly Glu Gly Cys Phe Gly Gln Val Val Leu Ala Glu Ala Ile
485 490 495Gly Leu Asp Lys
Asp Lys Pro Asn Arg Val Thr Lys Val Ala Val Lys 500
505 510Met Leu Lys Ser Asp Ala Thr Glu Lys Asp Leu
Ser Asp Leu Ile Ser 515 520 525Glu
Met Glu Met Met Lys Met Ile Gly Lys His Lys Asn Ile Ile Asn 530
535 540Leu Leu Gly Ala Cys Thr Gln Asp Gly Pro
Leu Tyr Leu Ile Val Glu545 550 555
560Tyr Ala Ser Lys Gly Asn Leu Arg Glu Tyr Leu Gln Ala Arg Arg
Pro 565 570 575Pro Gly Leu
Glu Tyr Cys Tyr Asn Pro Ser His Asn Pro Glu Glu Gln 580
585 590Leu Ser Ser Lys Asp Leu Val Ser Cys Ala
Tyr Gln Val Ala Arg Gly 595 600
605Met Glu Tyr Leu Ala Ser Lys Lys Cys Ile His Arg Asp Leu Ala Ala 610
615 620Arg Asn Val Leu Val Thr Glu Asp
Asn Val Met Lys Ile Ala Asp Phe625 630
635 640Gly Leu Ala Arg Asp Ile His His Ile Asp Tyr Tyr
Lys Lys Thr Thr 645 650
655Asn Gly Arg Leu Pro Val Lys Trp Met Ala Pro Glu Ala Leu Phe Asp
660 665 670Arg Ile Tyr Thr His Gln
Ser Asp Val Trp Ser Phe Gly Val Leu Leu 675 680
685Trp Glu Ile Phe Thr Leu Gly Gly Ser Pro Tyr Pro Gly Val
Pro Val 690 695 700Glu Glu Leu Phe Lys
Leu Leu Lys Glu Gly His Arg Met Asp Lys Pro705 710
715 720Ser Asn Cys Thr Asn Glu Leu Tyr Met Met
Met Arg Asp Cys Trp His 725 730
735Ala Val Pro Ser Gln Arg Pro Thr Phe Lys Gln Leu Val Glu Asp Leu
740 745 750Asp Arg Ile Val Ala
Leu Thr Ser Asn Gln Glu Tyr Leu Asp Leu Ser 755
760 765Met Pro Leu Asp Gln Tyr Ser Pro Ser Phe Pro Asp
Thr Arg Ser Ser 770 775 780Thr Cys Ser
Ser Gly Glu Asp Ser Val Phe Ser His Glu Pro Leu Pro785
790 795 800Glu Glu Pro Cys Leu Pro Arg
His Pro Ala Gln Leu Ala Asn Gly Gly 805
810 815Leu Lys Arg Arg 82027806PRTHomo sapiens
27Met Gly Ala Pro Ala Cys Ala Leu Ala Leu Cys Val Ala Val Ala Ile1
5 10 15Val Ala Gly Ala Ser Ser
Glu Ser Leu Gly Thr Glu Gln Arg Val Val 20 25
30Gly Arg Ala Ala Glu Val Pro Gly Pro Glu Pro Gly Gln
Gln Glu Gln 35 40 45Leu Val Phe
Gly Ser Gly Asp Ala Val Glu Leu Ser Cys Pro Pro Pro 50
55 60Gly Gly Gly Pro Met Gly Pro Thr Val Trp Val Lys
Asp Gly Thr Gly65 70 75
80Leu Val Pro Ser Glu Arg Val Leu Val Gly Pro Gln Arg Leu Gln Val
85 90 95Leu Asn Ala Ser His Glu
Asp Ser Gly Ala Tyr Ser Cys Arg Gln Arg 100
105 110Leu Thr Gln Arg Val Leu Cys His Phe Ser Val Arg
Val Thr Asp Ala 115 120 125Pro Ser
Ser Gly Asp Asp Glu Asp Gly Glu Asp Glu Ala Glu Asp Thr 130
135 140Gly Val Asp Thr Gly Ala Pro Tyr Trp Thr Arg
Pro Glu Arg Met Asp145 150 155
160Lys Lys Leu Leu Ala Val Pro Ala Ala Asn Thr Val Arg Phe Arg Cys
165 170 175Pro Ala Ala Gly
Asn Pro Thr Pro Ser Ile Ser Trp Leu Lys Asn Gly 180
185 190Arg Glu Phe Arg Gly Glu His Arg Ile Gly Gly
Ile Lys Leu Arg His 195 200 205Gln
Gln Trp Ser Leu Val Met Glu Ser Val Val Pro Ser Asp Arg Gly 210
215 220Asn Tyr Thr Cys Val Val Glu Asn Lys Phe
Gly Ser Ile Arg Gln Thr225 230 235
240Tyr Thr Leu Asp Val Leu Glu Arg Ser Pro His Arg Pro Ile Leu
Gln 245 250 255Ala Gly Leu
Pro Ala Asn Gln Thr Ala Val Leu Gly Ser Asp Val Glu 260
265 270Phe His Cys Lys Val Tyr Ser Asp Ala Gln
Pro His Ile Gln Trp Leu 275 280
285Lys His Val Glu Val Asn Gly Ser Lys Val Gly Pro Asp Gly Thr Pro 290
295 300Tyr Val Thr Val Leu Lys Thr Ala
Gly Ala Asn Thr Thr Asp Lys Glu305 310
315 320Leu Glu Val Leu Ser Leu His Asn Val Thr Phe Glu
Asp Ala Gly Glu 325 330
335Tyr Thr Cys Leu Ala Gly Asn Ser Ile Gly Phe Ser His His Ser Ala
340 345 350Trp Leu Val Val Leu Pro
Ala Glu Glu Glu Leu Val Glu Ala Asp Glu 355 360
365Ala Gly Ser Val Tyr Ala Gly Ile Leu Ser Tyr Gly Val Gly
Phe Phe 370 375 380Leu Phe Ile Leu Val
Val Ala Ala Val Thr Leu Cys Arg Leu Arg Ser385 390
395 400Pro Pro Lys Lys Gly Leu Gly Ser Pro Thr
Val His Lys Ile Ser Arg 405 410
415Phe Pro Leu Lys Arg Gln Val Ser Leu Glu Ser Asn Ala Ser Met Ser
420 425 430Ser Asn Thr Pro Leu
Val Arg Ile Ala Arg Leu Ser Ser Gly Glu Gly 435
440 445Pro Thr Leu Ala Asn Val Ser Glu Leu Glu Leu Pro
Ala Asp Pro Lys 450 455 460Trp Glu Leu
Ser Arg Ala Arg Leu Thr Leu Gly Lys Pro Leu Gly Glu465
470 475 480Gly Cys Phe Gly Gln Val Val
Met Ala Glu Ala Ile Gly Ile Asp Lys 485
490 495Asp Arg Ala Ala Lys Pro Val Thr Val Ala Val Lys
Met Leu Lys Asp 500 505 510Asp
Ala Thr Asp Lys Asp Leu Ser Asp Leu Val Ser Glu Met Glu Met 515
520 525Met Lys Met Ile Gly Lys His Lys Asn
Ile Ile Asn Leu Leu Gly Ala 530 535
540Cys Thr Gln Gly Gly Pro Leu Tyr Val Leu Phe Glu Tyr Ala Ala Lys545
550 555 560Gly Asn Leu Arg
Glu Phe Leu Arg Ala Arg Arg Pro Pro Gly Leu Asp 565
570 575Tyr Ser Phe Asp Thr Cys Lys Pro Pro Glu
Glu Gln Leu Thr Phe Lys 580 585
590Asp Leu Val Ser Cys Ala Tyr Gln Val Ala Arg Gly Met Glu Tyr Leu
595 600 605Ala Ser Gln Lys Cys Ile His
Arg Asp Leu Ala Ala Arg Asn Val Leu 610 615
620Val Thr Glu Asp Asn Val Met Lys Ile Ala Asp Phe Gly Leu Ala
Arg625 630 635 640Asp Val
His Asn Leu Asp Tyr Tyr Lys Lys Thr Thr Asn Gly Arg Leu
645 650 655Pro Val Lys Trp Met Ala Pro
Glu Ala Leu Phe Asp Arg Val Tyr Thr 660 665
670His Gln Ser Asp Val Trp Ser Phe Gly Val Leu Leu Trp Glu
Ile Phe 675 680 685Thr Leu Gly Gly
Ser Pro Tyr Pro Gly Ile Pro Val Glu Glu Leu Phe 690
695 700Lys Leu Leu Lys Glu Gly His Arg Met Asp Lys Pro
Ala Asn Cys Thr705 710 715
720His Asp Leu Tyr Met Ile Met Arg Glu Cys Trp His Ala Ala Pro Ser
725 730 735Gln Arg Pro Thr Phe
Lys Gln Leu Val Glu Asp Leu Asp Arg Val Leu 740
745 750Thr Val Thr Ser Thr Asp Glu Tyr Leu Asp Leu Ser
Ala Pro Phe Glu 755 760 765Gln Tyr
Ser Pro Gly Gly Gln Asp Thr Pro Ser Ser Ser Ser Ser Gly 770
775 780Asp Asp Ser Val Phe Ala His Asp Leu Leu Pro
Pro Ala Pro Pro Ser785 790 795
800Ser Gly Gly Ser Arg Thr 80528806PRTHomo sapiens
28Met Gly Ala Pro Ala Cys Ala Leu Ala Leu Cys Val Ala Val Ala Ile1
5 10 15Val Ala Gly Ala Ser Ser
Glu Ser Leu Gly Thr Glu Gln Arg Val Val 20 25
30Gly Arg Ala Ala Glu Val Pro Gly Pro Glu Pro Gly Gln
Gln Glu Gln 35 40 45Leu Val Phe
Gly Ser Gly Asp Ala Val Glu Leu Ser Cys Pro Pro Pro 50
55 60Gly Gly Gly Pro Met Gly Pro Thr Val Trp Val Lys
Asp Gly Thr Gly65 70 75
80Leu Val Pro Ser Glu Arg Val Leu Val Gly Pro Gln Arg Leu Gln Val
85 90 95Leu Asn Ala Ser His Glu
Asp Ser Gly Ala Tyr Ser Cys Arg Gln Arg 100
105 110Leu Thr Gln Arg Val Leu Cys His Phe Ser Val Arg
Val Thr Asp Ala 115 120 125Pro Ser
Ser Gly Asp Asp Glu Asp Gly Glu Asp Glu Ala Glu Asp Thr 130
135 140Gly Val Asp Thr Gly Ala Pro Tyr Trp Thr Arg
Pro Glu Arg Met Asp145 150 155
160Lys Lys Leu Leu Ala Val Pro Ala Ala Asn Thr Val Arg Phe Arg Cys
165 170 175Pro Ala Ala Gly
Asn Pro Thr Pro Ser Ile Ser Trp Leu Lys Asn Gly 180
185 190Arg Glu Phe Arg Gly Glu His Arg Ile Gly Gly
Ile Lys Leu Arg His 195 200 205Gln
Gln Trp Ser Leu Val Met Glu Ser Val Val Pro Ser Asp Arg Gly 210
215 220Asn Tyr Thr Cys Val Val Glu Asn Lys Phe
Gly Ser Ile Arg Gln Thr225 230 235
240Tyr Thr Leu Asp Val Leu Glu Arg Ser Pro His Arg Pro Ile Leu
Gln 245 250 255Ala Gly Leu
Pro Ala Asn Gln Thr Ala Val Leu Gly Ser Asp Val Glu 260
265 270Phe His Cys Lys Val Tyr Ser Asp Ala Gln
Pro His Ile Gln Trp Leu 275 280
285Lys His Val Glu Val Asn Gly Ser Lys Val Gly Pro Asp Gly Thr Pro 290
295 300Tyr Val Thr Val Leu Lys Thr Ala
Gly Ala Asn Thr Thr Asp Lys Glu305 310
315 320Leu Glu Val Leu Ser Leu His Asn Val Thr Phe Glu
Asp Ala Gly Glu 325 330
335Tyr Thr Cys Leu Ala Gly Asn Ser Ile Gly Phe Ser His His Ser Ala
340 345 350Trp Leu Val Val Leu Pro
Ala Glu Glu Glu Leu Val Glu Ala Asp Glu 355 360
365Ala Gly Ser Val Tyr Ala Gly Ile Leu Ser Tyr Gly Val Gly
Phe Phe 370 375 380Leu Phe Ile Leu Val
Val Ala Ala Val Thr Leu Cys Arg Leu Arg Ser385 390
395 400Pro Pro Lys Lys Gly Leu Gly Ser Pro Thr
Val His Lys Ile Ser Arg 405 410
415Phe Pro Leu Lys Arg Gln Val Ser Leu Glu Ser Asn Ala Ser Met Ser
420 425 430Ser Asn Thr Pro Leu
Val Arg Ile Ala Arg Leu Ser Ser Gly Glu Gly 435
440 445Pro Thr Leu Ala Asn Val Ser Glu Leu Glu Leu Pro
Ala Asp Pro Lys 450 455 460Trp Glu Leu
Ser Arg Ala Arg Leu Thr Leu Gly Lys Pro Leu Gly Glu465
470 475 480Gly Cys Phe Gly Gln Val Val
Met Ala Glu Ala Ile Gly Ile Asp Lys 485
490 495Asp Arg Ala Ala Lys Pro Val Thr Val Ala Val Lys
Met Leu Lys Asp 500 505 510Asp
Ala Thr Asp Lys Asp Leu Ser Asp Leu Val Ser Glu Met Glu Met 515
520 525Met Lys Met Ile Gly Lys His Lys Asn
Ile Ile Asn Leu Leu Gly Ala 530 535
540Cys Thr Gln Gly Gly Pro Leu Tyr Leu Leu Val Glu Tyr Ala Ala Lys545
550 555 560Gly Asn Leu Arg
Glu Phe Leu Arg Ala Arg Arg Pro Pro Gly Leu Asp 565
570 575Tyr Ser Phe Asp Thr Cys Lys Pro Pro Glu
Glu Gln Leu Thr Phe Lys 580 585
590Asp Leu Val Ser Cys Ala Tyr Gln Val Ala Arg Gly Met Glu Tyr Leu
595 600 605Ala Ser Gln Lys Cys Ile His
Arg Asp Leu Ala Ala Arg Asn Val Leu 610 615
620Val Thr Glu Asp Asn Val Met Lys Ile Ala Asp Phe Gly Leu Ala
Arg625 630 635 640Asp Val
His Asn Leu Asp Tyr Tyr Lys Lys Thr Thr Asn Gly Arg Leu
645 650 655Pro Val Lys Trp Met Ala Pro
Glu Ala Leu Phe Asp Arg Val Tyr Thr 660 665
670His Gln Ser Asp Val Trp Ser Phe Gly Val Leu Leu Trp Glu
Ile Phe 675 680 685Thr Leu Gly Gly
Ser Pro Tyr Pro Gly Ile Pro Val Glu Glu Leu Phe 690
695 700Lys Leu Leu Lys Glu Gly His Arg Met Asp Lys Pro
Ala Asn Cys Thr705 710 715
720His Asp Leu Tyr Met Ile Met Arg Glu Cys Trp His Ala Ala Pro Ser
725 730 735Gln Arg Pro Thr Phe
Lys Gln Leu Val Glu Asp Leu Asp Arg Val Leu 740
745 750Thr Val Thr Ser Thr Asp Glu Tyr Leu Asp Leu Ser
Ala Pro Phe Glu 755 760 765Gln Tyr
Ser Pro Gly Gly Gln Asp Thr Pro Ser Ser Ser Ser Ser Gly 770
775 780Asp Asp Ser Val Phe Ala His Asp Leu Leu Pro
Pro Ala Pro Pro Ser785 790 795
800Ser Gly Gly Ser Arg Thr 80529822PRTHomo sapiens
29Met Val Ser Trp Gly Arg Phe Ile Cys Leu Val Val Val Thr Met Ala1
5 10 15Thr Leu Ser Leu Ala Arg
Pro Ser Phe Ser Leu Val Glu Asp Thr Thr 20 25
30Leu Glu Pro Glu Glu Pro Pro Thr Lys Tyr Gln Ile Ser
Gln Pro Glu 35 40 45Val Tyr Val
Ala Ala Pro Gly Glu Ser Leu Glu Val Arg Cys Leu Leu 50
55 60Lys Asp Ala Ala Val Ile Ser Trp Thr Lys Asp Gly
Val His Leu Gly65 70 75
80Pro Asn Asn Arg Thr Val Leu Ile Gly Glu Tyr Leu Gln Ile Lys Gly
85 90 95Ala Thr Pro Arg Asp Ser
Gly Leu Tyr Ala Cys Thr Ala Ser Arg Thr 100
105 110Val Asp Ser Glu Thr Trp Tyr Phe Met Val Asn Val
Thr Asp Ala Ile 115 120 125Ser Ser
Gly Asp Asp Glu Asp Asp Thr Asp Gly Ala Glu Asp Phe Val 130
135 140Ser Glu Asn Ser Asn Asn Lys Arg Ala Pro Tyr
Trp Thr Asn Thr Glu145 150 155
160Lys Met Glu Lys Arg Leu His Ala Val Pro Ala Ala Asn Thr Val Lys
165 170 175Phe Arg Cys Pro
Ala Gly Gly Asn Pro Met Pro Thr Met Arg Trp Leu 180
185 190Lys Asn Gly Lys Glu Phe Lys Gln Glu His Arg
Ile Gly Gly Tyr Lys 195 200 205Val
Arg Asn Gln His Trp Ser Leu Ile Met Glu Ser Val Val Pro Ser 210
215 220Asp Lys Gly Asn Tyr Thr Cys Val Val Glu
Asn Glu Tyr Gly Ser Ile225 230 235
240Asn His Thr Tyr His Leu Asp Val Val Glu Arg Ser Pro His Arg
Pro 245 250 255Ile Leu Gln
Ala Gly Leu Pro Ala Asn Ala Ser Thr Val Val Gly Gly 260
265 270Asp Val Glu Phe Val Cys Lys Val Tyr Ser
Asp Ala Gln Pro His Ile 275 280
285Gln Trp Ile Lys His Val Glu Lys Asn Gly Ser Lys Tyr Gly Pro Asp 290
295 300Gly Leu Pro Tyr Leu Lys Val Leu
Lys His Ser Gly Ile Asn Ser Ser305 310
315 320Asn Ala Glu Val Leu Ala Leu Phe Asn Val Thr Glu
Ala Asp Ala Gly 325 330
335Glu Tyr Ile Cys Lys Val Ser Asn Tyr Ile Gly Gln Ala Asn Gln Ser
340 345 350Ala Trp Leu Thr Val Leu
Pro Lys Gln Gln Ala Pro Gly Arg Glu Lys 355 360
365Glu Ile Thr Ala Ser Pro Asp Tyr Leu Glu Ile Ala Ile Tyr
Cys Ile 370 375 380Gly Val Phe Leu Ile
Ala Cys Met Val Val Thr Val Ile Leu Cys Arg385 390
395 400Met Lys Asn Thr Thr Lys Lys Pro Asp Phe
Ser Ser Gln Pro Ala Val 405 410
415His Lys Leu Thr Lys Arg Ile Pro Leu Arg Arg Gln Val Thr Val Ser
420 425 430Ala Glu Ser Ser Ser
Ser Met Asn Ser Asn Thr Pro Leu Val Arg Ile 435
440 445Thr Thr Arg Leu Ser Ser Thr Ala Asp Thr Pro Met
Leu Ala Gly Val 450 455 460Ser Glu Tyr
Glu Leu Pro Glu Asp Pro Lys Trp Glu Phe Pro Arg Asp465
470 475 480Lys Leu Thr Leu Gly Lys Pro
Leu Gly Glu Gly Cys Phe Gly Gln Val 485
490 495Val Met Ala Glu Ala Val Gly Ile Asp Lys Asp Lys
Pro Lys Glu Ala 500 505 510Val
Thr Val Ala Val Lys Met Leu Lys Asp Asp Ala Thr Glu Lys Asp 515
520 525Leu Ser Asp Leu Val Ser Glu Met Glu
Met Met Lys Met Ile Gly Lys 530 535
540His Lys Asn Ile Ile Asn Leu Leu Gly Ala Cys Thr Gln Asp Gly Pro545
550 555 560Leu Tyr Val Ile
Phe Glu Tyr Ala Ser Lys Gly Asn Leu Arg Glu Tyr 565
570 575Leu Arg Ala Arg Arg Pro Pro Gly Met Glu
Tyr Ser Tyr Asp Ile Asn 580 585
590Arg Val Pro Glu Glu Gln Met Thr Phe Lys Asp Leu Val Ser Cys Thr
595 600 605Tyr Gln Leu Ala Arg Gly Met
Glu Tyr Leu Ala Ser Gln Lys Cys Ile 610 615
620His Arg Asp Leu Ala Ala Arg Asn Val Leu Val Thr Glu Asn Asn
Val625 630 635 640Met Lys
Ile Ala Asp Phe Gly Leu Ala Arg Asp Ile Asn Asn Ile Asp
645 650 655Tyr Tyr Lys Lys Thr Thr Asn
Gly Arg Leu Pro Val Lys Trp Met Ala 660 665
670Pro Glu Ala Leu Phe Asp Arg Val Tyr Thr His Gln Ser Asp
Val Trp 675 680 685Ser Phe Gly Val
Leu Met Trp Glu Ile Phe Thr Leu Gly Gly Ser Pro 690
695 700Tyr Pro Gly Ile Pro Val Glu Glu Leu Phe Lys Leu
Leu Lys Glu Gly705 710 715
720His Arg Met Asp Lys Pro Ala Asn Cys Thr Asn Glu Leu Tyr Met Met
725 730 735Met Arg Asp Cys Trp
His Ala Val Pro Ser Gln Arg Pro Thr Phe Lys 740
745 750Gln Leu Val Glu Asp Leu Asp Arg Ile Leu Thr Leu
Thr Thr Asn Glu 755 760 765Glu Tyr
Leu Asp Leu Ser Gln Pro Leu Glu Gln Tyr Ser Pro Ser Tyr 770
775 780Pro Asp Thr Arg Ser Ser Cys Ser Ser Gly Asp
Asp Ser Val Phe Ser785 790 795
800Pro Asp Pro Met Pro Tyr Glu Pro Cys Leu Pro Gln Tyr Pro His Ile
805 810 815Asn Gly Ser Val
Lys Thr 82030822PRTHomo sapiens 30Met Val Ser Trp Gly Arg Phe
Ile Cys Leu Val Val Val Thr Met Ala1 5 10
15Thr Leu Ser Leu Ala Arg Pro Ser Phe Ser Leu Val Glu
Asp Thr Thr 20 25 30Leu Glu
Pro Glu Glu Pro Pro Thr Lys Tyr Gln Ile Ser Gln Pro Glu 35
40 45Val Tyr Val Ala Ala Pro Gly Glu Ser Leu
Glu Val Arg Cys Leu Leu 50 55 60Lys
Asp Ala Ala Val Ile Ser Trp Thr Lys Asp Gly Val His Leu Gly65
70 75 80Pro Asn Asn Arg Thr Val
Leu Ile Gly Glu Tyr Leu Gln Ile Lys Gly 85
90 95Ala Thr Pro Arg Asp Ser Gly Leu Tyr Ala Cys Thr
Ala Ser Arg Thr 100 105 110Val
Asp Ser Glu Thr Trp Tyr Phe Met Val Asn Val Thr Asp Ala Ile 115
120 125Ser Ser Gly Asp Asp Glu Asp Asp Thr
Asp Gly Ala Glu Asp Phe Val 130 135
140Ser Glu Asn Ser Asn Asn Lys Arg Ala Pro Tyr Trp Thr Asn Thr Glu145
150 155 160Lys Met Glu Lys
Arg Leu His Ala Val Pro Ala Ala Asn Thr Val Lys 165
170 175Phe Arg Cys Pro Ala Gly Gly Asn Pro Met
Pro Thr Met Arg Trp Leu 180 185
190Lys Asn Gly Lys Glu Phe Lys Gln Glu His Arg Ile Gly Gly Tyr Lys
195 200 205Val Arg Asn Gln His Trp Ser
Leu Ile Met Glu Ser Val Val Pro Ser 210 215
220Asp Lys Gly Asn Tyr Thr Cys Val Val Glu Asn Glu Tyr Gly Ser
Ile225 230 235 240Asn His
Thr Tyr His Leu Asp Val Val Glu Arg Ser Pro His Arg Pro
245 250 255Ile Leu Gln Ala Gly Leu Pro
Ala Asn Ala Ser Thr Val Val Gly Gly 260 265
270Asp Val Glu Phe Val Cys Lys Val Tyr Ser Asp Ala Gln Pro
His Ile 275 280 285Gln Trp Ile Lys
His Val Glu Lys Asn Gly Ser Lys Tyr Gly Pro Asp 290
295 300Gly Leu Pro Tyr Leu Lys Val Leu Lys His Ser Gly
Ile Asn Ser Ser305 310 315
320Asn Ala Glu Val Leu Ala Leu Phe Asn Val Thr Glu Ala Asp Ala Gly
325 330 335Glu Tyr Ile Cys Lys
Val Ser Asn Tyr Ile Gly Gln Ala Asn Gln Ser 340
345 350Ala Trp Leu Thr Val Leu Pro Lys Gln Gln Ala Pro
Gly Arg Glu Lys 355 360 365Glu Ile
Thr Ala Ser Pro Asp Tyr Leu Glu Ile Ala Ile Tyr Cys Ile 370
375 380Gly Val Phe Leu Ile Ala Cys Met Val Val Thr
Val Ile Leu Cys Arg385 390 395
400Met Lys Asn Thr Thr Lys Lys Pro Asp Phe Ser Ser Gln Pro Ala Val
405 410 415His Lys Leu Thr
Lys Arg Ile Pro Leu Arg Arg Gln Val Thr Val Ser 420
425 430Ala Glu Ser Ser Ser Ser Met Asn Ser Asn Thr
Pro Leu Val Arg Ile 435 440 445Thr
Thr Arg Leu Ser Ser Thr Ala Asp Thr Pro Met Leu Ala Gly Val 450
455 460Ser Glu Tyr Glu Leu Pro Glu Asp Pro Lys
Trp Glu Phe Pro Arg Asp465 470 475
480Lys Leu Thr Leu Gly Lys Pro Leu Gly Glu Gly Cys Phe Gly Gln
Val 485 490 495Val Met Ala
Glu Ala Val Gly Ile Asp Lys Asp Lys Pro Lys Glu Ala 500
505 510Val Thr Val Ala Val Lys Met Leu Lys Asp
Asp Ala Thr Glu Lys Asp 515 520
525Leu Ser Asp Leu Val Ser Glu Met Glu Met Met Lys Met Ile Gly Lys 530
535 540His Lys Asn Ile Ile Asn Leu Leu
Gly Ala Cys Thr Gln Asp Gly Pro545 550
555 560Leu Tyr Leu Ile Val Glu Tyr Ala Ser Lys Gly Asn
Leu Arg Glu Tyr 565 570
575Leu Arg Ala Arg Arg Pro Pro Gly Met Glu Tyr Ser Tyr Asp Ile Asn
580 585 590Arg Val Pro Glu Glu Gln
Met Thr Phe Lys Asp Leu Val Ser Cys Thr 595 600
605Tyr Gln Leu Ala Arg Gly Met Glu Tyr Leu Ala Ser Gln Lys
Cys Ile 610 615 620His Arg Asp Leu Ala
Ala Arg Asn Val Leu Val Thr Glu Asn Asn Val625 630
635 640Met Lys Ile Ala Asp Phe Gly Leu Ala Arg
Asp Ile Asn Asn Ile Asp 645 650
655Tyr Tyr Lys Lys Thr Thr Asn Gly Arg Leu Pro Val Lys Trp Met Ala
660 665 670Pro Glu Ala Leu Phe
Asp Arg Val Tyr Thr His Gln Ser Asp Val Trp 675
680 685Ser Phe Gly Val Leu Met Trp Glu Ile Phe Thr Leu
Gly Gly Ser Pro 690 695 700Tyr Pro Gly
Ile Pro Val Glu Glu Leu Phe Lys Leu Leu Lys Glu Gly705
710 715 720His Arg Met Asp Lys Pro Ala
Asn Cys Thr Asn Glu Leu Tyr Met Met 725
730 735Met Arg Asp Cys Trp His Ala Val Pro Ser Gln Arg
Pro Thr Phe Lys 740 745 750Gln
Leu Val Glu Asp Leu Asp Arg Ile Leu Thr Leu Thr Thr Asn Glu 755
760 765Glu Tyr Leu Asp Leu Ser Gln Pro Leu
Glu Gln Tyr Ser Pro Ser Tyr 770 775
780Pro Asp Thr Arg Ser Ser Cys Ser Ser Gly Asp Asp Ser Val Phe Ser785
790 795 800Pro Asp Pro Met
Pro Tyr Glu Pro Cys Leu Pro Gln Tyr Pro His Ile 805
810 815Asn Gly Ser Val Lys Thr
82031511PRTHomo sapiens 31Met Ser Arg Gly Pro Glu Glu Val Asn Arg Leu Thr
Glu Ser Thr Tyr1 5 10
15Arg Asn Val Met Glu Gln Phe Asn Pro Gly Leu Arg Asn Leu Ile Asn
20 25 30Leu Gly Lys Asn Tyr Glu Lys
Ala Val Asn Ala Met Ile Leu Ala Gly 35 40
45Lys Ala Tyr Tyr Asp Gly Val Ala Lys Ile Gly Glu Ile Ala Thr
Gly 50 55 60Ser Pro Val Ser Thr Glu
Leu Gly His Val Leu Ile Glu Ile Ser Ser65 70
75 80Thr His Lys Lys Leu Asn Glu Ser Leu Asp Glu
Asn Phe Lys Lys Phe 85 90
95His Lys Glu Ile Ile His Glu Leu Glu Lys Lys Ile Glu Leu Asp Val
100 105 110Lys Tyr Met Asn Ala Thr
Leu Lys Arg Tyr Gln Thr Glu His Lys Asn 115 120
125Lys Leu Glu Ser Leu Glu Lys Ser Gln Ala Glu Leu Lys Lys
Ile Arg 130 135 140Arg Lys Ser Gln Gly
Ser Arg Asn Ala Leu Lys Tyr Glu His Lys Glu145 150
155 160Ile Glu Tyr Val Glu Thr Val Thr Ser Arg
Gln Ser Glu Ile Gln Lys 165 170
175Phe Ile Ala Asp Gly Cys Lys Glu Ala Leu Leu Glu Glu Lys Arg Arg
180 185 190Phe Cys Phe Leu Val
Asp Lys His Cys Gly Phe Ala Asn His Ile His 195
200 205Tyr Tyr His Leu Gln Ser Ala Glu Leu Leu Asn Ser
Lys Leu Pro Arg 210 215 220Trp Gln Glu
Thr Cys Val Asp Ala Ile Lys Val Pro Glu Lys Ile Met225
230 235 240Asn Met Ile Glu Glu Ile Lys
Thr Pro Ala Ser Thr Pro Val Ser Gly 245
250 255Thr Pro Gln Ala Ser Pro Met Ile Glu Arg Ser Asn
Val Val Arg Lys 260 265 270Asp
Tyr Asp Thr Leu Ser Lys Cys Ser Pro Lys Met Pro Pro Ala Pro 275
280 285Ser Gly Arg Ala Tyr Thr Ser Pro Leu
Ile Asp Met Phe Asn Asn Pro 290 295
300Ala Thr Ala Ala Pro Asn Ser Gln Arg Val Asn Asn Ser Thr Gly Thr305
310 315 320Ser Glu Asp Pro
Ser Leu Gln Arg Ser Val Ser Val Ala Thr Gly Leu 325
330 335Asn Met Met Lys Lys Gln Lys Val Lys Thr
Ile Phe Pro His Thr Ala 340 345
350Gly Ser Asn Lys Thr Leu Leu Ser Phe Ala Gln Gly Asp Val Ile Thr
355 360 365Leu Leu Ile Pro Glu Glu Lys
Asp Gly Trp Leu Tyr Gly Glu His Asp 370 375
380Val Ser Lys Ala Arg Gly Trp Phe Pro Ser Ser Tyr Thr Lys Leu
Leu385 390 395 400Glu Glu
Asn Glu Thr Glu Ala Val Thr Val Pro Thr Pro Ser Pro Thr
405 410 415Pro Val Arg Ser Ile Ser Thr
Val Asn Leu Ser Glu Asn Ser Ser Val 420 425
430Val Ile Pro Pro Pro Asp Tyr Leu Glu Cys Leu Ser Met Gly
Ala Ala 435 440 445Ala Asp Arg Arg
Ala Asp Ser Ala Arg Thr Thr Ser Thr Phe Lys Ala 450
455 460Pro Ala Ser Lys Pro Glu Thr Ala Ala Pro Asn Asp
Ala Asn Gly Thr465 470 475
480Ala Lys Pro Pro Phe Leu Ser Gly Glu Asn Pro Phe Ala Thr Val Lys
485 490 495Leu Arg Pro Thr Val
Thr Asn Asp Arg Ser Ala Pro Ile Ile Arg 500
505 51032838PRTHomo sapiens 32Met Ser Leu Gln Val Leu Asn
Asp Lys Asn Val Ser Asn Glu Lys Asn1 5 10
15Thr Glu Asn Cys Asp Phe Leu Phe Ser Pro Pro Glu Val
Thr Gly Arg 20 25 30Ser Ser
Val Leu Arg Val Ser Gln Lys Glu Asn Val Pro Pro Lys Asn 35
40 45Leu Ala Lys Ala Met Lys Val Thr Phe Gln
Thr Pro Leu Arg Asp Pro 50 55 60Gln
Thr His Arg Ile Leu Ser Pro Ser Met Ala Ser Lys Leu Glu Ala65
70 75 80Pro Phe Thr Gln Asp Asp
Thr Leu Gly Leu Glu Asn Ser His Pro Val 85
90 95Trp Thr Gln Lys Glu Asn Gln Gln Leu Ile Lys Glu
Val Asp Ala Lys 100 105 110Thr
Thr His Gly Ile Leu Gln Lys Pro Val Glu Ala Asp Thr Asp Leu 115
120 125Leu Gly Asp Ala Ser Pro Ala Phe Gly
Ser Gly Ser Ser Ser Glu Ser 130 135
140Gly Pro Gly Ala Leu Ala Asp Leu Asp Cys Ser Ser Ser Ser Gln Ser145
150 155 160Pro Gly Ser Ser
Glu Asn Gln Met Val Ser Pro Gly Lys Val Ser Gly 165
170 175Ser Pro Glu Gln Ala Val Glu Glu Asn Leu
Ser Ser Tyr Ser Leu Asp 180 185
190Arg Arg Val Thr Pro Ala Ser Glu Thr Leu Glu Asp Pro Cys Arg Thr
195 200 205Glu Ser Gln His Lys Ala Glu
Thr Pro His Gly Ala Glu Glu Glu Cys 210 215
220Lys Ala Glu Thr Pro His Gly Ala Glu Glu Glu Cys Arg His Gly
Gly225 230 235 240Val Cys
Ala Pro Ala Ala Val Ala Thr Ser Pro Pro Gly Ala Ile Pro
245 250 255Lys Glu Ala Cys Gly Gly Ala
Pro Leu Gln Gly Leu Pro Gly Glu Ala 260 265
270Leu Gly Cys Pro Ala Gly Val Gly Thr Pro Val Pro Ala Asp
Gly Thr 275 280 285Gln Thr Leu Thr
Cys Ala His Thr Ser Ala Pro Glu Ser Thr Ala Pro 290
295 300Thr Asn His Leu Val Ala Gly Arg Ala Met Thr Leu
Ser Pro Gln Glu305 310 315
320Glu Val Ala Ala Gly Gln Met Ala Ser Ser Ser Arg Ser Gly Pro Val
325 330 335Lys Leu Glu Phe Asp
Val Ser Asp Gly Ala Thr Ser Lys Arg Ala Pro 340
345 350Pro Pro Arg Arg Leu Gly Glu Arg Ser Gly Leu Lys
Pro Pro Leu Arg 355 360 365Lys Ala
Ala Val Arg Gln Gln Lys Ala Pro Gln Glu Val Glu Glu Asp 370
375 380Asp Gly Arg Ser Gly Ala Gly Glu Asp Pro Pro
Met Pro Ala Ser Arg385 390 395
400Gly Ser Tyr His Leu Asp Trp Asp Lys Met Asp Asp Pro Asn Phe Ile
405 410 415Pro Phe Gly Gly
Asp Thr Lys Ser Gly Cys Ser Glu Ala Gln Pro Pro 420
425 430Glu Ser Pro Glu Thr Arg Leu Gly Gln Pro Ala
Ala Glu Gln Leu His 435 440 445Ala
Gly Pro Ala Thr Glu Glu Pro Gly Pro Cys Leu Ser Gln Gln Leu 450
455 460His Ser Ala Ser Ala Glu Asp Thr Pro Val
Val Gln Leu Ala Ala Glu465 470 475
480Thr Pro Thr Ala Glu Ser Lys Glu Arg Ala Leu Asn Ser Ala Ser
Thr 485 490 495Ser Leu Pro
Thr Ser Cys Pro Gly Ser Glu Pro Val Pro Thr His Gln 500
505 510Gln Gly Gln Pro Ala Leu Glu Leu Lys Glu
Glu Ser Phe Arg Asp Pro 515 520
525Ala Glu Val Leu Gly Thr Gly Ala Glu Val Asp Tyr Leu Glu Gln Phe 530
535 540Gly Thr Ser Ser Phe Lys Glu Ser
Ala Leu Arg Lys Gln Ser Leu Tyr545 550
555 560Leu Lys Phe Asp Pro Leu Leu Arg Asp Ser Pro Gly
Arg Pro Val Pro 565 570
575Val Ala Thr Glu Thr Ser Ser Met His Gly Ala Asn Glu Thr Pro Ser
580 585 590Gly Arg Pro Arg Glu Ala
Lys Leu Val Glu Phe Asp Phe Leu Gly Ala 595 600
605Leu Asp Ile Pro Val Pro Gly Pro Pro Pro Gly Val Pro Ala
Pro Gly 610 615 620Gly Pro Pro Leu Ser
Thr Gly Pro Ile Val Asp Leu Leu Gln Tyr Ser625 630
635 640Gln Lys Asp Leu Asp Ala Val Val Lys Ala
Thr Gln Glu Glu Asn Arg 645 650
655Glu Leu Arg Ser Arg Cys Glu Glu Leu His Gly Lys Asn Leu Glu Leu
660 665 670Gly Lys Ile Met Asp
Arg Phe Glu Glu Val Val Tyr Gln Ala Met Glu 675
680 685Glu Val Gln Lys Gln Lys Glu Leu Ser Lys Ala Glu
Ile Gln Lys Val 690 695 700Leu Lys Glu
Lys Asp Gln Leu Thr Thr Asp Leu Asn Ser Met Glu Lys705
710 715 720Ser Phe Ser Asp Leu Phe Lys
Arg Phe Glu Lys Gln Lys Glu Val Ile 725
730 735Glu Gly Tyr Arg Lys Asn Glu Glu Ser Leu Lys Lys
Cys Val Glu Asp 740 745 750Tyr
Leu Ala Arg Ile Thr Gln Glu Gly Gln Arg Tyr Gln Ala Leu Lys 755
760 765Ala His Ala Glu Glu Lys Leu Gln Leu
Ala Asn Glu Glu Ile Ala Gln 770 775
780Val Arg Ser Lys Ala Gln Ala Glu Ala Leu Ala Leu Gln Ala Ser Leu785
790 795 800Arg Lys Glu Gln
Met Arg Ile Gln Ser Leu Glu Lys Thr Val Glu Gln 805
810 815Lys Thr Lys Glu Asn Glu Glu Leu Thr Arg
Ile Cys Asp Asp Leu Ile 820 825
830Ser Lys Met Glu Lys Ile 83533452PRTHomo sapiens 33Met Ser Glu
Thr Pro Ala Gln Cys Ser Ile Lys Gln Glu Arg Ile Ser1 5
10 15Tyr Thr Pro Pro Glu Ser Pro Val Pro
Ser Tyr Ala Ser Ser Thr Pro 20 25
30Leu His Val Pro Val Pro Arg Ala Leu Arg Met Glu Glu Asp Ser Ile
35 40 45Arg Leu Pro Ala His Leu Arg
Leu Gln Pro Ile Tyr Trp Ser Arg Asp 50 55
60Asp Val Ala Gln Trp Leu Lys Trp Ala Glu Asn Glu Phe Ser Leu Arg65
70 75 80Pro Ile Asp Ser
Asn Thr Phe Glu Met Asn Gly Lys Ala Leu Leu Leu 85
90 95Leu Thr Lys Glu Asp Phe Arg Tyr Arg Ser
Pro His Ser Gly Asp Val 100 105
110Leu Tyr Glu Leu Leu Gln His Ile Leu Lys Gln Arg Lys Pro Arg Ile
115 120 125Leu Phe Ser Pro Phe Phe His
Pro Gly Asn Ser Ile His Thr Gln Pro 130 135
140Glu Val Ile Leu His Gln Asn His Glu Glu Asp Asn Cys Val Gln
Arg145 150 155 160Thr Pro
Arg Pro Ser Val Asp Asn Val His His Asn Pro Pro Thr Ile
165 170 175Glu Leu Leu His Arg Ser Arg
Ser Pro Ile Thr Thr Asn His Arg Pro 180 185
190Ser Pro Asp Pro Glu Gln Arg Pro Leu Arg Ser Pro Leu Asp
Asn Met 195 200 205Ile Arg Arg Leu
Ser Pro Ala Glu Arg Ala Gln Gly Pro Arg Pro His 210
215 220Gln Glu Asn Asn His Gln Glu Ser Tyr Pro Leu Ser
Val Ser Pro Met225 230 235
240Glu Asn Asn His Cys Pro Ala Ser Ser Glu Ser His Pro Lys Pro Ser
245 250 255Ser Pro Arg Gln Glu
Ser Thr Arg Val Ile Gln Leu Met Pro Ser Pro 260
265 270Ile Met His Pro Leu Ile Leu Asn Pro Arg His Ser
Val Asp Phe Lys 275 280 285Gln Ser
Arg Leu Ser Glu Asp Gly Leu His Arg Glu Gly Lys Pro Ile 290
295 300Asn Leu Ser His Arg Glu Asp Leu Ala Tyr Met
Asn His Ile Met Val305 310 315
320Ser Val Ser Pro Pro Glu Glu His Ala Met Pro Ile Gly Arg Ile Ala
325 330 335Asp Cys Arg Leu
Leu Trp Asp Tyr Val Tyr Gln Leu Leu Ser Asp Ser 340
345 350Arg Tyr Glu Asn Phe Ile Arg Trp Glu Asp Lys
Glu Ser Lys Ile Phe 355 360 365Arg
Ile Val Asp Pro Asn Gly Leu Ala Arg Leu Trp Gly Asn His Lys 370
375 380Asn Arg Thr Asn Met Thr Tyr Glu Lys Met
Ser Arg Ala Leu Arg His385 390 395
400Tyr Tyr Lys Leu Asn Ile Ile Arg Lys Glu Pro Gly Gln Arg Leu
Leu 405 410 415Phe Arg Phe
Met Lys Thr Pro Asp Glu Ile Met Ser Gly Arg Thr Asp 420
425 430Arg Leu Glu His Leu Glu Ser Gln Glu Leu
Asp Glu Gln Ile Tyr Gln 435 440
445Glu Asp Glu Cys 45034573PRTArtificial SequenceAn artificially
synthesized polypeptide sequence 34Met Ser Glu Thr Pro Ala Gln Cys
Ser Ile Lys Gln Glu Arg Ile Ser1 5 10
15Tyr Thr Pro Pro Glu Ser Pro Val Pro Ser Tyr Ala Ser Ser
Thr Pro 20 25 30Leu His Val
Pro Val Pro Arg Ala Leu Arg Met Glu Glu Asp Ser Ile 35
40 45Arg Leu Pro Ala His Leu Arg Leu Gln Pro Ile
Tyr Trp Ser Arg Asp 50 55 60Asp Val
Ala Gln Trp Leu Lys Trp Ala Glu Asn Glu Phe Ser Leu Arg65
70 75 80Pro Ile Asp Ser Asn Thr Phe
Glu Met Asn Gly Lys Ala Leu Leu Leu 85 90
95Leu Thr Lys Glu Asp Phe Arg Tyr Arg Ser Pro His Ser
Gly Asp Val 100 105 110Leu Tyr
Glu Leu Leu Gln His Ile Leu Lys Gln Arg Lys Pro Arg Ile 115
120 125Leu Phe Ser Pro Phe Phe His Pro Gly Asn
Ser Ile His Thr Gln Pro 130 135 140Glu
Val Ile Leu His Gln Asn His Glu Glu Asp Asn Cys Val Gln Arg145
150 155 160Thr Pro Arg Pro Ser Val
Asp Asn Val His His Asn Pro Pro Thr Ile 165
170 175Glu Leu Leu His Arg Val Ser Ala Glu Ser Ser Ser
Ser Met Asn Ser 180 185 190Asn
Thr Pro Leu Val Arg Ile Thr Thr Arg Leu Ser Ser Thr Ala Asp 195
200 205Thr Pro Met Leu Ala Gly Val Ser Glu
Tyr Glu Leu Pro Glu Asp Pro 210 215
220Lys Trp Glu Phe Pro Arg Asp Lys Leu Thr Leu Gly Lys Pro Leu Gly225
230 235 240Glu Gly Cys Phe
Gly Gln Val Val Met Ala Glu Ala Val Gly Ile Asp 245
250 255Lys Asp Lys Pro Lys Glu Ala Val Thr Val
Ala Val Lys Met Leu Lys 260 265
270Asp Asp Ala Thr Glu Lys Asp Leu Ser Asp Leu Val Ser Glu Met Glu
275 280 285Met Met Lys Met Ile Gly Lys
His Lys Asn Ile Ile Asn Leu Leu Gly 290 295
300Ala Cys Thr Gln Asp Gly Pro Leu Tyr Val Ile Val Glu Tyr Ala
Ser305 310 315 320Lys Gly
Asn Leu Arg Glu Tyr Leu Arg Ala Arg Arg Pro Pro Gly Met
325 330 335Glu Tyr Ser Tyr Asp Ile Asn
Arg Val Pro Glu Glu Gln Met Thr Phe 340 345
350Lys Asp Leu Val Ser Cys Thr Tyr Gln Leu Ala Arg Gly Met
Glu Tyr 355 360 365Leu Ala Ser Gln
Lys Cys Ile His Arg Asp Leu Ala Ala Arg Asn Val 370
375 380Leu Val Thr Glu Asn Asn Val Met Lys Ile Ala Asp
Phe Gly Leu Ala385 390 395
400Arg Asp Ile Asn Asn Ile Asp Tyr Tyr Lys Lys Thr Thr Asn Gly Arg
405 410 415Leu Pro Val Lys Trp
Met Ala Pro Glu Ala Leu Phe Asp Arg Val Tyr 420
425 430Thr His Gln Ser Asp Val Trp Ser Phe Gly Val Leu
Met Trp Glu Ile 435 440 445Phe Thr
Leu Gly Gly Ser Pro Tyr Pro Gly Ile Pro Val Glu Glu Leu 450
455 460Phe Lys Leu Leu Lys Glu Gly His Arg Met Asp
Lys Pro Ala Asn Cys465 470 475
480Thr Asn Glu Leu Tyr Met Met Met Arg Asp Cys Trp His Ala Val Pro
485 490 495Ser Gln Arg Pro
Thr Phe Lys Gln Leu Val Glu Asp Leu Asp Arg Ile 500
505 510Leu Thr Leu Thr Thr Asn Glu Glu Tyr Leu Asp
Leu Ser Gln Pro Leu 515 520 525Glu
Gln Tyr Ser Pro Ser Tyr Pro Asp Thr Arg Ser Ser Cys Ser Ser 530
535 540Gly Asp Asp Ser Val Phe Ser Pro Asp Pro
Met Pro Tyr Glu Pro Cys545 550 555
560Leu Pro Gln Tyr Pro His Ile Asn Gly Ser Val Lys Thr
565 57035573PRTArtificial SequenceAn artificially
synthesized polypeptide sequence 35Met Ser Glu Thr Pro Ala Gln Cys
Ser Ile Lys Gln Glu Arg Ile Ser1 5 10
15Tyr Thr Pro Pro Glu Ser Pro Val Pro Ser Tyr Ala Ser Ser
Thr Pro 20 25 30Leu His Val
Pro Val Pro Arg Ala Leu Arg Met Glu Glu Asp Ser Ile 35
40 45Arg Leu Pro Ala His Leu Arg Leu Gln Pro Ile
Tyr Trp Ser Arg Asp 50 55 60Asp Val
Ala Gln Trp Leu Lys Trp Ala Glu Asn Glu Phe Ser Leu Arg65
70 75 80Pro Ile Asp Ser Asn Thr Phe
Glu Met Asn Gly Lys Ala Leu Leu Leu 85 90
95Leu Thr Lys Glu Asp Phe Arg Tyr Arg Ser Pro His Ser
Gly Asp Val 100 105 110Leu Tyr
Glu Leu Leu Gln His Ile Leu Lys Gln Arg Lys Pro Arg Ile 115
120 125Leu Phe Ser Pro Phe Phe His Pro Gly Asn
Ser Ile His Thr Gln Pro 130 135 140Glu
Val Ile Leu His Gln Asn His Glu Glu Asp Asn Cys Val Gln Arg145
150 155 160Thr Pro Arg Pro Ser Val
Asp Asn Val His His Asn Pro Pro Thr Ile 165
170 175Glu Leu Leu His Arg Val Ser Ala Glu Ser Ser Ser
Ser Met Asn Ser 180 185 190Asn
Thr Pro Leu Val Arg Ile Thr Thr Arg Leu Ser Ser Thr Ala Asp 195
200 205Thr Pro Met Leu Ala Gly Val Ser Glu
Tyr Glu Leu Pro Glu Asp Pro 210 215
220Lys Trp Glu Phe Pro Arg Asp Lys Leu Thr Leu Gly Lys Pro Leu Gly225
230 235 240Glu Gly Cys Phe
Gly Gln Val Val Met Ala Glu Ala Val Gly Ile Asp 245
250 255Lys Asp Lys Pro Lys Glu Ala Val Thr Val
Ala Val Lys Met Leu Lys 260 265
270Asp Asp Ala Thr Glu Lys Asp Leu Ser Asp Leu Val Ser Glu Met Glu
275 280 285Met Met Lys Met Ile Gly Lys
His Lys Asn Ile Ile Asn Leu Leu Gly 290 295
300Ala Cys Thr Gln Asp Gly Pro Leu Tyr Val Ile Phe Glu Tyr Ala
Ser305 310 315 320Lys Gly
Asn Leu Arg Glu Tyr Leu Arg Ala Arg Arg Pro Pro Gly Met
325 330 335Glu Tyr Ser Tyr Asp Ile Asn
Arg Val Pro Glu Glu Gln Met Thr Phe 340 345
350Lys Asp Leu Val Ser Cys Thr Tyr Gln Leu Ala Arg Gly Met
Glu Tyr 355 360 365Leu Ala Ser Gln
Lys Cys Ile His Arg Asp Leu Ala Ala Arg Asn Val 370
375 380Leu Val Thr Glu Asn Asn Val Met Lys Ile Ala Asp
Phe Gly Leu Ala385 390 395
400Arg Asp Ile Asn Asn Ile Asp Tyr Tyr Lys Lys Thr Thr Asn Gly Arg
405 410 415Leu Pro Val Lys Trp
Met Ala Pro Glu Ala Leu Phe Asp Arg Val Tyr 420
425 430Thr His Gln Ser Asp Val Trp Ser Phe Gly Val Leu
Met Trp Glu Ile 435 440 445Phe Thr
Leu Gly Gly Ser Pro Tyr Pro Gly Ile Pro Val Glu Glu Leu 450
455 460Phe Lys Leu Leu Lys Glu Gly His Arg Met Asp
Lys Pro Ala Asn Cys465 470 475
480Thr Asn Glu Leu Tyr Met Met Met Arg Asp Cys Trp His Ala Val Pro
485 490 495Ser Gln Arg Pro
Thr Phe Lys Gln Leu Val Glu Asp Leu Asp Arg Ile 500
505 510Leu Thr Leu Thr Thr Asn Glu Glu Tyr Leu Asp
Leu Ser Gln Pro Leu 515 520 525Glu
Gln Tyr Ser Pro Ser Tyr Pro Asp Thr Arg Ser Ser Cys Ser Ser 530
535 540Gly Asp Asp Ser Val Phe Ser Pro Asp Pro
Met Pro Tyr Glu Pro Cys545 550 555
560Leu Pro Gln Tyr Pro His Ile Asn Gly Ser Val Lys Thr
565 57036573PRTArtificial SequenceAn artificially
synthesized polypeptide sequence 36Met Ser Glu Thr Pro Ala Gln Cys
Ser Ile Lys Gln Glu Arg Ile Ser1 5 10
15Tyr Thr Pro Pro Glu Ser Pro Val Pro Ser Tyr Ala Ser Ser
Thr Pro 20 25 30Leu His Val
Pro Val Pro Arg Ala Leu Arg Met Glu Glu Asp Ser Ile 35
40 45Arg Leu Pro Ala His Leu Arg Leu Gln Pro Ile
Tyr Trp Ser Arg Asp 50 55 60Asp Val
Ala Gln Trp Leu Lys Trp Ala Glu Asn Glu Phe Ser Leu Arg65
70 75 80Pro Ile Asp Ser Asn Thr Phe
Glu Met Asn Gly Lys Ala Leu Leu Leu 85 90
95Leu Thr Lys Glu Asp Phe Arg Tyr Arg Ser Pro His Ser
Gly Asp Val 100 105 110Leu Tyr
Glu Leu Leu Gln His Ile Leu Lys Gln Arg Lys Pro Arg Ile 115
120 125Leu Phe Ser Pro Phe Phe His Pro Gly Asn
Ser Ile His Thr Gln Pro 130 135 140Glu
Val Ile Leu His Gln Asn His Glu Glu Asp Asn Cys Val Gln Arg145
150 155 160Thr Pro Arg Pro Ser Val
Asp Asn Val His His Asn Pro Pro Thr Ile 165
170 175Glu Leu Leu His Arg Val Ser Ala Glu Ser Ser Ser
Ser Met Asn Ser 180 185 190Asn
Thr Pro Leu Val Arg Ile Thr Thr Arg Leu Ser Ser Thr Ala Asp 195
200 205Thr Pro Met Leu Ala Gly Val Ser Glu
Tyr Glu Leu Pro Glu Asp Pro 210 215
220Lys Trp Glu Phe Pro Arg Asp Lys Leu Thr Leu Gly Lys Pro Leu Gly225
230 235 240Glu Gly Cys Phe
Gly Gln Val Val Met Ala Glu Ala Val Gly Ile Asp 245
250 255Lys Asp Lys Pro Lys Glu Ala Val Thr Val
Ala Val Lys Met Leu Lys 260 265
270Asp Asp Ala Thr Glu Lys Asp Leu Ser Asp Leu Val Ser Glu Met Glu
275 280 285Met Met Lys Met Ile Gly Lys
His Lys Asn Ile Ile Asn Leu Leu Gly 290 295
300Ala Cys Thr Gln Asp Gly Pro Leu Tyr Leu Ile Val Glu Tyr Ala
Ser305 310 315 320Lys Gly
Asn Leu Arg Glu Tyr Leu Arg Ala Arg Arg Pro Pro Gly Met
325 330 335Glu Tyr Ser Tyr Asp Ile Asn
Arg Val Pro Glu Glu Gln Met Thr Phe 340 345
350Lys Asp Leu Val Ser Cys Thr Tyr Gln Leu Ala Arg Gly Met
Glu Tyr 355 360 365Leu Ala Ser Gln
Lys Cys Ile His Arg Asp Leu Ala Ala Arg Asn Val 370
375 380Leu Val Thr Glu Asn Asn Val Met Lys Ile Ala Asp
Phe Gly Leu Ala385 390 395
400Arg Asp Ile Asn Asn Ile Asp Tyr Tyr Lys Lys Thr Thr Asn Gly Arg
405 410 415Leu Pro Val Lys Trp
Met Ala Pro Glu Ala Leu Phe Asp Arg Val Tyr 420
425 430Thr His Gln Ser Asp Val Trp Ser Phe Gly Val Leu
Met Trp Glu Ile 435 440 445Phe Thr
Leu Gly Gly Ser Pro Tyr Pro Gly Ile Pro Val Glu Glu Leu 450
455 460Phe Lys Leu Leu Lys Glu Gly His Arg Met Asp
Lys Pro Ala Asn Cys465 470 475
480Thr Asn Glu Leu Tyr Met Met Met Arg Asp Cys Trp His Ala Val Pro
485 490 495Ser Gln Arg Pro
Thr Phe Lys Gln Leu Val Glu Asp Leu Asp Arg Ile 500
505 510Leu Thr Leu Thr Thr Asn Glu Glu Tyr Leu Asp
Leu Ser Gln Pro Leu 515 520 525Glu
Gln Tyr Ser Pro Ser Tyr Pro Asp Thr Arg Ser Ser Cys Ser Ser 530
535 540Gly Asp Asp Ser Val Phe Ser Pro Asp Pro
Met Pro Tyr Glu Pro Cys545 550 555
560Leu Pro Gln Tyr Pro His Ile Asn Gly Ser Val Lys Thr
565 57037769PRTHomo sapiens 37Met Val Ser Trp Gly
Arg Phe Ile Cys Leu Val Val Val Thr Met Ala1 5
10 15Thr Leu Ser Leu Ala Arg Pro Ser Phe Ser Leu
Val Glu Asp Thr Thr 20 25
30Leu Glu Pro Glu Glu Pro Pro Thr Lys Tyr Gln Ile Ser Gln Pro Glu
35 40 45Val Tyr Val Ala Ala Pro Gly Glu
Ser Leu Glu Val Arg Cys Leu Leu 50 55
60Lys Asp Ala Ala Val Ile Ser Trp Thr Lys Asp Gly Val His Leu Gly65
70 75 80Pro Asn Asn Arg Thr
Val Leu Ile Gly Glu Tyr Leu Gln Ile Lys Gly 85
90 95Ala Thr Pro Arg Asp Ser Gly Leu Tyr Ala Cys
Thr Ala Ser Arg Thr 100 105
110Val Asp Ser Glu Thr Trp Tyr Phe Met Val Asn Val Thr Asp Ala Ile
115 120 125Ser Ser Gly Asp Asp Glu Asp
Asp Thr Asp Gly Ala Glu Asp Phe Val 130 135
140Ser Glu Asn Ser Asn Asn Lys Arg Ala Pro Tyr Trp Thr Asn Thr
Glu145 150 155 160Lys Met
Glu Lys Arg Leu His Ala Val Pro Ala Ala Asn Thr Val Lys
165 170 175Phe Arg Cys Pro Ala Gly Gly
Asn Pro Met Pro Thr Met Arg Trp Leu 180 185
190Lys Asn Gly Lys Glu Phe Lys Gln Glu His Arg Ile Gly Gly
Tyr Lys 195 200 205Val Arg Asn Gln
His Trp Ser Leu Ile Met Glu Ser Val Val Pro Ser 210
215 220Asp Lys Gly Asn Tyr Thr Cys Val Val Glu Asn Glu
Tyr Gly Ser Ile225 230 235
240Asn His Thr Tyr His Leu Asp Val Val Glu Arg Ser Pro His Arg Pro
245 250 255Ile Leu Gln Ala Gly
Leu Pro Ala Asn Ala Ser Thr Val Val Gly Gly 260
265 270Asp Val Glu Phe Val Cys Lys Val Tyr Ser Asp Ala
Gln Pro His Ile 275 280 285Gln Trp
Ile Lys His Val Glu Lys Asn Gly Ser Lys Tyr Gly Pro Asp 290
295 300Gly Leu Pro Tyr Leu Lys Val Leu Lys His Ser
Gly Ile Asn Ser Ser305 310 315
320Asn Ala Glu Val Leu Ala Leu Phe Asn Val Thr Glu Ala Asp Ala Gly
325 330 335Glu Tyr Ile Cys
Lys Val Ser Asn Tyr Ile Gly Gln Ala Asn Gln Ser 340
345 350Ala Trp Leu Thr Val Leu Pro Lys Gln Gln Ala
Pro Gly Arg Glu Lys 355 360 365Glu
Ile Thr Ala Ser Pro Asp Tyr Leu Glu Ile Ala Ile Tyr Cys Ile 370
375 380Gly Val Phe Leu Ile Ala Cys Met Val Val
Thr Val Ile Leu Cys Arg385 390 395
400Met Lys Asn Thr Thr Lys Lys Pro Asp Phe Ser Ser Gln Pro Ala
Val 405 410 415His Lys Leu
Thr Lys Arg Ile Pro Leu Arg Arg Gln Val Thr Val Ser 420
425 430Ala Glu Ser Ser Ser Ser Met Asn Ser Asn
Thr Pro Leu Val Arg Ile 435 440
445Thr Thr Arg Leu Ser Ser Thr Ala Asp Thr Pro Met Leu Ala Gly Val 450
455 460Ser Glu Tyr Glu Leu Pro Glu Asp
Pro Lys Trp Glu Phe Pro Arg Asp465 470
475 480Lys Leu Thr Leu Gly Lys Pro Leu Gly Glu Gly Cys
Phe Gly Gln Val 485 490
495Val Met Ala Glu Ala Val Gly Ile Asp Lys Asp Lys Pro Lys Glu Ala
500 505 510Val Thr Val Ala Val Lys
Met Leu Lys Asp Asp Ala Thr Glu Lys Asp 515 520
525Leu Ser Asp Leu Val Ser Glu Met Glu Met Met Lys Met Ile
Gly Lys 530 535 540His Lys Asn Ile Ile
Asn Leu Leu Gly Ala Cys Thr Gln Asp Gly Pro545 550
555 560Leu Tyr Val Ile Val Glu Tyr Ala Ser Lys
Gly Asn Leu Arg Glu Tyr 565 570
575Leu Arg Ala Arg Arg Pro Pro Gly Met Glu Tyr Ser Tyr Asp Ile Asn
580 585 590Arg Val Pro Glu Glu
Gln Met Thr Phe Lys Asp Leu Val Ser Cys Thr 595
600 605Tyr Gln Leu Ala Arg Gly Met Glu Tyr Leu Ala Ser
Gln Lys Cys Ile 610 615 620His Arg Asp
Leu Ala Ala Arg Asn Val Leu Val Thr Glu Asn Asn Val625
630 635 640Met Lys Ile Ala Asp Phe Gly
Leu Ala Arg Asp Ile Asn Asn Ile Asp 645
650 655Tyr Tyr Lys Lys Thr Thr Asn Gly Arg Leu Pro Val
Lys Trp Met Ala 660 665 670Pro
Glu Ala Leu Phe Asp Arg Val Tyr Thr His Gln Ser Asp Val Trp 675
680 685Ser Phe Gly Val Leu Met Trp Glu Ile
Phe Thr Leu Gly Gly Ser Pro 690 695
700Tyr Pro Gly Ile Pro Val Glu Glu Leu Phe Lys Leu Leu Lys Glu Gly705
710 715 720His Arg Met Asp
Lys Pro Ala Asn Cys Thr Asn Glu Leu Tyr Met Met 725
730 735Met Arg Asp Cys Trp His Ala Val Pro Ser
Gln Arg Pro Thr Phe Lys 740 745
750Gln Leu Val Glu Asp Leu Asp Arg Ile Leu Thr Leu Thr Thr Asn Glu
755 760 765Ile38709PRTHomo sapiens 38Met
Val Ser Trp Gly Arg Phe Ile Cys Leu Val Val Val Thr Met Ala1
5 10 15Thr Leu Ser Leu Ala Arg Pro
Ser Phe Ser Leu Val Glu Asp Thr Thr 20 25
30Leu Glu Pro Glu Glu Pro Pro Thr Lys Tyr Gln Ile Ser Gln
Pro Glu 35 40 45Val Tyr Val Ala
Ala Pro Gly Glu Ser Leu Glu Val Arg Cys Leu Leu 50 55
60Lys Asp Ala Ala Val Ile Ser Trp Thr Lys Asp Gly Val
His Leu Gly65 70 75
80Pro Asn Asn Arg Thr Val Leu Ile Gly Glu Tyr Leu Gln Ile Lys Gly
85 90 95Ala Thr Pro Arg Asp Ser
Gly Leu Tyr Ala Cys Thr Ala Ser Arg Thr 100
105 110Val Asp Ser Glu Thr Trp Tyr Phe Met Val Asn Val
Thr Asp Ala Ile 115 120 125Ser Ser
Gly Asp Asp Glu Asp Asp Thr Asp Gly Ala Glu Asp Phe Val 130
135 140Ser Glu Asn Ser Asn Asn Lys Arg Ala Pro Tyr
Trp Thr Asn Thr Glu145 150 155
160Lys Met Glu Lys Arg Leu His Ala Val Pro Ala Ala Asn Thr Val Lys
165 170 175Phe Arg Cys Pro
Ala Gly Gly Asn Pro Met Pro Thr Met Arg Trp Leu 180
185 190Lys Asn Gly Lys Glu Phe Lys Gln Glu His Arg
Ile Gly Gly Tyr Lys 195 200 205Val
Arg Asn Gln His Trp Ser Leu Ile Met Glu Ser Val Val Pro Ser 210
215 220Asp Lys Gly Asn Tyr Thr Cys Val Val Glu
Asn Glu Tyr Gly Ser Ile225 230 235
240Asn His Thr Tyr His Leu Asp Val Val Ala Pro Gly Arg Glu Lys
Glu 245 250 255Ile Thr Ala
Ser Pro Asp Tyr Leu Glu Ile Ala Ile Tyr Cys Ile Gly 260
265 270Val Phe Leu Ile Ala Cys Met Val Val Thr
Val Ile Leu Cys Arg Met 275 280
285Lys Asn Thr Thr Lys Lys Pro Asp Phe Ser Ser Gln Pro Ala Val His 290
295 300Lys Leu Thr Lys Arg Ile Pro Leu
Arg Arg Gln Val Thr Val Ser Ala305 310
315 320Glu Ser Ser Ser Ser Met Asn Ser Asn Thr Pro Leu
Val Arg Ile Thr 325 330
335Thr Arg Leu Ser Ser Thr Ala Asp Thr Pro Met Leu Ala Gly Val Ser
340 345 350Glu Tyr Glu Leu Pro Glu
Asp Pro Lys Trp Glu Phe Pro Arg Asp Lys 355 360
365Leu Thr Leu Gly Lys Pro Leu Gly Glu Gly Cys Phe Gly Gln
Val Val 370 375 380Met Ala Glu Ala Val
Gly Ile Asp Lys Asp Lys Pro Lys Glu Ala Val385 390
395 400Thr Val Ala Val Lys Met Leu Lys Asp Asp
Ala Thr Glu Lys Asp Leu 405 410
415Ser Asp Leu Val Ser Glu Met Glu Met Met Lys Met Ile Gly Lys His
420 425 430Lys Asn Ile Ile Asn
Leu Leu Gly Ala Cys Thr Gln Asp Gly Pro Leu 435
440 445Tyr Val Ile Val Glu Tyr Ala Ser Lys Gly Asn Leu
Arg Glu Tyr Leu 450 455 460Arg Ala Arg
Arg Pro Pro Gly Met Glu Tyr Ser Tyr Asp Ile Asn Arg465
470 475 480Val Pro Glu Glu Gln Met Thr
Phe Lys Asp Leu Val Ser Cys Thr Tyr 485
490 495Gln Leu Ala Arg Gly Met Glu Tyr Leu Ala Ser Gln
Lys Cys Ile His 500 505 510Arg
Asp Leu Ala Ala Arg Asn Val Leu Val Thr Glu Asn Asn Val Met 515
520 525Lys Ile Ala Asp Phe Gly Leu Ala Arg
Asp Ile Asn Asn Ile Asp Tyr 530 535
540Tyr Lys Lys Thr Thr Asn Gly Arg Leu Pro Val Lys Trp Met Ala Pro545
550 555 560Glu Ala Leu Phe
Asp Arg Val Tyr Thr His Gln Ser Asp Val Trp Ser 565
570 575Phe Gly Val Leu Met Trp Glu Ile Phe Thr
Leu Gly Gly Ser Pro Tyr 580 585
590Pro Gly Ile Pro Val Glu Glu Leu Phe Lys Leu Leu Lys Glu Gly His
595 600 605Arg Met Asp Lys Pro Ala Asn
Cys Thr Asn Glu Leu Tyr Met Met Met 610 615
620Arg Asp Cys Trp His Ala Val Pro Ser Gln Arg Pro Thr Phe Lys
Gln625 630 635 640Leu Val
Glu Asp Leu Asp Arg Ile Leu Thr Leu Thr Thr Asn Glu Glu
645 650 655Tyr Leu Asp Leu Ser Gln Pro
Leu Glu Gln Tyr Ser Pro Ser Tyr Pro 660 665
670Asp Thr Arg Ser Ser Cys Ser Ser Gly Asp Asp Ser Val Phe
Ser Pro 675 680 685Asp Pro Met Pro
Tyr Glu Pro Cys Leu Pro Gln Tyr Pro His Ile Asn 690
695 700Gly Ser Val Lys Thr70539707PRTHomo sapiens 39Met
Val Ser Trp Gly Arg Phe Ile Cys Leu Val Val Val Thr Met Ala1
5 10 15Thr Leu Ser Leu Ala Arg Pro
Ser Phe Ser Leu Val Glu Asp Thr Thr 20 25
30Leu Glu Pro Glu Asp Ala Ile Ser Ser Gly Asp Asp Glu Asp
Asp Thr 35 40 45Asp Gly Ala Glu
Asp Phe Val Ser Glu Asn Ser Asn Asn Lys Arg Ala 50 55
60Pro Tyr Trp Thr Asn Thr Glu Lys Met Glu Lys Arg Leu
His Ala Val65 70 75
80Pro Ala Ala Asn Thr Val Lys Phe Arg Cys Pro Ala Gly Gly Asn Pro
85 90 95Met Pro Thr Met Arg Trp
Leu Lys Asn Gly Lys Glu Phe Lys Gln Glu 100
105 110His Arg Ile Gly Gly Tyr Lys Val Arg Asn Gln His
Trp Ser Leu Ile 115 120 125Met Glu
Ser Val Val Pro Ser Asp Lys Gly Asn Tyr Thr Cys Val Val 130
135 140Glu Asn Glu Tyr Gly Ser Ile Asn His Thr Tyr
His Leu Asp Val Val145 150 155
160Glu Arg Ser Pro His Arg Pro Ile Leu Gln Ala Gly Leu Pro Ala Asn
165 170 175Ala Ser Thr Val
Val Gly Gly Asp Val Glu Phe Val Cys Lys Val Tyr 180
185 190Ser Asp Ala Gln Pro His Ile Gln Trp Ile Lys
His Val Glu Lys Asn 195 200 205Gly
Ser Lys Tyr Gly Pro Asp Gly Leu Pro Tyr Leu Lys Val Leu Lys 210
215 220Ala Ala Gly Val Asn Thr Thr Asp Lys Glu
Ile Glu Val Leu Tyr Ile225 230 235
240Arg Asn Val Thr Phe Glu Asp Ala Gly Glu Tyr Thr Cys Leu Ala
Gly 245 250 255Asn Ser Ile
Gly Ile Ser Phe His Ser Ala Trp Leu Thr Val Leu Pro 260
265 270Ala Pro Gly Arg Glu Lys Glu Ile Thr Ala
Ser Pro Asp Tyr Leu Glu 275 280
285Ile Ala Ile Tyr Cys Ile Gly Val Phe Leu Ile Ala Cys Met Val Val 290
295 300Thr Val Ile Leu Cys Arg Met Lys
Asn Thr Thr Lys Lys Pro Asp Phe305 310
315 320Ser Ser Gln Pro Ala Val His Lys Leu Thr Lys Arg
Ile Pro Leu Arg 325 330
335Arg Gln Val Thr Val Ser Ala Glu Ser Ser Ser Ser Met Asn Ser Asn
340 345 350Thr Pro Leu Val Arg Ile
Thr Thr Arg Leu Ser Ser Thr Ala Asp Thr 355 360
365Pro Met Leu Ala Gly Val Ser Glu Tyr Glu Leu Pro Glu Asp
Pro Lys 370 375 380Trp Glu Phe Pro Arg
Asp Lys Leu Thr Leu Gly Lys Pro Leu Gly Glu385 390
395 400Gly Cys Phe Gly Gln Val Val Met Ala Glu
Ala Val Gly Ile Asp Lys 405 410
415Asp Lys Pro Lys Glu Ala Val Thr Val Ala Val Lys Met Leu Lys Asp
420 425 430Asp Ala Thr Glu Lys
Asp Leu Ser Asp Leu Val Ser Glu Met Glu Met 435
440 445Met Lys Met Ile Gly Lys His Lys Asn Ile Ile Asn
Leu Leu Gly Ala 450 455 460Cys Thr Gln
Asp Gly Pro Leu Tyr Val Ile Val Glu Tyr Ala Ser Lys465
470 475 480Gly Asn Leu Arg Glu Tyr Leu
Arg Ala Arg Arg Pro Pro Gly Met Glu 485
490 495Tyr Ser Tyr Asp Ile Asn Arg Val Pro Glu Glu Gln
Met Thr Phe Lys 500 505 510Asp
Leu Val Ser Cys Thr Tyr Gln Leu Ala Arg Gly Met Glu Tyr Leu 515
520 525Ala Ser Gln Lys Cys Ile His Arg Asp
Leu Ala Ala Arg Asn Val Leu 530 535
540Val Thr Glu Asn Asn Val Met Lys Ile Ala Asp Phe Gly Leu Ala Arg545
550 555 560Asp Ile Asn Asn
Ile Asp Tyr Tyr Lys Lys Thr Thr Asn Gly Arg Leu 565
570 575Pro Val Lys Trp Met Ala Pro Glu Ala Leu
Phe Asp Arg Val Tyr Thr 580 585
590His Gln Ser Asp Val Trp Ser Phe Gly Val Leu Met Trp Glu Ile Phe
595 600 605Thr Leu Gly Gly Ser Pro Tyr
Pro Gly Ile Pro Val Glu Glu Leu Phe 610 615
620Lys Leu Leu Lys Glu Gly His Arg Met Asp Lys Pro Ala Asn Cys
Thr625 630 635 640Asn Glu
Leu Tyr Met Met Met Arg Asp Cys Trp His Ala Val Pro Ser
645 650 655Gln Arg Pro Thr Phe Lys Gln
Leu Val Glu Asp Leu Asp Arg Ile Leu 660 665
670Thr Leu Thr Thr Asn Glu Glu Glu Lys Lys Val Ser Gly Ala
Val Asp 675 680 685Cys His Lys Pro
Pro Cys Asn Pro Ser His Leu Pro Cys Val Leu Ala 690
695 700Val Asp Gln70540706PRTHomo sapiens 40Met Val Ser
Trp Gly Arg Phe Ile Cys Leu Val Val Val Thr Met Ala1 5
10 15Thr Leu Ser Leu Ala Arg Pro Ser Phe
Ser Leu Val Glu Asp Thr Thr 20 25
30Leu Glu Pro Glu Gly Ala Pro Tyr Trp Thr Asn Thr Glu Lys Met Glu
35 40 45Lys Arg Leu His Ala Val Pro
Ala Ala Asn Thr Val Lys Phe Arg Cys 50 55
60Pro Ala Gly Gly Asn Pro Met Pro Thr Met Arg Trp Leu Lys Asn Gly65
70 75 80Lys Glu Phe Lys
Gln Glu His Arg Ile Gly Gly Tyr Lys Val Arg Asn 85
90 95Gln His Trp Ser Leu Ile Met Glu Ser Val
Val Pro Ser Asp Lys Gly 100 105
110Asn Tyr Thr Cys Val Val Glu Asn Glu Tyr Gly Ser Ile Asn His Thr
115 120 125Tyr His Leu Asp Val Val Glu
Arg Ser Pro His Arg Pro Ile Leu Gln 130 135
140Ala Gly Leu Pro Ala Asn Ala Ser Thr Val Val Gly Gly Asp Val
Glu145 150 155 160Phe Val
Cys Lys Val Tyr Ser Asp Ala Gln Pro His Ile Gln Trp Ile
165 170 175Lys His Val Glu Lys Asn Gly
Ser Lys Tyr Gly Pro Asp Gly Leu Pro 180 185
190Tyr Leu Lys Val Leu Lys Ala Ala Gly Val Asn Thr Thr Asp
Lys Glu 195 200 205Ile Glu Val Leu
Tyr Ile Arg Asn Val Thr Phe Glu Asp Ala Gly Glu 210
215 220Tyr Thr Cys Leu Ala Gly Asn Ser Ile Gly Ile Ser
Phe His Ser Ala225 230 235
240Trp Leu Thr Val Leu Pro Ala Pro Gly Arg Glu Lys Glu Ile Thr Ala
245 250 255Ser Pro Asp Tyr Leu
Glu Ile Ala Ile Tyr Cys Ile Gly Val Phe Leu 260
265 270Ile Ala Cys Met Val Val Thr Val Ile Leu Cys Arg
Met Lys Asn Thr 275 280 285Thr Lys
Lys Pro Asp Phe Ser Ser Gln Pro Ala Val His Lys Leu Thr 290
295 300Lys Arg Ile Pro Leu Arg Arg Gln Val Thr Val
Ser Ala Glu Ser Ser305 310 315
320Ser Ser Met Asn Ser Asn Thr Pro Leu Val Arg Ile Thr Thr Arg Leu
325 330 335Ser Ser Thr Ala
Asp Thr Pro Met Leu Ala Gly Val Ser Glu Tyr Glu 340
345 350Leu Pro Glu Asp Pro Lys Trp Glu Phe Pro Arg
Asp Lys Leu Thr Leu 355 360 365Gly
Lys Pro Leu Gly Glu Gly Cys Phe Gly Gln Val Val Met Ala Glu 370
375 380Ala Val Gly Ile Asp Lys Asp Lys Pro Lys
Glu Ala Val Thr Val Ala385 390 395
400Val Lys Met Leu Lys Asp Asp Ala Thr Glu Lys Asp Leu Ser Asp
Leu 405 410 415Val Ser Glu
Met Glu Met Met Lys Met Ile Gly Lys His Lys Asn Ile 420
425 430Ile Asn Leu Leu Gly Ala Cys Thr Gln Asp
Gly Pro Leu Tyr Val Ile 435 440
445Val Glu Tyr Ala Ser Lys Gly Asn Leu Arg Glu Tyr Leu Arg Ala Arg 450
455 460Arg Pro Pro Gly Met Glu Tyr Ser
Tyr Asp Ile Asn Arg Val Pro Glu465 470
475 480Glu Gln Met Thr Phe Lys Asp Leu Val Ser Cys Thr
Tyr Gln Leu Ala 485 490
495Arg Gly Met Glu Tyr Leu Ala Ser Gln Lys Cys Ile His Arg Asp Leu
500 505 510Ala Ala Arg Asn Val Leu
Val Thr Glu Asn Asn Val Met Lys Ile Ala 515 520
525Asp Phe Gly Leu Ala Arg Asp Ile Asn Asn Ile Asp Tyr Tyr
Lys Lys 530 535 540Thr Thr Asn Gly Arg
Leu Pro Val Lys Trp Met Ala Pro Glu Ala Leu545 550
555 560Phe Asp Arg Val Tyr Thr His Gln Ser Asp
Val Trp Ser Phe Gly Val 565 570
575Leu Met Trp Glu Ile Phe Thr Leu Gly Gly Ser Pro Tyr Pro Gly Ile
580 585 590Pro Val Glu Glu Leu
Phe Lys Leu Leu Lys Glu Gly His Arg Met Asp 595
600 605Lys Pro Ala Asn Cys Thr Asn Glu Leu Tyr Met Met
Met Arg Asp Cys 610 615 620Trp His Ala
Val Pro Ser Gln Arg Pro Thr Phe Lys Gln Leu Val Glu625
630 635 640Asp Leu Asp Arg Ile Leu Thr
Leu Thr Thr Asn Glu Glu Tyr Leu Asp 645
650 655Leu Ser Gln Pro Leu Glu Gln Tyr Ser Pro Ser Tyr
Pro Asp Thr Arg 660 665 670Ser
Ser Cys Ser Ser Gly Asp Asp Ser Val Phe Ser Pro Asp Pro Met 675
680 685Pro Tyr Glu Pro Cys Leu Pro Gln Tyr
Pro His Ile Asn Gly Ser Val 690 695
700Lys Thr70541705PRTHomo sapiens 41Met Val Ser Trp Gly Arg Phe Ile Cys
Leu Val Val Val Thr Met Ala1 5 10
15Thr Leu Ser Leu Ala Arg Pro Ser Phe Ser Leu Val Glu Asp Thr
Thr 20 25 30Leu Glu Pro Glu
Glu Pro Pro Thr Lys Tyr Gln Ile Ser Gln Pro Glu 35
40 45Val Tyr Val Ala Ala Pro Gly Glu Ser Leu Glu Val
Arg Cys Leu Leu 50 55 60Lys Asp Ala
Ala Val Ile Ser Trp Thr Lys Asp Gly Val His Leu Gly65 70
75 80Pro Asn Asn Arg Thr Val Leu Ile
Gly Glu Tyr Leu Gln Ile Lys Gly 85 90
95Ala Thr Pro Arg Asp Ser Gly Leu Tyr Ala Cys Thr Ala Ser
Arg Thr 100 105 110Val Asp Ser
Glu Thr Trp Tyr Phe Met Val Asn Val Thr Asp Ala Ile 115
120 125Ser Ser Gly Asp Asp Glu Asp Asp Thr Asp Gly
Ala Glu Asp Phe Val 130 135 140Ser Glu
Asn Ser Asn Asn Lys Arg Ala Pro Tyr Trp Thr Asn Thr Glu145
150 155 160Lys Met Glu Lys Arg Leu His
Ala Val Pro Ala Ala Asn Thr Val Lys 165
170 175Phe Arg Cys Pro Ala Gly Gly Asn Pro Met Pro Thr
Met Arg Trp Leu 180 185 190Lys
Asn Gly Lys Glu Phe Lys Gln Glu His Arg Ile Gly Gly Tyr Lys 195
200 205Val Arg Asn Gln His Trp Ser Leu Ile
Met Glu Ser Val Val Pro Ser 210 215
220Asp Lys Gly Asn Tyr Thr Cys Val Val Glu Asn Glu Tyr Gly Ser Ile225
230 235 240Asn His Thr Tyr
His Leu Asp Val Val Glu Arg Ser Pro His Arg Pro 245
250 255Ile Leu Gln Ala Gly Leu Pro Ala Asn Ala
Ser Thr Val Val Gly Gly 260 265
270Asp Val Glu Phe Val Cys Lys Val Tyr Ser Asp Ala Gln Pro His Ile
275 280 285Gln Trp Ile Lys His Val Glu
Lys Asn Gly Ser Lys Tyr Gly Pro Asp 290 295
300Gly Leu Pro Tyr Leu Lys Val Leu Lys Val Ser Ala Glu Ser Ser
Ser305 310 315 320Ser Met
Asn Ser Asn Thr Pro Leu Val Arg Ile Thr Thr Arg Leu Ser
325 330 335Ser Thr Ala Asp Thr Pro Met
Leu Ala Gly Val Ser Glu Tyr Glu Leu 340 345
350Pro Glu Asp Pro Lys Trp Glu Phe Pro Arg Asp Lys Leu Thr
Leu Gly 355 360 365Lys Pro Leu Gly
Glu Gly Cys Phe Gly Gln Val Val Met Ala Glu Ala 370
375 380Val Gly Ile Asp Lys Asp Lys Pro Lys Glu Ala Val
Thr Val Ala Val385 390 395
400Lys Met Leu Lys Asp Asp Ala Thr Glu Lys Asp Leu Ser Asp Leu Val
405 410 415Ser Glu Met Glu Met
Met Lys Met Ile Gly Lys His Lys Asn Ile Ile 420
425 430Asn Leu Leu Gly Ala Cys Thr Gln Asp Gly Pro Leu
Tyr Val Ile Val 435 440 445Glu Tyr
Ala Ser Lys Gly Asn Leu Arg Glu Tyr Leu Arg Ala Arg Arg 450
455 460Pro Pro Gly Met Glu Tyr Ser Tyr Asp Ile Asn
Arg Val Pro Glu Glu465 470 475
480Gln Met Thr Phe Lys Asp Leu Val Ser Cys Thr Tyr Gln Leu Ala Arg
485 490 495Gly Met Glu Tyr
Leu Ala Ser Gln Lys Cys Ile His Arg Asp Leu Ala 500
505 510Ala Arg Asn Val Leu Val Thr Glu Asn Asn Val
Met Lys Ile Ala Asp 515 520 525Phe
Gly Leu Ala Arg Asp Ile Asn Asn Ile Asp Tyr Tyr Lys Lys Thr 530
535 540Thr Asn Gly Arg Leu Pro Val Lys Trp Met
Ala Pro Glu Ala Leu Phe545 550 555
560Asp Arg Val Tyr Thr His Gln Ser Asp Val Trp Ser Phe Gly Val
Leu 565 570 575Met Trp Glu
Ile Phe Thr Leu Gly Gly Ser Pro Tyr Pro Gly Ile Pro 580
585 590Val Glu Glu Leu Phe Lys Leu Leu Lys Glu
Gly His Arg Met Asp Lys 595 600
605Pro Ala Asn Cys Thr Asn Glu Leu Tyr Met Met Met Arg Asp Cys Trp 610
615 620His Ala Val Pro Ser Gln Arg Pro
Thr Phe Lys Gln Leu Val Glu Asp625 630
635 640Leu Asp Arg Ile Leu Thr Leu Thr Thr Asn Glu Glu
Tyr Leu Asp Leu 645 650
655Ser Gln Pro Leu Glu Gln Tyr Ser Pro Ser Tyr Pro Asp Thr Arg Ser
660 665 670Ser Cys Ser Ser Gly Asp
Asp Ser Val Phe Ser Pro Asp Pro Met Pro 675 680
685Tyr Glu Pro Cys Leu Pro Gln Tyr Pro His Ile Asn Gly Ser
Val Lys 690 695 700Thr70542704PRTHomo
sapiens 42Met Val Ser Trp Gly Arg Phe Ile Cys Leu Val Val Val Thr Met
Ala1 5 10 15Thr Leu Ser
Leu Ala Arg Pro Ser Phe Ser Leu Val Glu Asp Thr Thr 20
25 30Leu Glu Pro Glu Gly Ala Pro Tyr Trp Thr
Asn Thr Glu Lys Met Glu 35 40
45Lys Arg Leu His Ala Val Pro Ala Ala Asn Thr Val Lys Phe Arg Cys 50
55 60Pro Ala Gly Gly Asn Pro Met Pro Thr
Met Arg Trp Leu Lys Asn Gly65 70 75
80Lys Glu Phe Lys Gln Glu His Arg Ile Gly Gly Tyr Lys Val
Arg Asn 85 90 95Gln His
Trp Ser Leu Ile Met Glu Ser Val Val Pro Ser Asp Lys Gly 100
105 110Asn Tyr Thr Cys Val Val Glu Asn Glu
Tyr Gly Ser Ile Asn His Thr 115 120
125Tyr His Leu Asp Val Val Glu Arg Ser Pro His Arg Pro Ile Leu Gln
130 135 140Ala Gly Leu Pro Ala Asn Ala
Ser Thr Val Val Gly Gly Asp Val Glu145 150
155 160Phe Val Cys Lys Val Tyr Ser Asp Ala Gln Pro His
Ile Gln Trp Ile 165 170
175Lys His Val Glu Lys Asn Gly Ser Lys Tyr Gly Pro Asp Gly Leu Pro
180 185 190Tyr Leu Lys Val Leu Lys
Ala Ala Gly Val Asn Thr Thr Asp Lys Glu 195 200
205Ile Glu Val Leu Tyr Ile Arg Asn Val Thr Phe Glu Asp Ala
Gly Glu 210 215 220Tyr Thr Cys Leu Ala
Gly Asn Ser Ile Gly Ile Ser Phe His Ser Ala225 230
235 240Trp Leu Thr Val Leu Pro Ala Pro Gly Arg
Glu Lys Glu Ile Thr Ala 245 250
255Ser Pro Asp Tyr Leu Glu Ile Ala Ile Tyr Cys Ile Gly Val Phe Leu
260 265 270Ile Ala Cys Met Val
Val Thr Val Ile Leu Cys Arg Met Lys Asn Thr 275
280 285Thr Lys Lys Pro Asp Phe Ser Ser Gln Pro Ala Val
His Lys Leu Thr 290 295 300Lys Arg Ile
Pro Leu Arg Arg Gln Val Ser Ala Glu Ser Ser Ser Ser305
310 315 320Met Asn Ser Asn Thr Pro Leu
Val Arg Ile Thr Thr Arg Leu Ser Ser 325
330 335Thr Ala Asp Thr Pro Met Leu Ala Gly Val Ser Glu
Tyr Glu Leu Pro 340 345 350Glu
Asp Pro Lys Trp Glu Phe Pro Arg Asp Lys Leu Thr Leu Gly Lys 355
360 365Pro Leu Gly Glu Gly Cys Phe Gly Gln
Val Val Met Ala Glu Ala Val 370 375
380Gly Ile Asp Lys Asp Lys Pro Lys Glu Ala Val Thr Val Ala Val Lys385
390 395 400Met Leu Lys Asp
Asp Ala Thr Glu Lys Asp Leu Ser Asp Leu Val Ser 405
410 415Glu Met Glu Met Met Lys Met Ile Gly Lys
His Lys Asn Ile Ile Asn 420 425
430Leu Leu Gly Ala Cys Thr Gln Asp Gly Pro Leu Tyr Val Ile Val Glu
435 440 445Tyr Ala Ser Lys Gly Asn Leu
Arg Glu Tyr Leu Arg Ala Arg Arg Pro 450 455
460Pro Gly Met Glu Tyr Ser Tyr Asp Ile Asn Arg Val Pro Glu Glu
Gln465 470 475 480Met Thr
Phe Lys Asp Leu Val Ser Cys Thr Tyr Gln Leu Ala Arg Gly
485 490 495Met Glu Tyr Leu Ala Ser Gln
Lys Cys Ile His Arg Asp Leu Ala Ala 500 505
510Arg Asn Val Leu Val Thr Glu Asn Asn Val Met Lys Ile Ala
Asp Phe 515 520 525Gly Leu Ala Arg
Asp Ile Asn Asn Ile Asp Tyr Tyr Lys Lys Thr Thr 530
535 540Asn Gly Arg Leu Pro Val Lys Trp Met Ala Pro Glu
Ala Leu Phe Asp545 550 555
560Arg Val Tyr Thr His Gln Ser Asp Val Trp Ser Phe Gly Val Leu Met
565 570 575Trp Glu Ile Phe Thr
Leu Gly Gly Ser Pro Tyr Pro Gly Ile Pro Val 580
585 590Glu Glu Leu Phe Lys Leu Leu Lys Glu Gly His Arg
Met Asp Lys Pro 595 600 605Ala Asn
Cys Thr Asn Glu Leu Tyr Met Met Met Arg Asp Cys Trp His 610
615 620Ala Val Pro Ser Gln Arg Pro Thr Phe Lys Gln
Leu Val Glu Asp Leu625 630 635
640Asp Arg Ile Leu Thr Leu Thr Thr Asn Glu Glu Tyr Leu Asp Leu Ser
645 650 655Gln Pro Leu Glu
Gln Tyr Ser Pro Ser Tyr Pro Asp Thr Arg Ser Ser 660
665 670Cys Ser Ser Gly Asp Asp Ser Val Phe Ser Pro
Asp Pro Met Pro Tyr 675 680 685Glu
Pro Cys Leu Pro Gln Tyr Pro His Ile Asn Gly Ser Val Lys Thr 690
695 70043680PRTHomo sapiens 43Met Val Ser Trp
Gly Arg Phe Ile Cys Leu Val Val Val Thr Met Ala1 5
10 15Thr Leu Ser Leu Ala Arg Pro Ser Phe Ser
Leu Val Glu Asp Thr Thr 20 25
30Leu Glu Pro Glu Asp Ala Ile Ser Ser Gly Asp Asp Glu Asp Asp Thr
35 40 45Asp Gly Ala Glu Asp Phe Val Ser
Glu Asn Ser Asn Asn Lys Arg Ala 50 55
60Pro Tyr Trp Thr Asn Thr Glu Lys Met Glu Lys Arg Leu His Ala Val65
70 75 80Pro Ala Ala Asn Thr
Val Lys Phe Arg Cys Pro Ala Gly Gly Asn Pro 85
90 95Met Pro Thr Met Arg Trp Leu Lys Asn Gly Lys
Glu Phe Lys Gln Glu 100 105
110His Arg Ile Gly Gly Tyr Lys Val Arg Asn Gln His Trp Ser Leu Ile
115 120 125Met Glu Ser Val Val Pro Ser
Asp Lys Gly Asn Tyr Thr Cys Val Val 130 135
140Glu Asn Glu Tyr Gly Ser Ile Asn His Thr Tyr His Leu Asp Val
Val145 150 155 160Glu Arg
Ser Pro His Arg Pro Ile Leu Gln Ala Gly Leu Pro Ala Asn
165 170 175Ala Ser Thr Val Val Gly Gly
Asp Val Glu Phe Val Cys Lys Val Tyr 180 185
190Ser Asp Ala Gln Pro His Ile Gln Trp Ile Lys His Val Glu
Lys Asn 195 200 205Gly Ser Lys Tyr
Gly Pro Asp Gly Leu Pro Tyr Leu Lys Val Leu Lys 210
215 220His Ser Gly Ile Asn Ser Ser Asn Ala Glu Val Leu
Ala Leu Phe Asn225 230 235
240Val Thr Glu Ala Asp Ala Gly Glu Tyr Ile Cys Lys Val Ser Asn Tyr
245 250 255Ile Gly Gln Ala Asn
Gln Ser Ala Trp Leu Thr Val Leu Pro Lys Gln 260
265 270Gln Ala Pro Gly Arg Glu Lys Glu Ile Thr Ala Ser
Pro Asp Tyr Leu 275 280 285Glu Ile
Ala Ile Tyr Cys Ile Gly Val Phe Leu Ile Ala Cys Met Val 290
295 300Val Thr Val Ile Leu Cys Arg Met Lys Asn Thr
Thr Lys Lys Pro Asp305 310 315
320Phe Ser Ser Gln Pro Ala Val His Lys Leu Thr Lys Arg Ile Pro Leu
325 330 335Arg Arg Gln Val
Thr Val Ser Ala Glu Ser Ser Ser Ser Met Asn Ser 340
345 350Asn Thr Pro Leu Val Arg Ile Thr Thr Arg Leu
Ser Ser Thr Ala Asp 355 360 365Thr
Pro Met Leu Ala Gly Val Ser Glu Tyr Glu Leu Pro Glu Asp Pro 370
375 380Lys Trp Glu Phe Pro Arg Asp Lys Leu Thr
Leu Gly Lys Pro Leu Gly385 390 395
400Glu Gly Cys Phe Gly Gln Val Val Met Ala Glu Ala Val Gly Ile
Asp 405 410 415Lys Asp Lys
Pro Lys Glu Ala Val Thr Val Ala Val Lys Met Leu Lys 420
425 430Asp Asp Ala Thr Glu Lys Asp Leu Ser Asp
Leu Val Ser Glu Met Glu 435 440
445Met Met Lys Met Ile Gly Lys His Lys Asn Ile Ile Asn Leu Leu Gly 450
455 460Ala Cys Thr Gln Asp Gly Pro Leu
Tyr Val Ile Val Glu Tyr Ala Ser465 470
475 480Lys Gly Asn Leu Arg Glu Tyr Leu Arg Ala Arg Arg
Pro Pro Gly Met 485 490
495Glu Tyr Ser Tyr Asp Ile Asn Arg Val Pro Glu Glu Gln Met Thr Phe
500 505 510Lys Asp Leu Val Ser Cys
Thr Tyr Gln Leu Ala Arg Gly Met Glu Tyr 515 520
525Leu Ala Ser Gln Lys Cys Ile His Arg Asp Leu Ala Ala Arg
Asn Val 530 535 540Leu Val Thr Glu Asn
Asn Val Met Lys Ile Ala Asp Phe Gly Leu Ala545 550
555 560Arg Asp Ile Asn Asn Ile Asp Tyr Tyr Lys
Lys Thr Thr Asn Gly Arg 565 570
575Leu Pro Val Lys Trp Met Ala Pro Glu Ala Leu Phe Asp Arg Val Tyr
580 585 590Thr His Gln Ser Asp
Val Trp Ser Phe Gly Val Leu Met Trp Glu Ile 595
600 605Phe Thr Leu Gly Gly Ser Pro Tyr Pro Gly Ile Pro
Val Glu Glu Leu 610 615 620Phe Lys Leu
Leu Lys Glu Gly His Arg Met Asp Lys Pro Ala Asn Cys625
630 635 640Thr Asn Glu Leu Tyr Met Met
Met Arg Asp Cys Trp His Ala Val Pro 645
650 655Ser Gln Arg Pro Thr Phe Lys Gln Leu Val Glu Asp
Leu Asp Arg Ile 660 665 670Leu
Thr Leu Thr Thr Asn Glu Ile 675 68044732PRTHomo
sapiens 44Met Val Ser Trp Gly Arg Phe Ile Cys Leu Val Val Val Thr Met
Ala1 5 10 15Thr Leu Ser
Leu Ala Arg Pro Ser Phe Ser Leu Val Glu Asp Thr Thr 20
25 30Leu Glu Pro Glu Asp Ala Ile Ser Ser Gly
Asp Asp Glu Asp Asp Thr 35 40
45Asp Gly Ala Glu Asp Phe Val Ser Glu Asn Ser Asn Asn Lys Arg Ala 50
55 60Pro Tyr Trp Thr Asn Thr Glu Lys Met
Glu Lys Arg Leu His Ala Val65 70 75
80Pro Ala Ala Asn Thr Val Lys Phe Arg Cys Pro Ala Gly Gly
Asn Pro 85 90 95Met Pro
Thr Met Arg Trp Leu Lys Asn Gly Lys Glu Phe Lys Gln Glu 100
105 110His Arg Ile Gly Gly Tyr Lys Val Arg
Asn Gln His Trp Ser Leu Ile 115 120
125Met Glu Ser Val Val Pro Ser Asp Lys Gly Asn Tyr Thr Cys Val Val
130 135 140Glu Asn Glu Tyr Gly Ser Ile
Asn His Thr Tyr His Leu Asp Val Val145 150
155 160Glu Arg Ser Pro His Arg Pro Ile Leu Gln Ala Gly
Leu Pro Ala Asn 165 170
175Ala Ser Thr Val Val Gly Gly Asp Val Glu Phe Val Cys Lys Val Tyr
180 185 190Ser Asp Ala Gln Pro His
Ile Gln Trp Ile Lys His Val Glu Lys Asn 195 200
205Gly Ser Lys Tyr Gly Pro Asp Gly Leu Pro Tyr Leu Lys Val
Leu Lys 210 215 220Ala Ala Gly Val Asn
Thr Thr Asp Lys Glu Ile Glu Val Leu Tyr Ile225 230
235 240Arg Asn Val Thr Phe Glu Asp Ala Gly Glu
Tyr Thr Cys Leu Ala Gly 245 250
255Asn Ser Ile Gly Ile Ser Phe His Ser Ala Trp Leu Thr Val Leu Pro
260 265 270Ala Pro Gly Arg Glu
Lys Glu Ile Thr Ala Ser Pro Asp Tyr Leu Glu 275
280 285Ile Ala Ile Tyr Cys Ile Gly Val Phe Leu Ile Ala
Cys Met Val Val 290 295 300Thr Val Ile
Leu Cys Arg Met Lys Asn Thr Thr Lys Lys Pro Asp Phe305
310 315 320Ser Ser Gln Pro Ala Val His
Lys Leu Thr Lys Arg Ile Pro Leu Arg 325
330 335Arg Gln Val Thr Val Ser Ala Glu Ser Ser Ser Ser
Met Asn Ser Asn 340 345 350Thr
Pro Leu Val Arg Ile Thr Thr Arg Leu Ser Ser Thr Ala Asp Thr 355
360 365Pro Met Leu Ala Gly Val Ser Glu Tyr
Glu Leu Pro Glu Asp Pro Lys 370 375
380Trp Glu Phe Pro Arg Asp Lys Leu Thr Leu Gly Lys Pro Leu Gly Glu385
390 395 400Gly Cys Phe Gly
Gln Val Val Met Ala Glu Ala Val Gly Ile Asp Lys 405
410 415Asp Lys Pro Lys Glu Ala Val Thr Val Ala
Val Lys Met Leu Lys Asp 420 425
430Asp Ala Thr Glu Lys Asp Leu Ser Asp Leu Val Ser Glu Met Glu Met
435 440 445Met Lys Met Ile Gly Lys His
Lys Asn Ile Ile Asn Leu Leu Gly Ala 450 455
460Cys Thr Gln Asp Gly Pro Leu Tyr Val Ile Val Glu Tyr Ala Ser
Lys465 470 475 480Gly Asn
Leu Arg Glu Tyr Leu Arg Ala Arg Arg Pro Pro Gly Met Glu
485 490 495Tyr Ser Tyr Asp Ile Asn Arg
Val Pro Glu Glu Gln Met Thr Phe Lys 500 505
510Asp Leu Val Ser Cys Thr Tyr Gln Leu Ala Arg Gly Met Glu
Tyr Leu 515 520 525Ala Ser Gln Lys
Cys Ile His Arg Asp Leu Ala Ala Arg Asn Val Leu 530
535 540Val Thr Glu Asn Asn Val Met Lys Ile Ala Asp Phe
Gly Leu Ala Arg545 550 555
560Asp Ile Asn Asn Ile Asp Tyr Tyr Lys Lys Thr Thr Asn Gly Arg Leu
565 570 575Pro Val Lys Trp Met
Ala Pro Glu Ala Leu Phe Asp Arg Val Tyr Thr 580
585 590His Gln Ser Asp Val Trp Ser Phe Gly Val Leu Met
Trp Glu Ile Phe 595 600 605Thr Leu
Gly Gly Ser Pro Tyr Pro Gly Ile Pro Val Glu Glu Leu Phe 610
615 620Lys Leu Leu Lys Glu Gly His Arg Met Asp Lys
Pro Ala Asn Cys Thr625 630 635
640Asn Glu Leu Tyr Met Met Met Arg Asp Cys Trp His Ala Val Pro Ser
645 650 655Gln Arg Pro Thr
Phe Lys Gln Leu Val Glu Asp Leu Asp Arg Ile Leu 660
665 670Thr Leu Thr Thr Asn Glu Glu Tyr Leu Asp Leu
Ser Gln Pro Leu Glu 675 680 685Gln
Tyr Ser Pro Ser Tyr Pro Asp Thr Arg Ser Ser Cys Ser Ser Gly 690
695 700Asp Asp Ser Val Phe Ser Pro Asp Pro Met
Pro Tyr Glu Pro Cys Leu705 710 715
720Pro Gln Tyr Pro His Ile Asn Gly Ser Val Lys Thr
725 73045820PRTHomo sapiens 45Met Trp Ser Trp Lys Cys
Leu Leu Phe Trp Ala Val Leu Val Thr Ala1 5
10 15Thr Leu Cys Thr Ala Arg Pro Ser Pro Thr Leu Pro
Glu Gln Ala Gln 20 25 30Pro
Trp Gly Ala Pro Val Glu Val Glu Ser Phe Leu Val His Pro Gly 35
40 45Asp Leu Leu Gln Leu Arg Cys Arg Leu
Arg Asp Asp Val Gln Ser Ile 50 55
60Asn Trp Leu Arg Asp Gly Val Gln Leu Ala Glu Ser Asn Arg Thr Arg65
70 75 80Ile Thr Gly Glu Glu
Val Glu Val Gln Asp Ser Val Pro Ala Asp Ser 85
90 95Gly Leu Tyr Ala Cys Val Thr Ser Ser Pro Ser
Gly Ser Asp Thr Thr 100 105
110Tyr Phe Ser Val Asn Val Ser Asp Ala Leu Pro Ser Ser Glu Asp Asp
115 120 125Asp Asp Asp Asp Asp Ser Ser
Ser Glu Glu Lys Glu Thr Asp Asn Thr 130 135
140Lys Pro Asn Arg Met Pro Val Ala Pro Tyr Trp Thr Ser Pro Glu
Lys145 150 155 160Met Glu
Lys Lys Leu His Ala Val Pro Ala Ala Lys Thr Val Lys Phe
165 170 175Lys Cys Pro Ser Ser Gly Thr
Pro Asn Pro Thr Leu Arg Trp Leu Lys 180 185
190Asn Gly Lys Glu Phe Lys Pro Asp His Arg Ile Gly Gly Tyr
Lys Val 195 200 205Arg Tyr Ala Thr
Trp Ser Ile Ile Met Asp Ser Val Val Pro Ser Asp 210
215 220Lys Gly Asn Tyr Thr Cys Ile Val Glu Asn Glu Tyr
Gly Ser Ile Asn225 230 235
240His Thr Tyr Gln Leu Asp Val Val Glu Arg Ser Pro His Arg Pro Ile
245 250 255Leu Gln Ala Gly Leu
Pro Ala Asn Lys Thr Val Ala Leu Gly Ser Asn 260
265 270Val Glu Phe Met Cys Lys Val Tyr Ser Asp Pro Gln
Pro His Ile Gln 275 280 285Trp Leu
Lys His Ile Glu Val Asn Gly Ser Lys Ile Gly Pro Asp Asn 290
295 300Leu Pro Tyr Val Gln Ile Leu Lys Thr Ala Gly
Val Asn Thr Thr Asp305 310 315
320Lys Glu Met Glu Val Leu His Leu Arg Asn Val Ser Phe Glu Asp Ala
325 330 335Gly Glu Tyr Thr
Cys Leu Ala Gly Asn Ser Ile Gly Leu Ser His His 340
345 350Ser Ala Trp Leu Thr Val Leu Glu Ala Leu Glu
Glu Arg Pro Ala Val 355 360 365Met
Thr Ser Pro Leu Tyr Leu Glu Ile Ile Ile Tyr Cys Thr Gly Ala 370
375 380Phe Leu Ile Ser Cys Met Val Gly Ser Val
Ile Val Tyr Lys Met Lys385 390 395
400Ser Gly Thr Lys Lys Ser Asp Phe His Ser Gln Met Ala Val His
Lys 405 410 415Leu Ala Lys
Ser Ile Pro Leu Arg Arg Gln Val Ser Ala Asp Ser Ser 420
425 430Ala Ser Met Asn Ser Gly Val Leu Leu Val
Arg Pro Ser Arg Leu Ser 435 440
445Ser Ser Gly Thr Pro Met Leu Ala Gly Val Ser Glu Tyr Glu Leu Pro 450
455 460Glu Asp Pro Arg Trp Glu Leu Pro
Arg Asp Arg Leu Val Leu Gly Lys465 470
475 480Pro Leu Gly Glu Gly Cys Phe Gly Gln Val Val Leu
Ala Glu Ala Ile 485 490
495Gly Leu Asp Lys Asp Lys Pro Asn Arg Val Thr Lys Val Ala Val Lys
500 505 510Met Leu Lys Ser Asp Ala
Thr Glu Lys Asp Leu Ser Asp Leu Ile Ser 515 520
525Glu Met Glu Met Met Lys Met Ile Gly Lys His Lys Asn Ile
Ile Asn 530 535 540Leu Leu Gly Ala Cys
Thr Gln Asp Gly Pro Leu Tyr Val Ile Val Glu545 550
555 560Tyr Ala Ser Lys Gly Asn Leu Arg Glu Tyr
Leu Gln Ala Arg Arg Pro 565 570
575Pro Gly Leu Glu Tyr Cys Tyr Asn Pro Ser His Asn Pro Glu Glu Gln
580 585 590Leu Ser Ser Lys Asp
Leu Val Ser Cys Ala Tyr Gln Val Ala Arg Gly 595
600 605Met Glu Tyr Leu Ala Ser Lys Lys Cys Ile His Arg
Asp Leu Ala Ala 610 615 620Arg Asn Val
Leu Val Thr Glu Asp Asn Val Met Lys Ile Ala Asp Phe625
630 635 640Gly Leu Ala Arg Asp Ile His
His Ile Asp Tyr Tyr Lys Lys Thr Thr 645
650 655Asn Gly Arg Leu Pro Val Lys Trp Met Ala Pro Glu
Ala Leu Phe Asp 660 665 670Arg
Ile Tyr Thr His Gln Ser Asp Val Trp Ser Phe Gly Val Leu Leu 675
680 685Trp Glu Ile Phe Thr Leu Gly Gly Ser
Pro Tyr Pro Gly Val Pro Val 690 695
700Glu Glu Leu Phe Lys Leu Leu Lys Glu Gly His Arg Met Asp Lys Pro705
710 715 720Ser Asn Cys Thr
Asn Glu Leu Tyr Met Met Met Arg Asp Cys Trp His 725
730 735Ala Val Pro Ser Gln Arg Pro Thr Phe Lys
Gln Leu Val Glu Asp Leu 740 745
750Asp Arg Ile Val Ala Leu Thr Ser Asn Gln Glu Tyr Leu Asp Leu Ser
755 760 765Met Pro Leu Asp Gln Tyr Ser
Pro Ser Phe Pro Asp Thr Arg Ser Ser 770 775
780Thr Cys Ser Ser Gly Glu Asp Ser Val Phe Ser His Glu Pro Leu
Pro785 790 795 800Glu Glu
Pro Cys Leu Pro Arg His Pro Ala Gln Leu Ala Asn Gly Gly
805 810 815Leu Lys Arg Arg
82046812PRTHomo sapiens 46Met Ala Ala Val Thr Arg Asp Phe Gly Glu Met Leu
Leu His Ser Gly1 5 10
15Arg Val Leu Pro Ala Glu Ala Gln Pro Trp Gly Ala Pro Val Glu Val
20 25 30Glu Ser Phe Leu Val His Pro
Gly Asp Leu Leu Gln Leu Arg Cys Arg 35 40
45Leu Arg Asp Asp Val Gln Ser Ile Asn Trp Leu Arg Asp Gly Val
Gln 50 55 60Leu Ala Glu Ser Asn Arg
Thr Arg Ile Thr Gly Glu Glu Val Glu Val65 70
75 80Gln Asp Ser Val Pro Ala Asp Ser Gly Leu Tyr
Ala Cys Val Thr Ser 85 90
95Ser Pro Ser Gly Ser Asp Thr Thr Tyr Phe Ser Val Asn Val Ser Asp
100 105 110Ala Leu Pro Ser Ser Glu
Asp Asp Asp Asp Asp Asp Asp Ser Ser Ser 115 120
125Glu Glu Lys Glu Thr Asp Asn Thr Lys Pro Asn Arg Met Pro
Val Ala 130 135 140Pro Tyr Trp Thr Ser
Pro Glu Lys Met Glu Lys Lys Leu His Ala Val145 150
155 160Pro Ala Ala Lys Thr Val Lys Phe Lys Cys
Pro Ser Ser Gly Thr Pro 165 170
175Asn Pro Thr Leu Arg Trp Leu Lys Asn Gly Lys Glu Phe Lys Pro Asp
180 185 190His Arg Ile Gly Gly
Tyr Lys Val Arg Tyr Ala Thr Trp Ser Ile Ile 195
200 205Met Asp Ser Val Val Pro Ser Asp Lys Gly Asn Tyr
Thr Cys Ile Val 210 215 220Glu Asn Glu
Tyr Gly Ser Ile Asn His Thr Tyr Gln Leu Asp Val Val225
230 235 240Glu Arg Ser Pro His Arg Pro
Ile Leu Gln Ala Gly Leu Pro Ala Asn 245
250 255Lys Thr Val Ala Leu Gly Ser Asn Val Glu Phe Met
Cys Lys Val Tyr 260 265 270Ser
Asp Pro Gln Pro His Ile Gln Trp Leu Lys His Ile Glu Val Asn 275
280 285Gly Ser Lys Ile Gly Pro Asp Asn Leu
Pro Tyr Val Gln Ile Leu Lys 290 295
300Thr Ala Gly Val Asn Thr Thr Asp Lys Glu Met Glu Val Leu His Leu305
310 315 320Arg Asn Val Ser
Phe Glu Asp Ala Gly Glu Tyr Thr Cys Leu Ala Gly 325
330 335Asn Ser Ile Gly Leu Ser His His Ser Ala
Trp Leu Thr Val Leu Glu 340 345
350Ala Leu Glu Glu Arg Pro Ala Val Met Thr Ser Pro Leu Tyr Leu Glu
355 360 365Ile Ile Ile Tyr Cys Thr Gly
Ala Phe Leu Ile Ser Cys Met Val Gly 370 375
380Ser Val Ile Val Tyr Lys Met Lys Ser Gly Thr Lys Lys Ser Asp
Phe385 390 395 400His Ser
Gln Met Ala Val His Lys Leu Ala Lys Ser Ile Pro Leu Arg
405 410 415Arg Gln Val Ser Ala Asp Ser
Ser Ala Ser Met Asn Ser Gly Val Leu 420 425
430Leu Val Arg Pro Ser Arg Leu Ser Ser Ser Gly Thr Pro Met
Leu Ala 435 440 445Gly Val Ser Glu
Tyr Glu Leu Pro Glu Asp Pro Arg Trp Glu Leu Pro 450
455 460Arg Asp Arg Leu Val Leu Gly Lys Pro Leu Gly Glu
Gly Cys Phe Gly465 470 475
480Gln Val Val Leu Ala Glu Ala Ile Gly Leu Asp Lys Asp Lys Pro Asn
485 490 495Arg Val Thr Lys Val
Ala Val Lys Met Leu Lys Ser Asp Ala Thr Glu 500
505 510Lys Asp Leu Ser Asp Leu Ile Ser Glu Met Glu Met
Met Lys Met Ile 515 520 525Gly Lys
His Lys Asn Ile Ile Asn Leu Leu Gly Ala Cys Thr Gln Asp 530
535 540Gly Pro Leu Tyr Val Ile Val Glu Tyr Ala Ser
Lys Gly Asn Leu Arg545 550 555
560Glu Tyr Leu Gln Ala Arg Arg Pro Pro Gly Leu Glu Tyr Cys Tyr Asn
565 570 575Pro Ser His Asn
Pro Glu Glu Gln Leu Ser Ser Lys Asp Leu Val Ser 580
585 590Cys Ala Tyr Gln Val Ala Arg Gly Met Glu Tyr
Leu Ala Ser Lys Lys 595 600 605Cys
Ile His Arg Asp Leu Ala Ala Arg Asn Val Leu Val Thr Glu Asp 610
615 620Asn Val Met Lys Ile Ala Asp Phe Gly Leu
Ala Arg Asp Ile His His625 630 635
640Ile Asp Tyr Tyr Lys Lys Thr Thr Asn Gly Arg Leu Pro Val Lys
Trp 645 650 655Met Ala Pro
Glu Ala Leu Phe Asp Arg Ile Tyr Thr His Gln Ser Asp 660
665 670Val Trp Ser Phe Gly Val Leu Leu Trp Glu
Ile Phe Thr Leu Gly Gly 675 680
685Ser Pro Tyr Pro Gly Val Pro Val Glu Glu Leu Phe Lys Leu Leu Lys 690
695 700Glu Gly His Arg Met Asp Lys Pro
Ser Asn Cys Thr Asn Glu Leu Tyr705 710
715 720Met Met Met Arg Asp Cys Trp His Ala Val Pro Ser
Gln Arg Pro Thr 725 730
735Phe Lys Gln Leu Val Glu Asp Leu Asp Arg Ile Val Ala Leu Thr Ser
740 745 750Asn Gln Glu Tyr Leu Asp
Leu Ser Met Pro Leu Asp Gln Tyr Ser Pro 755 760
765Ser Phe Pro Asp Thr Arg Ser Ser Thr Cys Ser Ser Gly Glu
Asp Ser 770 775 780Val Phe Ser His Glu
Pro Leu Pro Glu Glu Pro Cys Leu Pro Arg His785 790
795 800Pro Ala Gln Leu Ala Asn Gly Gly Leu Lys
Arg Arg 805 81047820PRTHomo sapiens 47Met
Trp Ser Trp Lys Cys Leu Leu Phe Trp Ala Val Leu Val Thr Ala1
5 10 15Thr Leu Cys Thr Ala Arg Pro
Ser Pro Thr Leu Pro Glu Gln Ala Gln 20 25
30Pro Trp Gly Ala Pro Val Glu Val Glu Ser Phe Leu Val His
Pro Gly 35 40 45Asp Leu Leu Gln
Leu Arg Cys Arg Leu Arg Asp Asp Val Gln Ser Ile 50 55
60Asn Trp Leu Arg Asp Gly Val Gln Leu Ala Glu Ser Asn
Arg Thr Arg65 70 75
80Ile Thr Gly Glu Glu Val Glu Val Gln Asp Ser Val Pro Ala Asp Ser
85 90 95Gly Leu Tyr Ala Cys Val
Thr Ser Ser Pro Ser Gly Ser Asp Thr Thr 100
105 110Tyr Phe Ser Val Asn Val Ser Asp Ala Leu Pro Ser
Ser Glu Asp Asp 115 120 125Asp Asp
Asp Asp Asp Ser Ser Ser Glu Glu Lys Glu Thr Asp Asn Thr 130
135 140Lys Pro Asn Pro Val Ala Pro Tyr Trp Thr Ser
Pro Glu Lys Met Glu145 150 155
160Lys Lys Leu His Ala Val Pro Ala Ala Lys Thr Val Lys Phe Lys Cys
165 170 175Pro Ser Ser Gly
Thr Pro Asn Pro Thr Leu Arg Trp Leu Lys Asn Gly 180
185 190Lys Glu Phe Lys Pro Asp His Arg Ile Gly Gly
Tyr Lys Val Arg Tyr 195 200 205Ala
Thr Trp Ser Ile Ile Met Asp Ser Val Val Pro Ser Asp Lys Gly 210
215 220Asn Tyr Thr Cys Ile Val Glu Asn Glu Tyr
Gly Ser Ile Asn His Thr225 230 235
240Tyr Gln Leu Asp Val Val Glu Arg Ser Pro His Arg Pro Ile Leu
Gln 245 250 255Ala Gly Leu
Pro Ala Asn Lys Thr Val Ala Leu Gly Ser Asn Val Glu 260
265 270Phe Met Cys Lys Val Tyr Ser Asp Pro Gln
Pro His Ile Gln Trp Leu 275 280
285Lys His Ile Glu Val Asn Gly Ser Lys Ile Gly Pro Asp Asn Leu Pro 290
295 300Tyr Val Gln Ile Leu Lys Thr Ala
Gly Val Asn Thr Thr Asp Lys Glu305 310
315 320Met Glu Val Leu His Leu Arg Asn Val Ser Phe Glu
Asp Ala Gly Glu 325 330
335Tyr Thr Cys Leu Ala Gly Asn Ser Ile Gly Leu Ser His His Ser Ala
340 345 350Trp Leu Thr Val Leu Glu
Ala Leu Glu Glu Arg Pro Ala Val Met Thr 355 360
365Ser Pro Leu Tyr Leu Glu Ile Ile Ile Tyr Cys Thr Gly Ala
Phe Leu 370 375 380Ile Ser Cys Met Val
Gly Ser Val Ile Val Tyr Lys Met Lys Ser Gly385 390
395 400Thr Lys Lys Ser Asp Phe His Ser Gln Met
Ala Val His Lys Leu Ala 405 410
415Lys Ser Ile Pro Leu Arg Arg Gln Val Thr Val Ser Ala Asp Ser Ser
420 425 430Ala Ser Met Asn Ser
Gly Val Leu Leu Val Arg Pro Ser Arg Leu Ser 435
440 445Ser Ser Gly Thr Pro Met Leu Ala Gly Val Ser Glu
Tyr Glu Leu Pro 450 455 460Glu Asp Pro
Arg Trp Glu Leu Pro Arg Asp Arg Leu Val Leu Gly Lys465
470 475 480Pro Leu Gly Glu Gly Cys Phe
Gly Gln Val Val Leu Ala Glu Ala Ile 485
490 495Gly Leu Asp Lys Asp Lys Pro Asn Arg Val Thr Lys
Val Ala Val Lys 500 505 510Met
Leu Lys Ser Asp Ala Thr Glu Lys Asp Leu Ser Asp Leu Ile Ser 515
520 525Glu Met Glu Met Met Lys Met Ile Gly
Lys His Lys Asn Ile Ile Asn 530 535
540Leu Leu Gly Ala Cys Thr Gln Asp Gly Pro Leu Tyr Val Ile Val Glu545
550 555 560Tyr Ala Ser Lys
Gly Asn Leu Arg Glu Tyr Leu Gln Ala Arg Arg Pro 565
570 575Pro Gly Leu Glu Tyr Cys Tyr Asn Pro Ser
His Asn Pro Glu Glu Gln 580 585
590Leu Ser Ser Lys Asp Leu Val Ser Cys Ala Tyr Gln Val Ala Arg Gly
595 600 605Met Glu Tyr Leu Ala Ser Lys
Lys Cys Ile His Arg Asp Leu Ala Ala 610 615
620Arg Asn Val Leu Val Thr Glu Asp Asn Val Met Lys Ile Ala Asp
Phe625 630 635 640Gly Leu
Ala Arg Asp Ile His His Ile Asp Tyr Tyr Lys Lys Thr Thr
645 650 655Asn Gly Arg Leu Pro Val Lys
Trp Met Ala Pro Glu Ala Leu Phe Asp 660 665
670Arg Ile Tyr Thr His Gln Ser Asp Val Trp Ser Phe Gly Val
Leu Leu 675 680 685Trp Glu Ile Phe
Thr Leu Gly Gly Ser Pro Tyr Pro Gly Val Pro Val 690
695 700Glu Glu Leu Phe Lys Leu Leu Lys Glu Gly His Arg
Met Asp Lys Pro705 710 715
720Ser Asn Cys Thr Asn Glu Leu Tyr Met Met Met Arg Asp Cys Trp His
725 730 735Ala Val Pro Ser Gln
Arg Pro Thr Phe Lys Gln Leu Val Glu Asp Leu 740
745 750Asp Arg Ile Val Ala Leu Thr Ser Asn Gln Glu Tyr
Leu Asp Leu Ser 755 760 765Met Pro
Leu Asp Gln Tyr Ser Pro Ser Phe Pro Asp Thr Arg Ser Ser 770
775 780Thr Cys Ser Ser Gly Glu Asp Ser Val Phe Ser
His Glu Pro Leu Pro785 790 795
800Glu Glu Pro Cys Leu Pro Arg His Pro Ala Gln Leu Ala Asn Gly Gly
805 810 815Leu Lys Arg Arg
82048733PRTHomo sapiens 48Met Trp Ser Trp Lys Cys Leu Leu Phe
Trp Ala Val Leu Val Thr Ala1 5 10
15Thr Leu Cys Thr Ala Arg Pro Ser Pro Thr Leu Pro Glu Gln Asp
Ala 20 25 30Leu Pro Ser Ser
Glu Asp Asp Asp Asp Asp Asp Asp Ser Ser Ser Glu 35
40 45Glu Lys Glu Thr Asp Asn Thr Lys Pro Asn Arg Met
Pro Val Ala Pro 50 55 60Tyr Trp Thr
Ser Pro Glu Lys Met Glu Lys Lys Leu His Ala Val Pro65 70
75 80Ala Ala Lys Thr Val Lys Phe Lys
Cys Pro Ser Ser Gly Thr Pro Asn 85 90
95Pro Thr Leu Arg Trp Leu Lys Asn Gly Lys Glu Phe Lys Pro
Asp His 100 105 110Arg Ile Gly
Gly Tyr Lys Val Arg Tyr Ala Thr Trp Ser Ile Ile Met 115
120 125Asp Ser Val Val Pro Ser Asp Lys Gly Asn Tyr
Thr Cys Ile Val Glu 130 135 140Asn Glu
Tyr Gly Ser Ile Asn His Thr Tyr Gln Leu Asp Val Val Glu145
150 155 160Arg Ser Pro His Arg Pro Ile
Leu Gln Ala Gly Leu Pro Ala Asn Lys 165
170 175Thr Val Ala Leu Gly Ser Asn Val Glu Phe Met Cys
Lys Val Tyr Ser 180 185 190Asp
Pro Gln Pro His Ile Gln Trp Leu Lys His Ile Glu Val Asn Gly 195
200 205Ser Lys Ile Gly Pro Asp Asn Leu Pro
Tyr Val Gln Ile Leu Lys Thr 210 215
220Ala Gly Val Asn Thr Thr Asp Lys Glu Met Glu Val Leu His Leu Arg225
230 235 240Asn Val Ser Phe
Glu Asp Ala Gly Glu Tyr Thr Cys Leu Ala Gly Asn 245
250 255Ser Ile Gly Leu Ser His His Ser Ala Trp
Leu Thr Val Leu Glu Ala 260 265
270Leu Glu Glu Arg Pro Ala Val Met Thr Ser Pro Leu Tyr Leu Glu Ile
275 280 285Ile Ile Tyr Cys Thr Gly Ala
Phe Leu Ile Ser Cys Met Val Gly Ser 290 295
300Val Ile Val Tyr Lys Met Lys Ser Gly Thr Lys Lys Ser Asp Phe
His305 310 315 320Ser Gln
Met Ala Val His Lys Leu Ala Lys Ser Ile Pro Leu Arg Arg
325 330 335Gln Val Thr Val Ser Ala Asp
Ser Ser Ala Ser Met Asn Ser Gly Val 340 345
350Leu Leu Val Arg Pro Ser Arg Leu Ser Ser Ser Gly Thr Pro
Met Leu 355 360 365Ala Gly Val Ser
Glu Tyr Glu Leu Pro Glu Asp Pro Arg Trp Glu Leu 370
375 380Pro Arg Asp Arg Leu Val Leu Gly Lys Pro Leu Gly
Glu Gly Cys Phe385 390 395
400Gly Gln Val Val Leu Ala Glu Ala Ile Gly Leu Asp Lys Asp Lys Pro
405 410 415Asn Arg Val Thr Lys
Val Ala Val Lys Met Leu Lys Ser Asp Ala Thr 420
425 430Glu Lys Asp Leu Ser Asp Leu Ile Ser Glu Met Glu
Met Met Lys Met 435 440 445Ile Gly
Lys His Lys Asn Ile Ile Asn Leu Leu Gly Ala Cys Thr Gln 450
455 460Asp Gly Pro Leu Tyr Val Ile Val Glu Tyr Ala
Ser Lys Gly Asn Leu465 470 475
480Arg Glu Tyr Leu Gln Ala Arg Arg Pro Pro Gly Leu Glu Tyr Cys Tyr
485 490 495Asn Pro Ser His
Asn Pro Glu Glu Gln Leu Ser Ser Lys Asp Leu Val 500
505 510Ser Cys Ala Tyr Gln Val Ala Arg Gly Met Glu
Tyr Leu Ala Ser Lys 515 520 525Lys
Cys Ile His Arg Asp Leu Ala Ala Arg Asn Val Leu Val Thr Glu 530
535 540Asp Asn Val Met Lys Ile Ala Asp Phe Gly
Leu Ala Arg Asp Ile His545 550 555
560His Ile Asp Tyr Tyr Lys Lys Thr Thr Asn Gly Arg Leu Pro Val
Lys 565 570 575Trp Met Ala
Pro Glu Ala Leu Phe Asp Arg Ile Tyr Thr His Gln Ser 580
585 590Asp Val Trp Ser Phe Gly Val Leu Leu Trp
Glu Ile Phe Thr Leu Gly 595 600
605Gly Ser Pro Tyr Pro Gly Val Pro Val Glu Glu Leu Phe Lys Leu Leu 610
615 620Lys Glu Gly His Arg Met Asp Lys
Pro Ser Asn Cys Thr Asn Glu Leu625 630
635 640Tyr Met Met Met Arg Asp Cys Trp His Ala Val Pro
Ser Gln Arg Pro 645 650
655Thr Phe Lys Gln Leu Val Glu Asp Leu Asp Arg Ile Val Ala Leu Thr
660 665 670Ser Asn Gln Glu Tyr Leu
Asp Leu Ser Met Pro Leu Asp Gln Tyr Ser 675 680
685Pro Ser Phe Pro Asp Thr Arg Ser Ser Thr Cys Ser Ser Gly
Glu Asp 690 695 700Ser Val Phe Ser His
Glu Pro Leu Pro Glu Glu Pro Cys Leu Pro Arg705 710
715 720His Pro Ala Gln Leu Ala Asn Gly Gly Leu
Lys Arg Arg 725 73049731PRTHomo sapiens
49Met Trp Ser Trp Lys Cys Leu Leu Phe Trp Ala Val Leu Val Thr Ala1
5 10 15Thr Leu Cys Thr Ala Arg
Pro Ser Pro Thr Leu Pro Glu Gln Asp Ala 20 25
30Leu Pro Ser Ser Glu Asp Asp Asp Asp Asp Asp Asp Ser
Ser Ser Glu 35 40 45Glu Lys Glu
Thr Asp Asn Thr Lys Pro Asn Pro Val Ala Pro Tyr Trp 50
55 60Thr Ser Pro Glu Lys Met Glu Lys Lys Leu His Ala
Val Pro Ala Ala65 70 75
80Lys Thr Val Lys Phe Lys Cys Pro Ser Ser Gly Thr Pro Asn Pro Thr
85 90 95Leu Arg Trp Leu Lys Asn
Gly Lys Glu Phe Lys Pro Asp His Arg Ile 100
105 110Gly Gly Tyr Lys Val Arg Tyr Ala Thr Trp Ser Ile
Ile Met Asp Ser 115 120 125Val Val
Pro Ser Asp Lys Gly Asn Tyr Thr Cys Ile Val Glu Asn Glu 130
135 140Tyr Gly Ser Ile Asn His Thr Tyr Gln Leu Asp
Val Val Glu Arg Ser145 150 155
160Pro His Arg Pro Ile Leu Gln Ala Gly Leu Pro Ala Asn Lys Thr Val
165 170 175Ala Leu Gly Ser
Asn Val Glu Phe Met Cys Lys Val Tyr Ser Asp Pro 180
185 190Gln Pro His Ile Gln Trp Leu Lys His Ile Glu
Val Asn Gly Ser Lys 195 200 205Ile
Gly Pro Asp Asn Leu Pro Tyr Val Gln Ile Leu Lys Thr Ala Gly 210
215 220Val Asn Thr Thr Asp Lys Glu Met Glu Val
Leu His Leu Arg Asn Val225 230 235
240Ser Phe Glu Asp Ala Gly Glu Tyr Thr Cys Leu Ala Gly Asn Ser
Ile 245 250 255Gly Leu Ser
His His Ser Ala Trp Leu Thr Val Leu Glu Ala Leu Glu 260
265 270Glu Arg Pro Ala Val Met Thr Ser Pro Leu
Tyr Leu Glu Ile Ile Ile 275 280
285Tyr Cys Thr Gly Ala Phe Leu Ile Ser Cys Met Val Gly Ser Val Ile 290
295 300Val Tyr Lys Met Lys Ser Gly Thr
Lys Lys Ser Asp Phe His Ser Gln305 310
315 320Met Ala Val His Lys Leu Ala Lys Ser Ile Pro Leu
Arg Arg Gln Val 325 330
335Thr Val Ser Ala Asp Ser Ser Ala Ser Met Asn Ser Gly Val Leu Leu
340 345 350Val Arg Pro Ser Arg Leu
Ser Ser Ser Gly Thr Pro Met Leu Ala Gly 355 360
365Val Ser Glu Tyr Glu Leu Pro Glu Asp Pro Arg Trp Glu Leu
Pro Arg 370 375 380Asp Arg Leu Val Leu
Gly Lys Pro Leu Gly Glu Gly Cys Phe Gly Gln385 390
395 400Val Val Leu Ala Glu Ala Ile Gly Leu Asp
Lys Asp Lys Pro Asn Arg 405 410
415Val Thr Lys Val Ala Val Lys Met Leu Lys Ser Asp Ala Thr Glu Lys
420 425 430Asp Leu Ser Asp Leu
Ile Ser Glu Met Glu Met Met Lys Met Ile Gly 435
440 445Lys His Lys Asn Ile Ile Asn Leu Leu Gly Ala Cys
Thr Gln Asp Gly 450 455 460Pro Leu Tyr
Val Ile Val Glu Tyr Ala Ser Lys Gly Asn Leu Arg Glu465
470 475 480Tyr Leu Gln Ala Arg Arg Pro
Pro Gly Leu Glu Tyr Cys Tyr Asn Pro 485
490 495Ser His Asn Pro Glu Glu Gln Leu Ser Ser Lys Asp
Leu Val Ser Cys 500 505 510Ala
Tyr Gln Val Ala Arg Gly Met Glu Tyr Leu Ala Ser Lys Lys Cys 515
520 525Ile His Arg Asp Leu Ala Ala Arg Asn
Val Leu Val Thr Glu Asp Asn 530 535
540Val Met Lys Ile Ala Asp Phe Gly Leu Ala Arg Asp Ile His His Ile545
550 555 560Asp Tyr Tyr Lys
Lys Thr Thr Asn Gly Arg Leu Pro Val Lys Trp Met 565
570 575Ala Pro Glu Ala Leu Phe Asp Arg Ile Tyr
Thr His Gln Ser Asp Val 580 585
590Trp Ser Phe Gly Val Leu Leu Trp Glu Ile Phe Thr Leu Gly Gly Ser
595 600 605Pro Tyr Pro Gly Val Pro Val
Glu Glu Leu Phe Lys Leu Leu Lys Glu 610 615
620Gly His Arg Met Asp Lys Pro Ser Asn Cys Thr Asn Glu Leu Tyr
Met625 630 635 640Met Met
Arg Asp Cys Trp His Ala Val Pro Ser Gln Arg Pro Thr Phe
645 650 655Lys Gln Leu Val Glu Asp Leu
Asp Arg Ile Val Ala Leu Thr Ser Asn 660 665
670Gln Glu Tyr Leu Asp Leu Ser Met Pro Leu Asp Gln Tyr Ser
Pro Ser 675 680 685Phe Pro Asp Thr
Arg Ser Ser Thr Cys Ser Ser Gly Glu Asp Ser Val 690
695 700Phe Ser His Glu Pro Leu Pro Glu Glu Pro Cys Leu
Pro Arg His Pro705 710 715
720Ala Gln Leu Ala Asn Gly Gly Leu Lys Arg Arg 725
73050822PRTHomo sapiens 50Met Trp Ser Trp Lys Cys Leu Leu Phe
Trp Ala Val Leu Val Thr Ala1 5 10
15Thr Leu Cys Thr Ala Arg Pro Ser Pro Thr Leu Pro Glu Gln Ala
Gln 20 25 30Pro Trp Gly Ala
Pro Val Glu Val Glu Ser Phe Leu Val His Pro Gly 35
40 45Asp Leu Leu Gln Leu Arg Cys Arg Leu Arg Asp Asp
Val Gln Ser Ile 50 55 60Asn Trp Leu
Arg Asp Gly Val Gln Leu Ala Glu Ser Asn Arg Thr Arg65 70
75 80Ile Thr Gly Glu Glu Val Glu Val
Gln Asp Ser Val Pro Ala Asp Ser 85 90
95Gly Leu Tyr Ala Cys Val Thr Ser Ser Pro Ser Gly Ser Asp
Thr Thr 100 105 110Tyr Phe Ser
Val Asn Val Ser Asp Ala Leu Pro Ser Ser Glu Asp Asp 115
120 125Asp Asp Asp Asp Asp Ser Ser Ser Glu Glu Lys
Glu Thr Asp Asn Thr 130 135 140Lys Pro
Asn Arg Met Pro Val Ala Pro Tyr Trp Thr Ser Pro Glu Lys145
150 155 160Met Glu Lys Lys Leu His Ala
Val Pro Ala Ala Lys Thr Val Lys Phe 165
170 175Lys Cys Pro Ser Ser Gly Thr Pro Asn Pro Thr Leu
Arg Trp Leu Lys 180 185 190Asn
Gly Lys Glu Phe Lys Pro Asp His Arg Ile Gly Gly Tyr Lys Val 195
200 205Arg Tyr Ala Thr Trp Ser Ile Ile Met
Asp Ser Val Val Pro Ser Asp 210 215
220Lys Gly Asn Tyr Thr Cys Ile Val Glu Asn Glu Tyr Gly Ser Ile Asn225
230 235 240His Thr Tyr Gln
Leu Asp Val Val Glu Arg Ser Pro His Arg Pro Ile 245
250 255Leu Gln Ala Gly Leu Pro Ala Asn Lys Thr
Val Ala Leu Gly Ser Asn 260 265
270Val Glu Phe Met Cys Lys Val Tyr Ser Asp Pro Gln Pro His Ile Gln
275 280 285Trp Leu Lys His Ile Glu Val
Asn Gly Ser Lys Ile Gly Pro Asp Asn 290 295
300Leu Pro Tyr Val Gln Ile Leu Lys Thr Ala Gly Val Asn Thr Thr
Asp305 310 315 320Lys Glu
Met Glu Val Leu His Leu Arg Asn Val Ser Phe Glu Asp Ala
325 330 335Gly Glu Tyr Thr Cys Leu Ala
Gly Asn Ser Ile Gly Leu Ser His His 340 345
350Ser Ala Trp Leu Thr Val Leu Glu Ala Leu Glu Glu Arg Pro
Ala Val 355 360 365Met Thr Ser Pro
Leu Tyr Leu Glu Ile Ile Ile Tyr Cys Thr Gly Ala 370
375 380Phe Leu Ile Ser Cys Met Val Gly Ser Val Ile Val
Tyr Lys Met Lys385 390 395
400Ser Gly Thr Lys Lys Ser Asp Phe His Ser Gln Met Ala Val His Lys
405 410 415Leu Ala Lys Ser Ile
Pro Leu Arg Arg Gln Val Thr Val Ser Ala Asp 420
425 430Ser Ser Ala Ser Met Asn Ser Gly Val Leu Leu Val
Arg Pro Ser Arg 435 440 445Leu Ser
Ser Ser Gly Thr Pro Met Leu Ala Gly Val Ser Glu Tyr Glu 450
455 460Leu Pro Glu Asp Pro Arg Trp Glu Leu Pro Arg
Asp Arg Leu Val Leu465 470 475
480Gly Lys Pro Leu Gly Glu Gly Cys Phe Gly Gln Val Val Leu Ala Glu
485 490 495Ala Ile Gly Leu
Asp Lys Asp Lys Pro Asn Arg Val Thr Lys Val Ala 500
505 510Val Lys Met Leu Lys Ser Asp Ala Thr Glu Lys
Asp Leu Ser Asp Leu 515 520 525Ile
Ser Glu Met Glu Met Met Lys Met Ile Gly Lys His Lys Asn Ile 530
535 540Ile Asn Leu Leu Gly Ala Cys Thr Gln Asp
Gly Pro Leu Tyr Val Ile545 550 555
560Val Glu Tyr Ala Ser Lys Gly Asn Leu Arg Glu Tyr Leu Gln Ala
Arg 565 570 575Arg Pro Pro
Gly Leu Glu Tyr Cys Tyr Asn Pro Ser His Asn Pro Glu 580
585 590Glu Gln Leu Ser Ser Lys Asp Leu Val Ser
Cys Ala Tyr Gln Val Ala 595 600
605Arg Gly Met Glu Tyr Leu Ala Ser Lys Lys Cys Ile His Arg Asp Leu 610
615 620Ala Ala Arg Asn Val Leu Val Thr
Glu Asp Asn Val Met Lys Ile Ala625 630
635 640Asp Phe Gly Leu Ala Arg Asp Ile His His Ile Asp
Tyr Tyr Lys Lys 645 650
655Thr Thr Asn Gly Arg Leu Pro Val Lys Trp Met Ala Pro Glu Ala Leu
660 665 670Phe Asp Arg Ile Tyr Thr
His Gln Ser Asp Val Trp Ser Phe Gly Val 675 680
685Leu Leu Trp Glu Ile Phe Thr Leu Gly Gly Ser Pro Tyr Pro
Gly Val 690 695 700Pro Val Glu Glu Leu
Phe Lys Leu Leu Lys Glu Gly His Arg Met Asp705 710
715 720Lys Pro Ser Asn Cys Thr Asn Glu Leu Tyr
Met Met Met Arg Asp Cys 725 730
735Trp His Ala Val Pro Ser Gln Arg Pro Thr Phe Lys Gln Leu Val Glu
740 745 750Asp Leu Asp Arg Ile
Val Ala Leu Thr Ser Asn Gln Glu Tyr Leu Asp 755
760 765Leu Ser Met Pro Leu Asp Gln Tyr Ser Pro Ser Phe
Pro Asp Thr Arg 770 775 780Ser Ser Thr
Cys Ser Ser Gly Glu Asp Ser Val Phe Ser His Glu Pro785
790 795 800Leu Pro Glu Glu Pro Cys Leu
Pro Arg His Pro Ala Gln Leu Ala Asn 805
810 815Gly Gly Leu Lys Arg Arg 82051808PRTHomo
sapiens 51Met Gly Ala Pro Ala Cys Ala Leu Ala Leu Cys Val Ala Val Ala
Ile1 5 10 15Val Ala Gly
Ala Ser Ser Glu Ser Leu Gly Thr Glu Gln Arg Val Val 20
25 30Gly Arg Ala Ala Glu Val Pro Gly Pro Glu
Pro Gly Gln Gln Glu Gln 35 40
45Leu Val Phe Gly Ser Gly Asp Ala Val Glu Leu Ser Cys Pro Pro Pro 50
55 60Gly Gly Gly Pro Met Gly Pro Thr Val
Trp Val Lys Asp Gly Thr Gly65 70 75
80Leu Val Pro Ser Glu Arg Val Leu Val Gly Pro Gln Arg Leu
Gln Val 85 90 95Leu Asn
Ala Ser His Glu Asp Ser Gly Ala Tyr Ser Cys Arg Gln Arg 100
105 110Leu Thr Gln Arg Val Leu Cys His Phe
Ser Val Arg Val Thr Asp Ala 115 120
125Pro Ser Ser Gly Asp Asp Glu Asp Gly Glu Asp Glu Ala Glu Asp Thr
130 135 140Gly Val Asp Thr Gly Ala Pro
Tyr Trp Thr Arg Pro Glu Arg Met Asp145 150
155 160Lys Lys Leu Leu Ala Val Pro Ala Ala Asn Thr Val
Arg Phe Arg Cys 165 170
175Pro Ala Ala Gly Asn Pro Thr Pro Ser Ile Ser Trp Leu Lys Asn Gly
180 185 190Arg Glu Phe Arg Gly Glu
His Arg Ile Gly Gly Ile Lys Leu Arg His 195 200
205Gln Gln Trp Ser Leu Val Met Glu Ser Val Val Pro Ser Asp
Arg Gly 210 215 220Asn Tyr Thr Cys Val
Val Glu Asn Lys Phe Gly Ser Ile Arg Gln Thr225 230
235 240Tyr Thr Leu Asp Val Leu Glu Arg Ser Pro
His Arg Pro Ile Leu Gln 245 250
255Ala Gly Leu Pro Ala Asn Gln Thr Ala Val Leu Gly Ser Asp Val Glu
260 265 270Phe His Cys Lys Val
Tyr Ser Asp Ala Gln Pro His Ile Gln Trp Leu 275
280 285Lys His Val Glu Val Asn Gly Ser Lys Val Gly Pro
Asp Gly Thr Pro 290 295 300Tyr Val Thr
Val Leu Lys Ser Trp Ile Ser Glu Ser Val Glu Ala Asp305
310 315 320Val Arg Leu Arg Leu Ala Asn
Val Ser Glu Arg Asp Gly Gly Glu Tyr 325
330 335Leu Cys Arg Ala Thr Asn Phe Ile Gly Val Ala Glu
Lys Ala Phe Trp 340 345 350Leu
Ser Val His Gly Pro Arg Ala Ala Glu Glu Glu Leu Val Glu Ala 355
360 365Asp Glu Ala Gly Ser Val Tyr Ala Gly
Ile Leu Ser Tyr Gly Val Gly 370 375
380Phe Phe Leu Phe Ile Leu Val Val Ala Ala Val Thr Leu Cys Arg Leu385
390 395 400Arg Ser Pro Pro
Lys Lys Gly Leu Gly Ser Pro Thr Val His Lys Ile 405
410 415Ser Arg Phe Pro Leu Lys Arg Gln Val Ser
Leu Glu Ser Asn Ala Ser 420 425
430Met Ser Ser Asn Thr Pro Leu Val Arg Ile Ala Arg Leu Ser Ser Gly
435 440 445Glu Gly Pro Thr Leu Ala Asn
Val Ser Glu Leu Glu Leu Pro Ala Asp 450 455
460Pro Lys Trp Glu Leu Ser Arg Ala Arg Leu Thr Leu Gly Lys Pro
Leu465 470 475 480Gly Glu
Gly Cys Phe Gly Gln Val Val Met Ala Glu Ala Ile Gly Ile
485 490 495Asp Lys Asp Arg Ala Ala Lys
Pro Val Thr Val Ala Val Lys Met Leu 500 505
510Lys Asp Asp Ala Thr Asp Lys Asp Leu Ser Asp Leu Val Ser
Glu Met 515 520 525Glu Met Met Lys
Met Ile Gly Lys His Lys Asn Ile Ile Asn Leu Leu 530
535 540Gly Ala Cys Thr Gln Gly Gly Pro Leu Tyr Val Leu
Val Glu Tyr Ala545 550 555
560Ala Lys Gly Asn Leu Arg Glu Phe Leu Arg Ala Arg Arg Pro Pro Gly
565 570 575Leu Asp Tyr Ser Phe
Asp Thr Cys Lys Pro Pro Glu Glu Gln Leu Thr 580
585 590Phe Lys Asp Leu Val Ser Cys Ala Tyr Gln Val Ala
Arg Gly Met Glu 595 600 605Tyr Leu
Ala Ser Gln Lys Cys Ile His Arg Asp Leu Ala Ala Arg Asn 610
615 620Val Leu Val Thr Glu Asp Asn Val Met Lys Ile
Ala Asp Phe Gly Leu625 630 635
640Ala Arg Asp Val His Asn Leu Asp Tyr Tyr Lys Lys Thr Thr Asn Gly
645 650 655Arg Leu Pro Val
Lys Trp Met Ala Pro Glu Ala Leu Phe Asp Arg Val 660
665 670Tyr Thr His Gln Ser Asp Val Trp Ser Phe Gly
Val Leu Leu Trp Glu 675 680 685Ile
Phe Thr Leu Gly Gly Ser Pro Tyr Pro Gly Ile Pro Val Glu Glu 690
695 700Leu Phe Lys Leu Leu Lys Glu Gly His Arg
Met Asp Lys Pro Ala Asn705 710 715
720Cys Thr His Asp Leu Tyr Met Ile Met Arg Glu Cys Trp His Ala
Ala 725 730 735Pro Ser Gln
Arg Pro Thr Phe Lys Gln Leu Val Glu Asp Leu Asp Arg 740
745 750Val Leu Thr Val Thr Ser Thr Asp Glu Tyr
Leu Asp Leu Ser Ala Pro 755 760
765Phe Glu Gln Tyr Ser Pro Gly Gly Gln Asp Thr Pro Ser Ser Ser Ser 770
775 780Ser Gly Asp Asp Ser Val Phe Ala
His Asp Leu Leu Pro Pro Ala Pro785 790
795 800Pro Ser Ser Gly Gly Ser Arg Thr
80552694PRTHomo sapiens 52Met Gly Ala Pro Ala Cys Ala Leu Ala Leu Cys Val
Ala Val Ala Ile1 5 10
15Val Ala Gly Ala Ser Ser Glu Ser Leu Gly Thr Glu Gln Arg Val Val
20 25 30Gly Arg Ala Ala Glu Val Pro
Gly Pro Glu Pro Gly Gln Gln Glu Gln 35 40
45Leu Val Phe Gly Ser Gly Asp Ala Val Glu Leu Ser Cys Pro Pro
Pro 50 55 60Gly Gly Gly Pro Met Gly
Pro Thr Val Trp Val Lys Asp Gly Thr Gly65 70
75 80Leu Val Pro Ser Glu Arg Val Leu Val Gly Pro
Gln Arg Leu Gln Val 85 90
95Leu Asn Ala Ser His Glu Asp Ser Gly Ala Tyr Ser Cys Arg Gln Arg
100 105 110Leu Thr Gln Arg Val Leu
Cys His Phe Ser Val Arg Val Thr Asp Ala 115 120
125Pro Ser Ser Gly Asp Asp Glu Asp Gly Glu Asp Glu Ala Glu
Asp Thr 130 135 140Gly Val Asp Thr Gly
Ala Pro Tyr Trp Thr Arg Pro Glu Arg Met Asp145 150
155 160Lys Lys Leu Leu Ala Val Pro Ala Ala Asn
Thr Val Arg Phe Arg Cys 165 170
175Pro Ala Ala Gly Asn Pro Thr Pro Ser Ile Ser Trp Leu Lys Asn Gly
180 185 190Arg Glu Phe Arg Gly
Glu His Arg Ile Gly Gly Ile Lys Leu Arg His 195
200 205Gln Gln Trp Ser Leu Val Met Glu Ser Val Val Pro
Ser Asp Arg Gly 210 215 220Asn Tyr Thr
Cys Val Val Glu Asn Lys Phe Gly Ser Ile Arg Gln Thr225
230 235 240Tyr Thr Leu Asp Val Leu Glu
Arg Ser Pro His Arg Pro Ile Leu Gln 245
250 255Ala Gly Leu Pro Ala Asn Gln Thr Ala Val Leu Gly
Ser Asp Val Glu 260 265 270Phe
His Cys Lys Val Tyr Ser Asp Ala Gln Pro His Ile Gln Trp Leu 275
280 285Lys His Val Glu Val Asn Gly Ser Lys
Val Gly Pro Asp Gly Thr Pro 290 295
300Tyr Val Thr Val Leu Lys Val Ser Leu Glu Ser Asn Ala Ser Met Ser305
310 315 320Ser Asn Thr Pro
Leu Val Arg Ile Ala Arg Leu Ser Ser Gly Glu Gly 325
330 335Pro Thr Leu Ala Asn Val Ser Glu Leu Glu
Leu Pro Ala Asp Pro Lys 340 345
350Trp Glu Leu Ser Arg Ala Arg Leu Thr Leu Gly Lys Pro Leu Gly Glu
355 360 365Gly Cys Phe Gly Gln Val Val
Met Ala Glu Ala Ile Gly Ile Asp Lys 370 375
380Asp Arg Ala Ala Lys Pro Val Thr Val Ala Val Lys Met Leu Lys
Asp385 390 395 400Asp Ala
Thr Asp Lys Asp Leu Ser Asp Leu Val Ser Glu Met Glu Met
405 410 415Met Lys Met Ile Gly Lys His
Lys Asn Ile Ile Asn Leu Leu Gly Ala 420 425
430Cys Thr Gln Gly Gly Pro Leu Tyr Val Leu Val Glu Tyr Ala
Ala Lys 435 440 445Gly Asn Leu Arg
Glu Phe Leu Arg Ala Arg Arg Pro Pro Gly Leu Asp 450
455 460Tyr Ser Phe Asp Thr Cys Lys Pro Pro Glu Glu Gln
Leu Thr Phe Lys465 470 475
480Asp Leu Val Ser Cys Ala Tyr Gln Val Ala Arg Gly Met Glu Tyr Leu
485 490 495Ala Ser Gln Lys Cys
Ile His Arg Asp Leu Ala Ala Arg Asn Val Leu 500
505 510Val Thr Glu Asp Asn Val Met Lys Ile Ala Asp Phe
Gly Leu Ala Arg 515 520 525Asp Val
His Asn Leu Asp Tyr Tyr Lys Lys Thr Thr Asn Gly Arg Leu 530
535 540Pro Val Lys Trp Met Ala Pro Glu Ala Leu Phe
Asp Arg Val Tyr Thr545 550 555
560His Gln Ser Asp Val Trp Ser Phe Gly Val Leu Leu Trp Glu Ile Phe
565 570 575Thr Leu Gly Gly
Ser Pro Tyr Pro Gly Ile Pro Val Glu Glu Leu Phe 580
585 590Lys Leu Leu Lys Glu Gly His Arg Met Asp Lys
Pro Ala Asn Cys Thr 595 600 605His
Asp Leu Tyr Met Ile Met Arg Glu Cys Trp His Ala Ala Pro Ser 610
615 620Gln Arg Pro Thr Phe Lys Gln Leu Val Glu
Asp Leu Asp Arg Val Leu625 630 635
640Thr Val Thr Ser Thr Asp Glu Tyr Leu Asp Leu Ser Ala Pro Phe
Glu 645 650 655Gln Tyr Ser
Pro Gly Gly Gln Asp Thr Pro Ser Ser Ser Ser Ser Gly 660
665 670Asp Asp Ser Val Phe Ala His Asp Leu Leu
Pro Pro Ala Pro Pro Ser 675 680
685Ser Gly Gly Ser Arg Thr 6905310PRTHomo sapiens 53Gly Pro Leu Tyr
Val Ile Val Glu Tyr Ala1 5 105410PRTHomo
sapiens 54Gly Pro Leu Tyr Val Leu Val Glu Tyr Ala1 5
10
User Contributions:
Comment about this patent or add new information about this topic: